Cancer Drug Discovery and Development Series Editor: Beverly A. Teicher
For further volumes: http://www.springer.com/series/7625
Rebecca G. Bagley Editor
The Tumor Microenvironment
Editor Rebecca G. Bagley Genzyme Corporation Framingham MA, USA
[email protected]
ISBN 978-1-4419-6614-8 e-ISBN 978-1-4419-6615-5 DOI 10.1007/978-1-4419-6615-5 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2010934382 © Springer Science+Business Media, LLC 2010 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer soft-ware, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
Preface
The fact that tumors are composed of both tumor cells and host cells has long been known. These tumor-associated cells include vascular endothelial cells and pericytes, as well as inflammatory cells such as neutrophils, monocytes, macrophages, mast cells and eosinophils, and lymphocytes. The tumor cells also interact with stromal cells and with elements of the tissue extracellular matrix. What has been less appreciated is the role that these cells could have in modulating the growth, invasion, and metastasis of the tumor. Early on, the elements of what we now call the tumor microenvironment were considered to be more or less innocent bystanders to the role of the tumor cells as they grew and invaded local sites. Today, there is an increased understanding of the critical role of the tumor microenvironment as dramatically influencing the course of tumor development and dissemination. This volume represents a superb compilation of the latest thoughts and data regarding the role of each essential component of the tumor microenvironment in cancer development and progression. Perhaps, the earliest recognition of the role of nonmalignant cells as cancer regulators was the recognition that lymphocytes can participate in what was termed “immune surveillance” in the 1960s. Our understanding of tumor immunity has improved markedly since then, and there are now successful clinical studies showing the potential use of immune-based therapies in cancer treatment. The role of tumor infiltrating lymphocytes is nicely discussed here in the chapter by Fu and Yu, with a special emphasis on the potential prognostic implications of the presence of these cells at a tumor site. Natural killer cells, first shown to be involved in tumor surveillance by Herlyn in the 1980s, also have multiple effects on tumors as discussed in the chapter by Arai. Additional immune and inflammatory cells are also discussed. These include macrophages, which have effects on both tumor cells and blood vessels, and mast cells, which have a potent and somewhat underappreciated effect on tumor growth that is clarified in the chapter by Angelidou and Zhang. A picture emerges of the tumor as a city filled with diverse cellular inhabitants who operate in the role of a “zoning board” in telling the tumor how fast it can expand and into what spaces it can grow. An extremely important regulator of tumor growth and metastasis is the tumor vasculature. Again, tumors were known to be filled with functional blood vessels for many decades before Judah Folkman explained how they might influence tumor v
vi
Preface
growth. His theory of tumor angiogenesis predicted that anti-angiogenic agents might be developed to combat cancer and this prediction has been borne out. In many cases, the predominant signal for angiogenesis is tissue hypoxia and a very strong section of this book deals with the effects of hypoxia on the tumor and on the vascular components of the tumor. The potential translational aspects of this field is just emerging and a compelling discussion of the novel therapies that target the hypoxia induced transcription factor, HIF-1-alpha can be found in the book’s opening chapter by Rapisarda and Melillo. Along with the immune cells, inflammatory cells, and vascular cells, the tumor surrounds stromal cells including fibroblasts and other mesenchymal cells. The interplay between stromal cells and tumor cells is an extremely vibrant area of study and is nicely discussed in the chapter by Orimo. Of course, a principal function of these cells is to produce and remodel the elements of the extracellular matrix as described in the contribution by DeClerck. These proteins can present a barrier to tumor invasion and metastasis. Excellent and comprehensive discussions of the role of collagens and of fibronectin as well as their binding partners the integrins and tetraspanins can be found in the section on the extracellular matrix. The modulation of the matrix by cancer cells is discussed in detail in the chapter on matrix metalloproteases and cancer cell invasion by Zucker and Cao. The interplay of tumor cells and the microenvironment is mirrored in the complex interactions of tumor cells, fibroblasts, matrix elements, and the various cells that produce either matrix metalloproteases or their natural inhibitors. No contemporary discussion of the role of the tumor microenvironment could be complete without an in-depth examination of the existence and potential role of stem cells in the establishment of human tumors and in their metastatic dissemination. This is a relatively new field and comes with the attendant controversies that often characterize new areas of investigation. This can make for very exciting reading, as it does in the chapters on cancer stem cells by Giordano, on endothelial cell precursors by Shaked and on mesenchymal stem cells by Banerjee. It is safe to say that the exact contribution of all of these progenitor, precursor and stem cell populations to cancer is an emerging and truly important field of inquiry. These chapters beautifully capture the scientific foment that characterizes the study of these cells and their role in cancer. Perhaps, the most exciting aspect of the increased attention paid to the tumor microenvironment is the promise that new approaches to cancer therapy can be derived from our paying attention to these non-tumor elements and to their interactions with the tumor cells. This is beautifully captured throughout this book. One senses an emerging optimism that the tumor microenvironment is not only important, but that it represents a treasure trove of potential therapeutic opportunities such as the ones described in the chapter on secreted growth factors as therapeutic targets by Teicher. Whether one starts out as a skeptic, or as a devotee, this excellent and comprehensive compilation will educate the reader and stimulate new ideas about tumors as an integrated combination of cellular, secreted, stromal, and matrix elements that each represents a potential therapeutic target. Boston, MA
Bruce Zetter
Contents
Part I: Physiological Parameters 1 Combination Strategies Targeting Hypoxia Inducible Factor 1 (HIF-1) for Cancer Therapy.................................................... Annamaria Rapisarda and Giovanni Melillo
3
2 The Tumor Microenvironment: New Insights into Regulation of Tumor pH by Carbonic Anhydrases.............................. Pawel Swietach, Adrian L. Harris, and Richard D. Vaughan-Jones
23
3 Hypoxia, Gene Expression, and Metastasis........................................... Olga V. Razorenova and Amato J. Giaccia 4 Molecular Mechanisms Regulating Expression and Function of Cancer-Associated Carbonic Anhydrase IX..................... Jaromir Pastorek and Silvia Pastorekova 5 Glycolytic Pathway as a Target for Tumor Inhibition.......................... Weiqin Lu and Peng Huang
43
59 91
Part II: Malignant Cells 6 Aberrant DNA Methylation in Cancer Cells......................................... Toshikazu Ushijima
121
7 DNA Repair and Redox Signaling.......................................................... Mark R. Kelley, Millie M. Georgiadis, and Melissa L. Fishel
133
8 Cancer Stem Cells and Microenvironment............................................ Mario Federico and Antonio Giordano
169
9 Epithelial–Mesenchymal Transition in Development and Diseases...................................................................... Yadi Wu and Binhua P. Zhou
187 vii
viii
Contents
10 Invasion and Metastasis......................................................................... Douglas M. Noonan, Giuseppina Pennesi, and Adriana Albini 11 Dormancy of Disseminated Tumor Cells: Reciprocal Crosstalk with the Microenvironment.................................................. Paloma Bragado, Aparna C. Ranganathan, and Julio A. Aguirre-Ghiso
213
229
Part III: Vasculature and Stroma 12 Impact of Endothelial Progenitor Cells on Tumor Angiogenesis and Outcome of Antiangiogenic Therapy: New Perspectives on an Ongoing Controversy.................................... Robert S. Kerbel, Francesco Bertolini, and Yuval Shaked 13 Bone Marrow Derived Mesenchymal Stem/Stromal Cells and Tumor Growth....................................................................... Pravin J. Mishra and Debabrata Banerjee 14 Integrin Signaling in Lymphangiogenesis............................................ Barbara Garmy-Susini 15 Role of Pericytes in Resistance to Antiangiogenic Therapy................................................................................................... Koji Matsuo, Chunhua Lu, Mian M.K. Shazad, Robert L. Coleman, and Anil K. Sood 16 Tumour-Promoting Stromal Myofibroblasts in Human Carcinomas........................................................................... Urszula M. Polanska, Kieran T. Mellody, and Akira Orimo
257
275 289
311
325
Part IV: Immune-Mediated Cells 17 Mast Cells and Tumor Microenvironment.......................................... Theoharis C. Theoharides, Konstantinos-Dionysios Alysandratos, Asimenia Angelidou, and Bodi Zhang
353
18 Macrophages in the Tumor Microenvironment.................................. Monica Escorcio-Correia and Thorsten Hagemann
371
19 The Prognostic Significance of Tumor-Infiltrating Lymphocytes........................................................................................... Ping Yu and Yang-Xin Fu
385
Contents
20 The Pro-inflammatory Milieu and Its Role in Malignant Epithelial Initiation................................................................................ Adam Yagui-Beltrán, Qizhi Tang, and David M. Jablons 21 Natural Killer Cells for Adoptive Immunotherapy............................ Jonathan E. Benjamin and Sally Arai
ix
409 431
Part V: Extracellular Matrix 22 Fibronectin.............................................................................................. Andreas Menrad
457
23 Collagen in Cancer................................................................................. Janelle L. Lauer and Gregg B. Fields
477
24 Integrins and Cancer............................................................................. Laurie G. Hudson and M. Sharon Stack
509
25 Matrix Metalloproteinases and Cancer Cell Invasion/Metastasis................................................................................ Stanley Zucker and Jian Cao 26 Tetraspanins and Cancer Metastasis.................................................... Margot Zöller
531 555
Part VI: Secreted Proteins 27 Chemokines and Metastasis.................................................................. Kalyan C. Nannuru, Seema Singh, and Rakesh K. Singh
601
28 Transforming Growth Factor-b in Lung Cancer, Carcinogenesis, and Metastasis............................................................ Sonia B. Jakowlew
633
29 Cooperative Interactions Between Integrins and Growth Factor Signaling in Pathological Angiogenesis.................................... Jennifer Roth, Eric Tweedie, and Peter C. Brooks
673
30 The Extracellular Matrix and the Growth and Survival of Tumors......................................................................... Yves A. DeClerck
695
x
Contents
31 Secreted Growth Factors as Therapeutic Targets............................... Beverly A. Teicher
711
32 Adrenomedullin...................................................................................... Rebecca G. Bagley
733
Index................................................................................................................
749
Contributors
Julio A. Aguirre-Ghiso Division of Hematology and Oncology, Departments of Medicine and Department of Otolaryngology, Tisch Cancer Institute, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1079, New York, NY 10029, USA Adriana Albini IRCCS Multimedica, Via Fantoli 16/15, 20138 Milano, Italy Konstantinos-Dionysios Alysandratos, MD Tufts University School of Medicine, 136 Harrison Ave., Boston, MA 02111, USA Asimenia Angelidou, MD Tufts University School of Medicine, 136 Harrison Ave., Boston, MA 02111, USA Sally Arai, MD Division of Blood and Marrow Transplantation, Stanford School of Medicine, 300 Pasteur Drive, H3249 MC 5623, Stanford, CA 94305, USA, Rebecca G. Bagley Genzyme Corporation, 49 New York Ave, Framingham, MA 01701, USA Debabrata Banerjee Department of Medicine and Pharmacology, Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, USA Jonathan E. Benjamin Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA, USA
xi
xii
Contributors
Francesco Bertolini, MD/PhD Department of Hematology-Oncology, European Institute of Oncology, Milan, Italy Paloma Bragado, PhD Division of Hematology and Oncology, Department of Medicine and Department of Otolaryngology, Mount Sinai School of Medicine – NYU, New York, NY 10029, USA Peter C. Brooks Maine Medical Center Research Institute, Center for Molecular Medicine, 81 Research Drive, Scarborough, ME, USA Jian Cao, PhD Stony Brook University, Room 004, Life Sciences Building, Stony Brook, NY 11794-5200, USA Robert L. Coleman, MD Department of Gynecologic Oncology, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, University of Texas, Houston, TX, USA Yves A. DeClerck Departments of Pediatrics and Biochemistry and Molecular Biology, University of Southern California and The Saban Research Institute of Childrens Hospital Los Angeles, Los Angeles, CA 20027, USA Monica Escorcio-Correia, PhD Barts and The London School of Medicine and Dentistry, Institute of Cancer, Charterhouse Square, London, UK EC1M 6BQ Mario Federico, MD Sbarro Health Research Organization, Temple University, BioLife Science Building, Suite 333, 1900 N. 12th Street, Philadelphia, PA 19122, USA; Section of Clinical Oncology, University of Palermo, Palermo, Italy Gregg B. Fields Department of Biochemistry, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA Melissa L. Fishel, PhD Herman B. Wells Center for Pediatric Research, Indiana University, 980 W. Walnut Street, Indianapolis, IN 46202, USA
Contributors
Yang-Xin Fu, MD/PhD Department of Pathology and Section of Dermatology/ Department of Medicine, University of Chicago, 5841 S. Maryland Ave, MC 3083, Chicago, IL 60637, USA Barbara Garmy-Susini Unité mixte Inserm U858, Institut de Médecine Moléculaire de Rangueil, IFR 150, 1, Avenue Jean Poulhès, BP 84225 31432, Toulouse Cedex 4, France Millie M. Georgiadis, PhD Herman B. Wells Center for Pediatric Research, Indiana University, 980 W. Walnut Street, Indianapolis, IN 46202, USA Amato J. Giaccia Division of Radiation and Cancer Biology, Stanford University, Stanford, CA 94305, USA Antonio Giordano Biology Department, Sbarro Health Research Organization, Temple University, Philadelphia, PA, USA Thorsten Hagemann Barts and The London School of Medicine and Dentistry, Institute of Cancer, Charterhouse Square, London, EC1M 6BQ, UK Adrian L. Harris Weatherall Institute of Molecular Medicine, Oxford University, Oxford OX3 9DS, UK Peng Huang Department of Molecular Pathology, The University of Texas MD, Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA Laurie G. Hudson, PhD University of New Mexico College of Pharmacy, Albuquerque, NM, USA David Jablons, MD Department of Surgery, University of California San Francisco, San Francisco, CA 94143, USA Sonia B. Jakowlew National Cancer Institute, Center for Cancer Training, Cancer Training Branch, Bethesda, MD 20892, USA
xiii
xiv
Contributors
Mark R. Kelley Department of Pediatrics, Section of Hematology/Oncology, Herman B Wells Center for Pediatric Research, Indiana University, Indianapolis, IN 46202, USA Robert S. Kerbel, PhD Department of Cellular and Molecular Biology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada Janelle L. Lauer, PhD The University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA Chunhua Lu, MD/PhD Department of Gynecologic Oncology, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA Weiqin Lu, PhD MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA Koji Matsuo, MD Department of Gynecologic Oncology, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA Giovanni Melillo SAIC-Frederick, Inc., DTP-Tumor Hypoxia Laboratory, Developmental Therapeutics Program, National Cancer Institute – Frederick, Building 432, Room 218, Frederick, MD 21702, USA Kieran T. Mellody, BSc./MPhil Paterson Institute for Cancer Research, The University of Manchester, Wilmslow Road, Manchester, England M20 4BX Andreas Menrad Antibody Therapeutics Genzyme Europe Research, 310 Cambridge Science Park, Milton Road, Cambridge, CB4 OWG, UK Pravin J. Mishra, MS Department of Medicine, Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, 195 Little Albany St, New Brunswick, NJ 08901, USA Kalyan C. Nannuru, PhD Department of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198-5900, USA
Contributors
xv
Douglas M. Noonan, PhD Universita degli Studi dell’Insubria, Varese, Italy Akira Orimo CR-UK Stromal-Tumour Interaction Group, Paterson Institute for Cancer Research, The University of Manchester, Wilmslow Road, Manchester, M20 4BX, UK Jaromir Pastorek Centre of Molecular Medicine, Slovak Academy of Sciences, Dubravska cesta 9, 845 05 Bratislava, Slovak Republic Silvia Pastorekova Centre of Molecular Medicine, Slovak Academy of Sciences, Dubravask cesta 9, Bratislava 845 05, Slovak Republic Giuseppina Pennesi, MD IRCCS Multimedica, Via Fantoli 16/15, 20138 Milano, Italy Urszula M. Polanska, Msc/PhD Paterson Institute for Cancer Research, The University of Manchester, Wilmslow Road, Manchester, England M20 4BX Aparna C. Ranganathan, PhD Division of Hematology and Oncology, Department of Medicine and Department of Otolaryngology, Mount Sinai School of Medicine – NYU, New York, NY 10029, USA Annamaria Rapisarda, PhD SAIC-Frederick, Inc., DTP-Tumor Hypoxia Laboratory, Developmental Therapeutics Program, National Cancer Institute – Frederick, Building 432, Room 218, Frederick, MD 21702, USA Olga V. Razorenova, PhD Division of Radiation and Cancer Biology, Stanford University School of Medicine, 269 Campus Drive, Stanford, CA 94305, USA Jennifer M. Roth, MS Center for Molecular Medicine, Maine Medical Center Research Institute, 81 Research Drive, Scarborough, ME 04074, USA Yuval Shaked Department of Molecular Pharmacology, Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel
xvi
Contributors
M. Sharon Stack University of Missouri School of Medicine, M214C Medical Sciences Building, 1 Hospital Drive, Columbia, MO 65212, USA Mian M. K. Shazad, MS/MD Department of Gynecologic Oncology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA; Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, USA Rakesh K. Singh Department of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198-5900, USA Seema Singh, PhD Department of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198-5900, USA Anil K. Sood Department of Gynecologic Oncology, Cancer Biology, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA Center for RNA Interference and Non-Coding RNA, University of Texas, Houston, TX, USA Pawel Swietach, DPhil Deparment of Physiology, Anatomy & Genetics, Oxford University, Oxford OX1 3PT, UK Qizi Tang, PhD Department of Surgery, University of California San Francisco, San Francisco, CA 94143, USA Beverly A. Teicher Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701-9322, USA
[email protected] Theoharis C. Theoharides Tufts University School of Medicine, 136 Harrison Ave., Boston, MA 02111, USA Eric Tweedie, BS Center for Molecular Medicine, Maine Medical Center Research Institute, 81 Research Drive, Scarborough, ME 04074, USA
Contributors
xvii
Toshikazu Ushijima National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan Richard D. Vaughan-Jones, PhD Deparment of Physiology, Anatomy & Genetics, Oxford University, Oxford OX1 3PT, UK Yadi Wu, PhD Department of Molecular and Biomedical Pharmacology, Markey Cancer Center and University of Kentucky School of Medicine, BBSRB room B336, 741 South Limestone, Lexington, KY 40506-0509, USA Adam Yagui-Beltrán Department of Surgery, Division of Adult Thoracic Surgery, The Helen Diller Family Comprehensive Cancer Center Thoracic Surgery, University of California San Francisco, 1600 Divisadero, Room A-743, San Francisco, CA 94143-1724, USA Ping Yu The Committee on Immunology and Department of Pathology and Section of Dermatology/Department of Medicine, University of Chicago, 5841 S. Maryland Ave, Chicago, IL 60637, USA Bruce Zettler, PhD Childrens’s Hospital, Boston Harvarel Medical School, 300 Lougwood Ave., Boston, MA 02115, USA Bodi Zhang, MD/MPH Tufts University School of Medicine, 136 Harrison Ave., Boston, MA 02111, USA Binhua P. Zhou Markey Cancer Center, University of Kentucky School of Medicine, Lexington, KY, USA and Department of Molecular and Cellular Biochemistry, University of Kentucky School of Medicine, Lexington, KY, USA
xviii
Margot Zöller Department of Tumor Cell Biology, University Hospital of Surgery, Im Neuenheimer Feld 365, D-69120, Heidelberg, Germany and Department of Tumor Progression and Immune Defense, German Cancer Research Center, Heidelberg, Germany and Department of Applied Genetics, University of Karlsruhe, Karlsruhe, Germany Stanley Zucker Veterans Affairs Medical Center, Northport, NY 11768, USA and Stony Brook University, Stony Brook, NY 11794, USA
Contributors
Part I
Physiological Parameters
Chapter 1
Combination Strategies Targeting Hypoxia Inducible Factor 1 (HIF-1) for Cancer Therapy Annamaria Rapisarda and Giovanni Melillo
Abstract Solid tumors often present regions of decreased oxygen levels (hypoxia) due to an imbalance between increased oxygen consumption and insufficient oxygen delivery from the aberrant tumor vasculature. Intratumor hypoxia is associated with altered cellular metabolism, an invasive and metastatic phenotype, as well as resistance to radiation and chemotherapy. The discovery of Hypoxia Inducible Factor-1 (HIF-1), a transcription factor critically involved in cellular responses to hypoxia and tumor progression, has provided evidence of a potential molecular target of intratumor hypoxia that could be exploited for the development of novel cancer therapeutics. A growing number of small molecule inhibitors of HIF-1, which act by distinct molecular mechanisms, have been described so far. However, HIF-1 expression in human cancers is focal and heterogeneous, consistent with the possibility that single agent HIF-1 inhibitors may have limited clinical activity. It is then plausible that combination strategies aimed at maximizing the clinical potential of HIF-1 inhibition may be more effective. We will discuss current approaches used for targeting HIF-1, emphasizing in particular opportunities for rationally designed combination strategies aimed at exploiting vulnerable features of the tumor microenvironment.
Introduction Whereas each tumor type reflects a heterogeneous collection of genetic and epigenetic alterations, hypoxia represents a unifying characteristic of human tumors, being a widely represented feature of the tumor microenvironment. Intratumor hypoxia not only affects cells that are located far from a functional blood vessel but also originates from an imbalance between increased oxygen consumption of rapidly G. Melillo (*) DTP-Tumor Hypoxia Laboratory, Bldg. 432, Room 218, SAIC – Frederick, Inc., NCI at Frederick, Frederick, MD 21702, USA e-mail:
[email protected] R.G. Bagley (ed.), The Tumor Microenvironment, Cancer Drug Discovery and Development, DOI 10.1007/978-1-4419-6615-5_1, © Springer Science+Business Media, LLC 2010
3
4
A. Rapisarda and G. Melillo
growing tumor cells and inadequate oxygen supply from a structurally and functionally abnormal tumor vasculature. The fluctuation of oxygen levels in the tumor microenvironment results in the induction of an array of responses in tumor cells, such as inactivation of apoptotic pathways and activation of pro-survival pathways, induction of a more invasive and metastatic phenotype, switch to a glycolytic metabolism and induction of angiogenesis, responses aimed at providing adaptation to, or escape from, the hypoxic microenvironment. Clinically, hypoxia is associated with resistance to standard treatment, including chemotherapy and radiation therapy, and is predictive of metastasis and poor outcome in a variety of tumor types (Hockel and Vaupel 2001; Brown and Giaccia 1998; Brizel et al. 1996; Semenza 2007). Hypoxia controls the expression of hundreds of genes, many of which are regulated by Hypoxia Inducible Factor-1 (HIF-1), a master regulator of the transcriptional response to oxygen deprivation (Semenza 2007; Manalo et al. 2005). HIF-1 is a heterodimeric protein comprised of a constitutively expressed HIF-1b (also known as aryl hydrocarbon receptor nuclear translocator, ARNT) subunit and a HIF-a subunit, which is regulated by oxygen concentrations (Wang et al. 1995; Wang and Semenza 1995). Under normoxic onditions, HIF-a is rapidly hydroxylated on two proline residues by oxygen-dependent prolyl hydroxylases (PHDs) and targeted for ubiquitylation and proteasomal degradation in a VHL-dependent fashion. In addition, HIF-1a can be hydroxylated on an asparagine residue (Asn803) by Factor Inhibiting HIF-1 (FIH), hence inhibiting the recruitment of the co-activator p300/CBP and transcriptional activity. In contrast, under hypoxic conditions the HIF-a subunit is stabilized and translocates to the nucleus where it dimerizes with HIF-1b and, by binding to hypoxia responsive elements (HREs), activates transcription of hundreds of target genes involved in key steps of tumorigenesis, including angiogenesis, metabolism, proliferation, metastasis, and differentiation (Semenza 2008) (Fig. 1.1). Overwhelming evidence indicates that HIF-a (HIF-1a and/or HIF2a) is indeed over-expressed in the majority of human cancers (Zhong et al. 1999; Talks et al. 2000; Bos et al. 2001), where it is associated with patient mortality and poor response to treatment (Table 1.1) (Aebersold et al. 2001; Birner et al. 2000, 2001b; Bos et al. 2003; Koukourakis et al. 2006). Notably, increased HIF-1a expression is associated with a variety of genetic alterations frequently detected in human cancers, including loss of function of tumor suppressor genes, such as VHL, PTEN, and CDKN2A (which encodes ARF) or oncogenic gain of function, such as RAS, SRC, and BCR-ABL (Semenza 2003). In addition, the involvement of receptor tyrosine kinase-dependent signaling pathways, including EGFR, HER2/Neu, and the PI3K/AKT/mTOR and MAPK pathways, in the induction of HIF-1a expression also suggests that many of these pathways converge on or implicate HIF-1 in mediating cell survival and growth (Pouyssegur et al. 2006; Majumder et al. 2004; Pore et al. 2006; Hudson et al. 2002). Therefore, HIF-1 has become an attractive target for the development of novel cancer therapeutics and despite the challenges associated with the discovery and development of small molecule inhibitors of transcription factors, many HIF-1 inhibitors which may potentially be useful for cancer therapy have been described so far (Onnis et al. 2009; Melillo 2007; Welsh et al. 2006; Melillo 2006).
1 Combination Strategies Targeting Hypoxia Inducible Factor 1
5
Angiogenic factors
(VEGF, FGF2, PDGF, PIGF, Tie2)
VHL binding Proteosomal degradation
Inhibition of transcriptional activity
P402 OH
Drug resistance
(Telomerase, Oct4)
(MDR1/ABCB-1, ABCG-2)
Glycolitic metabolism, pH regulation
HIF- α P564 OH HIF- α N803OH PHDs
RTKs/mTOR
(GLUT1, PDK1, PGK1, HK2, LDH-A, CA9, MCT4)
FIH
Survival, Proliferation
HIF- α
HIF-1 translation
mRNA transcription
O2 concentration
Immortalization and stem cells
β
α
Dimerization Cofactors recruitment DNA binding
(Cyclin D1, VEGF, IGF2, TGF-α)
Migration (CXCR4, SDF-1 α)
Invasion Metastasis (UPAR, Met, LOX)
Fig. 1.1 Regulation of Hypoxia Inducible factor-a (HIF-a) and HIF-1 dependent gene expression. Under normal oxygen conditions, HIF-a is continuously translated and rapidly degraded through the VHL-proteasome pathway following hydroxylation of proline residues by PHDs. Factor inhibiting HIF-1 mediates the hydroxylation of an asparagine residue, thus inhibiting the recruitment of the co-activator p300/CBP and HIF-1 transcriptional activity. All these processes are inhibited when oxygen concentration decreases, hence the HIF-a subunit is stabilized, translocates to the nucleus where it dimerizes with HIF-1b and induces the transcription of a large number of genes involved in crucial aspects of tumorigenesis. In addition, receptor tyrosine kinase-dependent signaling pathways can increase the rate of HIF-1a translation, at least in part, through the activation of mTOR
Small Molecule Inhibitors of HIF-1 The approach most widely used so far to identify HIF-1 inhibitors has been cell-based high throughput screens (HTS) using reporter gene assays (Rapisarda et al. 2002). The main advantage of cell-based HTS is the potential for the identification of unrecognized pathways associated with the activation of the target being investigated. However, determining the mechanism of action of active “hits” may be time consuming and chances to identify highly specific inhibitors is very low. Indeed, the majority of HIF-1 inhibitors described so far lack specificity, which complicates the pharmacological validation of HIF-1 inhibitors for cancer therapy, and either target signaling pathways that are involved in HIF-1 regulation or inhibit HIF-1a protein accumulation and/or transcriptional activity. Examples of agents that target signaling pathways implicated in the HIF-1a expression include
6
A. Rapisarda and G. Melillo
Table 1.1 Human cancers in which HIF-1a over-expression has been associated with patient mortality Cancer type
Reference
Astrocytoma (diffuse) Bladder (superficial urothelial)a Bladder (transitional cells) Breast Breast (c-Erb2 positive) Breast (positive linfonode) Breast (negative linfonode) Cervix (early stage) Cervix (radiation therapy) Cervix (grade IB-IIIB, radiation therapy) Endometrial Gastric Gastrointestinal stromal tumor (stomach) Lung (nonsmall cell lung carcinoma) Melanoma (malignant)b Oligodendrioglioma Oropharynx-squamous cell carcinoma Ovariana Pancreas
Korkolopoulou et al. (2004) Theodoropoulos et al. (2004) Theodoropoulos et al. (2005) Vleugel et al. (2005) and Dales et al. (2005) Giatromanolaki et al. (2007) Schindl et al. (2002) Bos et al. (2003) Birner et al. (2000) Burri et al. (2003) Bachtiary et al. (2003) Sivridis et al. (2002) Griffiths et al. (2007) Takahashi et al. (2003) Swinson et al. (2004) Giatromanolaki et al. (2003) Birner et al. (2001a) Aebersold et al. (2001) Birner et al. (2001b) Sun et al. (2007)
Combination of HIF-1a over-expression and mutant p53 HIF-2a over-expression
a
b
inhibitors of mTOR (Majumder et al. 2004; Hudson et al. 2002), AKT (Tan et al. 2005), Her2/Neu (Laughner et al. 2001), EGFR (Pore et al. 2006; Koukourakis et al. 2003; Zhong et al. 2000), and Bcr-Abl (Mayerhofer et al. 2002) (Fig. 1.2). Since HIF-1a accumulation is controlled primarily at the level of protein translation or protein degradation, many of the HIF-1 inhibitors identified thus far do indeed decrease HIF-1a protein levels by a number of distinct molecular mechanisms. HIF-1 inhibitors that affect protein translation, although by mechanisms not always clearly elucidated, include topoisomerase I (topotecan and EZN-2208, a pegylated form of SN38) (Rapisarda et al. 2004a, b; Sapra et al. 2008) and topoisomerase II inhibitors (NSC644221) (Creighton-Gutteridge et al. 2007), microtubule stabilizing (taxanes and epothilones) and destabilizing agents (Mabjeesh et al. 2003; Escuin et al. 2005), cardiac glycosides (Zhang et al. 2008), PX-478, which also increases HIF-1a degradation (Koh et al. 2008) and farnesyltransferase inhibitors (Han et al. 2005). Agents that appear to affect primarily HIF-1a degradation include inhibitors of the chaperon protein Hsp90 (17-AAG, 17-DMAG) (Isaacs et al. 2002; Mabjeesh et al. 2002), and HDAC inhibitors (vorinostat, LAQ824, FK228) (Ellis et al. 2009), which may also block HIF-1a transcriptional activity (Kong et al. 2006), and YC-1, which activates soluble guanylate cyclase (sGC) (Kim et al. 2006a). Another mechanism by which HIF-1 may be inhibited is at the level of transactivation. In addition to chetomin (Kung et al. 2004), which
1 Combination Strategies Targeting Hypoxia Inducible Factor 1
HIF-1 β
α
Co-factors Recruitment Transcriptional activity DNA binding
NSC50352
7 Chetomin Bortezomib Vorinostat Amphotericin
HIF-1-dependent gene expression
Echinomycin Polyamides Doxorubicin
Dimerization
HIF-1 β 17AAG,17DMAG YC-1, SCH66336 NS398, ibuprofen celecoxib
HIF-1 α
RTKs/mTOR
Translation Degradation
Temsirolimus Everolimus Gefitinib Erlotinib Cetuximab Herceptin
TPT,SN38 NSC644221, Digoxin Candidaspongiolide PX478, 2ME2
Proteasome HIF-1 α mRNA
HIF-1 α antisense RNA Aminoflavone
Fig. 1.2 Signaling pathways targeted by small molecule inhibitors of HIF-1
was originally identified as a small molecule that interferes with the interaction between HIF-1a C-TAD and p300/CBP, inhibition of the proteasome (bortezomib, Velcade®) has also been associated with blockade of HIF-1 transcriptional activity, despite the paradoxical increase of HIF-1a protein, although the exact mechanism of action remains to be fully elucidated (Shin et al. 2008; Kaluz et al. 2008). Finally, modulation of HIF-1a mRNA levels using antisense oligonucleotides (EZN-2968) (Greenberger et al. 2008) or the AhR ligand aminoflavone (Terzuoli et al. submitted) also leads to inhibition of HIF-1 expression. However, in order to identify HIF-1 small molecule inhibitors with a higher degree of selectivity, efforts are ongoing to target protein–protein interaction, a challenging yet potentially highly rewarding strategy, in an attempt to interfere with HIF-a/HIF-1b dimerization (Yang et al. 2005; Park et al. 2006; Scheuermann et al. 2009). In addition, examples of HIF-1 inhibitors that affect HIF-1 DNA binding to the HRE have been provided, including synthetic polyamides (Olenyuk et al. 2004), echinomycin (Kong et al. 2005), and anthracyclines (Lee et al. 2009), which represent a conceptually attractive strategy to inhibit HIF-1. Many of the HIF-1 inhibitors described above are either FDA approved or are in early clinical development (Table 1.2). Results of ongoing clinical trials of HIF-1 inhibitors in patients with cancer will provide information regarding both inhibition of HIF-1 and potential clinical activity of this emerging therapeutic approach.
8
A. Rapisarda and G. Melillo
Table 1.2 HIF-1 inhibitors FDA approved or in clinical development with potential mechanism of action Agent
Target
Mechanism
Reference
EZN-2968 Aminoflavone
HIF-1a mRNA AhR
Greenberger et al. (2008) Terzuoli, submitted
Topotecan EZN-2208 PX-478 Erlotinib, gefitinib, cetuximab Trastuzumab Temsirolimus, everolimus 17AAG, 17DMAG
Topoisomerase 1 Topoisomerase 1 unknown EGFR
Degradation HIF-1a mRNA processing Translation Translation Translation Signaling
Her2/Neu mTOR
Translation Translation
HSP90
Degradation
Doxorubicin Bortezomib
DNA Proteasome
Vorinostat, LAQ824, FK228
HDAC
DNA binding Transcriptional activity Degradation, transcriptional activity
Rapisarda et al. (2004b) Sapra et al. (2008) Welsh et al. (2004) Pore et al. (2006) and Luwor et al. (2005) Koukourakis et al. (2003) Del et al. (2006) and Wan et al. (2006) Isaacs et al. (2002) and Mabjeesh et al. (2002) Lee et al. (2009) Kaluz et al. (2006) Kong et al. (2006), Mie et al. (2003), and Qian et al. (2006)
Targeting HIF-1: Single Agent or Combination? The potential therapeutic benefit of HIF-1 inhibition has been extensively documented in preclinical models using both genetic and pharmacological tools, and consistent inhibition of tumor growth and angiogenesis has been demonstrated in different tumor types (Semenza 2003; Melillo 2006). However, the lack of selective HIF-1 inhibitors and reliable biomarkers associated with HIF-1 inhibition in tumor tissue, associated with the hardly predictive nature of results obtained in xenograft models, have significantly hampered the validation of HIF-1 as a target in human cancers. For instance, it is still largely unclear whether tumor regression should be an expected, although desirable, outcome of single agent HIF-1 inhibition. Evidence has been provided that HIF-1 inhibition might be most effective when used in early, rather than late, stages of tumor progression (Li et al. 2005), a situation rarely encountered in clinical oncology practice, where the majority of patients present with metastatic disease. In addition, even conceptually, inhibition of HIF-1 expressing cells, as a single agent strategy, may not be particularly effective for a number of reasons, including the focal and heterogeneous expression of HIF-1a in solid tumors, the reliance of cancer cells on HIF-1-independent pathways in oxygenated areas of the tumor, and the overall well-established redundancy of oncogenic signaling pathways that may be hardly affected by single agent strategies. In addition, the broad involvement of HIF-1 in a number of biological pathways that are
1 Combination Strategies Targeting Hypoxia Inducible Factor 1
9
relevant for tumorigenesis provides unique opportunities for combination therapies that may take advantage of the different approaches available in the current therapeutic armamentarium. A better understanding of the role that HIF-1 plays in the biology of human cancers and in the context of available therapeutic strategies will provide valuable information for the design of rational combinations that may target vulnerable aspects of the tumor microenvironment.
Molecularly Targeted Agents and HIF-1 Inhibition Combination strategies aimed at targeting multiple and redundant signaling pathways that contribute to oncogenesis are a mainstay of current therapeutic efforts in oncology for the potential to both prevent the emergence of resistant clones and translate in a better therapeutic outcome. Indeed, combinations of molecularly targeted agents, with or without chemotherapy, are currently being tested in virtually any tumor type with the goal of assessing safety of administration and potential therapeutic efficacy. As mentioned above, several novel targeted agents currently in clinical development or FDA approved also inhibit HIF-1, raising the possibility that combination strategies incorporating these agents may already provide examples in which inhibition of HIF-1 may potentially contribute to the therapeutic efficacy. Experimental evidence in support of this conclusion has been provided by combination of the mTOR inhibitor rapamycin with the HDAC inhibitor LBH589, which showed increased antitumor activity in prostate and renal cell cancer xenografts models (Verheul et al. 2008). Interestingly, the concomitant inhibition of HDACs and mTOR resulted in a greater inhibition of HIF-1a protein levels relative to what was achieved by each agent alone, possibly due to the activity of these inhibitors at different levels of HIF-1a regulation including translation, protein stability, and transcriptional activity. In addition, experiments conducted in colon cancer xenograft models using low doses of rapamycin in combination with the camptothecin analog irinotecan (a topoisomerase I inhibitor) showed a marked increase in antitumor activity associated with a profound inhibition of HIF-1a protein accumulation that was not observed with either agent alone (Pencreach et al. 2009). Interestingly, previous studies in a human glioma xenograft model had suggested that daily, but not intermittent, administration of single agent topotecan, a topoisomerase I HIF-1 inhibitor, downregulated HIF-1a expression in tumor tissue and caused inhibition of tumor growth and angiogenesis (Rapisarda et al. 2004c). These examples emphasize how HIF-1 inhibition may be an underappreciated therapeutic consequence of molecularly targeted agents currently in clinical development. A better understanding of the potential contribution of HIF-1 inhibition to therapeutic activity of these combinations may help in selecting patients more likely to respond and in designing optimal schedules of administration to maximize inhibition of HIF-1-dependent responses.
10
A. Rapisarda and G. Melillo
Hypoxic Cells Are More Resistant to Chemotherapy and Radiation Therapy It has long been recognized that hypoxic cells are more resistant to conventional therapeutic approaches, including chemotherapy and radiation therapy. Likewise, it is well appreciated that resistant hypoxic cells may contribute to treatment failure and poor prognosis of patients whose cancers are more hypoxic. Resistance to radiotherapy and chemotherapy in hypoxic tumors has been attributed to a multitude of mechanisms, including direct effects (decreased generation of oxygendependent radical formation or decreased drug accessibility to the more distant hypoxic cells) and indirect effects (clonal selection of cells adapted to hypoxia) (Brown and Giaccia 1998; Vaupel et al. 2001). Hypoxia exerts selective pressure on cells for loss of p53, regulates the transcription of several genes pivotal for the selection of a resistant phenotype, such as multidrug resistance gene 1 (MDR-1) and ABCG-2 and ABCB-1 (ABC transporters), induces expression of VEGF and other pro-angiogenic factors (important for the survival of endothelial cells following radiation), downregulates genes involved in DNA mismatch repair (MSH2, MSH6, NSB1, and BRCA1) leading to increased genomic instability (Huang 2008), and finally induces genes important for survival of cancer cells (Bertout et al. 2008; Huang 2008). Many of the effects described above are mediated by HIF-1; therefore, it is conceivable that inhibition of HIF-1 may contribute in a number of ways to combination therapies by counteracting mechanisms that are activated in the tumor microenvironment to generate resistance and by sensitizing cancer cells to available therapeutic strategies.
Combination of HIF-1 Inhibitors with Chemotherapy The potential contribution of HIF-1a to cellular resistance to chemotherapy has been suggested by evidence in both experimental models and the clinical setting. Initial clinical observations indicated that high levels of HIF-1a expression were associated with incomplete responses to radiation and chemotherapy in patients with head and neck squamous cancers (Aebersold et al. 2001; Koukourakis et al. 2003). Formal evidence that HIF-1a may be implicated in mediating resistance to conventional chemotherapeutic agents was provided by studies showing that MDR-1, one of the most widely expressed efflux pumps that mediate resistance to chemotherapy, is a direct HIF-1 target gene (Comerford et al. 2002). In addition, it was shown that HIF-1a deficient mouse embryonic fibroblasts were more sensitive to carboplatin, etoposide (a topoisomerase II inhibitor), and irradiation (agents that cause double-strand DNA breaks) but not to the topoisomerase 1 inhibitor SN38 (that generates single-strand DNA breaks) (Unruh et al. 2003), suggesting that HIF-1-mediated resistance to chemotherapy cannot simply be explained by upregulation of MDR-1. Resistance to etoposide, a
1 Combination Strategies Targeting Hypoxia Inducible Factor 1
11
topoisomerase II inhibitor, also appears to correlate with HIF-1-dependent induction of anti-apoptotic genes and downregulation of topoisomerase IIa (Sermeus et al. 2008; Sullivan and Graham 2009). The potential synergistic activity of HIF-1 inhibition in combination with chemotherapy has been formally tested in a glioma xenograft model in which HIF-1a expression was downregulated by an inducible shRNA system (Li et al. 2006). Earlier evidence had indicated that HIF-1a downregulation by shRNA effectively inhibited tumor growth, although the effect was more pronounced in early rather than late stages of tumor progression (Li et al. 2005). The combination of the cytotoxic drug temozolomide with HIF-1a knockdown exhibited a super-additive therapeutic effect compared with either approach alone, demonstrating that HIF-1 inhibition impacted on sensitivity to chemotherapy (Li et al. 2006). However, the same authors showed no benefit of a combination between HIF-1 inhibition and the angiogenesis inhibitor ABT-869 (a multitargeted receptor tyrosine kinase inhibitor). It is interesting to note that following treatment with ABT-869, large tumors that are less likely to be responsive to HIF-1a inhibition became sensitive to HIF-1a knockdown, suggesting that anti-angiogenic treatment might partially alleviate the “resistance” of large tumors to HIF-1a knockdown and sensitize tumors to HIF-1 inhibition. Further studies in preclinical models, ultimately with validation in clinical trials, are required to fully explore the potential of HIF-1 inhibition to modulate cellular sensitivity to chemotherapeutic agents and to block stress pathways induced by chemotherapy in the tumor microenvironment. Combination of HIF-1 Inhibitors with Radiation Therapy Hypoxia is an important factor contributing to tumor radioresistance, a phenomenon initially explained by the reduced generation of oxygen radicals in hypoxic tissues and consequent decrease in radiation-induced DNA damage (Moeller et al. 2007). In reality, more complex biological pathways are implicated in the effects of radiation therapy on hypoxic tumors. Clinical studies have suggested that high levels of HIF-1a expression correlate with poor local control in patients with oropharyngeal cancers (Aebersold et al. 2001) and evidence from preclinical studies has indicated that HIF-1 deficient tumors are more radiosensitive than their wild-type counterpart (Zhang et al. 2004; Moeller et al. 2005; Williams et al. 2005). Moreover, it has been shown that radiation increases HIF-1a levels and induces the expression of HIF-1-dependent genes in tumors (Moeller et al. 2004), consistent with the possibility that HIF-1 activation may be part of compensatory pathways that might mediate resistance to radiation therapy. However, further studies have shown that HIF-1 may have divergent effects on radiosensitivity. On the one hand, HIF-1 might be involved in the induction of apoptosis by increasing p53 phosphorylation following radiation treatment, thus sensitizing cancer cells to radiation (Moeller et al. 2005). On the other side, it is well appreciated that the tumor vasculature is an important target of radiation therapy and a major determinant of response
12
A. Rapisarda and G. Melillo
(Garcia-Barros et al. 2003), thus the induction of angiogenic factors, including VEGF, by HIF-1 may actually protect endothelial cells from radiation-induced apoptosis (Gupta et al. 2002). Indeed, combination of the HIF-1 inhibitor YC-1 with radiation blocked radiation induced HIF-1 upregulation and resulted in significant vascular destruction, suggesting that combining HIF-1 blockade with radiation may increase antitumor efficacy (Moeller et al. 2004). In addition, the HIF-1 inhibitor PX-478 increased therapeutic efficacy of radiation by blocking HIF-1-dependent effects on the tumor microenvironment in addition to a direct effect on tumor cell survival (Schwartz et al. 2009). Finally, recent evidence also suggests that HIF-2a inhibition sensitizes renal cancer cells to radiation therapy by increasing p53 activity and inducing apoptosis (Bertout et al. 2009). Given the complexity of the role that HIF signaling may play in the response of tumor tissue to radiation therapy, careful consideration should be given to the identification of tumor types and features of the tumor microenvironment that may predict for or be associated with a positive interaction between radiation therapy and HIF-1 inhibition.
Intratumor Hypoxia as a Potential Mechanism of Resistance to Anti-angiogenic Therapies The excitement associated with the introduction of anti-angiogenic agents for cancer therapy has been partially blunted by the limited single agent activity of this therapeutic strategy and by the development of resistance, a phenomenon originally unanticipated for an approach targeted to “normal,” genetically stable endothelial cells. While anti-angiogenic therapies have shown clinical benefit in combination with chemotherapy in metastatic colorectal cancer, advanced nonsmall cell lung cancer, and metastatic breast cancer (Ferrara 2005; Shojaei and Ferrara 2007; Ellis and Hicklin 2008), the single agent activity has been well below expectations and has been demonstrated only in few tumor types, including in renal cell carcinoma and more recently gliomas. More importantly, clinical benefit has only been transient and most tumors eventually become resistant and relapse. In addition to “intrinsic” resistance in patients who do not respond to anti-angiogenic agents, several mechanisms of “acquired” resistance have been proposed, including upregulation of alternative pro-angiogenic signals, production of pro-angiogenic factors by stromal cells, recruitment of bone marrow derived pro-angiogenic cells, increased pericyte coverage of the vasculature, and activation of invasive phenotypes (Rapisarda and Mellilo 2009). Interestingly, many of the responses implicated in resistance to anti-angiogenic therapy may be mediated by the products of genes induced by HIF-1. The consequences of effective anti-angiogenic therapy on the tumor microenvironment are still poorly understood and partly controversial, which limits our ability to develop rational combination therapies. On the one hand, “normalization” of tumor vasculature has been proposed, with consequent decrease in interstitial pressure and
1 Combination Strategies Targeting Hypoxia Inducible Factor 1
13
better delivery of chemotherapy (Jain 2005); on the other hand, vascular “regression” has been demonstrated in several experimental models and appears to be a logical consequence of effective inhibition of tumor vasculature (Kerbel and Folkman 2002). The latter scenario is associated with an increase in intratumor hypoxia, which not only might be mechanistically involved in mediating resistance to anti-angiogenic therapies but also might provide unique opportunities for combination strategies (Paez-Ribes et al. 2009; Loges et al. 2009). Indeed, while expression of HIF-1a in solid tumors is focal and heterogeneous, detected predominantly in perinecrotic areas, “therapy-induced” hypoxia, which may be associated with the administration of antiangiogenic therapies, will lead to a more persistent and protracted expression of HIF-1a. Higher levels of HIF-1 in the tumor microenvironment may not only contribute to drug resistance in general, but also provide a mechanism of “escape” for tumor cells overcoming the potential therapeutic effects of anti-angiogenic agents. Thus, it is conceivable that combination of anti-angiogenic therapy with HIF-1 inhibition may have synergistic therapeutic activity by targeting HIF-1 in the context of a “hypoxic stressed” tumor microenvironment. Combination of Anti-angiogenic Therapies and HIF-1 Inhibitors To test the hypothesis that anti-angiogenic therapies may be more efficacious in combination with HIF-1 inhibition, we combined topotecan, a topoisomerase I inhibitor that downregulates HIF-1a protein in vitro and in vivo (Rapisarda et al. 2004b, c), with the anti-VEGF antibody bevacizumab in a glioma xenograft model. Indeed, we found that inhibition of HIF-1a by topotecan in a hypoxic stressed tumor microenvironment resulted in a more pronounced antitumor effect, relative to either agent alone. The effects on tumor growth were associated with significantly decreased HIF-1 transcriptional activity and reduced tumor cell proliferation (Rapisarda et al. 2009), consistent with the hypothesis that targeting HIF-1a activity may abrogate compensatory pathways required for cancer cell survival. Moreover, recent studies showed that genetic disruption of both HIF-1a and HIF-2a expression in colon cancer xenografts improves tumor response to sunitinib (a multitargeted receptor tyrosine kinase inhibitor) (Burkitt et al. 2009). This effect was mediated by a marked decrease in tumor angiogenesis and perfusion, through inhibition of multiple pro-angiogenic factors, as well as a marked decrease in tumor cells proliferation. To further support the role that HIF-1 inhibition might play in combination with anti-angiogenic therapies, it is interesting to point out that the combination of bevacizumab and irinotecan (another topoisomerase I inhibitor that also inhibits HIF-1) has shown clinical benefit in glioblastoma patients with a six-month overall survival of 62–77% (Vredenburgh et al. 2007; Chen et al. 2007). Further studies are required to better define the patient population that may benefit from these combination approaches, in particular by better understanding when and to what extent anti-angiogenic therapy is indeed associated with increased intratumor hypoxia and HIF-1a expression.
14
A. Rapisarda and G. Melillo
Cancer Cell Metabolism and the Hypoxic Tumor Microenvironment More than 80 years ago, Otto Warburg observed that cancer cells avidly take up glucose and produce lactic acid under aerobic conditions, a process subsequently referred to as the Warburg effect or aerobic glycolysis. The exact molecular mechanism(s) regulating cancer cells dependence on glycolysis remain unclear, but it is likely that a combination of effects due to oncogenic alterations and the hypoxic tumor microenvironment play a role. Many genetic alterations associated with the cancer phenotype promote glycolysis and, at the same time, suppress oxidative phosphorylation. For instance, p53 plays an important role in regulating both “aerobic” and “anaerobic” respiration, while c-Myc expression activates the transcription of several glycolytic enzymes (Kroemer and Pouyssegur 2008). The largest functional group of genes consistently upregulated by HIF-1 in a number of cell types is associated with glucose metabolism. HIF-1 increases the expression of the transporters necessary for the entry of glucose into the cell, the genes involved in the enzymatic breakdown of glucose to pyruvate and the enzymes involved in the metabolism of pyruvate. In hypoxic cells, pyruvate is converted by lactate dehydrogenase (LDH) to lactate, which is then released into the extracellular space. HIF-1 also controls cellular oxygen consumption by (a) inducing the expression of PDH kinase 1 (PDK1), which inhibits pyruvate dehydrogenase (PDH) and the conversion of pyruvate to acetyl-CoA, ultimately decreasing mitochondrial respiration (Papandreou et al. 2006; Kim et al. 2006b) and (b) reducing mitochondrial mass, by counteracting the stimulatory action of c-Myc on mitochondrial biogenesis (Zhang et al. 2007). It is conceivable then that these metabolic changes utilized by cancer cells to survive in a hypoxic, nutrient deprived tumor microenvironment might also offer therapeutic opportunities to selectively target hypoxic cells and spare normal tissues.
HIF-1 Inhibitors in Combination Strategies Targeting Tumor Metabolism Cancer cells, but not normal cells, are thought to be “addicted” to glycolysis and attempts are being pursued to explore the possibility to target glycolysis for cancer therapy. However, the activity of 2-deoxyglucose (2-DG, a competitive inhibitor of glucose), as single agent, has been limited by evidence of toxicities in clinical trials (Denko 2008). Interestingly, genetic knockdown of HIF-1a, as well as treatment with CCI-779 (an inhibitor of mTOR that decreases HIF-1 activity), sensitizes cancer cells in vitro to 2-DG (Maher et al. 2007; Wangpaichitr et al. 2008), suggesting that HIF-1 inhibitors might be used to increase the therapeutic efficacy of 2-DG. An original approach has been proposed to increase oxygen consumption in cancer cells by reversing the inhibition of mitochondrial function using either the HIF-1 inhibitor echinomycin or the PDK-1 inhibitor dichloroacetate (DCA) (Cairns et al. 2007). The pharmacological induced increase in oxygen consumption, associated
1 Combination Strategies Targeting Hypoxia Inducible Factor 1
15
with the limited oxygen supply due to the dysfunctional tumor vasculature, made the tumors more hypoxic and sensitized cancer cells to the hypoxic cytotoxin tirapazamine. These data suggest that HIF-1 inhibitors might have a potential role in combination strategies aimed at targeting tumor metabolism or oxygen consumption.
Conclusion In the complex biology of human cancers, HIF-1 is yet another attractive target for the development of cancer therapeutics. The role of HIF-1 in human cancers has been extensively investigated and accumulating evidence implicates HIF-1 in a number of biological processes associated with resistance to therapy and tumor progression. Hence, HIF-1 inhibition appears as a logical therapeutic strategy and many small molecule inhibitors of HIF-1 have been described, several of which are validated in preclinical models. However, we have still limited understanding of when and to what extent inhibition of HIF-1 in cancer patients may be effective. Single agent studies are required to have a better appreciation of the biological consequence associated with HIF-1 inhibition in human cancers, yet the lack of selective pharmacological inhibitors of HIF-1 significantly hinders this task. On the other hand, we have learned over the last few years that targeting multiple signaling pathways deregulated in cancer cells may be a more effective therapeutic strategy. The broad involvement of HIF-1 in many biological processes associated with and required for tumor progression provides unique opportunities for the development of combination therapies. A better understanding of the role played by HIF-1 in pathways associated with the administration of chemotherapy, radiation and anti-angiogenic therapies may unveil vulnerable aspects of the tumor microenvironment that could be exploited for the rational design of combination strategies. Acknowledgments The authors would like to thank members of the Tumor Hypoxia Laboratory and Dr. R. H. Shoemaker for helpful discussion. This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. N01-CO-12400. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government. This research was supported in part by the Developmental Therapeutics Program, DCTD, of the National Cancer Institute, NIH.
References Aebersold DM, Burri P, Beer KT et al (2001) Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61:2911–2916.
16
A. Rapisarda and G. Melillo
Bachtiary B, Schindl M, Potter R et al (2003) Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 9:2234–2240. Bertout JA, Patel SA, Simon MC (2008) The impact of O2 availability on human cancer. Nat Rev Cancer 8:967–975. Bertout JA, Majmundar AJ, Gordan JD et al (2009) HIF2{alpha} inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci USA 106:14391–14396. Birner P, Schindl M, Obermair A et al (2000) Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60:4693–4696. Birner P, Gatterbauer B, Oberhuber G et al (2001a) Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 92:165–171. Birner P, Schindl M, Obermair A et al (2001b) Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7:1661–1668. Bos R, Zhong H, Hanrahan CF et al (2001) Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93:309–314. Bos R, van der GP, Greijer AE et al (2003) Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97:1573–1581. Brizel DM, Scully SP, Harrelson JM et al (1996) Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56:941–943. Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58:1408–1416. Burkitt K, Chun SY, Dang DT et al (2009) Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment. Mol Cancer Ther 8(5):1148–1156. Burri P, Djonov V, Aebersold DM et al (2003) Significant correlation of hypoxia-inducible factor1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 56:494–501. Cairns RA, Papandreou I, Sutphin PD et al (2007) Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci USA 104:9445–9450. Chen W, Delaloye S, Silverman DH et al (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25:4714–4721. Comerford KM, Wallace TJ, Karhausen J et al (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62:3387–3394. Creighton-Gutteridge M, Cardellina JH, Stephen AG et al (2007) Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clin Cancer Res 13:1010–1018. Dales JP, Garcia S, Meunier-Carpentier S et al (2005) Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 116:734–739. Del BD, Ciuffreda L, Trisciuoglio D et al (2006) Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66:5549–5554. Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8:705–713. Ellis LM, Hicklin DJ (2008) Pathways mediating resistance to vascular endothelial growth factortargeted therapy. Clin Cancer Res 14:6371–6375. Ellis L, Hammers H, Pili R (2009) Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 280(2):145–153. Escuin D, Kline ER, Giannakakou P (2005) Both microtubule-stabilizing and microtubuledestabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 65:9021–9028.
1 Combination Strategies Targeting Hypoxia Inducible Factor 1
17
Ferrara N (2005) VEGF as a therapeutic target in cancer. Oncology 69(Suppl 3):11–16. Garcia-Barros M, Paris F, Cordon-Cardo C et al (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300:1155–1159. Giatromanolaki A, Sivridis E, Kouskoukis C et al (2003) Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 13:493–501. Giatromanolaki A, Koukourakis MI, Simopoulos C et al (2007) Metastatic cancer cells from c-erbB-2 negative primary breast cancer maintain the original c-erbB-2/HIF1alpha phenotype. Cancer Biol Ther 6:153–155. Greenberger LM, Horak ID, Filpula D et al (2008) A RNA antagonist of hypoxia-inducible factor1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 7:3598–3608. Griffiths EA, Pritchard SA, Valentine HR et al (2007) Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer 96:95–103. Gupta VK, Jaskowiak NT, Beckett MA et al (2002) Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 8:47–54. Han JY, Oh SH, Morgillo F et al (2005) Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 97:1272–1286. Hockel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266–276. Huang LE (2008) Carrot and stick: HIF-alpha engages c-Myc in hypoxic adaptation. Cell Death Differ 15:672–677. Hudson CC, Liu M, Chiang GG et al (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004–7014. Isaacs JS, Jung YJ, Mimnaugh EG et al (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277:29936–29944. Jain RK (2005) Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19:7–16. Kaluz S, Kaluzova M, Stanbridge EJ (2006) Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain. Mol Cell Biol 26:5895–5907. Kaluz S, Kaluzova M, Stanbridge EJ (2008) Comment on the role of FIH in the inhibitory effect of bortezomib on hypoxia-inducible factor-1. Blood 111:5258–5259. Kerbel R and Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727–739. Kim HL, Yeo EJ, Chun YS et al (2006a) A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent. Int J Oncol 29:255–260. Kim JW, Tchernyshyov I, Semenza GL et al (2006b) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3:177–185. Koh MY, Spivak-Kroizman T, Venturini S et al (2008) Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther 7:90–100. Kong D, Park EJ, Stephen AG et al (2005) Echinomycin, a small-molecule inhibitor of hypoxiainducible factor-1 DNA-binding activity. Cancer Res 65:9047–9055. Kong X, Lin Z, Liang D et al (2006) Histone deacetylase inhibitors induce VHL and ubiquitinindependent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 26:2019–2028. Koukourakis MI, Simopoulos C, Polychronidis A et al (2003) The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/ VEGF pre-treatment status? Anticancer Res 23:1673–1680.
18
A. Rapisarda and G. Melillo
Korkolopoulou P, Patsouris E, Konstantinidou AE et al (2004) Hypoxia-inducible factor 1alpha/ vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol 30:267–278. Koukourakis MI, Bentzen SM, Giatromanolaki A et al (2006) Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24:727–735. Kroemer G and Pouyssegur J (2008) Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 13:472–482. Kung AL, Zabludoff SD, France DS et al (2004) Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6:33–43. Laughner E, Taghavi P, Chiles K et al (2001) HER2 (neu) signaling increases the rate of hypoxiainducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995–4004. Lee K, Qian DZ, Rey S et al (2009) Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA 106:2353–2358. Li L, Lin X, Staver M et al (2005) Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 65:7249–7258. Li L, Lin X, Shoemaker AR et al (2006) Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. Clin Cancer Res 12:4747–4754. Loges S, Mazzone M, Hohensinner P et al (2009) Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15:167–170. Luwor RB, Lu Y, Li X et al (2005) The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24:4433–4441. Mabjeesh NJ, Post DE, Willard MT et al (2002) Geldanamycin induces degradation of hypoxiainducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62:2478–2482. Mabjeesh NJ, Escuin D, LaVallee TM et al (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3:363–375. Maher JC, Wangpaichitr M, Savaraj N et al (2007) Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Mol Cancer Ther 6:732–741. Majumder PK, Febbo PG, Bikoff R et al (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10:594–601. Manalo DJ, Rowan A, Lavoie T et al (2005) Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105:659–669. Mayerhofer M, Valent P, Sperr WR et al (2002) BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100:3767–3775. Melillo G (2006) Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 4:601–605. Melillo G (2007) Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 26:341–352. Mie LY, Kim SH, Kim HS et al (2003) Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun 300:241–246. Moeller BJ, Cao Y, Li CY et al (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5:429–441. Moeller BJ, Dreher MR, Rabbani ZN et al (2005) Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8:99–110.
1 Combination Strategies Targeting Hypoxia Inducible Factor 1
19
Moeller BJ, Richardson RA, Dewhirst MW (2007) Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev 26:241–248. Olenyuk BZ, Zhang GJ, Klco JM et al (2004) Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci USA 101: 16768–16773. Onnis B, Rapisarda A, Melillo G (2009) Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med in press.. Paez-Ribes M, Allen E, Hudock J et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220–231. Papandreou I, Cairns RA, Fontana L et al (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3:187–197. Park EJ, Kong D, Fisher R et al (2006) Targeting the PAS-A domain of HIF-1alpha for development of small molecule inhibitors of HIF-1. Cell Cycle 5:1847–1853. Pencreach E, Guerin E, Nicolet C et al (2009) Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clin Cancer Res 15:1297–1307. Pore N, Jiang Z, Gupta A et al (2006) EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 66:3197–3204. Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441:437–443. Qian DZ, Kachhap SK, Collis SJ et al (2006) Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 66:8814–8821. Rapisarda A, Melillo G (2009) Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat 12:74–80. Rapisarda A, Uranchimeg B, Scudiero DA et al (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62:4316–4324. Rapisarda A, Shoemaker RH, Melillo G (2004a) Targeting topoisomerase I to inhibit hypoxia inducible factor 1. Cell Cycle 3:172–175. Rapisarda A, Uranchimeg B, Sordet O et al (2004b) Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 64:1475–1482. Rapisarda A, Zalek J, Hollingshead M et al (2004c) Schedule-dependent inhibition of hypoxiainducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64:6845–6848. Rapisarda A, Hollingshead M, Uranchimeg B et al (2009) Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 8:1867–1877. Sapra P, Zhao H, Mehlig M et al (2008) Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res 14:1888–1896. Scheuermann TH, Tomchick DR, Machius M et al (2009) Artificial ligand binding within the HIF2alpha PAS-B domain of the HIF2 transcription factor. Proc Natl Acad Sci USA 106:450–455. Schindl M, Schoppmann SF, Samonigg H et al (2002) Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8:1831–1837. Schwartz DL, Powis G, Thitai-Kumar A et al (2009) The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther 8:947–958. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732. Semenza GL (2007) Hypoxia and cancer. Cancer Metastasis Rev 26:223–224. Semenza GL (2008) Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 60:591–597.
20
A. Rapisarda and G. Melillo
Sermeus A, Cosse JP, Crespin M et al (2008) Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity. Mol Cancer 7:27. Shin DH, Chun YS, Lee DS et al (2008) Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 111:3131–3136. Shojaei F, Ferrara N (2007) Antiangiogenic therapy for cancer: an update. Cancer J 13:345–348. Sivridis E, Giatromanolaki A, Gatter KC et al (2002) Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95:1055–1063. Sullivan R, Graham CH (2009) Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1. Mol Cancer Ther 8:1702–1713. Sun HC, Qiu ZJ, Liu J et al (2007) Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol 30: 1359–1367. Swinson DE, Jones JL, Cox G et al (2004) Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer 111:43–50. Takahashi R, Tanaka S, Hiyama T et al (2003) Hypoxia-inducible factor-1alpha expression and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncol Rep 10:797–802. Talks KL, Turley H, Gatter KC et al (2000) The expression and distribution of the hypoxiainducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumorassociated macrophages. Am J Pathol 157:411–421. Tan C, de Noronha RG, Roecker AJ et al (2005) Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 65:605–612. Theodoropoulos VE, Lazaris AC, Sofras F et al (2004) Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 46:200–208. Theodoropoulos VE, Lazaris AC, Kastriotis I et al (2005) Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int 95:425–431. Unruh A, Ressel A, Mohamed HG et al (2003) The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22:3213–3220. Vaupel P, Kelleher DK, Hockel M (2001) Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28:29–35. Verheul HM, Salumbides B, van EK et al (2008) Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 14:3589–3597. Vleugel MM, Greijer AE, Shvarts A et al (2005) Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol 58:172–177. Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729. Wan X, Shen N, Mendoza A et al (2006) CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 8:394–401. Wang GL and Semenza GL (1995) Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270:1230–1237. Wang GL, Jiang BH, Rue EA et al (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helixPAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92:5510–5514. Wangpaichitr M, Savaraj N, Maher J et al (2008) Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines. Mol Cancer Ther 7:1506–1513. Welsh S, Williams R, Kirkpatrick L et al (2004) Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 3:233–244.
1 Combination Strategies Targeting Hypoxia Inducible Factor 1
21
Welsh SJ, Koh MY, Powis G (2006) The hypoxic inducible stress response as a target for cancer drug discovery. Semin Oncol 33:486–497. Williams KJ, Telfer BA, Xenaki D et al (2005) Enhanced response to radiotherapy in tumors deficient in the function of hypoxia-inducible factor-1. Radiother Oncol 75:89–98. Yang J, Zhang L, Erbel PJ et al (2005) Functions of the Per/ARNT/Sim domains of the hypoxiainducible factor. J Biol Chem 280:36047–36054. Zhang X, Kon T, Wang H et al (2004) Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res 64:8139–8142. Zhang H, Gao P, Fukuda R et al (2007) HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11:407–420. Zhang H, Qian DZ, Tan YS et al (2008) Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA 105:19579–19586. Zhong H, De Marzo AM, Laughner E et al (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830–5835. Zhong H, Chiles K, Feldser D et al (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541–1545.
Chapter 2
The Tumor Microenvironment: New Insights into Regulation of Tumor pH by Carbonic Anhydrases Pawel Swietach, Adrian L. Harris, and Richard D. Vaughan-Jones
Abstract Intracellular pH (pHi) is a powerful modulator of cell function. There is a narrow range of pHi, usually between 7.0 and 7.5, over which cell growth and development is optimal. Metabolism, particularly cellular respiration, tends to disturb this favorable steady state. The survival of cells undergoing such an acid challenge relies on efficient mechanisms for regulating pHi. In solid tumors, pHi regulation is challenged by their heavy demand for energy and poor blood supply. Inadequately perfused cancer cells deprive the milieu of oxygen, forcing a switchover to the less energy efficient, anaerobic mode of respiration. To meet energy demands, cells upregulate respiration and excrete more acid which lowers extracellular pH (pHe). The tumor extracellular milieu is believed to exert Darwinian selection in favor of cancer cells and against normal cells, based on the cell’s capacity to protect pHi under hypoxia and low pHe. In this chapter, we describe the pathways operating in tumors for removing acid and regulating pHi, with particular emphasis on membrane transporters and carbonic anhydrase (CA) enzymes. We discuss these pathways in terms of survival adaptations and possible targets for anticancer therapy.
Biological Importance of pH The hydrogen atom is very common in the human body, and despite being the lightest of elements, it comprises about a tenth of total body mass. Virtually all hydrogen atoms are bonded by means of electron transfer or sharing with other elements. In many such compounds, the hydrogen nucleus can dissociate reversibly from the remainder of the molecule. In the case of the most common isotope 1 H, the hydrogen nucleus is solely a proton, and therefore the H+ dissociation and
A.L. Harris (*) Weatherall Institute of Molecular Medicine, Oxford University, Oxford OX3 9DS, UK e-mail:
[email protected] R.G. Bagley (ed.), The Tumor Microenvironment, Cancer Drug Discovery and Development, DOI 10.1007/978-1-4419-6615-5_2, © Springer Science+Business Media, LLC 2010
23
24
P. Swietach et al.
association reactions are dubbed deprotonation and protonation, respectively. Water, the biological solvent that contributes towards 60% of the body’s mass, also undergoes reversible deprotonation, and in pure form equilibrates at a “neutral” H+ ion concentration ([H+]) of 1027 M. Acids and bases are defined as molecules that increase and decrease [H+], respectively. To avoid the use of exponential notation, the acidity/basicity of a solution is commonly expressed as the negative logarithm of molar [H+], and given the symbol pH (Boron 2004). Many biologically relevant molecules are weak acids and weak bases. Proteins, for instance, are chains of weak acids/bases. Weak acids/bases exist in dynamic equilibrium between their protonated and unprotonated forms, the concentration ratio of which is very sensitive to pH. Since the H+ ion has very high charge density, pH will have a major impact on the physico-chemical properties of weak acids/ bases. This is particularly relevant to proteins, where charge distribution is linked to structure and function (Boron 2004; Swietach et al. 2007). Indeed, intracellular pH (pHi) is a potent and universal regulator of cellular physiology (Boron 2004; Swietach et al. 2007; Roos and Boron 1981; Vaughan-Jones et al. 2008; Isfort et al. 1993; McConkey and Orrenius 1996). Displacements of pHi by only a fraction of a unit can lead to patho-physiological responses and apoptotic death (Park et al. 1999). Cells must defend their optimal pHi by corrective (homeostatic) mechanisms. A major challenge to these housekeeping mechanisms is metabolic acid production, a process that takes place in all respiring cells throughout their life. To counteract metabolic acid loading, excess intracellular H+ ions must be removed across the cell membrane into the extracellular space and out of the body at the lungs and kidneys. Despite its tiny radius, the highly-polarizing H+ ion is poorly permeant across the lipid bilayer of cell membranes. To allow transmembrane H+ - traffic, cells have evolved transport proteins for H+ ions (e.g. Na+/H+ exchange), or other means of facilitated H+ ion diffusion (e.g. its reaction with HCO3– to form membrane-permeant CO2). The performance of these mechanisms can be compromised by the accumulation of extracellular acid, either as a result of allosteric H+ - inhibition of transport proteins (Vaughan-Jones and Wu 1990; Aronson 1985) or by the collapse diffusion gradients that drive acid-efflux (Swietach et al. 2008, 2009). Through these mechanisms, extracellular pH (pHe) can feedback onto pHi homeostasis. In turn, pHe depends on the diffusive coupling across the extracellular space and with blood. Efficient pHi regulation is central to the survival of metabolically-active tissues, particularly those with relatively poor blood perfusion. Solid tumors are characterized by a high acid production rate (Gatenby and Gillies 2004; Gillies et al. 2008) and inadequate blood supply (Swietach et al. 2007; Vaupel et al. 1989; Kallinowski et al. 1989; Stubbs et al. 2000). Although cancer cells, by definition, harbor a number of mutated gene products, the bulk of cellular protein is no different from normal cells and bears a similar pHi sensitivity, carving a narrow pHi range for survival. The growth of tumors may depend critically on the ability of cancer cells to remove intracellular acid more efficiently than normal cells. The conditions that are characteristic of tumors, notably hypoxia and low pHe (Griffiths et al. 2001; Gatenby et al. 2006), may be tolerated by cancer cells, but not by normal cells, thereby selecting against the latter (Fang et al. 2008). In this chapter, we describe
2 The Tumor Microenvironment
25
the mechanisms for controlling pHi in solid tumors, with particular emphasis on the role of CO2/HCO3– buffer and its enzyme catalyst, carbonic anhydrase (CA).
Sources of Cellular Acid Cellular Respiration A large number of biochemical reactions produce or consume H+ ions, but production of lactic acid by anaerobic respiration and carbon dioxide (CO2) by aerobic respiration are quantitatively the most important acid fluxes that can alter pHi. Glucose, the major respiratory substrate in tumors, produces 2 × H+ plus 2 × lactate (i.e. ionized lactic acid) by the cytosolic O2-independent glycolytic pathway, or 6 × CO2 plus 6 × H2O through O2-dependent mitochondrial pathways. In addition, during periods of nucleic acid synthesis, glucose can yield 1 × CO2 through an additional cytosolic pathway called the pentose phosphate shunt (Helmlinger et al. 2002). Upon hydration, CO2 yields H+ and HCO3−. Assuming equilibrium at pH 7, the molar H+ – yield per aerobically and anaerobically respired glucose is 5.3 and 2.0, respectively (aciddissociation constants for CO2 and lactic acid are 1026.2 and 1024 M, respectively). Tumors demand a particularly high respiratory rate to energize their substantial growth and development. Glucose yields almost 20 times more energy (ATP molecules) when it is respired to CO2 rather than lactic acid. The carbon atoms of lactic acid are less oxidized than those in CO2, and still have considerable energy trapped in their bonds. Indeed, lactic acid can be respired further to CO2. Based on energy efficiency alone, it would be sensible for tumors to prefer aerobic respiration. But to benefit from this higher energy yield, tumors need functional mitochondria and adequate O2 supply. As solid tumors develop, they grow away from their basement membrane and vasculature. This increases the diffusion distance for O2 delivery. Furthermore, the elevated O2 demand in cancer cells that are closer to blood vessels greatly reduces O2 availability in more distal cells, and shortens the distance over which cells are adequately oxygenated. This distance, known as the Krogh radius (Krogh 1919), can be as little as a few cell layers thick in tumors (Dewhirst et al. 1994). Beyond the Krogh radius, tissue becomes hypoxic. In addition to inadequate and highly disorganized vasculature (Thomlinson and Gray 1955), the extent of hypoxia within tumors is increased by variable and discontinuous blood flow (Vaupel et al. 1989; Helmlinger et al. 1997). The size of the hypoxic region can be visualized by pimonidazole staining (Fig. 2.1a). Low O2 tension (<1%) blocks the degradation of hypoxia-inducible factor (HIF), a transcription factor that otherwise has a very short lifetime under normoxia. HIF was discovered as an inducer of erythropoietin expression (Semenza and Wang 1992), and is now an established regulator of genes involved in glucose metabolism (e.g. Glut-1 for glucose uptake, Fig. 2.1b) and pH regulation (e.g. CA9, a carbonic anhydrase isoform, Fig. 2.1c) (Semenza 2003). Hypoxia forces glucose to be respired anaerobically by blocking O2-dependent mitochondrial reactions and
26
P. Swietach et al.
Fig. 2.1 Tumor hypoxia and its correlation with hypoxia-induced proteins, modified from Airley et al. (2003). Serial sections of cervix carcinoma biopsies, immuno-stained for (a) pimonidazole, (b) Glut-1, and (c) CAIX, showing similarities in distribution and pattern. Magnification 200×. Shaded arrows point in the direction of decreasing O2, as assessed by increasing pimonidazole staining
by HIF-induced expression of pyruvate dehydrogenase kinase (PDK) and lactate dehydrogenase (LDH), which divert pyruvate away from mitochondrial reactions (PDK) and towards lactic acid production (LDH) (Semenza et al. 1994).
The Warburg Effect Under uncompromised O2 supply, it is in the interest of cellular energetics to respire aerobically. This phenomenon, called the Pasteur effect, is a coordinated effort by adenosine nucleotides (Ramaiah et al. 1964), redox potentials (Cerdan et al. 2006), and transcription factors (Hardie 2003) to favor the production of CO2 over lactic acid. In an apparent violation of the Pasteur effect, cancer cells typically show constitutive upregulation of lactic acid production even under normoxic conditions. This observation, called the Warburg effect (Gatenby and Gillies 2004; Warburg 1930), is central to cancer biology and is proposed to arise as a result of the stabilization of HIF by lactic acid (Lu et al. 2002), aberrant HIF degradation by mutated von Hippel–Lindau protein (Ivanov et al. 1998), or dysfunctional transcription factors, such as c-myc, which regulate carbohydrate turnover (Liao and Dickson 2000). The persistence of the Warburg effect in cancer cells must provide a benefit for survival that outweighs the lower ATP yield of anaerobic respiration. One advantage of the Warburg effect is its lack of dependence on O2 supply, which is highly unreliable in tumors (Gatenby and Gillies 2004). Fluctuating blood flow has been proposed to promote cancer development by selecting for cells that survive repeated hypoxia-reoxygenation cycles (Gatenby and Gillies 2004; Kimura et al. 1996), i.e. those supporting the Warburg phenomenon. A second plausible benefit of the Warburg effect is the greater acid-yield per ATP molecule generated, seven-fold higher than aerobic respiration. It has been suggested that lactic acid overproduction sets up an acidic microenvironment that is critical for the transition from pre-invasive to malignant carcinoma (Gatenby and Gillies 2004). A positive correlation has been established between glycolytic flux (and hence acid production) and tumor aggressiveness and invasiveness (Gatenby
2 The Tumor Microenvironment
27
and Gillies 2004). Since glucose supply is usually plentiful, it is feasible to upregulate lactic acid production (viz., the Warburg effect) and deposit a greater amount of acid than possible with aerobic respiration, while still catering for cellular energy demands. The near-universal enhancement of glucose utilization by tumors, shown by 18fluorodeoxyglucose positron emission tomography (Gambhir 2002), supports this model of enhanced acid production. According to modern hypotheses of cancer progression, an acidic extracellular milieu (a) encourages cancer cell development and (b) is lethal to normal cells. There is growing evidence for an important role for H+-sensitive G-protein coupled receptors (OGR1 (Ludwig et al. 2003) and G2A (Murakami et al. 2004)) in transducing extracellular acidity into a proliferation signal (Huang et al. 2008). In a neuroblastoma cell line, low pHe activates the inositol-1,4,5-trisphosphate (IP3) signaling pathway, which triggers Ca2+ release from intracellular stores and the activation of the MEK/ERK pathway. In addition, acidic pHe has been shown to favor tumor invasiveness by increasing cell migration, decreasing cell adhesion, and disrupting the extracellular matrix (Gatenby and Gillies 2004; Gatenby and Gawlinski 1996; Kato et al. 1992; Martinez-Zaguilan et al. 1996; Schlappack et al. 1991; Stock and Schwab 2009). Cancer cells are believed to survive better in an acidic extracellular microenvironment by acquiring a more potent acid-extruding phenotype that protects the intracellular compartment from acid buildup (Swietach et al. 2007; Gatenby et al. 2007). Inadequate acid extrusion in normal cells may explain the lethality of low pHe therein (Fig. 2.2).
Fig. 2.2 Cartoon of acid production from a normal cell (smooth outline) and a cancer cell (rigged outline) in an hypoxic region of a tumor, beyond the Krogh radius from a blood vessel (wavy cylinder on right). The cancer cell (bottom cell with jagged outline) produces more acid (gray-filled H+ ions) than the normal cell (top cell with smooth outline, emitting white-filled H+ ions). Extracellular acid (produced mainly by the overactive cancer cell) favors cancer cell growth and development, but has detrimental effects on normal cells due to their lack of sufficient acid-extruding mechanisms to protect the intracellular space from acidification
28
P. Swietach et al.
Transport of Acid Across the Surface Membrane Intracellular and Extracellular pH in Tumors For many decades after Otto Warburg’s seminal finding that tumors overproduce lactic acid, it was assumed that both pHi and pHe are acidic in cancers. The low pH detected using microelectrodes (Kallinowski et al. 1989; Wike-Hooley et al. 1984) was deemed to support this hypothesis, until 31P nuclear magnetic resonance (NMR) revealed alkaline pH in solid tumors (Griffiths et al. 1981). These apparently conflicting reports are easily reconciled by considering that 31P NMR reports mainly pHi, whereas electrodes are sensitive mainly to pHe. Subsequent NMR measurements with extracellular probes such as 3-aminopropylphosphonate confirmed low pHe (Gillies et al. 1994). Therefore, the major difference between cancer and normal tissue is that the former has lower pHe, typically around 6.9 (Vaupel et al. 1990), but as low as 6.0 in some reports (Gillies et al. 2002). Tumors, like normal tissue, require modestly alkaline pHi to support growth, as shown by in vitro (Park et al. 1999; Chiche et al. 2009) and in vivo (Chiche et al. 2009) experiments. The maintenance of high pHi at low pHe requires efficient acid extrusion, a phenotype that is now considered characteristic of cancer cells.
Regulation of Tumor pH by Membrane Transport There are four challenges to efficient pH–i regulation in tumors. Firstly, the demand placed on pHi - regulating mechanisms is considerable. Tumors respire glucose at 0.1–1.0 mM/min (Vaupel et al. 1989) and generate acid equivalents at a rate that could promptly disturb resting free [H+] (~0.06 mM at pHi 7.2). Secondly, the transmembrane efflux of CO2 and lactic acid is limited by their membrane permeability and intracellular dissociation into membrane-impermeant ions (H+, HCO3–, lactate). Of the two acid products, lactic acid is less readily excreted than CO2 because (a) lactic acid is a larger and more polar molecule than CO2, and therefore is less able to cross the membrane’s lipid bilayer, (b) H+ and lactate produced anaerobically stay 99.9% dissociated in cytoplasm because of the high acid dissociation constant of lactic acid (10–4 M), whereas CO2 dissociates less strongly, with a ~90% yield at equilibrium (at pH 7; CO2 dissociation constant of 10–6.2 M). For every molecule of weak acid produced, anaerobic respiration leads to more intracellular H+ ion trapping than aerobic respiration, and therefore places a greater demand for H+ extruding mechanisms. However, intracellular conversion of CO2 into H+ and HCO3– can be catalyzed by intracellular isoforms of CA, a ubiquitously expressed enzyme (Swietach et al. 2007; Maren 1967; Supuran 2008). In a diffusion-reaction steady-state, intracellular hydration of CO2 reduces the capacity of its diffusive flux out of cells.
2 The Tumor Microenvironment
29
Thirdly, the share of cellular ATP for active acid extrusion is limited and cannot impinge on ATP reserves for growth and development. This may be particularly rate limiting in tumors that rely on energy inefficient anaerobic respiration. Finally, acid extruding mechanisms must be adequately active at low pHe. Extracellular H+ ions have been shown to have an inhibitory effect on transporters such as Na+/H+ exchange (Vaughan-Jones and Wu 1990; Aronson 1985). This would significantly reduce the capacity for acid extrusion in tumors with low pHe. To compensate for this, cancer cells may express a higher density of acid/base transporters, or express isoforms that are less susceptible to inhibition by low pHe.
Efflux of Metabolic Acid Figure 2.3 illustrates pathways for pHi regulation in tumor cells. Without specific mechanisms for transporting acid equivalents, cells would have to rely on the passive efflux of their acid products. CO2 and, to a lesser extent, lactic acid can cross the lipid bilayer, but efficient efflux requires a facilitated permeation pathway. Such
Fig. 2.3 The role of membrane transporters in facilitating acid efflux. Aerobic (left) and anaerobic (right) respiration of glucose yield the acid products CO2 and lactic acid, respectively. CO2 and, to a lesser degree, lactic acid are membrane-permeant and can exit across the surface membrane. At near-neutral pH, however, a fraction of CO2 and lactic acid will ionize. To control intracellular pH, cells express several transporters to facilitate transmembrane acid removal: AQP, aquaporins; MCT, monocarboxylic acid transport; HE, H+-ion extrusion; BT, HCO3– transport
30
P. Swietach et al.
facilitated transport can occur through aquaporin gas channels for CO2 (Nakhoul et al. 1998) (Fig. 2.3a) and by monocarboxylic acid transporters (MCT) for H++lactate (equivalent to lactic acid) co-transport (Halestrap and Price 1999) (Fig. 2.3b). Isoforms MCT1 and MCT4 have been identified in cancer. Furthermore, hypoxia induces MCT4 expression to match the HIF-induced rise in lactic acid production (Ullah et al. 2006).
Buffering of H+ Ions Like all weak acids, lactic acid and hydrated CO2 undergo deprotonation in aqueous medium. The magnitude of the intracellular [H+] rise can be reduced by means of pH buffering, for example: Buffer + H + ↔ HBuffer + Cells have high intracellular buffering capacity because of the proteins, peptides, amino acids, and other weak acids/bases that they harbor. On their own, buffers offer limited protection from acid loading as they can minimize, but cannot remove, pHi disturbances. Typically, it takes many mmol/L of acid to reduce pHi by one unit (Swietach et al. 2008, 2009). However, chronic acid loading over the lifetime of a cell would eventually saturate buffer sites and drive pHi into the lethal range. Cells can counteract buffer saturation by keeping the concentration of protonated and unprotonated buffer constant. In a so-called open buffer system, the concentration of either form of buffer can be restored by transport to or from the extracellular space. The major “open” buffer system in cells is CO2/HCO3–. Intracellular H+ ions react with HCO3– forming membrane permeant CO2 that can exit cells freely. Intracellular buffering is then restored by HCO32 uptake, e.g. by means of Na+-dependent Cl–/HCO3– exchange (Lee and Tannock 1998) (Fig. 2.3c). The effectiveness of this mechanism at protecting pHi depends critically on the availability of extracellular HCO3– for cellular uptake and on efficient CO2 venting. The extracellular space of most tissues is often assumed to be an infinite compartment with solutes at well-controlled concentrations. However, in tumors with poor blood flow, the extracellular milieu may not provide adequate HCO3– (particularly at low pHe) to perpetuate pH buffering by CO2/HCO3–. Under those circumstances, excess H+ ions may have to be extruded by HCO3–-independent mechanisms.
Extrusion of H+ Ions Excess H+ ions can be removed from cells by means of membrane-bound transporter proteins. High levels of Na+/H+ exchangers (NHE) (Swietach et al. 2008;
2 The Tumor Microenvironment
31
Lee and Tannock 1998; McLean et al. 2000) and vacuolar-type H+ ATPase (V-ATPase) pumps (Martinez-Zaguilan et al. 1993) have been detected in many types of cancer cell (Fig. 2.3d). Fibroblasts transfected with V-ATPase (Gillies et al. 1990) or NHE (Reshkin et al. 2000) become tumorigenic, suggesting an important role for H+ extruders in developing the cancer phenotype. In breast cancer, expression levels of V-ATPase are high and in excess of NHE, and correlate with metastatic potential (Sennoune et al. 2004). Experimental evidence supports the notion that H+ extruders contribute to extracellular acidification and help to keep pHi in a range that is favorable for growth (Sennoune et al. 2004; Fais et al. 2007). The enhanced capacity for secreting acid into the extracellular space may be a means of autocrine/paracrine signaling, in which cell proliferation is triggered via extracellularly activated G-protein coupled receptors sensitive to H+ (Huang et al. 2008). It is noteworthy that H+ extrusion and buffering do not remove the anionic conjugate base of the metabolic acid (lactate and HCO3–); therefore, additional mechanisms are required to remove or metabolize these. HCO3– efflux in exchange for extracellular Cl– can occur by means of transporters belonging to the SLC4 (Alper 2006) and SLC26 (Mount and Romero 2004) families. Recently described pathways for organic anion transport on SLC26 (Mount and Romero 2004) and SLC21 (Hagenbuch and Meier 2004) carriers may offer non-H+-coupled means of transporting lactate or its catabolic derivatives.
Regulation of pH Using Nonrespiratory Sources of H+ Ions In the discussion so far, the substrate for transmembrane acid flux was the acid generated by cellular respiration. In metabolically active cancer cells, this is the most substantial source of acid. However, the finding that solid tumors with genetically attenuated glycolysis are still able to acidify their extracellular space suggests that cancer cells can excrete acid from intracellular H+ donors other than metabolically generated acid (Newell et al. 1993; Yamagata et al. 1998). Intracellular buffers provide a substantial pool of H+ ions that can be used to fine-tune pHi independently of the cell’s metabolic activity. Without this reserve of H+ ions, the only means of fine-tuning pHi would be to adjust the balance between metabolic acid production and its transmembrane removal. If, for instance, the production and excretion of metabolic acid is perfectly matched, but a rise in pHi is desired, then the cell must extrude its reserve H+ ions. NHE is a major candidate for finetuning pHi, because of the plethora of signaling molecules that target its activity (Vaughan-Jones and Swietach 2008). Experiments have shown that NHE-driven intracellular alkalinization triggers early stages of neoplastic transformation (Reshkin et al. 2000), and is concomitant with cell cycle progression (Cardone et al. 2005).
32
P. Swietach et al.
Role of Carbonic Anhydrase in Acid-Equivalent Transport Intracellular and Extracellular Carbonic Anhydrase Isoforms Several steps in the pathways illustrated in Fig. 2.3 depend on the forward and backward rate constants in the equilibrium: CO2 + H 2 O ↔ HCO3− + H + The kinetics of pH buffering by CO2/HCO3– and CO2 hydration (and the reverse reaction) depend critically on CA expression levels. The first description of CA activity was based on the intracellular compartment of red blood cells (Meldrum and Roughton 1933). The high intracellular CA (CAi) activity in these cells is now considered to be an exception rather than rule, as typical CAi levels in most cells accelerate CO2 hydration by several, rather than several thousand, fold (Swietach et al. 2007, 2008, 2009; Leem and Vaughan-Jones 1998). The moderate CA catalysis inside cells is a compromise that (a) supports adequate intracellular CO2/HCO3– buffering kinetics (e.g. for the reaction between intracellular HCO3– and lactic acid, Fig. 2.3c) and (b) prevents excessive hydration of cell-generated CO2 (e.g. from aerobic production, Fig. 2.3a) that would trap H+ and HCO3– inside cells. Known catalytically-active intracellular CA isoforms include CA1, CA2, CA3, CA7, and CA13 (Maren 1967; Supuran 2008). Recently, a number of membrane-bound CA isoforms with extracellular-facing catalytic sites (CAe) have been described, including CA4, CA9, CA12, and CA14 (Maren 1967; Supuran 2008; Geers and Gros 2000; Pastorek et al. 1994). Two of these, CA9 and CA12, are hypoxically induced (Wykoff et al. 2000; Loncaster et al. 2001; Airley et al. 2003) and correlate positively with cancer aggressiveness and poor prognosis (Haapasalo et al. 2006; Driessen et al. 2006; Beasley et al. 2001; Chia et al. 2001; Koukourakis et al. 2001), although CA12 is also induced by estrogen in breast cancer and is associated then with a good outcome. It has been postulated that CAe activity in tumors accelerates acid extrusion (Swietach et al. 2007, 2008, 2009; Chiche et al. 2009; Svastova et al. 2004). Figure 2.4 illustrates the possible mechanisms by which CAe activity achieves such facilitation.
Facilitated CO2 Diffusion Efficient CO2 efflux from aerobically respiring cells (Fig. 2.3a) can be curtailed by CO2 buildup in poorly perfused extracellular spaces. The outward transmembrane [CO2] gradient can be increased by hydrating extracellular CO2 into HCO3– and H+ (Swietach et al. 2009; Svastova et al. 2004) (Fig. 2.4a). Theoretical modeling predicts that optimal CO2 venting out of cells can be achieved by favoring extracellular over intracellular CO2 hydration (Swietach et al. 2009). This can be implemented by expressing CAe at a higher level than CAi. In multicellular spheroid models,
2 The Tumor Microenvironment
33
expression of CA9 activity has been shown to reduce intracellular acidity (Swietach et al. 2008, 2009) and increase extracellular acidity (Swietach et al. 2009) in a manner that is sensitive to CAe inhibitors. There is evidence, at least from some cell lines, that overexpression of CA9 decreases overall CAi activity (Swietach et al. 2008, 2009), thereby shifting the site of CO2 hydration from the intracellular to the extracellular compartment. This CAe catalyzed pathway is an example of facilitated CO2 diffusion, and results in a fall of pHe. An apparent contradiction may be inferred from the role of an hypoxia-inducible enzyme (CA9, CA12) in facilitating the efflux of aerobically generated CO2 (Fig. 2.4a). However, the CA9 gene is among the most hypoxia sensitive (Wykoff et al. 2000). Along a radial gradient of decreasing oxygen, CA9 levels are likely to rise ahead of the downregulation of aerobic respiration. The mechanism illustrated in Fig. 2.4a may operate in the intermediate zone, where hypoxia is sufficient to induce CAe but inadequate to block aerobic respiration. In more proximal, oxygenated regions, CAe activity becomes redundant due to the small cell-to-capillary distance for CO2 diffusion (Swietach et al. 2009). CAe-facilitated CO2 diffusion can also take in anaerobically respiring cells. The substrate for CAe catalysis could be CO2 generated by the pentose phosphate
Fig. 2.4 The role of extracellular carbonic anhydrase (CAe) in facilitating efflux of aerobic (left) and anaerobic (right) acid-products. (a) Aerobically generated CO2 crosses the membrane passively down a diffusion gradient, maintained in the outward direction by CAe-catalyzed hydration of excreted CO2. (b) Anaerobically generated lactic acid (HLac), buffered by intracellular HCO3–, produces CO2. The CO2 thus generated exits the cells down a diffusion gradient maintained in the outward direction by CAe-catalyzed hydration. HCO3– generated extracellularly is transported into the cell by BT (e.g. Na+–HCO3– cotransport) to complete the cycle. (c) The products of intracellular CO2 hydration, H+ and HCO3–, are transported out of cells by H+ extruders (HE, e.g. Na+/H+ exchange) and bicarbonate transporters (BT, e.g. Cl–/HCO3– exchange). CAe-catalyzed buffering of H+ ions with HCO3– minimizes possible inhibition of HE by low pHe. (d) HLac flux on monocarboxylic acid transporters (MCT) is maintained in the outward direction by CAe-catalyzed titration of HLac and HCO3–. Water omitted for clarity. Pathways in the upper half tend to decrease pHe, and those in the lower half tend to increase pHe. All pathways stimulate acid efflux and raise pHi
34
P. Swietach et al.
shunt. A more important source of CO2 is intracellular buffering of lactic acid by HCO3–, a reaction catalyzed by CAi, if present (Figs. 2.3c and 2.4b). In addition to supporting an outward [CO2] gradient, CAe activity also generates extracellular HCO3– that is then taken up by cells to replenish intracellular CO2/HCO3– buffering capacity.
Facilitated H+ Diffusion A fraction of aerobically generated CO2 will undergo intracellular hydration, particularly in the presence of CAi activity. Extrusion of the resulting H+ ions will then reduce pHe, which may feedback negatively on transport activity, e.g. by means of allosteric auto-inhibition, as shown for NHE (Vaughan-Jones and Wu 1990; Aronson 1985). CAe activity can support H+ - transport by catalyzing the buffering of cell-extruded H+ ions with extracellular HCO3– (Fig. 2.4c). As a consequence of such facilitated H+ diffusion, pHe increases. In anaerobically respiring cells, the yield of intracellular lactic acid titration can be compromised, particularly under conditions of limited HCO3– uptake, e.g. inadequate transport activity or low extracellular substrate. Intracellular lactic acid that does not react with HCO3– can be extruded by MCT as H++lactate (Fig. 2.3b). CAe activity can stimulate this pathway as well, again by titrating the extruded acid with extracellular HCO3–. This converts lactic acid into CO2, a more mobile and less ionizing acid. Consequently, pHe increases and maintains a steeper outward gradient for H+-lactate co-transport (Fig. 2.4d). This pathway is another example of facilitated H+ diffusion.
The Transport Metabolon In the aforementioned pathways, CA activity works in functional association with membrane transporters. This functional coupling has been dubbed the “transport metabolon” and some reports have also proposed a structural basis for the CA-transporter interaction (Sterling et al. 2001; Becker et al. 2005). The transport metabolon was originally proposed for the collaboration between CAi isoforms and Cl−/HCO3− exchange (Sterling et al. 2001), but there is now evidence for a similar interaction between CAe isoforms and HCO3− transporters (Alvarez et al. 2003; Morgan et al. 2007). As membrane transport is a diffusion-reaction process, the transport metabolon ensures that, through the provision and consumption of transport substrate, the membrane-translocation step is not rate-limited by the cis supply and trans removal of solute. The functional significance of the transport metabolon has, however, been questioned (Lu et al. 2006), particularly under conditions of freely available and equilibrated extracellular CO2/HCO3− buffer (Swietach et al. 2008).
2 The Tumor Microenvironment
35
The Dominant Role for Carbonic Anhydrase in Tumors The balance between the four CAe-assisted pHi-regulatory pathways illustrated in Fig. 2.4 will depend on (a) the dominant mode of cellular respiration, (b) the expression and activity of transporter proteins, and (c) the availability of substrate, such as extracellular HCO3– (Swietach et al. 2009). In hypoxic regions, and in cancer cells showing a pronounced Warburg effect, lactic acid production dominates. Elsewhere, in regions of tumors with functional mitochondria and adequate oxygenation, aerobic respiration to CO2 will form the bulk of acid production. However, the transmembrane flux of CO2 versus H+ (lactic acid) may not follow the pattern of aerobic versus anaerobic respiration. In several cancer cell lines, HCO3–dependent transport has been shown to dominate pHi regulation over HCO3–independent fluxes, such as NHE (Swietach et al. 2008, 2009; Lee and Tannock 1998). This provides the transport-protein machinery to support intracellular lactic acid titration with HCO3–, and hence transmembrane CO2 efflux in glycolytic cells. In the corresponding tumors, the source of CO2 for transmembrane efflux would vary with distance from blood vessels, from aerobic CO2 production to titration of lactic acid by HCO3–. A high overall CO2 secretion rate is in agreement with in vivo data showing high extracellular CO2 levels in rodent solid tumors (Gullino et al. 1965) and that 70% of acid output in colon cancers is in the form of CO2 (Griffiths et al. 2001; Holm et al. 1995). CAe-assisted CO2 versus H+ diffusion can be distinguished on the basis of the effect of CAe inhibitors on pHe. In spheroids grown from CA9-transfected cells, CAe inhibitors increase pHe (Swietach et al. 2009). This suggests that the major effect of CAe catalysis in this preparation is to facilitate CO2 diffusion (Fig. 2.4a, b). The balance between CAe-assisted CO2 versus H+ diffusion in cancers in vivo awaits such pharmacological investigation. A dominance of the former would offer an elegant mechanistic link between two well-established correlations, that between tumor aggressiveness and low pHe (Vaupel et al. 1989; Gatenby et al. 2006; Gillies et al. 2002) and between tumor aggressiveness and the expression of CA9 and/or CA12 (Chia et al. 2001; Generali et al. 2006; Giatromanolaki et al. 2001; Koukourakis et al. 2006).
Future Directions and Outlook for Therapy Acidification of the extracellular milieu, in combination with powerful mechanisms to protect pHi, are believed to be a central hallmark of the aggressive cancer phenotype. Restoration of alkaline pHe is predicted to remove the survival advantage that cancer cells have over normal cells and to discourage invasive behavior and progression towards malignant forms of the cancer (Fang et al. 2008). In addition, raising pHe reduces ionization of weak basic drugs used in chemotherapy, such as epirubicin (Generali et al. 2006), and thereby increases drug penetrability to intracellular targets (Raghunand et al. 2001).
36
P. Swietach et al.
The use of bicarbonate salts to alkalinize blood, with the anticipated rise in tumor pHe, has been proposed as a means of tackling cancer (Raghunand et al. 2001). A more selective and specific therapy proposes pH-regulating transporters and enzymes as targets. Inhibition of these proteins has been proposed to be cancer’s Achilles heel (Fang et al. 2008). Recently, three targets for inhibition have been postulated as plausible therapeutic approaches to treating cancer: (a) H+ pumps, (b) monocarboxylic acid (H+-lactate) transporters, and (c) extracellular CA isoforms. Inhibition of V-ATPase activity using interference RNA reduces metastasis (Fais et al. 2007), and its pharmacological inhibition (e.g. with omeprazole) has been shown to improve responses to chemotherapy in solid tumors (Luciani et al. 2004) and promote death of B-cell tumors (De Milito et al. 2007). Fibroblasts transfected with the E7 oncogene failed to undergo intracellular alkalinization and neoplastic transformation when incubated with the NHE inhibitor, 5-(N,N-dimethyl) amiloride (Reshkin et al. 2000). Inhibition of MCT by cinnamate derivatives and, putatively, by lonidamine leads to cellular lactic acid accumulation and intracellular acidification, which are shown to be lethal in neuroblastoma cells (Fang et al. 2006). Although the efficacy of inhibiting V-ATPase, NHE, and MCT has been demonstrated in some in vitro cell lines and in vivo animal tumor models, the use of these drugs in anticancer therapy is not without drawbacks. Cancer cells tend to overexpress isoforms of V-ATPase, NHE, and MCT, but many noncancer cells also rely on these transporters for survival. The lack of a basis for tumor specificity would trigger drug toxicity and uncalibrated effects on whole-body physiology. Before experimental evidence for tumor-associated CAe isoforms was produced, the broad spectrum CA inhibitor acetazolamide has been shown to reduce in vivo tumor growth (Teicher et al. 1993). Following the discovery of CA9, the sulfonamide CA9-inhibitor indisulam was demonstrated to have powerful anticancer effects (Owa et al. 1999). The tumor-associated CAe isoforms, CA9 and CA12, offer an inhibitory target that is almost exclusive to cancer (with the exception of normal gastric mucosa). Membrane-impermeant, CA9- and CA12-selective inhibitors would target tumors, with minimal predicted side effects on other tissues. An impressive range of membrane-impermeant CAe inhibitors has been synthesized, and the effectiveness of these as anticancer drugs is currently being researched (Supuran 2008). Prodrugs activated by the extracellular acid environment would be another selective approach. Other therapeutic strategies based on tumor-specific CAe isoforms may include inhibitory antibodies, vaccines to develop T-cell antiCA9 or anti-CA12 responses, and targeted antibody therapy. Regulation of tumor pHi remains an intensively researched and hotly debated topic. Furthering our knowledge about the special adaptations found in tumors should improve our overall understanding of pH homeostasis, and may reveal more efficacious and safer anticancer therapy. Acknowledgments This work has been supported by the Medical Research Council and Royal Society (PS), Cancer Research UK (ALH) and British Heart Foundation (RDV-J).
2 The Tumor Microenvironment
37
References Airley RE, Loncaster J, Raleigh JA, Harris AL, Davidson SE, Hunter RD, West CM, Stratford IJ (2003) GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 104:85–91. Alper SL (2006) Molecular physiology of SLC4 anion exchangers. Exp Physiol 91:153–161. Alvarez BV, Loiselle FB, Supuran CT, Schwartz GJ, Casey JR (2003) Direct extracellular interaction between carbonic anhydrase IV and the human NBC1 sodium/bicarbonate co-transporter. Biochemistry 42:12321–12329. Aronson PS (1985) Kinetic properties of the plasma membrane Na+-H+ exchanger. Annu Rev Physiol 47:545–560. Beasley NJ, Wykoff CC, Watson PH, Leek R, Turley H, Gatter K, Pastorek J, Cox GJ, Ratcliffe P, Harris AL (2001) Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 61:5262–5267. Becker HM, Hirnet DC, Fecher-Trost, Sultemeyer D, Deitmer JW (2005) Transport activity of MCT1 expressed in Xenopus oocytes is increased by interaction with carbonic anhydrase. J Biol Chem 280:39882–39889. Boron WF (2004) Regulation of intracellular pH. Adv Physiol Educ 28:160–179. Cardone RA, Casavola V, Reshkin SJ (2005) The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer 5:786–795. Cerdan S, Rodrigues TB, Sierra A, Benito M, Fonseca LL, Fonseca CP, Garcia-Martin ML (2006) The redox switch/redox coupling hypothesis. Neurochem Int 48:523–530. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, Harris AL (2001) Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase ix, in invasive breast carcinoma. J Clin Oncol 19:3660–3668. Chiche J, Ilc K, Laferriere J, Trottier E, Dayan F, Mazure NM, Brahimi-Horn MC, Pouyssegur J (2009) Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 69: 358–368. De Milito A, Iessi E, Logozzi M, Lozupone F, Spada M, Marino ML, Federici C, Perdicchio M, Matarrese P, Lugini L, Nilsson A, Fais S (2007) Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res 67:5408–5417. Dewhirst MW, Secomb TW, Ong ET, Hsu R, Gross JF (1994) Determination of local oxygen consumption rates in tumors. Cancer Res 54:3333–3336. Driessen, A., Landuyt W, Pastorekova S, Moons J, Goethals L, Haustermans K, Nafteux P, Penninckx F, Geboes K, Lerut T, Ectors N (2006) Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg 243:334–340. Fais S, De Milito A, You H, Qin W (2007) Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res 67:10627–10630. Fang J, Quinones QJ, Holman TL, Morowitz MJ, Wang Q, Zhao H, Sivo F, Maris JM, Wahl ML (2006) The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol Pharmacol 70:2108–2115. Fang JS, Gillies RD, Gatenby RA (2008) Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin Cancer Biol 18:330–337. Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2:683–693. Gatenby RA, Gawlinski ET (1996) A reaction-diffusion model of cancer invasion. Cancer Res 56:5745–5753.
38
P. Swietach et al.
Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ (2006) Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res 66:5216–5223. Gatenby RA, Smallbone K, Maini PK, Rose F, Averill J, Nagle RB, Worrall L, Gillies RJ (2007) Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer 97:646–653. Geers C, Gros G (2000) Carbon dioxide transport and carbonic anhydrase in blood and muscle. Physiol Rev 80:681–715. Generali D, Fox SB, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield SM, Bruzzi P, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Bottini A, Harris AL (2006) Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/ tamoxifen therapy for breast cancer. Endocr Relat Cancer 13:921–930. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, Harris AL (2001) Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61:7992–7998. Gillies RJ, Liu Z, Bhujwalla Z (1994) 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. Am J Physiol 267:C195–203. Gillies RJ, Martinez-Zaguilan R, Martinez GM, Serrano R, Perona R (1990) Tumorigenic 3T3 cells maintain an alkaline intracellular pH under physiological conditions. Proc Natl Acad Sci USA 87:7414–7418. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM (2002) MRI of the tumor microenvironment. J Magn Reson Imaging 16:430–450. Gillies RJ, Robey I, Gatenby RA (2008) Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49(Suppl 2):24S–42S. Griffiths JR, Stevens AN, Iles RA, Gordon RE, Shaw D (1981) 31P-NMR investigation of solid tumours in the living rat. Biosci Rep 1:319–325. Griffiths JR, McIntyre DJ, Howe FA, Stubbs M (2001) Why are cancers acidic? A carrier-mediated diffusion model for H+ transport in the interstitial fluid. Novartis Found Symp 240:46–62. Gullino PM, Grantham FH, Smith SH, Haggerty AC (1965) Modifications of the acid-base status of the internal milieu of tumors. J Natl Cancer Inst 34:857–869. Hagenbuch, B., Meier PJ (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653–665. Halestrap AP, Price NT (1999) The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 343(Pt 2):281–299. Hardie DG (2003) Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144:5179–5183. Helmlinger G, Yuan F, Dellian M, Jain RK (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3:177–182. Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK (2002) Acid production in glycolysisimpaired tumors provides new insights into tumor metabolism. Clin Cancer Res 8:1284–1291. Haapasalo JA, Nordfors KM, Hilvo M, Rantala IJ, Soini Y, Parkkila AK, Pastorekova S, Pastorek J, Parkkila SM, Haapasalo HK (2006) Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 12:473–477. Holm E, Hagmuller E, Staedt U, Schlickeiser G, Gunther HJ, Leweling H, Tokus M, Kollmar HB (1995) Substrate balances across colonic carcinomas in humans. Cancer Res 55:1373–1378. Huang WC, Swietach P, Vaughan-Jones RD, Ansorge O, Glitsch MD (2008) Extracellular acidification elicits spatially and temporally distinct Ca2+ signals. Curr Biol 18:781–785. Isfort RJ, Cody DB, Asquith TN, Ridder GM, Stuard SB, LeBoeuf RA (1993) Induction of protein phosphorylation, protein synthesis, immediate-early-gene expression and cellular proliferation by intracellular pH modulation. Implications for the role of hydrogen ions in signal transduction. Eur J Biochem 213:349–357.
2 The Tumor Microenvironment
39
Ivanov SV, Kuzmin I, Wei MH, Pack S, Geil L, Johnson BE, Stanbridge EJ, Lerman MI (1998) Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 95:12596–12601. Kallinowski F, Schlenger KH, Runkel S, Kloes M, Stohrer M, Okunieff P, Vaupel P (1989) Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res 49:3759–3764. Kimura H, Braun RD, Ong ET, Hsu R, Secomb TW, Papahadjopoulos D, Hong K, Dewhirst MW (1996) Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 56:5522–5528. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, Gatter KC, Harris AL (2001) Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 7:3399–3403. Koukourakis MI, Pitiakoudis M, Giatromanolaki A, Tsarouha A, Polychronidis A, Sivridis E, Simopoulos C (2006) Oxygen and glucose consumption in gastrointestinal adenocarcinomas: correlation with markers of hypoxia, acidity and anaerobic glycolysis. Cancer Sci 97: 1056–1060. Krogh A (1919) The number and distribution of capillaries in muscles with calculations of the oxygen pressure head necessary for supplying the tissue. J Physiol 52:409–415. Lee AH, Tannock IF (1998) Heterogeneity of intracellular pH and of mechanisms that regulate intracellular pH in populations of cultured cells. Cancer Res 58:1901–1908. Leem CH, Vaughan-Jones RD (1998) Out-of-equilibrium pH transients in the guinea-pig ventricular myocyte. J Physiol 509 (Pt 2):471–485. Liao DJ, Dickson RB (2000) c-Myc in breast cancer. Endocr Relat Cancer 7:143–164. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ, West CM (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61:6394–6399. Lu H, Forbes RA, Verma A (2002) Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277:23111–23115. Lu J, Daly CM, Parker MD, Gill HS, Piermarini PM, Pelletier MF, Boron WF (2006) Effect of human carbonic anhydrase II on the activity of the human electrogenic Na/HCO3 cotransporter NBCe1-A in Xenopus oocytes. J Biol Chem 281:19241–19250. Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F, Federici C, Iessi E, Parmiani G, Arancia G, Belardelli F, Fais S (2004) Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 96:1702–1713. Ludwig MG, Vanek M, Guerini D, Gasser JA, Jones CE, Junker U, Hofstetter H, Wolf RM, Seuwen K (2003) Proton-sensing G-protein-coupled receptors. Nature 425:93–98. Maren TH (1967) Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol Rev 47:595–781. Martinez-Zaguilan R, Lynch RM, Martinez GM, Gillies RJ (1993) Vacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells. Am J Physiol 265:C1015–1029. Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ (1996) Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 14:176–186. McConkey DJ, Orrenius S (1996) Signal transduction pathways in apoptosis. Stem Cells 14:619–631. McLean LA, Roscoe J, Jorgensen NK, Gorin FA, Cala PM (2000) Malignant gliomas display altered pH regulation by NHE1 compared with nontransformed astrocytes. Am J Physiol Cell Physiol 278:C676–C688. Meldrum NU, Roughton FJ (1933) Carbonic anhydrase. Its preparation and properties. J Physiol 80:113–142. Morgan PE, Pastorekova S, Stuart-Tilley AK, Alper SL, Casey JR (2007) Interactions of transmembrane carbonic anhydrase, CAIX, with bicarbonate transporters.. Am J Physiol Cell Physiol. 293:C738–C748.
40
P. Swietach et al.
Mount DB, Romero MF (2004) The SLC26 gene family of multifunctional anion exchangers. Pflugers Arch 447:710–721. Murakami N, Yokomizo T, Okuno T, Shimizu T (2004) G2A is a proton-sensing G-protein-coupled receptor antagonized by lysophosphatidylcholine. J Biol Chem 279:42484–42491. Kato Y, Nakayama Y, Umeda M, Miyazaki K (1992) Induction of 103-kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines. J Biol Chem 267:11424–11430. Nakhoul NL, Davis BA, Romero MF, Boron WF (1998) Effect of expressing the water channel aquaporin-1 on the CO2 permeability of Xenopus oocytes. Am J Physiol 274:C543–C548. Newell K, Franchi A, Pouyssegur J, Tannock I (1993) Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. Proc Natl Acad Sci USA 90:1127–1131. Owa T, Yoshino H, Okauchi T, Yoshimatsu K, Ozawa Y, Sugi NH, Nagasu T, Koyanagi N, Kitoh K (1999) Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J Med Chem 42:3789–3799. Park HJ, Lyons JC, Ohtsubo T, Song CW (1999) Acidic environment causes apoptosis by increasing caspase activity. Br J Cancer 80:1892–1897. Pastorek J, Pastorekova S, Callebaut I, Mornon JP, Zelnik V, Opavsky R, Zat’ovicova M, Liao S, Portetelle D, Stanbridge EJ et al (1994) Cloning and characterization of MN, a human tumorassociated protein with a domain homologous to carbonic anhydrase and a putative helixloop-helix DNA binding segment. Oncogene 9:2877–2888. Ramaiah A, Hathaway JA, Atkinson DE (1964). Adenylate as a Metabolic Regulator. Effect on Yeast Phosphofructokinase Kinetics. J Biol Chem 239:3619–3622. Raghunand N, Mahoney B, van Sluis R, Baggett B, Gillies RJ (2001) Acute metabolic alkalosis enhances response of C3H mouse mammary tumors to the weak base mitoxantrone. Neoplasia 3:227–235. Reshkin SJ, Bellizzi A, Caldeira S, Albarani V, Malanchi I, Poignee M, Alunni-Fabbroni M, Casavola V, Tommasino M (2000) Na+/H+ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB J 14:2185–2197. Roos A, Boron WF (1981) Intracellular pH. Physiol Rev 61:296–434. Schlappack OK, Zimmermann A, Hill RP (1991) Glucose starvation and acidosis: effect on experimental metastatic potential, DNA content and MTX resistance of murine tumour cells. Br J Cancer 64:663–670. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732. Semenza GL, Wang GL (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12:5447–5454. Semenza GL, Roth PH, Fang HM, Wang GL (1994) Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 269:23757–23763. Sennoune SR, Bakunts K, Martinez GM, Chua-Tuan JL, Kebir Y, Attaya MN, Martinez-Zaguilan R (2004) Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol 286:C1443–C1452. Sterling D, Reithmeier RA, Casey JR (2001) A transport metabolon. Functional interaction of carbonic anhydrase II and chloride/bicarbonate exchangers. J Biol Chem 276:47886–47894. Stock C, Schwab A (2009) Protons make tumor cells move like clockwork. Pflugers Arch 458(2):981–992. Stubbs M, McSheehy PM, Griffiths JR, Bashford CL (2000) Causes and consequences of tumour acidity and implications for treatment. Mol Med Today 6:15–19. Supuran CT (2008) Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature Rev (Drug Discoveries) 7:1–14. Svastova E, Hulikova A, Rafajova M, Zat’ovicova M, Gibadulinova A, Casini A, Cecchi A, Scozzafava A, Supuran CT, Pastorek J, Pastorekova S (2004) Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 577:439–445.
2 The Tumor Microenvironment
41
Swietach P, Vaughan-Jones RD, Harris AL (2007) Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 26:299–310. Swietach P, Wigfield S, Cobden P, Supuran CT, Harris AL, Vaughan-Jones RD (2008) Tumorassociated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem 283:20473–20483. Swietach P, Patiar S, Supuran CT, Harris AL, Vaughan-Jones RD (2009) The role of carbonic anhydrase 9 in regulating extracellular and intracellular pH in three-dimensional tumor cell growths. J Biol Chem 284:20299–20310. Teicher BA, Liu SD, Liu JT, Holden SA, Herman TS (1993) A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res 13:1549–1556. Thomlinson RH, Gray LH (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9:539–549. Ullah MS, Davies AJ, Halestrap AP (2006) The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 281:9030–9037. Vaughan-Jones RD, Swietach P (2008) Pushing and pulling the cardiac sodium/hydrogen exchanger. Circ Res 103:773–775. Vaughan-Jones RD, Wu ML (1990) Extracellular H+ inactivation of Na(+)-H+ exchange in the sheep cardiac Purkinje fibre. J Physiol 428:441–466. Vaughan-Jones RD, Spitzer KW, Swietach P (2008) Intracellular pH regulation in heart. J Mol Cell Cardiol 46(3):318–313. Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49:6449–6465. Vaupel P, Kallinowski F, Okunieff P (1990) Blood flow, oxygen consumption and tissue oxygenation of human tumors. Adv Exp Med Biol 277:895–905. Warburg O (1930) The metabolism of tumours. Arnold Constable, London. Wike-Hooley JL, Haveman J, Reinhold HS (1984) The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol 2:343–366. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60:7075–7083. Yamagata M, Hasuda K, Stamato T, Tannock IF (1998) The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. Br J Cancer 77:1726–1731.
Chapter 3
Hypoxia, Gene Expression, and Metastasis Olga V. Razorenova and Amato J. Giaccia
Abstract Metastasis is the primary cause of death from cancer due to the spread of disease throughout the body. Increasing evidence suggests that the hypoxic microenvironment serves as a driving force for the metastatic process. Fifty to sixty percent of solid tumors contain hypoxic areas, where the gene expression is reprogrammed by low oxygen microenvironment leading to aggressive invasive cancer cell behavior. Hypoxia upregulates multiple genes involved in different steps of metastatic process, including angiogenesis, proliferation, migration, invasion, motility, adhesion, ECM remodeling, and survival. Moreover, hypoxia confers tumor cells with chemo- and radio-resistance. At the end of this chapter, we discuss the facts linking hypoxia and cancer stem cells (CSC) mainly through the ability of hypoxic microenvironment to shift cells toward the undifferentiated phenotype. Abbreviations AKT ARNT CC-RCC CNS CSC EMT FAK FIH GSC HIF HRE
protein kinase B arylhydrocarbon receptor nuclear translocator clear cell renal cell carcinoma central nervous system cancer stem cell epithelial–mesenchymal transition focal adhesion kinase factor inhibiting HIF glioma stem cell hypoxia-inducible factor hypoxia-responsive element
A.J. Giaccia (*) Division of Radiation and Cancer Biology, Stanford University, Stanford, CA 94305, USA e-mail:
[email protected] R.G. Bagley (ed.), The Tumor Microenvironment, Cancer Drug Discovery and Development, DOI 10.1007/978-1-4419-6615-5_3, © Springer Science+Business Media, LLC 2010
43
44
IDH1 iPS a-KG LOH LOX MAPK NSC PHDs 1–3 PI-3K pVHL VHL WT
O.V. Razorenova and A.J. Giaccia
isocitrate dehydrogenase 1 induced pluripotent stem cell a-ketoglutarate loss of heterozygosity lysyl oxidase mitogen-activated protein kinase neural stem cell prolyl-4-hydroxylases 1–3 phosphoinositide 3 kinase von Hippel–Lindau protein von Hippel–Lindau gene wild-type
The Link Between Hypoxia and Metastasis Metastatic disease is the primary cause of death from cancer due to its spread beyond the primary affected organ to multiple organs in the body (secondary sites). The metastatic process is complex and can be divided into several major steps: (1) invasion and migration of tumor cells, leading to intravasation; (2) survival in the circulation (resistance to anoikis); (3) adhesion and migration, leading to extravasation; (4) survival in the new microenvironment; and (5) proliferation in the secondary site (Fig. 3.1) (Chan and Giaccia 2007; Nguyen et al. 2009). These processes require the involvement of a variety of effector molecules. It has been estimated that 50–60% of solid tumors contain areas of hypoxic and/or anoxic regions (Vaupel and Mayer 2007). Moreover, hypoxia correlates with poor patient outcome and the presence of metastases in multiple tumor types (Hockel et al. 1993, 1996; Brizel et al. 1996; Nordsmark et al. 1996; Fyles et al. 1998). Despite these correlations, it is not clear whether hypoxia provides the appropriate microenvironment promoting metastatic spread or metastasis is a simple consequence of chemo- and radio-resistance of cells in hypoxic regions. Hypoxic cells survive chemotherapy because many chemotherapeutic agents require proliferating cells to induce cytotoxicity and hypoxic cells divide slowly (Shannon et al. 2003). The second cause of failure is the need for vasculature to deliver drugs to cancer cells, which is absent or defective in hypoxic regions (Kizaka-Kondoh et al. 2003). An additional contribution to chemotherapy resistance is through the hypoxic induction of multidrug transporters, leading to the transport of drugs out of the cell (Comerford et al. 2002; Wartenberg et al. 2003). Radiation therapy relies on molecular oxygen to form cytotoxic, double-strand breaks in the cancer cell DNA, which is limited under hypoxic conditions (Kallman and Dorie 1986; Hall 1994). The majority of studies now provide convincing evidence that hypoxia is not only capable to confer cells with chemo- and radio-resistance, but also shifts gene expression to promote the metastatic process (see below).
3 Hypoxia, Gene Expression, and Metastasis
hypoxia
45
intravasation angiogenic factor secretion
adh
esio
n
angiogenesis
extravasation
organ2
surv i
val
organ1
survival, proliferation
Fig. 3.1 Major steps of the metastatic process
Causes and Consequences of Tumor Hypoxia The physiologic range of oxygen for most tissues is between 4 and 8% oxygen (normoxia) in contrast to the 20% level of oxygen used for tissue culture experiments (Gardner and Corn 2008). For each tissue, the range of oxygen tensions can vary accordingly to need; thus, under physiologic conditions it is difficult to establish a universal value to define hypoxia. In this regard, the functional definition of hypoxia is the state when oxygen delivery does not meet the demands of the given tissue. Cellular hypoxia (<1–5% oxygen) is a common stress in normal development (Huang et al. 2004) and numerous pathological conditions, including cancer and ischemia (Giaccia et al. 2003; Semenza 2003). Hypoxic areas in tumors develop as a result of an imbalance between oxygen supply and consumption (Papandreou et al. 2005; Vaupel and Mayer 2007). The expanding tumor mass increases the distance of certain tumor areas from local blood vessels, limiting the oxygen supply. Additionally, at later stages of tumor growth, when a tumor establishes an extensive vasculature to increase oxygen supply, the defects in blood vessel structure contribute to hypoxia reoxygenation of certain tumor areas (Endrich et al. 1979; Grunt et al. 1985; Shah-Yukich and Nelson 1988; Dewhirst et al. 1989). The malformed tumor vasculature is twisted, tortuous with blind ends and can possess arterio-venous shunts. Moreover, tumor vessels are devoid of their normal multilayer complex structure and are leaky and predisposed to dilation and constriction, resulting in transient changes in tissue oxygenation (Carmeliet 2005). The main consequence of hypoxic exposure is the stabilization of hypoxiainducible factors (HIFs), which are critical regulators of gene transcription (Giaccia et al. 2003). The hypoxic microenvironment of the tumor leads to HIF stabilization, which induces gene expression changes in order to adapt to hypoxia (Semenza
46
O.V. Razorenova and A.J. Giaccia
2003; Lee et al. 2004); some of these changes, in turn, allow the acquisition of prometastatic properties of cells (invasiveness, migration, adhesion, and survival) (Giaccia et al. 2003; Semenza 2003). Indeed, HIF stabilization in solid tumors does not simply correlate with poor patient prognosis, but HIFs are active players in the metastatic process (Le et al. 2004; Chan and Giaccia 2007; Rankin and Giaccia 2008; Qing and Simon 2009). There are three known HIF-a molecules (Rankin and Giaccia 2008): HIF-1a, HIF-2a, and HIF-3a, which are all hypoxia inducible with a similar mechanism of regulation by oxygen. HIF-1a is ubiquitously expressed, while HIF-2a expression is restricted to specific cell types: endothelial cells, glial cells, type II pneumocytes, cardiomyocytes, kidney fibroblasts, interstitial cells of the pancreas and duodenum, and hepatocytes (Wiesener et al. 2003). Our knowledge of HIF-3a is currently very limited and some studies suggest that it might act as a dominantnegative regulator of HIF-1a and HIF-2a by generation of an alternatively spliced isoform (Makino et al. 2001). Both HIF-1a and HIF-2a are detected in a variety of human tumors, and elevated HIF-1a expression correlates with poor patient outcome in head and neck cancer, nasopharyngeal carcinoma, colorectal, pancreatic, breast, cervical, osteosarcoma, endometrial, ovarian, bladder, glioblastoma, and gastric carcinomas, while elevated HIF-2a expression correlates with poor patient outcome in hepatocellular, colorectal carcinoma, melanoma, ovarian, and nonsmall cell lung cancers (Rankin and Giaccia 2008). Hypoxic conditions are stress conditions that trigger the cell to make a decision to live or to die. In response to hypoxia, as a pro-survival signal, HIF-a stability and activity increases (Giaccia et al. 2003; Semenza 2003). HIF-mediated gene expression allows cells to respond to a low oxygen environment by increasing oxygen delivery and metabolically to adapt to decreased oxygen availability. HIFs regulate expression of multiple target genes that are involved in glycolysis, angiogenesis, proliferation, migration, etc., by binding to hypoxia-responsive elements (HREs) (5¢RCGTG3¢) in their genomic regulatory regions (Semenza 2003; Le et al. 2004; Chan and Giaccia 2007).
HIF Regulation by Oxygen In untransformed cells, HIF-a activity is oxygen dependent and is tightly regulated (Fig. 3.2). Under normoxia, HIF-1a is hydroxylated on two conserved proline residues, prolines 402 and 564, by prolyl-4-hydroxylases 1–3 (PHDs 1–3) (Ivan et al. 2001; Jaakkola et al. 2001). This hydroxylation reaction requires oxygen and a-ketoglutarate (a-KG) as substrates, and iron and ascorbate as cofactors. When hydroxylated, HIF-1a is recognized by the pVHL protein, which allows the formation of a complex with Elongins B and C, cullin 2, and RING-H2 protein ring-box1. This complex functions as E3 ubiquitin ligase, and ubiquitinated HIF-1a gets degraded in the proteasome (Pause et al. 1999). Under hypoxic conditions, hydroxylation of HIF-1a decreases in an oxygen-dependent manner as oxygen serves as a substrate in the hydroxylation reaction. HIF-1a without proline hydroxyl marks is
3 Hypoxia, Gene Expression, and Metastasis
Normoxia Presence of oxygen Cofactors: ascorbate Fe2+
Hypoxia Absence of oxygen pVHL
pVHL PHDs
HIFα
47
OH
O2 α-KG
OH
Ub Ub Ub
HIFα
HIFα
FIH
p300/ CBP
p300/ CBP
OH
26S
I
F
α
HIFα HIFβ
transcription of HIF target genes
5’RCGTG 3’YGCAC
metabolism angiogenesis invasion migration proliferation
H
Fig. 3.2 Oxygen-dependent HIF regulation. R, purine; Y, pyrimidine
not recognized by pVHL, becomes stabilized, and dimerizes with its constitutively expressed partner HIF-1b (also known as arylhydrocarbon receptor nuclear translocator, ARNT). HIF-a/HIF-1b; heterodimer acts in the nucleus and activates transcription by recruiting the transcriptional co-activators such as p300/CBP (Giaccia et al. 2003; Semenza 2003). The interaction between HIF and p300/CBP is also oxygen dependent and is regulated by factor inhibiting HIF (FIH) (Mahon et al. 2001). Under normoxia, FIH hydroxylates asparagine 803 in HIF-1a transactivation domain and prevents p300/CBP binding. Thus, HIF activation under hypoxia consists of HIF-a stabilization and effective p300/CBP binding.
HIF Regulation by Genetic Alterations of Upstream Regulators Many studies have shown that hypoxia is not the only mechanism of HIF activation. HIF-a stability and activity are tightly controlled in primary cells by multiple signaling pathways. Not surprisingly cancer cells acquire mutations in genes, involved
48
O.V. Razorenova and A.J. Giaccia
into HIF regulation, allowing its activation in tumors under normoxic conditions. As described above, pVHL plays a central role in regulating HIF stability (Fig. 3.2). Genetic inactivation of the VHL gene results in HIF-a stabilization and activation, leading to upregulation of target gene expression under normoxia (Iliopoulos et al. 1996; Maxwell et al. 1999; Giaccia et al. 2003; Kaelin 2008). Germ-line mutations in VHL result in VHL disease, also known as familial Von Hippel–Lindau syndrome (Latif et al. 1993). Affected individuals are born with one wild-type (WT) allele and another mutant allele. In these individuals the remaining, WT VHL allele, is eliminated by a loss of heterozygosity (LOH). Von Hippel–Lindau syndrome is characterized by the high frequency of development of several cancer types, including central nervous system (CNS) and retinal hemangioblastomas, clear-cell renal cell carcinomas (CC-RCCs), and pheochromocytomas. VHL is also inactivated in the majority of sporadic RCCs and hemangioblastomas (up to 80% of cases) (Gnarra et al. 1993; Sprenger et al. 2001; Maynard and Ohh 2004). Families at risk for developing pheochromocytoma almost invariably harbor VHL missense mutations, in contrast to families without pheochromocytomas, which frequently harbor VHL deletions or truncation mutations (Chen et al. 1995; Zbar et al. 1996). Most likely genotype–phenotype correlations in VHL disease reflect the degree of impairment of pVHL function by different mutations (Hoffman et al. 2001; Li et al. 2007). Thus, VHL is a bona fide tumor suppressor gene. One of the best studied functions of HIF-1a is the regulation of glucose metabolism by glycolytic enzymes. Importantly, cell metabolic pathways feedback to HIF to allow tight control of energy generating process. Thus, mutations in isocitrate dehydrogenase 1 (IDH1), which occur in certain types of brain tumors, were found to impair a-KG synthesis. Because a-KG is a substrate in HIF-a hydroxylation reaction (Fig. 3.2), impairment of IDH1 function leads to increased HIF-a stability (Zhao et al. 2009). Importantly, IDH1 acts as a homodimer and mutations in IDH1 not only inactivate the gene product of the mutated allele, but confirm the mutated protein with the dominant-negative activity toward the WT allele (Zhao et al. 2009). This fact explains why the LOH for IDH1 is not observed in tumors. Thus, IDH1 appears to be another tumor suppressor gene involved in HIF-a destabilization. Activation of phosphoinositide 3 kinase/Akt (PI-3K/Akt) and mitogen-activated protein kinase (MAPK) signaling pathways is frequently observed in multiple types of cancer and it was shown that they can induce HIF activity (Berra et al. 2000; Blancher et al. 2001; Jiang et al. 2001; Sodhi et al. 2001). The PI-3K pathway is activated in cancer by enhanced growth factor signaling (Zelzer et al. 1998), activation of oncogenes (positive regulators) or inactivation of PTEN (Zundel et al. 2000), or TSC2 (Brugarolas et al. 2003) (negative regulators). To date, the detailed mechanism of PI-3K/Akt-mediated HIF regulation is unknown, but several studies show it to be mTOR dependent, where mTOR contributes to increased HIF protein synthesis (Hudson et al. 2002; Majumder et al. 2004). On the other hand, MAPK can directly phosphorylate HIF-a and increase its stabilization. In summary, HIF activity can be regulated at multiple levels: oxygen concentration, a-KG synthesis (substrates in hydroxylation reaction), and VHL mutation
3 Hypoxia, Gene Expression, and Metastasis
49
(impairment of HIF-a ubiquitination). One can envision additional ways to stabilize HIF, including mutations in prolines 402 and 564, proteasome inhibition, and treatment with iron chelators. Indeed, these are widely used as artificial means of HIF stabilization; and HIF mutations are rarely found in tumors.
HIF Target Genes Involved in the Metastatic Process Hypoxia promotes metastasis through the regulation of key genes involved in different steps of metastatic process, including angiogenesis, proliferation, migration, invasion, motility, adhesion, ECM remodeling, and survival (list of hypoxia-regulated genes can be found elsewhere) (Giaccia et al. 2003; Semenza 2003; Le et al. 2004; Maynard and Ohh 2007). It is important to note that approximately 1–1.5% of the genome is transcriptionally regulated by hypoxia, and many of these genes have been shown to be HIF regulated (Harris 2002; Semenza 2003, 2007). For some solid tumors, angiogenesis is a critical step in the metastatic process, whereas in other cancers (e.g. ovarian cancer and scirrhous adenocarcinoma), the vasculature is not involved in the metastatic spread. In these tumors, cells from the primary tumor shed to the peritoneal cavity, where they establish secondary lesions. In this case, the group of genes involved in angiogenesis is not relevant for the metastatic spread of these cancer types. The role of individual hypoxia-inducible genes in metastasis has just started to be investigated. This lack of direct in vivo evidence about their role in the metastatic process comes from the fact that many of hypoxia-regulated genes are affecting primary tumor growth, which complicates studies on their roles in metastatic spread. It is believed that the larger the primary tumor, the more cells from that tumor can colonize the secondary organs to form lesions. On the other hand, the establishment of metastasis from one cell requires extensive cell growth. Moreover many hypoxia-inducible genes are multifunctional, involved in several processes, like VEGF, which stimulates cancer cell migration (process not affecting tumor growth) and angiogenesis (affects tumor growth). Furthermore, HIFs activate a diverse array of target genes, which sometimes have opposite functions, like proapoptotic (transcriptional induction of BNIP3, BNIP3L, RTP801 and NIX, and stabilization of p53) and antiapoptotic (transcriptional induction of ADM, IGF2, IGF-BP1, 2, 3, TGF-a, VEGF, Bcl-w like, Pim1, 2). Thus, a shift in the balance of opposing signals as well as the mutation repertoire of a given cancer cell will affect tumor cell behavior under hypoxic conditions. An additional complexity comes from the observation that HIFs not only directly upregulate gene expression, by binding to target promoters, but also indirectly upregulate and downregulate gene expression through downstream signaling. The most significant example of indirect downregulation of gene expression is the E-cadherin (see below). The epithelial–mesenchymal transition (EMT) is one of the primary cellular mechanisms known to be involved in the metastatic process (Berx et al. 2007; Guarino et al. 2007; Tse and Kalluri 2007; Gavert and Ben-Ze’ev 2008). Epithelial
50
O.V. Razorenova and A.J. Giaccia
cells form cell–cell contacts through adherens junctions, whereas the mesenchymal phenotype is characterized by reduced cell–cell contacts, lost cell polarity, and increased interaction with extracellular matrix via integrins and focal adhesion kinase (FAK) (Avizienyte and Frame 2005; McLean et al. 2005). Epithelial cells, which undergo EMT, show a dedifferentiated morphology and become more motile and invasive. Epithelial cells can be reprogrammed to mesenchymal state by hypoxia and HIF that involve suppression of E-cadherin and increased cell motility (Cannito et al. 2008; Sahlgren et al. 2008; Yang et al. 2008). E-cadherin is a cellular adhesion molecule that regulates cell–cell adhesion (for review, see Hanahan and Weinberg 2000). E-cadherin inactivation enhances metastatic potential and its overexpression in cancer inhibits metastasis (Hanahan and Weinberg 2000). HIF has recently been described as a critical factor for the regulation of E-cadherin expression in ovarian carcinoma (Imai et al. 2003) and VHL-deficient CC-RCC (Esteban et al. 2006; Evans et al. 2007). The HIF-mediated upregulation of E-cadherin repressors Twist, Snail, Slug, and SIP1 serves as a mechanism of E-cadherin downregulation (Evans et al. 2007; Vesuna et al. 2008; Yoshida et al. 2009). Twist, a basic helix-loop-helix transcription factor, is a master regulator of gastrulation and mesoderm specification during embryonic development. HIF-1a was shown to regulate the expression of Twist through the HRE located in the Twist proximal promoter (Yang and Wu 2008; Yang et al. 2008). Co-expression of HIF1a, Twist, and Snail in primary tumors of head and neck squamous cell carcinoma patients correlates with the development of metastases and a poor prognosis (Yang et al. 2008). Importantly, the key role of Twist in metastasis was demonstrated by manipulation of Twist expression in highly metastatic mammary carcinoma cells. The downregulation of Twist expression in these cells led to the inhibition of their ability to metastasize from the mammary fat pad to the lung (Yang et al. 2004, 2006). In human breast cancers, high levels of Twist expression are correlated with invasive lobular carcinoma, a highly infiltrating tumor type associated with loss of E-cadherin expression (Yang et al. 2004). Lysyl oxidase (LOX), an amine oxidase involved in extracellular matrix formation, was shown to be regulated by hypoxia and HIFs (Erler et al. 2006; Erler and Giaccia 2006). Expression of LOX is associated with hypoxia in breast cancer as well as head and neck tumors, and correlates with poor patient outcome, including lower metastasis-free and overall survival rates (Erler et al. 2006; Le et al. 2009). Inhibition of LOX pharmacologically, genetically, or using a neutralizing antibody, in an orthotopic breast cancer model suppressed the metastatic potential of the tumor cells without affecting primary tumor growth (Erler et al. 2006). In vitro LOX regulated cell invasion and migration through regulating the activity of FAK. Moreover, LOX is critical for “premetastatic niche” formation in organs, where it relocates after being secreted by hypoxic primary tumors, crosslinks collagen IV in the basement membrane, and promotes CD11b+ myeloid cell recruitment (Erler et al. 2009). CD11b+ cells adhere to crosslinked collagen IV and produce matrix metalloproteinase-2, which cleaves collagen, enhancing the invasion and recruitment of bone marrow derived cells and metastasizing tumor cells.
3 Hypoxia, Gene Expression, and Metastasis
51
Hypoxia, Cancer Stem Cells, and Metastasis In the recent years, our view of cancer has been transformed by the “cancer stem cell” (CSC) theory (Reya et al. 2001; Pardal et al. 2003). Multiple studies have identified CSC subpopulations of cells within leukemias (Lapidot et al. 1994; Bonnet and Dick 1997), gliomas (Singh et al. 2003, 2004), breast (Al-Hajj et al. 2003), colon (Dalerba et al. 2007; O’Brien et al. 2007; Ricci-Vitiani et al. 2007), pancreatic (Li et al. 2007), bladder (Chan et al. 2009), melanoma (Boiko et al. 2010) cancers, head and neck squamous cell carcinoma (Prince et al. 2007), which have high self-renewal capacity, as well as more differentiated cancer cells (nonCSCs), which have very limited proliferative potential, making them incapable to drive tumor growth. The presence of CSC in tumors along with non-CSC makes tumor a complex hierarchically organized tissue. Moreover, it appears that many cancer therapies, while killing the bulk of tumor cells, fail to eliminate CSCs, which are resistant to chemo- and radiation treatment (Bao et al. 2006; Hambardzumyan et al. 2006; Li et al. 2008; Liu et al. 2006; Todaro et al. 2007; Wulf et al. 2001), allowing them to regenerate new tumors. Interestingly, many parallels can be drawn between CSCs and cancer cells residing in the hypoxic microenvironment. There is a striking correlation between chemo- and radiation resistance of CSCs and cancer cells in hypoxic regions. Increasing evidence suggests that hypoxia has the potential to inhibit tumor cell differentiation (Jogi et al. 2002; Helczynska et al. 2003), and thus plays a direct role in the maintenance of CSCs (Keith and Simon 2007; Hill et al. 2009). The role of hypoxia in general and HIFs in particular in maintaining the undifferentiated and pluripotent state of normal stem cells (SCs) is well documented (Cipolleschi et al. 1993, 2000; Lee et al. 2001; Ezashi et al. 2005; Parmar et al. 2007). Embryonic stem cells (ESCs) express the transcription factor Oct4 regulated by hypoxia during development (Covello et al. 2006). Moreover, the activity of Oct4, Sox2, and c-Myc used to reprogram fibroblasts to induced pluripotent stem (iPS) cell state (Takahashi and Yamanaka 2006; Takahashi et al. 2007; Wernig et al. 2007) is modulated by hypoxia. Oct4 is a HIF-2 target gene (Covello et al. 2006), Sox2 is hypoxia inducible in CD133+ neural CSCs and human ES cells (Forristal et al. 2009; McCord et al. 2009), and activity of c-Myc is induced by HIF-2 and inhibited by HIF-1. HIF-2 potentiates c-Myc activity by enhancing its physical association with Sp1, Miz1, and Max, although the precise mechanisms regulating these events are not yet fully understood (Gordan et al. 2007). HIF-1 antagonizes c-Myc activity by competing for binding to the transcription factor Sp1 under hypoxic conditions resulting in inhibition of c-Myc-dependent cell-cycle progression (Koshiji et al. 2004). Hypoxic regulation of Oct4, Sox2, and c-Myc simultaneously in one cell type needs to be investigated, opening the possibility that hypoxic exposure of fibroblasts or forced HIF-2 overexpression might lead to the iPS phenotype. In addition, Notch was shown to maintain a dedifferentiated state in multiple cell types under hypoxia (Gustafsson et al. 2005), where the formation of HIF-1a/Notch ICD domain complex enhanced Notch signaling (Sahlgren et al. 2008).
52
O.V. Razorenova and A.J. Giaccia
Interestingly, PTEN appears to be the negative regulator of SC pool (Groszer et al. 2001; Zheng et al. 2008), because deletion of PTEN results in an increase of neural stem cells (NSCs) numbers along with tumor expansion. Thus, the normal NSCs are finding a way to circumvent PTEN tumor suppressor function in order to become malignant. As discussed above, PTEN is a documented negative regulator of HIF, acting through the PI3K/Akt pathway (Zundel et al. 2000). In recent years, direct links between hypoxia, HIFs, and CSCs have emerged. Growing CD133+ neural CSCs at 7% oxygen compared to 20% reduced their doubling time and increased their self-renewal potential as reflected by clonogenicity (McCord et al. 2009). Growth of neural CSCs at 7% oxygen also resulted in an increase in the expression levels of the NSC markers CD133 and nestin as well as the SC markers Oct4 and Sox2. In addition, HIF-1 activity was not changed in CD133+ CSCs grown at 7%, and HIF-2 was expressed at higher levels (McCord et al. 2009). Another study showed that HIF-2a and multiple HIF-regulated genes are preferentially expressed in glioma stem cells (GSCs) in comparison to nonGSCs and normal neural progenitors (Li et al. 2009). Targeting HIFs in GSCs inhibited self-renewal, proliferation, and survival in vitro, and attenuated tumor initiation potential of GSCs in vivo. The third study showed that hypoxia (1% oxygen) promoted the self-renewal capacity and maintained the undifferentiated phenotype of CD133+ human glioma-derived CSCs, accompanied with expansion of cells bearing CXCR4 (CD184), CD44 (low), and A2B5 surface markers (Soeda et al. 2009). Knockdown of HIF-1a abrogated the hypoxia-mediated CD133-positive CSC expansion. On the other hand, mTOR signal and HIF-1 were shown to negatively regulate CD133 expression in cancer cell lines under 0.1% oxygen (which is close to anoxia) (Matsumoto et al. 2009). In support of the hypothesis that cells might be shifted into the iPS state by forced HIF expression, glioblastoma nonCSCs were unexpectedly found to possess plasticity under hypoxic conditions (2% oxygen), which helped to maintain self-renewal of glioblastoma CSCs and promoted reprogramming of glioblastoma non-CSCs toward a CSC phenotype (Heddleston et al. 2009). Thus, it looks like the oxygen concentration in the normal and CSC niche is very important and it has to be determined whether physiologic oxygen conditions or conditions of hypoxia/anoxia favor CSC and normal SC maintenance. In this case, the apparent discrepancy between the two reports about CD133 expression under hypoxia can be explained by differential effects on HIF-1 and 2 and by different oxygen levels. Because CSCs are capable of self-renewal, and are responsible for the long-term maintenance of tumor growth, it has been predicted that they might be also involved in metastases (Dalerba and Clarke 2007; Hermann et al. 2007). Thus, tumor initiating CD133+ pancreatic CSC population can be subdivided into CXCR4- (nonmetastatic) and CXCR4+ (metastatic) subpopulations. Bulk CD133+ cells (containing a mixture of CD133+/CXCR4+ and CD133+/CXCR4- cells) and individual CD133+/ CXCR4+ and CD133+/CXCR4- populations show similar tumor growth abilities. However, CD133+/CXCR4- tumors do not form spontaneous metastases during the time of experiment. A similar effect was obtained by pharmacological inhibition of
3 Hypoxia, Gene Expression, and Metastasis
53
CXCR4. CXCR4 is the receptor for the CXCL12/SDF-1 chemokine, which is involved in the control of leukocyte trafficking under physiological conditions. In cancer, CXCR4 was shown to regulate migration and metastasis (Muller et al. 2001; Balkwill 2004); notably, its ligand SDF-1 is highly expressed at common sites of metastasis, including the lung, bone marrow, and liver, and might direct CXCR4-expressing tumor cells to secondary metastatic sites (Kucia et al. 2005; Arya et al. 2007). An interesting twist in this story is that CXCR4 (Staller et al. 2003; Phillips et al. 2005; Zagzag et al. 2006) as well as its ligand SDF-1 (Ceradini et al. 2004) are hypoxia-inducible genes and HIF is a potent inducer of CXCR4 in VHL-deficient RCCs, nonsmall cell lung cancer, glioblastomas, and SDF-1 in endothelial cells (Staller et al. 2003; Ceradini et al. 2004; Phillips et al. 2005; Zagzag et al. 2006).
Conclusion The metastatic process is a complex multistep process requiring programming of cancer cells toward mesenchymal undifferentiated phenotype, with dominating promigratory and pro-survival signals. This phenotype is largely achieved through the tumor microenvironment, where cancer cells reside. The growing amount of evidence now shows that hypoxia creates a powerful niche, capable of shifting gene expression in cancer cells through stimulation of HIF activity toward pro-metastatic phenotype and protecting cells from chemo- and radiation treatment. Development of drugs, specifically targeting hypoxic cells, grows rapidly.
References Al-Hajj M, Wicha MS et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983–3988. Arya M, Ahmed H et al (2007) Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration. Tumour Biol 28(3):123–131. Avizienyte E, Frame MC (2005) Src and FAK signalling controls adhesion fate and the epithelialto-mesenchymal transition. Curr Opin Cell Biol 17(5):542–547. Balkwill F (2004) The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14(3):171–179. Bao S, Wu Q et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120):756–760. Berra E, Pages G et al (2000) MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev 19(1–2):139–145. Berx G, Raspe E et al (2007) Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis 24(8):587–597. Blancher C, Moore JW et al (2001) Effects of ras and von Hippel–Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor
54
O.V. Razorenova and A.J. Giaccia
expression and their regulation by the phosphatidylinositol 3’-kinase/Akt signaling pathway. Cancer Res 61(19):7349–7355. Boiko AD, Razorenova OV et al (2010) Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466:133–137. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3(7):730–737. Brizel DM, Scully SP et al (1996) Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56(5):941–943. Brugarolas JB, Vazquez F et al (2003) TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4(2):147–158. Cannito S, Novo E et al (2008) Redox mechanisms switch on hypoxia-dependent epithelial– mesenchymal transition in cancer cells. Carcinogenesis 29(12):2267–2278. Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69(Suppl 3):4–10. Ceradini DJ, Kulkarni AR et al (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10(8):858–864. Chan DA, Giaccia AJ (2007) Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 26(2):333–339. Chan KS, Espinosa I et al (2009) Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 106(33):14016–14021. Chen F, Kishida T et al (1995) Germline mutations in the von Hippel–Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5(1):66–75. Cipolleschi MG, Dello Sbarba P et al (1993) The role of hypoxia in the maintenance of hematopoietic stem cells. Blood 82(7):2031–2037. Cipolleschi MG, Rovida E et al (2000) The expansion of murine bone marrow cells preincubated in hypoxia as an in vitro indicator of their marrow-repopulating ability. Leukemia 14(4):735–739. Comerford KM, Wallace TJ et al (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62(12):3387–3394. Covello KL, Kehler J et al (2006) HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20(5):557–570. Dalerba P, Clarke MF (2007) Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell 1(3):241–242. Dalerba P, Dylla SJ et al (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104(24):10158–10163. Dewhirst MW, Tso CY et al (1989) Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature. Int J Radiat Oncol Biol Phys 17(1):91–99. Endrich B, Reinhold HS et al (1979) Tissue perfusion inhomogeneity during early tumor growth in rats. J Natl Cancer Inst 62(2):387–395. Erler JT, Giaccia AJ (2006) Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res 66(21):10238–10241. Erler JT, Bennewith KL et al (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440(7088):1222–1226. Erler JT, Bennewith KL et al (2009) Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15(1):35–44. Esteban MA, Tran MG et al (2006) Regulation of E-cadherin expression by VHL and hypoxiainducible factor. Cancer Res 66(7):3567–3575. Evans AJ, Russell RC et al (2007) VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol 27(1):157–169. Ezashi T, Das P et al (2005) Low O2 tensions and the prevention of differentiation of hES cells. Proc Natl Acad Sci USA 102(13):4783–4788. Forristal CE, Wright KL et al (2009) Hypoxia inducible factors regulate pluripotency and proliferation in human embryonic stem cells cultured at reduced oxygen tensions. Reproduction 139(1):85–97.
3 Hypoxia, Gene Expression, and Metastasis
55
Fyles AW, Milosevic M et al (1998) Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48(2):149–156. Gardner LB, Corn PG (2008) Hypoxic regulation of mRNA expression. Cell Cycle 7(13): 1916–1924. Gavert N, Ben-Ze’ev A (2008) Epithelial–mesenchymal transition and the invasive potential of tumors. Trends Mol Med 14(5):199–209. Giaccia A, Siim BG et al (2003) HIF-1 as a target for drug development. Nat Rev Drug Discov 2(10):803–811. Gnarra JR, Glenn GM et al (1993) Molecular genetic studies of sporadic and familial renal cell carcinoma. Urol Clin North Am 20(2):207–216. Gordan JD, Bertout JA et al (2007) HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11(4):335–347. Groszer M, Erickson R et al (2001) Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 294(5549):2186–2189. Grunt TW, Lametschwandtner A et al (1985) The vascular pattern of basal cell tumors: light microscopy and scanning electron microscopic study on vascular corrosion casts. Microvasc Res 29(3):371–386. Guarino M, Rubino B et al (2007) The role of epithelial–mesenchymal transition in cancer pathology. Pathology 39(3):305–318. Gustafsson MV, Zheng X et al (2005) Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 9(5):617–628. Hall EJ (1994) Molecular biology in radiation therapy: the potential impact of recombinant technology on clinical practice. Int J Radiat Oncol Biol Phys 30(5):1019–1028. Hambardzumyan D, Squatrito M et al (2006) Radiation resistance and stem-like cells in brain tumors. Cancer Cell 10(6):454–456. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70. Harris AL (2002) Hypoxia – a key regulatory factor in tumour growth. Nat Rev Cancer 2(1):38–47. Heddleston JM, Li Z et al (2009) The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8(20): 3274–3284, Helczynska K, Kronblad A et al (2003) Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res 63(7):1441–1444. Hermann PC, Huber SL et al (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1(3):313–323. Hill RP, Marie-Egyptienne DT et al (2009) Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 19(2):106–111. Hockel M, Knoop C et al (1993) Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26(1):45–50. Hockel M, Schlenger K et al (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56(19):4509–4515. Hoffman MA, Ohh M et al (2001) von Hippel–Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10(10):1019–1027. Huang ST, Vo KC et al (2004) Developmental response to hypoxia. FASEB J 18(12):1348–1365. Hudson CC, Liu M et al (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22(20):7004–7014.Iliopoulos O, Levy AP et al (1996) Negative regulation of hypoxia-inducible genes by the von Hippel– Lindau protein. Proc Natl Acad Sci USA 93(20):10595–10599. Imai T, Horiuchi A et al (2003) Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 163(4):1437–1447. Ivan M, Kondo K et al (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292(5516):464–468. Jaakkola P, Mole DR et al (2001) Targeting of HIF-alpha to the von Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292(5516):468–472.
56
O.V. Razorenova and A.J. Giaccia
Jiang BH, Jiang G et al (2001) Phosphatidylinositol 3-kinase signaling controls levels of hypoxiainducible factor 1. Cell Growth Differ 12(7):363–369. Jogi A, Ora I et al (2002) Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci USA 99(10):7021–7026. Kaelin WG Jr (2008) The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8(11):865–873. Kallman RF, Dorie MJ (1986) Tumor oxygenation and reoxygenation during radiation therapy: their importance in predicting tumor response. Int J Radiat Oncol Biol Phys 12(4):681–685. Keith B, Simon MC (2007) Hypoxia-inducible factors, stem cells, and cancer. Cell 129(3):465–472. Kizaka-Kondoh S, Inoue M et al (2003) Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 94(12):1021–1028. Koshiji M, Kageyama Y et al (2004) HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 23(9):1949–1956. Kucia M, Reca R et al (2005) Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23(7):879–894. Lapidot T, Sirard C et al (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464):645–648. Latif F, Tory K et al (1993) Identification of the von Hippel–Lindau disease tumor suppressor gene. Science 260(5112):1317–1320. Le QT, Denko NC et al (2004) Hypoxic gene expression and metastasis. Cancer Metastasis Rev 23(3–4):293–310. Le QT, Harris J et al (2009) Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90–03. J Clin Oncol 27(26):4281–4286. Lee YM, Jeong CH et al (2001) Determination of hypoxic region by hypoxia marker in developing mouse embryos in vivo: a possible signal for vessel development. Dev Dyn 220(2):175–186. Lee JW, Bae SH et al (2004) Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med 36(1):1–12. Li C, Heidt DG et al (2007) Identification of pancreatic cancer stem cells. Cancer Res 67(3):1030–1037. Li L, Zhang L et al (2007) Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol 27(15):5381–5392. Li X, Lewis MT et al (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100(9):672–679. Li Z, Bao S et al (2009) Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15(6):501–513. Liu G, Yuan X et al (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67. Mahon PC, Hirota K et al (2001) FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15(20):2675–2686. Majumder PK, Febbo PG et al (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10(6):594–601. Makino Y, Cao R et al (2001) Inhibitory PAS domain protein is a negative regulator of hypoxiainducible gene expression. Nature 414(6863):550–554. Matsumoto K, Arao T et al (2009) mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res 69(18):7160–7164. Maxwell PH, Wiesener MS et al (1999) The tumour suppressor protein VHL targets hypoxiainducible factors for oxygen-dependent proteolysis. Nature 399(6733):271–275. Maynard MA, Ohh M (2004) Von Hippel–Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol 24(1):1–13. Maynard MA, Ohh M (2007) The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci 64(16):2170–2180.
3 Hypoxia, Gene Expression, and Metastasis
57
McCord AM, Jamal M et al (2009) Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 7(4):489–497. McLean GW, Carragher NO et al (2005) The role of focal-adhesion kinase in cancer – a new therapeutic opportunity. Nat Rev Cancer 5(7):505–515. Muller A, Homey B et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50–56. Nguyen DX, Bos PD et al (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9(4):274–284. Nordsmark M, Hoyer M et al (1996) The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 35(4):701–708. O’Brien CA, Pollett A et al (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445(7123):106–110. Papandreou I, Powell A et al (2005) Cellular reaction to hypoxia: sensing and responding to an adverse environment. Mutat Res 569(1–2):87–100. Pardal R, Clarke MF et al (2003) Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3(12):895–902. Parmar K, Mauch P et al (2007) Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 104(13):5431–5436. Pause A, Peterson B et al (1999) Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein. Proc Natl Acad Sci USA 96(17): 9533–9538. Phillips RJ, Mestas J et al (2005) Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 280(23):22473–22481. Prince ME, Sivanandan R et al (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104(3): 973–978. Qing G, Simon MC (2009) Hypoxia inducible factor-2alpha: a critical mediator of aggressive tumor phenotypes. Curr Opin Genet Dev 19(1):60–66. Rankin EB, Giaccia AJ (2008) The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15(4):678–685. Reya T, Morrison SJ et al (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105–111. Ricci-Vitiani L, Lombardi DG et al (2007) Identification and expansion of human colon-cancerinitiating cells. Nature 445(7123):111–115. Sahlgren C, Gustafsson MV et al (2008) Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA 105(17):6392–6397. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721–732. Semenza GL (2007) Hypoxia and cancer. Cancer Metastasis Rev 26(2):223–224. Shah-Yukich AA, Nelson AC (1988) Characterization of solid tumor microvasculature: a threedimensional analysis using the polymer casting technique. Lab Invest 58(2):236–244. Shannon AM, Bouchier-Hayes DJ et al (2003) Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29(4):297–307. Singh SK, Clarke ID et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18):5821–5828. Singh SK, Hawkins C et al (2004) Identification of human brain tumour initiating cells. Nature 432(7015):396–401. Sodhi A, Montaner S et al (2001) MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. Biochem Biophys Res Commun 287(1):292–300. Soeda A, Park M et al (2009) Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28(45):3949–3959.
58
O.V. Razorenova and A.J. Giaccia
Sprenger SH, Gijtenbeek JM et al (2001) Characteristic chromosomal aberrations in sporadic cerebellar hemangioblastomas revealed by comparative genomic hybridization. J Neurooncol 52(3):241–247. Staller P, Sulitkova J et al (2003) Chemokine receptor CXCR4 downregulated by von Hippel– Lindau tumour suppressor pVHL. Nature 425(6955):307–311. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663–676. Takahashi K, Tanabe K et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861–872. Todaro M, Alea MP et al (2007) Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1(4):389–402. Tse JC, Kalluri R (2007) Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 101(4):816–829. Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26(2):225–239. Vesuna F, van Diest P et al (2008) Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun 367(2):235–241. Wartenberg M, Ling FC et al (2003) Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J 17(3):503–505. Wernig M, Meissner A et al (2007) In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448(7151):318–324. Wiesener MS, Jurgensen JS et al (2003) Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 17(2):271–273. Wulf GG, Wang RY et al (2001) A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98(4):1166–1173. Yang J, Mani SA et al (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117(7):927–939. Yang J, Mani SA et al (2006) Exploring a new twist on tumor metastasis. Cancer Res 66(9):4549–4552. Yang MH, Wu KJ (2008) TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development. Cell Cycle 7(14):2090–2096. Yang MH, Wu MZ et al (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10(3):295–305. Yoshida J, Horiuchi A et al (2009) Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression. Med Mol Morphol 42(2):82–91. Zagzag D, Lukyanov Y et al (2006) Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 86(12): 1221–1232. Zbar B, Kishida T et al (1996) Germline mutations in the Von Hippel–Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 8(4):348–357. Zelzer E, Levy Y et al (1998) Insulin induces transcription of target genes through the hypoxiainducible factor HIF-1alpha/ARNT. EMBO J 17(17):5085–5094. Zhao S, Lin Y et al (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324(5924):261–265. Zheng H, Ying H et al (2008) p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455(7216):1129–1133. Zundel W, Schindler C et al (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14(4):391–396.
Chapter 4
Molecular Mechanisms Regulating Expression and Function of Cancer-Associated Carbonic Anhydrase IX Jaromir Pastorek and Silvia Pastorekova
Abstract Hypoxia and acidosis are typical physiological factors of tumor microenvironment acting in concert to support invasive and metastatic propensity of tumor cells through rearrangement of their gene expression profile and remodeling of their phenotype. Induction of carbonic anhydrase IX (CA IX) has recently been recognized as one of the important molecular events observed in tumor cells exposed to hypoxia. CA IX can serve as a “tag” of hypoxic areas in many tumor types and thereby provides a diagnostic tool as well as a target for selective delivery of anticancer immunotherapy. Moreover, CA IX actively contributes to pH regulation which protects tumor cells from acidosis and thereby provides a target for anticancer therapy based on reduction of tumor cell survival via inhibition of CA IX enzyme activity. Both aspects attract considerable attention but their full appraisal and further development require deeper understanding of the mechanisms behind CA IX expression and functioning. Here, we summarize and discuss the “state of the art” of CA IX field in context of its relevance for tumor microenvironment.
Carbonic Anhydrases Acid–base balance mediated by equilibrium between carbon dioxide and carbonic acid is essential for proper functioning of metabolically active cells, tissues, and organs in virtually all living organisms. Although reversible conversion of carbon dioxide to carbonic acid followed by dissociation of carbonic acid to bicarbonate ion and a proton can proceed spontaneously, turnover of this reaction is not fast enough to satisfactorily supply physiological processes and therefore, it needs to be catalyzed by zinc-binding enzymes traditionally called carbonic anhydrases (CAs).
J. Pastorek (*) Department of Molecular Medicine, Institute of Virology, Slovak Academy of Sciences, Dubravska cesta 9, 845 05 Bratislava, Slovak Republic e-mail:
[email protected] R.G. Bagley (ed.), The Tumor Microenvironment, Cancer Drug Discovery and Development, DOI 10.1007/978-1-4419-6615-5_4, © Springer Science+Business Media, LLC 2010
59
60
J. Pastorek and S. Pastorekova
CAs are present all over the kingdoms of animals, plants, fungi, and bacteria (including archeabacteria), and are encoded by five genetically unrelated families (a–e), each containing diverse isoforms (Supuran 2008). Human CAs belong to a-CA family, which is characterized by a deep and wide active site pocket that contains three histidine residues coordinating catalytic zinc at the bottom of the active site cleft and the fourth histidine residue functioning as a proton shuttle between the active site and solution shifting between inward and outward orientation (Zheng et al. 2008). Twelve out of fifteen human a-CA isoforms are catalytically active (CA I–IV, VA, VB, VI, VII, IX, XII–XIV). In addition to histidine residues, they contain also other conserved amino acids involved in formation of inner and outer layers of the active site cavity. The CA isoezymes differ by their catalytic activity that ranges from extremely high (in case of CA II and CA IX that belong to most efficient enzymes in general) through high/intermediate (CA IV, V, VI, VII, XII, XIV) to very low (CA I, III), as shown in Fig. 4.1. Three acatalytic isoforms (CA VIII, X, XI) lack one of three critical zinc-coordinating histidines. Moreover, there are two CA-related proteins that function as receptor protein tyrosine phosphatases (RPTPb/g). Their incompletely conserved, catalytically silent CA domain pocket serves as a ligand-binding site for neuronal adhesion molecule contactin (Peles et al. 1995).
Fig. 4.1 Schematic illustration of the human CA isoforms, their domain composition, enzyme activity, and subcellular localization. Cytoplasmic and mitochondrial CAs consist only of the CA domain, secreted CA contains a short C-terminal extension, membrane-associated CAs in addition have a transmembrane anchor and, except for CA IV, also the cytoplasmic tail. CA IX is the only isoform containing the N-terminal PG-like domain. Structure of the CA IX isoforms is depicted in more detail on the left side. It includes signal peptide (SP), proteoglycan-like segment (PG), carbonic anhydrase domain (CA), transmembrane anchor (TM), and intracytoplasmic tail (IC). Conserved zinc-binding histidines are indicated by black circles, cysteines are shown as white squares, and intramolecular disulfidic bond is drawn as dotted line. Numbers designate amino acids encompassed within the individual domains
4 Molecular Mechanisms Regulating Expression
61
Evolutionarily oldest human CA isoenzymes contain an extracellular catalytic domain and are either transmembrane (CA IX, XII, XIV), or membrane-associated via GPI anchor (CA IV) or secreted (CA VI). The transmembrane CAs also contain a hydrophobic region and a relatively conserved intracellular tail. In addition, CA IX possesses an N-terminal proteoglycan-like region. The younger CAs (I, II, III, V, VII) are intracellular isoenzymes containing a sole CA domain. Except CA VA and VB that reside in the mitochondrion, all intracellular CAs are located in the cytoplasm. Finally, the evolutionarily youngest cluster includes inactive cytoplasmic isoforms mentioned above. CAs are spread throughout the human body. Some of them are ubiquitous (CA II) or broadly distributed (CA IV, XII, XIII), others are confined to only few tissues/cell types such as muscle and adipocytes (CA III), liver (CA VA), and saliva and milk (CA VI). Cells/organs of the most abundant CA expression include the red blood cells, brain, lung, gut, liver, kidney, and testis, where various concurrently present CA isoforms cooperatively contribute to breathing, synaptic transmission, CSF secretion, production of ocular fluid, bone resorption, secretion of gastric acid, urine acidification, sperm maturation, etc. In metabolically active tissues such as kidney or stomach epithelia, the active CAs located in various subcellular compartments or on the opposite sites of the plasma membrane can interact with bicarbonate transporters or biosynthetic enzymes to form spatially and functionally coordinated protein complexes called metabolons (McMurtrie et al. 2004). In bicarbonate transport metabolon, CAs can improve the transmembrane movement of bicarbonate ion, which is a membrane-impermeable molecule transported by integral membrane bicarbonate transporters and exchangers (Casey 2006). The role of CAs is to increase the local concentration of bicarbonate in order to accelerate its flux across the membrane and thereby regulate intracellular and extracellular pH (McMurtrie et al. 2004). CAs are essential components of physiological processes and disbalance in their expression is associated with several diseases. These include on the one hand osteopetrosis and mental retardation due to CA II deficiency and, on the other hand, glaucoma, diabetic retinopathy, epilepsy, obstructive pulmonary disease, obesity and various neurological diseases linked with abnormally high expression of CA II, III, XII, and other isoforms. Some of these diseases are successfully treated with inhibitors of CA activity used as primary or supplementary therapy, for the others, new derivatives of CA inhibitors are under development as promising drugs (Pastorekova et al. 2004b). Although importance of CAs in cancer has been demonstrated relatively recently, inspections into their expression in tumor cells and tissues have been initiated a long time ago. Several independent studies revealed reduced activity and/or decreased levels of cytosolic isoforms CA I, II, III, XIII in colorectal, hepatocellular, and lung tumors (when compared to their normal counterparts) indicating that these isoforms are predominantly needed for differentiated cells/tissues (Chiang et al. 2002; Kivela et al. 2001; Kummola et al. 2005; Kuo et al. 2003; Mori et al. 1993; Yoshiura et al. 2005). This conclusion has, however, few exceptions, including CA II expression in endothelium of malignant melanomas and meningiomas and a recently discovered
62
J. Pastorek and S. Pastorekova
extremely high expression of CA II in gastrointestinal stromal tumors (Haapasalo et al. 2007; Yoshiura et al. 2005; Parkkila et al. 2010). Relationship of the mitochondrial CA VA and VB isoforms to cancer remains unexplored, although they might be relevant for biosynthesis of metabolic intermediates in proliferating tumor cells. Finally, out of four CA isoforms localized at the cell surface, only CA IX and XII showed consistent link with tumor tissues and are systematically investigated as promising targets for anticancer therapy (Pastorekova et al. 2008). Especially CA IX, which is almost exclusively expressed in tumors, attracts considerable interest with expectation that unraveling its regulation and functional contribution to tumor phenotype will provide clues for development of new anticancer strategies.
Molecular Features of CA IX CA IX (initially named MN antigen) was identified in HeLa cervical carcinoma cells as a density-induced cell surface protein associated with tumor phenotype of human cell lines and tissue specimens (Pastorekova et al. 1992; Zavada et al. 1993). Primary structure of the MN antigen was derived from cDNA and genomic sequences and was found to contain a well-conserved carbonic anhydrase domain located in the large extracellular part of the molecule (Pastorek et al. 1994) (Fig. 4.1). This CA domain shows a significant identity to secreted isozyme CA VI (40.8%) and cytosolic isozyme CA II (35.8%), respectively, and possesses all important amino acids required for the catalytic activity. It is N-glycosylated by 4 kDa high mannose sugar chain attached to N346 and is catalytically active. At the time of MN protein discovery, this was the ninth mammalian CA identified and thus it was renamed to CA IX (Hewett-Emmett and Tashian 1996). In addition to catalytic domain, CA IX (as the only CA isoform) contains an N-terminal PG-like region homologous to keratan sulfate attachment domain of a large proteoglycan aggreccan (Opavsky et al. 1996). According to mass spectrometric analysis, this part of the molecule appears to contain a keratan sulfate glycosaminoglycan chain of about 3.5 kDa that is presumably attached to T115, in the article numbered T78 (without signal peptide) (Hilvo et al. 2008). Presence of such modification might have important biological implications analogous to keratan sulfate chain of CD44 metastasis-related protein, which mediates interactions with constituents of extracellular matrix. However, experimental proof of this concept has not been given for CA IX so far. The PG-like region has also another important feature – it predominantly contains negatively charged acidic amino acids that are mostly arranged within four identical and three imperfect GEEDLP repeats. This results in remarkably acidic character of the PG-like region that seems to have a significant impact on the catalytic activity of CA IX as an intrinsic buffer optimizing CO2 hydration at acidic pH values characteristic for solid tumors (Innocenti et al. 2009). Thus, activity of the entire extracellular portion of CA IX (including PG and CA domains) expressed in baculovirus system exceeds that of CA II
4 Molecular Mechanisms Regulating Expression
63
(the best known catalyst) and reaches maximum at pH values around 6.5 in contrast to other CA isoforms which have optimum catalytic efficiency around pH 7. C-terminal part of the catalytic domain is extended with a little juxtamembrane fragment, followed by a hydrophobic transmembrane (TM) region and a short intracellular tail (IC). The IC tail is well conserved among the transmembrane CA isoforms (CA IX, XII, XIV) and its removal leads to loss of cell surface location of CA IX despite preserved TM region suggesting that IC mediates protein–protein interactions that maintain CA IX at its proper position (Hulikova et al. 2009). In vitro mutagenesis of the submembrane cluster of basic amino acids revealed that IC tail participates in inside-out signaling that affects functions of the extracellular CA IX portion (Hulikova et al. 2009). In addition, the IC tail contains three potential phosphorylation sites (T443, S448, andY449). While Y449 participates in EGFRinduced signal transduction to Akt kinase (Dorai et al. 2005), phosphorylated T443 is critical for modulation of the pH regulatory function of CA IX (manuscript in preparation). Molecular weight of CA IX analyzed under reducing conditions and visualized on Western blot corresponds to 58/54 kDa. Existence of two forms of the protein remains unexplained and the data attributing the double band to different parts of CA IX molecule are still controversial. Interestingly, in non-reducing conditions, CA IX is capable to form oligomers that were initially considered for trimers (or tetramers). This supposition was based on the molecular weight of about 153 kDa and on other indices including the capability of CA IX to fit into envelope of the vesicular stomatitis virus and form the virus pseudotypes (Pastorekova et al. 1992; Zavada et al. 1993). The latter aspect was shown to require trimerization or tetramerization (Kreis and Lodish 1986). In fact, CA IX molecule contains four cysteine residues, three of them located in the catalytic domain and one in the region just above the plasma membrane. While C156 and C336 are placed at the positions analogous to intra-molecular S–S bond-forming cysteines in other CAs, the additional two residues C174 and C409 might be theoretically available for intermolecular S–S bonds. Biochemical and crystallographic studies confirmed the proposed intramolecular S–S bond, but they also suggested that CA domain of CA IX forms dimer stabilized by homologous S–S bridge between C174 corresponding to C41 according to CA I numbering (Alterio et al. 2009). Although results of the biochemical and crystallographic analyses do not support the concept of CA IX trimerization, it is still possible that the discrepancy results from the absence of the regions flanking the catalytic domain, as it was observed also in other cases, such as with Fas receptor or TRAF6 (Scott et al. 2009; Yin et al. 2009). Crystallographic analysis brought very important structural data on the CA IX catalytic domain that is similar to other a-CAs (Alterio et al. 2009). It has a compact globular appearance with a large conical cavity containing zinc ion at the bottom. The entrance to the active site is occupied by three arginine residues R95, R97, and R167, which are not conserved in other CA isoforms and have been proposed to mediate crosstalk of CA domain with acidic PG-like region presumably implicated in steric control of the substrate accession or the proton-transfer reaction. The active site and the N-terminus of the catalytic domain face the extracellular space, whereas
64
J. Pastorek and S. Pastorekova
its C-terminus is oriented toward the plasma membrane. This arrangement is fully compatible with the role of CA IX in extracellular acidification of tumor microenvironment.
CA IX Tissue Distribution CA IX protein expression has been studied in a broad range of human tissues. Most of these studies were performed using the monoclonal antibody M75 that recognizes a repetitive linear epitope in the PG-like domain of both native and denatured CA IX (Zavada et al. 2000) and is therefore suitable for virtually all immunodetection methods including immunohistochemistry on both paraffinembedded and frozen sections (even those archived for years), immunoblotting, immunoprecipitation, flow cytometry, etc. Additional antibodies produced by our team (Zat’ovicova et al. 2003) are mostly directed to CA domain and bind to conformational epitopes (thus they do not work in immunoblotting) similarly to well-known monoclonal antibody G250 that was generated even before the discovery of CA IX against a renal cell carcinoma antigen later shown to be identical to CA IX (Oosterwijk 2008a, b). New human monoclonal antibodies described recently display excellent CA IX binding properties (Ahlskog et al. 2009b). Some of these antibodies have a great potential as diagnostic and therapeutic tools. Noteworthy, a commercial antibody NB100 was advertised to give the same staining pattern as M75, but later demonstration of its significant non-specific reactivity against tubulin considerably reduces its value for detection of CA IX (Li et al. 2009). Overall expression pattern of CA IX is characterized by limited expression in normal tissues and broad distribution in different tumors. Physiological expression of CA IX is linked with epithelial tissues of the gastrointestinal tract with the highest CA IX level in all principal cell types of the glandular gastric mucosa and in the gallbladder epithelium. CA IX is also present in the small intestine and proximal colon, but its level decreases toward rectum (Pastorekova et al. 1997). Intestinal CA IX is expressed in the cryptal epithelial cells that possess the greatest proliferative activity (Saarnio et al. 1998). CA IX is also abundant in the gallbladder mucosa, while the pancreatic ducts show only weak expression. In all gastrointestinal epithelia, CA IX is present in the basolateral membranes, suggesting its possible involvement in intercellular communication, maintenance of tissue integrity, and regulation of basolateral ion transport (Pastorekova et al. 1997). Based on gastric phenotype of CA IX-deficient mice that includes hyperplasia, numerous cysts, and abnormal lineage development but no change in gastric pH, CA IX plays a role in gastric morphogenesis and control of cell proliferation and/or differentiation (Gut et al. 2002). CA IX is also expressed in some other healthy tissues, albeit at much lower levels compared to alimentary tract. These include linings of the body cavity, reproductive tract, ventricular linings of CNS, and choroid plexus (Ivanov et al. 2001). The other normal human tissues are CA IX negative.
4 Molecular Mechanisms Regulating Expression
65
In contrast, CA IX expression is readily detected at significant levels in diverse tumors, including carcinomas of the uterine cervix, kidney, brain, head and neck, esophagus and lung, colon, breast, ovaria, endometrium, vulva, bladder, etc. (Bartosova et al. 2002; Haapasalo et al. 2006; Ivanov et al. 2001; Jarvela et al. 2008; Kowalewska et al. 2005; Liao et al. 1994, 1997; McKiernan et al. 1997; Niemela et al. 2007; Saarnio et al. 1998; Turner et al. 1997; Vermylen et al. 1999). From an unknown reason, CA IX is only occasionally expressed in the prostate carcinomas (Smyth et al. 2009).
Regulation of CA IX Expression Presence of CA IX in cancerous tissues of different origin suggests that it represents a phenomenon common to all solid tumors. In accord with this supposition, it has been proven that transcription of CA IX is principally driven by hypoxia that occurs in variable extent in virtually all tumor tissues. Hypoxia often develops in growing tumors due to insufficient supply of oxygen by irregular and functionally inadequate vasculature. This creates a selective pressure favoring those tumor cells that are capable to induce adaptative responses including shift to anaerobic glycolysis, angiogenesis, reduced proliferation and cell adhesion, increased pH regulation, etc. Consequently, hypoxic cells gain oncogenic metabolism, resistance to conventional anticancer treatment, and more aggressive phenotype with metastatic potential (Harris 2002). At the molecular level, hypoxia leads to reprogramming of the cell’s transcriptional profile, which is principally governed by a master transcription factor HIF, i.e. hypoxia inducible factor (Coleman and Ratcliffe 2007), illustrated in Fig. 4.2. HIF is a heterodimer consisting of an oxygen-regulated a subunit (existing in three isoforms) and a constitutive b subunit. In normoxia, HIF-a is modified by oxygendependent prolyl hydroxylases (PHDs) and an asparaginyl hydroxylase (factor inhibiting HIF, named FIH), enzymes that belong to the Fe(II) and 2-oxoglutarate dioxygenase superfamily. FIH hydroxylates N803 in the C-terminal activation domain of human HIF-1a and thereby prevents its interaction with transcriptional coactivators. Prolyl hydroxylases hydoxylate P564 and P402 in the oxygen-dependent degradation domain, thus leading to HIF-a recognition by pVHL tumor suppressor protein, followed by its rapid ubiquitilation and proteasome degradation (Hirota and Semenza 2005). In hypoxia and/or following oncogenic activation or loss of VHL function, HIF-a escapes modifications by PHDs and FIH, enters the nucleus, dimerizes with the constitutive b subunit of HIF, interacts with coactivators, and forms an active transcriptional complex (Ruas and Poellinger 2005). This complex binds DNA at sites containing the hypoxia-response element (HRE; 5¢-RCGTG-3¢), which is present in the promoters of a wide spectrum of target genes encoding functionally diverse proteins involved in angiogenesis (VEGF, VEGF receptor, transforming growth factor TGF-b), vascular tonus (nitric oxide synthase), erythropoiesis (erythropoietin-1),
66
J. Pastorek and S. Pastorekova
Fig. 4.2 Hypoxia-induced HIF-1-mediated transcriptional activation of CA9 gene. The left side shows the situation in normoxia. When oxygen supply is sufficient, prolyl hydroxylases (PHD) and factor inhibiting HIF (FIH) modify a-subunit of hypoxia-inducible factor 1 (HIF-a). Hydroxylation of conserved prolines in HIF-a molecule leads to its recognition by von Hippel– Lindau tumor suppressor protein (VHL), which triggers HIF-a ubiquitilation and degradation. Hydroxylaion of N-terminal asparagine blocks binding of co-activators. This principally results in the absence of active HIF-a from normoxic cells. The right part shows the situation in hypoxia. Lack of oxygen keeps hydroxylases inactive, HIF-a is not modified and remains protected from recognition by VHL. This results in stabilization and accumulation of HIF-a, translocation to nucleus, dimerization with HIF-b, interaction with co-activators, and formation of active transcription complex, which induces expression of target genes, including CA9. This induction can be modified by additional pathways not shown in the figure and leads to exposure of CA IX protein on the surface of hypoxic cells
glycolysis (glucose transporters GLUT-1,3, lactate dehydrogenase LDH-A, pyruvate dehydrogenase kinase PDK1), ion transport and pH regulation (natrium-proton exchanger NHE1, monocarboxylate transporter MCT4), remodeling of extracellular matrix (matrix metalloproteinase MMP-2, cathepsin D), adhesion and migration (hepatocyte growth factor receptor c-Met, transcription factors Snail/Slug), cell proliferation and survival (insulin growth factor-binding protein), drug resistance (P glycoprotein), and additional cellular phenomena linked with tolerance of tumor cells to hypoxia. Genomic position of HRE differs among the transcriptional targets of HIF, in some cases representing enhancer rather than promoter element (Camenisch et al. 2001). In case of the CA9 gene, HRE is an important component of the core promoter and its position adjacent to transcription initiation site (–3/–10) makes it a key regulatory element principally determining CA9 gene expression (Wykoff et al. 2000). This HRE element binds HIF-1 (rather than HIF-2) and cooperates with a neighboring consensus sequence binding SP1 transcription factor (Kaluz et al. 2002). The HRE-SP1 module is critical for transcriptional activation of the CA9 gene both in hypoxia and in high cell density (creating pericellular hypoxia) and its mutagenesis leads to reduction or complete loss of the promoter activity (Kopacek et al. 2005). Additional regulatory elements present within the CA9 promoter, including AP-1 binding site and position/orientation-independent
4 Molecular Mechanisms Regulating Expression
67
silencer, play secondary roles as they just modulate the outcome of the transcriptional activation triggered by HIF-1-SP1 (Kaluz et al. 1999). As recently discussed, CA9 transcription profile primarily reflects the transcriptional activity (not the level) of HIF-1 (Kaluz et al. 2009). In accord, different pathways that affect HIF-1 can also increase the expression of CA9 gene, such as MAPK and PI3 kinase pathways, Notch pathway, HBx oncoprotein of hepatitis B virus, and v-Src and c-Src oncoproteins (Holotnakova et al. 2010; Kopacek et al. 2005; Sansone et al. 2007; Takacova et al. 2010). Moreover, hypoxia-induced CA9 gene expression requires an intact unfolded protein response (UPR) pathway, which operates via ATF4 transcription factor that binds to CA9 promoter (van den Beucken et al. 2009a, b). Under normoxic conditions, expression of CA9 gene is down-regulated by pVHL tumor suppressor protein, which negatively regulates HIF-1a. However, CA9 expression is not suppressed by the mutated variants of pVHL lacking the elongin binding domain which is required for the interaction of pVHL with elongins B/C and integration of pVHL within a ubiquitin ligase complex (Ivanov et al. 1998). This explains why CA IX protein is overexpressed in a high percentage of renal cell carcinomas (RCC) that frequently carry an inactivating mutation in the VHL gene (Mandriota et al. 2002). Extracellular acidosis, which frequently occurs in tumor microenvironment, contributes to CA9 transcription at least in some tumor cell types, such as those derived from glioblastoma (Ihnatko et al. 2006). CA9 induction by acidosis can be observed in both absence and presence of hypoxia. Promoter analysis revealed involvement of SP1 and HRE promoter elements and showed that acidosis can modulate CA9 expression only when basic CA9 activation through MAPK and/or PI3K pathways is preserved. However, inconsistent effects of acidosis on CA9 expression were obtained in other cell types possibly due to their differential sensitivity to acidosis-associated stress (Willam et al. 2006). Finally, transcription of CA9 gene can be negatively controlled by methylation of CA9 promoter and by treatment with xenobiotics (Ashida et al. 2002; Cho et al. 2000; Jakubickova et al. 2005; Takacova et al. 2009). CA9 is also a subject of post-transcriptional regulation via alternative splicing that produces two types of transcripts – a full-length transcript encoding a plasma membrane-localized and functionally competent CA IX protein, and a truncated mRNA lacking exons 8/9 and producing a cytoplasmic/secreted form of CA IX protein with decreased enzyme activity (Barathova et al. 2008). The longer transcript is regulated by hypoxia and linked to tumor phenotype, whereas the shorter one is expressed at low level independently of hypoxia and is therefore detectable also under normoxia and in the normal tissues. This is very important for the correct design of primers used in the clinical studies of cancer- and/or hypoxia-related expression of CA9, where the alternatively spliced variant can provide a falsepositive signal. As recently demonstrated in non-small cell lung carcinoma, fulllength CA9 transcript is the most accurate surrogate of hypoxic stress and represents the only variant with a prognostic role (Malentacchi et al. 2009). These data indicate the importance of a separate measurement of the two isoforms in cancer and
68
J. Pastorek and S. Pastorekova
the need of an accurate re-evaluation of most studies on the clinical role of CA9 mRNA in cancer diagnosis. At the posttranslational level, CA IX protein shows high stability, with the halflife of about 38 h (as determined in reoxygenated HeLa cells), and therefore represents a marker of both present and past hypoxia (Rafajova et al. 2004). The final amount of CA IX protein is regulated by shedding of its ectodomain (ECD) to culture medium and to body fluids of tumor patients (Zatovicova et al. 2005; Zavada et al. 2003). Constitutive shedding of CA IX ECD releases approximately 10% of the cell-associated protein and is sensitive to metalloproteinase-inhibitor batimastat. Hypoxia maintains the normal rate of the basal ECD release, thus leading to a concomitant increase in cell-associated and extracellular levels of CA IX. The CA IX ECD shedding can be several fold induced by treatment with phorbol12-myristate-13-acetate and pervanadate. This activated shedding is mediated by TNF-a-converting enzyme (TACE/ADAM17). Thus, cleavage of CA IX ectodomain appears to be a regulated process that responds to signal transduction-related stimuli and may contribute to adaptive changes in the protein composition of tumor cells and of their microenvironment. In this context, it is noteworthy that the extracellular domain of CA IX shed to body fluids is a promising circulating cancer marker for patient selection, and monitoring of treatment outcome (Carney 2007). Finally, posttranslational modifications, such as phosphorylation, regulate the CA IX-mediated signal transduction (Dorai et al. 2005) as well as the functional status of CA IX (the latter aspect has just been experimentally proven). Taken all data together, it can be concluded that control of CA9 gene expression is a complex process, which affects biogenesis of CA IX protein at several levels, including the functional activation (as discussed in the text below). It is also evident that hypoxic pathway is a major regulator of CA IX.
Role of CA IX in Cancer Hypoxic regulation of CA9 gene indicates that it is a part of the adaptive mechanisms of tumor cells exposed to hypoxia (and associated acidosis) and that the cells need the CA IX protein to survive these stresses typical for tumor microenvironment. In accord with this supposition, it has been demonstrated that CA IX protein is functionally involved in pH regulation and in cell adhesion–migration–invasion, which are important phenomena contributing to tumor progression. The need for increased pH regulation is related to metabolic changes triggered by hypoxia. Insufficient oxygen delivery to hypoxic tumor areas restricts energy production by oxidative phosphorylation and induces metabolic shift of hypoxic cells to glycolysis, which can produce ATP in the absence of oxygen. For this purpose, HIF-1 coordinates up-regulation of virtually all glycolytic enzymes and glucose transporters, as well as lactate dehydrogenase isoforms LDH-A and LHD5, which convert pyruvate to lactate, and also pyruvate dehydrogenase kinase 1, which prevents entry of pyruvate into the Krebs cycle and reinforces the glycolytic
4 Molecular Mechanisms Regulating Expression
69
metabolism (Brahimi-Horn and Pouyssegur 2007). Although glycolysis is less efficient in energy production than respiration, its metabolic intermediates can be utilized for biosynthetic reactions and this makes it useful for proliferating tumor cells in both anaerobic and aerobic conditions, in accord with the classical Warburg’s observation (Gatenby and Gillies 2004). For that reason, tumor cells depend on oncogenic metabolism, in which glycolysis predominates over respiration to extent depending on oxygen availability and activation of different oncogenic pathways. Glycolysis generates lactate as an end-product, but the oncogenic metabolism produces also excess of protons and CO2 (Helmlinger et al. 2002). These acidic products have to be eliminated from tumor cells to maintain neutral intracellular pH and preserve proliferation and survival. The acidic waste then accumulates in the extracellular space because of its insufficient removal by inadequate tumor vasculature and causes extracellular acidosis (Stubbs et al. 2000). Acidosis develops especially in tumor regions that suffer from hypoxia. This is supported by correlation between the mean profiles of partial oxygen pressure and intratumoral pH values (Helmlinger et al. 1997), as well as by VHL/HIF pathway controlled expression of several pH regulating molecules (Karumanchi et al. 2001). Importantly, acidic extracellular pH (pHe) has been associated with tumor progression via multiple effects including up-regulation of angiogenic factors and proteases, increased invasion, and impaired immune functions (Fukumura and Jain 2007; Raghunand et al. 2003). In addition, it can influence the uptake of anticancer drugs and modulate the response of tumor cells to conventional therapy (Teicher 2009). Tumor cells utilize two main mechanisms to regulate their pH – lactate/proton extrusion and bicarbonate uptake (Fig. 4.3). Lactic acid and protons are extruded mostly by the H+/monocarboxylate transporters (MCT4 and MCT1) and the Na+/H+ exchanger (NHE1). Bicarbonate ions are imported by anion exchangers (e.g. AE2) or Na+/bicarbonate co-transporters (NBC1) and react with intracellular protons, thereby increasing the intracellular production of CO2, which diffuses across the plasma membrane to extracellular space. However, origin of the extracellular bicarbonate ions in an acidic pericellular milieu was unclear until CA IX was described as a component of hypoxic tumor phenotype (Stubbs et al. 2000). CA IX seems to be “designed” for this purpose, because its high catalytic activity is insensitive to lactate and reaches maximum at pH 6.5 typical for acidic tumor microenvironment (both aspects contrasting with other CA isoforms) (Innocenti et al. 2005, 2009). In addition, the catalytic domain of CA IX is localized on the cell surface and its entrance is exposed to extracellular space in the position suitable for accommodating CO2 substrate (Alterio et al. 2009). Moreover, CA IX activity is inhibited by bicarbonate suggesting that it operates mainly in catalysis of CO2 hydration to produce bicarbonate rather than to utilize it (Innocenti et al. 2005). Finally, CA IX spatially and functionally cooperates with bicarbonate exchangers/ transporters in bicarbonate transport metabolon (Morgan et al. 2007). According to a recent concept, bicarbonate locally produced by CA IX from extracellular CO2 is directly consumed for transport and neutralization of intracellular pH in tumor cells, whereas proton produced in the same reaction remains
70
J. Pastorek and S. Pastorekova
Fig. 4.3 Role of CA IX as a component of pH regulatory machinery in cancer cell. Hypoxia induces expression of many proteins involved in metabolism and pH regulation including GLUT-1 and glycolytic enzymes. This causes shift to glycolysis that produces excess of lactate and protons. To preserve neutral intracellular pH, these acidic products are extruded by HIF-1-regulated monocarboxylate transporter (MCT4) and the Na+/H+-exchanger (NHE1) and acidify the extracellular microenvironment. Tumor cells also produce CO2 that diffuses across the plasma membrane. Extracellular CO2 is hydrated in a reaction catalyzed by CA IX, which produces protons and bicarbonate ions. Protons remain outside of cell and further enhance acidosis. Bicarbonate ions are delivered directly to bicarbonate transporters (BT) for accelerated inward transport to cytoplasm where they buffer protons and contribute to intracellular pH neutralization. This produces CO2 that leaves the cell by diffusion and may enter new round of hydration
outside of cells and increases extracellular acidosis (Fig. 4.3). In accord with this concept, CA IX role in pH regulation was demonstrated using different cellular models either with constitutive overexpression of CA IX or with suppression of CA IX by RNA interference. The first proof was obtained using MDCK cells grown in monolayer, in which CA IX could acidify the culture medium in hypoxia but not in normoxia, suggesting that hypoxia activates the catalytic performance of CA IX (Svastova et al. 2004). Additional evidence was obtained in three-dimensional multicellular spheroids generated from transfected HCT116 cells (Swietach et al. 2008, 2009). There, the ectopic expression of CA IX resulted in less prominent core intracellular acidity and in enhanced core extracellular acidity. The data obtained in spheroids and interpreted in the framework
4 Molecular Mechanisms Regulating Expression
71
of tumor microenvironment indicate that CA IX facilitates CO2 excretion from cells and that this effect depends on the cellular CO2/lactic acid emission ratio set by local oxygenation and bicarbonate uptake (Swietach et al. 2009). Finally, in hypoxic LS174Tr tumor cells, CA IX was shown to contribute to extracellular acidification in response to a CO2 load and to maintenance of a neutral-alkaline intracellular pH (Chiche et al. 2009b). This latest study also demonstrated that CA IX preserves tumor cell survival in a range of acidic extracellular pH (6.0– 6.8). Moreover, CA IX silencing led to a 40% reduction in xenograft tumor volume supporting the view that hypoxia-induced CA IX is a significant tumor pro-survival pH-regulating enzyme. Interestingly, parallel suppression of CA IX and XII caused dramatic 85% reduction in tumor growth, suggesting cooperation/ compensation of these transmembrane CA isoforms (although suppression of CA XII alone had no effect). The second function of CA IX is linked to cell adhesion and related processes, such as motility, migration, and invasion, which facilitate tumor progression. Again, the insight into this role of CA IX was obtained in the study of E-cadherin-mediated cell–cell adhesion in CA IX-transfected MDCK cells (Svastova et al. 2003). Ectopic expression of CA IX resulted in decreased intercellular contacts, reduced aggregation, and increased dissociation. Similarly to some oncoproteins, such as EFGR and Muc-1, CA IX acts via competitive interaction with b-catenin, thereby disconnecting E-cadherin from adhesion contacts with actin cytoskeleton. The capability of CA IX to interfere with the function of E-cadherin in those tumors that express both proteins might contribute to acquisition of more aggressive phenotype. Since decreased cell adhesion is a prerequisite of motile/migratory phenotype, it was tempting to examine possible involvement of CA IX. Recent experiments using various cell models have shown that expression of CA IX leads to increased scattering, better wound healing, and improved transwell migration both with and without HGF stimulation (manuscript in preparation). On the other hand, the suppression of CA IX by RNA interference decreases the wound healing capacity of tumor cells (Chiche et al. 2010). In this context, it is important to note that motility and migration require not only coordinated formation and release of cell adhesion contacts, digestion and reorganization of the extracellular matrix, but also intense local ion and water transport across the plasma membrane. All of these operations depend on intracellular and extracellular pH regulation. Thus, cell migration is significantly affected by mechanisms that protect tumor cells from hypoxia and acidosis (Stock and Schwab 2009). This knowledge is integrated into a model, in which protruding edge of migrating cell is occupied and driven by different components of ion transport and pH regulating machinery (including CA IX). On this basis, it is conceivable that the catalytic activity plays a considerable role in CA IX-induced de-adhesion, motility, and migration and that the PG domain, implicated in these processes, requires a cooperation with the CA domain (and possibly also with intracellular tail) of CA IX. Initial experimental data favor this idea (unpublished data).
72
J. Pastorek and S. Pastorekova
Clinical Value of CA IX Association with different solid tumors and up-regulation by hypoxia predisposes CA IX to serve as an intrinsic marker of hypoxia and prognostic indicator (Potter and Harris 2004). Moreover, expression pattern and functional involvement of CA IX in hypoxic tumor phenotype make it a suitable target for anticancer treatment (Pastorekova et al. 2006). Both aspects already found a considerable support in clinical studies, in vivo models, and even in the clinical trials. When considering CA IX as a marker of hypoxia, it is important to take into account temporal parameters of its induction and stability. Based on cell culture data, CA IX protein appears on the cell surface several hours after exposure of cell culture to hypoxia, reaching maximum level at around 16 h (Rafajova et al. 2004). Due to its high stability, CA IX remains detectable for several days also in reoxygenated cells. Moreover, CA9 gene is responsive to a broad range of oxygen concentrations representing severe to moderate hypoxia, with optimum between 1 and 2% atmospheric O2 in culture conditions. These parameters differ from those of HIF-1a, which is both quickly induced and short-lived protein as well as from metabolic labels, such as pimonidazole, which accumulates only in severely hypoxic cells (as indicated by narrow perinecrotic incorporation pattern). Furthermore, HIF-1a staining only detects protein levels, but not the transactivation status, which actually determines induction of transcriptional targets. All these facts can explain why there is incomplete overlap between HIF-1a staining and CA IX staining in tumor tissue specimens, and why there are areas with presence of CA IX in absence of HIF-1a and vice versa. From the similar reasons, partial discrepancy exists also between CA IX and other HIF-1 targets, such as VEGF (which is secreted and considerably regulated by non-hypoxic pathways), GLUT-1 (which shows the highest response at 0.1% O2), and surely also other HIF-regulated molecules that all differ with respect to time and magnitude of induction, stability, and other characteristics (Lendahl et al. 2009). Such enormous variability suggests that there is no ideal intrinsic hypoxia marker, since each hypoxia-induced molecule or metabolic label represents only certain facet of the hypoxic response. Indeed, this can be taken as an advantage – for example, comparison of the spatial distribution of CA IX and pimonidazole allows for the discrimination between hypoxic and reoxygenated areas, which might have different clinical impact (Shin et al. 2007). Nevertheless, based on numerous studies it appears that CA IX is the best available indicator of chronic hypoxia and as such, it also seems to have prognostic and/or predictive value in certain tumor types, particularly derived from brain, lung, breast, colon, cervix, ovaria, etc. Although some groups reported absence of significant association with cancer prognosis, most of the published papers state that CA IX expression can be utilized as an independent predictor of poor outcome after therapy and indicator of worse cancer development (summarized in Table 4.1). In this respect, renal cell carcinomas (particularly of clear cell type) represent a special category of tumors, in which CA IX expression is frequent and high due to genetic defect in VHL gene, and absent or non-functional pVHL protein.
Independent prognostic factor for both progression-free survival and overall survival in high-risk early-stage cervical cancer Elevated expression associated with more frequent distant metastases in early-stage cervical cancer Strong correlation to metastasis, important indicator for more aggressive systemic therapy Up-regulated in hypoxic human cervical tumors and ssociated with poor prognosis
Associated with aggressive phenotype and chemo-resistance of basal-like breast tumors Independent prognostic factor with respect to relapse-free survival Correlates with poor prognosis in invasive breast carcinoma In both univariate and multivariate analysis, survival is significantly inferior in patients with invasive breast tumors expressing CA IX Independent prognostic marker in premenopausal patients with one to three positive lymph nodes and a putative marker of radiation resistance Negative predictor of treatment efficacy in ER-positive patients on the adjuvant tamoxifen after primary chemo-endocrine therapy Associated with a significantly shorter disease-free survival in patients with HIF-a-negative breast tumors Perinecrotic HIF-a overexpression with strong expression of CA IX and GLUT-1 associated with poor prognosis in invasive breast cancer Associated with worse relapse-free and overall survival in an unselected cohort of patients with invasive breast cancer
Cervical carcinoma
Breast carcinoma
Chia et al. (2001) (continued)
Vleugel et al. (2005)
Generali et al. (2006a)
Generali et al. (2006b)
Brennan et al. (2006)
Tan et al. (2009) Crabb et al. (2008) Trastour et al. (2007) Hussain et al. (2007)
Kim et al. (2006) Loncaster et al. (2001)
Kirkpatrick et al. (2008)
Liao et al. (2010)
Table 4.1 Overview of clinical studies on relationship of CA IX to cancer progression, prognosis, and/or treatment outcome (non-RCC tumors) Tumor type Proposed clinical value of CA IX Reference
4 Molecular Mechanisms Regulating Expression 73
Proposed clinical value of CA IX
Co-expression of CA IX and HIF-a associated with poor prognosis in oral squamous cell carcinoma patients Combined CA IX and HIF-a significantly predictive of overall survival in patients with advanced head-and-neck cancer Better local control in radiotherapy-treated laryngeal carcinoma patients having tumors with non-hypoxic profile (low CA IX, low HIF-a) Significant association with postoperative recurrence and poor overall survival in surgically treated oral squamous cell carcinoma High CA IX and Ki-67 expression associated with poorer overall survival and shorter diseasefree survival in patients with squamous cell carcinoma of the tongue Independent correlation with prognosis when combined with GLUT-1
Poorer outcome in patients with oligodendroglial tumors Significant parameter for the survival of patients with grades II/III astrocytic gliomas Poor prognosis in astrocytic tumor patients
Expression by cancer-associated fibroblasts predicts lower survival rate in patients with lung adenocarcinoma Full-length CA IX transcript associated with lymph node involvement, tumor stage, and poor prognosis Indicates poor prognosis for patients with stages I+II lung adenocarcinoma The most reliable hypoxia marker for predicting tumor aggressiveness Indicator for poor disease-free survival in early-stage non-small-cell lung cancer Associated with a poor prognosis in non-small-cell lung cancer
Intensity predicts disease-free survival and disease-specific survival in patients with rectal cancer
Correlates with extremely poor prognosis in esophageal and gastric adenocarcinomas Has a tripartite role as a diagnostic, prognostic, and therapeutic molecular marker in urothelial carcinoma of the bladder Correlates with clinical outcome in transitional cell carcinoma of the bladder Predicts for poor prognosis in patients with deep, large, and high-grade soft tissue sarcoma
Head-and-neck cancer
Brain tumors
Lung carcinoma
Colorectal carcinoma
Other tumors
Table 4.1 (continued)
Tumor type
Hussain et al. (2004) Maseide et al. (2004)
Driessen et al. (2006) Klatte et al. (2009)
Korkeila et al. (2009)
Kon-no et al. (2006) Kim et al. (2005) Kim et al. (2004) Swinson et al. (2003)
Malentacchi et al. (2009)
Nakao et al. (2009)
Jarvela et al. (2008) Korkolopoulou et al. (2007) Haapasalo et al. (2006)
De Schutter et al. (2005)
Kim et al. (2007)
Choi et al. 2008)
Schrijvers et al. (2008)
Kappler et al. (2008)
Eckert et al. (2010)
Reference
74 J. Pastorek and S. Pastorekova
4 Molecular Mechanisms Regulating Expression
75
Resulting activation of HIF pathway leads to constitutive up-regulation of HIF targets including CA IX independently of physiological hypoxia (Mandriota et al. 2002). In contrast to other tumor types, CA IX expression in RCC decreases with increasing tumor grade and stage. This is apparently because CA IX is a target of HIF-1a that predominates early in VHL disease but is later displaced by tumor growth-promoting isoform HIF-2a (Raval et al. 2005). Correspondingly, decreased CA IX levels are independently associated with poor prognosis in advanced RCC (Bui et al. 2003). However, levels of CA IX can be upregulated by interferons (IFN-a and IFN-g), which can increase the therapeutic responses in 5–25% of patients with metastatic RCC (Brouwers et al. 2003b). Furthermore, high CA IX expression was suggested as an important predictor of better outcome in RCC patients receiving interleukin-2-based therapy (Atkins et al. 2005). In several recent reviews, CA IX has been proposed to be the most significant molecular marker described in kidney cancer (Pantuck et al. 2008; Signoretti et al. 2008). Assessment of CA IX expression in biopsies offers a new means for stratification of cancer patients and rational selection of appropriate treatment strategy – an approach highly desirable in recent clinical oncology. However, in certain phases of cancer management, the patients would benefit from non-invasive monitoring of CA IX shed to blood circulation. Data published so far suggest that serum CA IX levels in RCC patients correlate with tumor size and stage of the disease, and support the use of soluble CA IX as a biomarker of progression and postoperative recurrence (Zhou et al. 2009). Furthermore, in vivo imaging of CA IX is recently coming to the scene as a very promising approach for pre-surgical diagnosis of RCC (Divgi et al. 2007; Zhang 2008). The imaging tool called REDECTANE® developed by WILEX AG company is based on radioactively labeled monoclonal antibody G250 originally generated by Oosterwijk and coworkers (Lam et al. 2005). The radiolabeled antibody WX-G250 targets clear cell renal cell carcinoma and accumulates in the tumor tissue via binding to CA IX followed by receptor-mediated internalization (Durrbach et al. 1999). The G250 accumulation can be visualized by means of positron emission tomography (PET) (Divgi et al. 2007). A proof-of-concept study showed that REDECTANE® could predict clear cell RCC with a specificity of 100% and a sensitivity of 94%. Moreover, Phase II clinical study demonstrated that the combination of REDECTANE® with PET and computer tomography (CT) versus the standard use of CT alone could improve the diagnosis of renal masses (http://www.wilex.com).
CA IX Targeting Strategies CA IX usefulness as therapeutic target stems from the following facts: (a) strong association with different tumors and low or absent expression in normal tissues, (b) induction by hypoxia and correlation with aggressive phenotype, (c) localization
76
J. Pastorek and S. Pastorekova
on the cell surface allowing interaction with antibodies or drugs, and (d) direct functional involvement in hypoxic tumor phenotype. These facts create a basis for two principal strategies of targeting CA IX-expressing tumor cells – immunotherapy with specific antibodies inducing cytotoxicity and functional inhibition of the CA IX catalytic activity leading to disruption of pH control. The first approach has been consistently studied in pre-clinical and clinical experiments in patients with renal cell carcinomas. Although advanced RCC show reduced CA IX expression, the cut-off was set to 85% (i.e. the expression is considered low when less than 85% of cells display CA IX) and this is still a very high proportion of targetable cells. Again, the major tool here is the monoclonal antibody G250 (Brouwers et al. 2003a; Mulders et al. 2004). Chimeric G250 (composed of variable regions of murine G250 and constant regions derived from human IgG) is recently produced by WILEX AG under commercial name RENCAREX®. Its effector mechanism is ADCC (antibody-dependent cell cytotoxicity). In Phase I and II studies, RENCAREX® has shown good safety and tolerability and a promising efficacy profile. The purpose of the ongoing Phase III study (called ARISER) is to assess the effect of adjuvant treatment with RENCAREX® on disease-free survival and overall survival in RCC patients with a high risk of recurrence following surgery (nephrectomy). Additional monoclonal antibodies potentially suitable for immunotherapeutic purposes are under development. Some of them display similar binding properties and capacity to internalize as G250 and exhibit anticancer effects in animal models (Zatovicova et al. in press). The second approach – functional inhibition of cancer-related carbonic anhydrases – is only at early stage of investigation and is based on carbonic anhydrase inhibitors (sulfonamides and their derivatives) that are mostly produced and characterized by Supuran and coworkers, who were the first to introduce the concept of their use as anticancer drugs (Supuran 2007). Sulfonamides and related compounds generally show non-selective inhibitory activity toward different CA isoenzymes including CA IX, which can be inhibited by a broad range of compounds (see Table 4.2). Interestingly, efficient CA IX inhibition was observed also with celecoxib and valdecoxib, sulfonamide inhibitors of cyclooxygense 2 (COX-2, a key enzyme of arachidonic acid metabolism involved in colorectal carcinoma), and with inhibitors of steroid sulfatase (implicated in production of active steroids in breast cancer) (Weber et al. 2004; Winum et al. 2003a). This may suggest that the mode of action of these drugs could involve targeting of CAs. As demonstrated by several recent papers, increased selectivity toward CA IX can be successfully achieved by modulating the physical and chemical properties of the compounds via attachment of different side chains and other modifications. Certain alterations can introduce or improve the membrane impermeability so that the inhibitor can bind only or predominantly to extracellularly exposed CAs. The other changes can modify the size or surface topology that fits better into active site cavity of CA IX than into other isoforms. Some types of modifications increase the efficiency of inhibition so that they work even at subnanomolar concentrations. This approach was used for development of several
Acetazolamide Aromatic and heterocyclic sulfonamides Halogenated sulfonamides Aliphatic sulfamates Sulfamates or bis-sulfamates (+ steroid sulfatase inhibitors) E7070 (indisulam) anticancer drug in clinical development Non-steroidal anti-inflammatory inhibitors of COX-2 Positively-charged pyridinium derivatives of sulfanilamides Polyfluorinated sulfonamides Sulfonamides incorporating 1,2,4-triazine moieties Sulfonamides derived from 4-isothiocyanato-benzolamide Carboxylates Bis-sulfamates Sulfonamides incorporating hydrazino moieties Boron-containing sulfamides, sulfonamides, and sulfamates
Abbate et al. (2004) Weber et al. (2004)
Potent inhibition of CA I, II, IX in the range of 15–31 nM Unexpected nanomolar inhibition of CA I, II, IV, IX by celecoxib and valdecoxib First selective, membrane-impermeant inhibitors targeting CA IX
Effective inhibitors of CA IX suitable for boron neutron capture therapy targeting hypoxic tumors
The first subnanomolar and selective CA IX inhibitor CA IX-selective inhibitors with selectivity ratios for CA IX over CA II inhibition in the range of 166–706 Excellent inhibitory properties against CA IX with inhibition constants in the range of 3.2–23 nM Lactate insensitivity of CA IX Low nanomolar CA IX inhibitors with good selectivity ratio Several low nanomolar CA IX inhibitors
Ilies et al. (2003) Winum et al. (2003b) Winum et al. (2003a)
CA IX inhibition profile different from CA I, II, IV Efficient CA IX inhibition in the range of 9–23 nM Efficient CA IX inhibition in the range of 18–63 nM
(continued)
Winum et al. (2005a)
Innocenti et al. (2005) Winum et al. (2005c) Winum et al. (2005b)
Cecchi et al. (2004)
Vullo et al. (2004) Garaj et al. (2004)
Pastorekova et al. (2004a)
Parkkila et al. (2000) Vullo et al. (2003)
Inhibition of in vitro migration of renal carcinoma cells Several nanomolar CA IX inhibitors
Table 4.2 Summary of sulfonamide inhibitors, their derivatives, and other compounds tested against different CA isoforms including CA IX Inhibitor type Inhibition properties Reference
4 Molecular Mechanisms Regulating Expression 77
Imatinib (Glivec/Gleevec) and nilotinib (Tasigna)
Inhibitor-coated gold nanoparticles Coumarin derivatives
Bioreductive nitro-containing sulfonamides Biphenylsulfonamides
Mercaptans increase the inhibitory power (52.8- to 243-fold) over the corresponding oxidized derivatives Several potent and selective inhibitors of CA IX
Aromatic sulfonamides activatable in hypoxic tumors Glycoconjugate benzene sulfonamides Antiepileptic drug sulthiame Glycosyl-thioureido-sulfonamides Potent inhibitor of CA II, VII, IX, XII (6–56 nM) Low nM binding to CA IX and XII, high selectivity ratios in the range of 107–955 Some CA IX inhibitors with excellent selectivity ratios (in the range of 10–1395) Inhibitors of CA IX with cytotoxic activity against human colon, lung, and breast cancer cell lines Selective inhibition of CA IX (membrane impermeant) Bind at the entrance of the active site cavity, one of them highly selective for CA IX Inhibited all 13 catalytically active CA isoforms in the range of 4.1 nM–20.2 mM
Inhibition properties
Table 4.2 (continued)
Inhibitor type
Parkkila et al. (2009)
Stiti et al. (2008) Maresca et al. (2010)
Morsy et al. (2009)
D’Ambrosio et al. (2008)
Temperini et al. (2007) Smaine et al. (2007)
Wilkinson et al. (2006)
Saczewski et al. (2006)
Reference
78 J. Pastorek and S. Pastorekova
4 Molecular Mechanisms Regulating Expression
79
compounds with a reasonable selectivity ratio favoring inhibition activities against CA IX compared to other isoforms, in particular CA II (Table 4.2). Another strategy was used to generate hypoxia-activated inhibitors. Different 2-mercapto-substituted-benzenesulfonamides and their disulfides/sulfones showed consistently increased inhibitory power (52.8- to 243-fold) over the corresponding oxidized (S–S type) derivatives (Saczewski et al. 2006). The best representatives out of these differentially acting derivatives can serve as lead compounds for further development of CA IX -specific inhibitors with therapeutic potential against cancer. Since the inhibition data were obtained using the purified recombinant catalytic domain of CA IX, experiments with native protein in cellular context are needed to determine their effective concentrations and consequences of their application. Noteworthy, fluorescein-conjugated carbonic anhydrase inhibitor thioureidohomosulfanilamide (FITC-CAI) was found to bind only to hypoxic cells expressing CA IX, but neither to CA IX-positive normoxic cells nor the CA IX-negative controls (Cecchi et al. 2005; Svastova et al. 2004). Moreover, the FITC-CAI binding was perturbed by reoxygenation (Dubois et al. 2007). This interesting finding suggests that CA IX active site is accessible to sulfonamide only under hypoxic conditions. Results of in vivo imaging confirm previous in vitro data demonstrating that CAI binding and retention requires exposure to hypoxia (Dubois et al. 2009). Thus, labeled sulfonamides may provide a powerful tool to visualize hypoxic tumors. This may represent a promising approach to patient selection for CA IX-directed therapies based on the functional inhibition of CA IX. CA inhibitors can be used as anticancer drugs to compromise the survival of tumor cells due to perturbed pH control, or in combination with conventional chemotherapeutics to improve their uptake and efficacy due to modulated pH gradient. The first option is based on significance of the proper pH control in tumor cells, particularly in those that suffer from hypoxia. It is well established that extracellular acidosis supports cancer progression, whereas neutral intracellular pH is required for survival of hypoxic cancer cells (Stubbs et al. 2000). Inhibition or reduction of extracellular acidosis by carbonic anhydrase inhibitors thus offers a possible therapeutic approach to retardation of tumor progression (Pouyssegur et al. 2006). On the other hand, inhibition of CA activity can lead to inability of tumor cells to neutralize their intracellular pH and adapt to metabolic stress. In fact, several sulfonamide derivatives were capable of reducing an extracellular acidification and intracellular neutralization mediated by CA IX, suggesting that these compounds interfere with the activity of CA IX in cell culture model (Svastova et al. 2004; Swietach et al. 2009). In addition, changes in extracellular pH can affect therapeutic outcome of conventional chemotherapy by influencing the uptake of weakly electrolytic anticancer drugs (Kozin et al. 2001; Vukovic and Tannock 1997). In particular, reduction of extracellular acidosis can increase the uptake and cytotoxic effects of weakly basic drugs, including doxorubicin. Interestingly, chronic ingestion of sodium bicarbonate solution was shown to enhance the capacity of doxorubicin to decrease the tumor size (Raghunand et al. 2003).
80
J. Pastorek and S. Pastorekova
In line with these suppositions, older but forward-looking study showed that acetazolamide, a classical CA inhibitor, reduced in vivo growth of tumor when given alone and produced additive tumor growth delays when administered in combination with various chemotherapeutic compounds (Teicher et al. 1993). This was recently supported using more sophisticated approach, based on two acetazolamide derivatives containing either a charged fluorophore or an albumin-binding moiety, which restrict binding to carbonic anhydrase IX and XII present on tumor cells (Ahlskog et al. 2009a). In vivo studies showed the preferential targeting of tumor cells by the fluorescent acetazolamide derivative and the ability of the albuminbinding acetazolamide derivative to cause tumor retardation in a SK-RC-52 (RCC) xenograft model of cancer. Additional in vivo experiments with promising preliminary results are underway.
Conclusion Our present knowledge on CA IX clearly suggests that this hypoxia-induced molecule is an important component of the tumor microenvironment and that many tumors need CA IX to survive microenvironmental stresses. This addiction of tumor cells to CA IX makes it a useful marker of hypoxia, prognostic indicator, and therapeutic target. Although main strategies of diagnostic and therapeutic exploitation of CA IX have been rationally designed, their concepts were experimentally proven, practically evaluated (in part), and several specific tools are available; further preclinical and clinical studies are necessary to translate all proposed applications to the benefit of cancer patients.
References Abbate F, Casini A, Owa T, Scozzafava A, Supuran CT (2004) Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett 14:217–223 Ahlskog JK, Dumelin CE, Trussel S, Marlind J, Neri D (2009a) In vivo targeting of tumorassociated carbonic anhydrases using acetazolamide derivatives. Bioorg Med Chem Lett 19:4851–4856 Ahlskog JK, Schliemann C, Marlind J, Qureshi U, Ammar A, Pedley RB, Neri D (2009b) Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br J Cancer 101:645–657 Alterio V, Hilvo M, Di Fiore A, Supuran CT, Pan P, Parkkila S, Scaloni A, Pastorek J, Pastorekova S, Pedone C, Scozzafava A, Monti SM, De Simone G (2009) Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci USA 106:16233–16238 Ashida S, Nishimori I, Tanimura M, Onishi S, Shuin T (2002) Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma. J Cancer Res Clin Oncol 128:561–568
4 Molecular Mechanisms Regulating Expression
81
Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S (2005) Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11:3714–3721 Barathova M, Takacova M, Holotnakova T, Gibadulinova A, Ohradanova A, Zatovicova M, Hulikova A, Kopacek J, Parkkila S, Supuran CT, Pastorekova S, Pastorek J (2008) Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype. Br J Cancer 98:129–136 Bartosova M, Parkkila S, Pohlodek K, Karttunen TJ, Galbavy S, Mucha V, Harris AL, Pastorek J, Pastorekova S (2002) Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. J Pathol 197:314–321 Brahimi-Horn MC, Pouyssegur J (2007) Hypoxia in cancer cell metabolism and pH regulation. Essays Biochem 43:165–178 Brennan DJ, Jirstrom K, Kronblad A, Millikan RC, Landberg G, Duffy MJ, Ryden L, Gallagher WM, O’Brien SL (2006) CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 12:6421–6431 Brouwers AH, Buijs WC, Oosterwijk E, Boerman OC, Mala C, De Mulder PH, Corstens FH, Mulders PF, Oyen WJ (2003a) Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. Clin Cancer Res 9:3953S–3960S Brouwers H, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC (2003b) Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma. Cancer Biother Radiopharm 18:539–547 Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, Belldegrun AS (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9:802–811 Camenisch G, Stroka DM, Gassmann M, Wenger RH (2001) Attenuation of HIF-1 DNA-binding activity limits hypoxia-inducible endothelin-1 expression. Pflugers Arch 443:240–249 Carney WP (2007) Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. Expert Rev Mol Diagn 7:309–319 Casey JR (2006) Why bicarbonate? Biochem Cell Biol 84:930–939 Cecchi A, Hulikova A, Pastorek J, Pastorekova S, Scozzafava A, Winum JY, Montero JL, Supuran CT (2005) Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem 48:4834–4841 Cecchi A, Winum JY, Innocenti A, Vullo D, Montero JL, Scozzafava A, Supuran CT (2004) Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanatobenzolamide. Bioorg Med Chem Lett 14:5775–5780 Coleman ML, Ratcliffe PJ (2007) Oxygen sensing and hypoxia-induced responses. Essays Biochem 43:1–15 Crabb SJ, Bajdik CD, Leung S, Speers CH, Kennecke H, Huntsman DG, Gelmon KA (2008) Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study. Breast Cancer Res 10:R6 D’Ambrosio K, Vitale RM, Dogne JM, Masereel B, Innocenti A, Scozzafava A, De Simone G, Supuran CT (2008) Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII. J Med Chem 51: 3230–3237 De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R, Nuyts S (2005) The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/– chemotherapy. BMC Cancer 5:42
82
J. Pastorek and S. Pastorekova
Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM, Old LJ, Russo P (2007) Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 8:304–310 Dorai T, Sawczuk IS, Pastorek J, Wiernik PH, Dutcher JP (2005) The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer 41:2935–2947 Driessen A, Landuyt W, Pastorekova S, Moons J, Goethals L, Haustermans K, Nafteux P, Penninckx F, Geboes K, Lerut T, Ectors N (2006) Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg 243:334–340 Dubois L, Douma K, Supuran CT, Chiu RK, van Zandvoort MA, Pastorekova S, Scozzafava A, Wouters BG, Lambin P (2007) Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol 83:367–373 Dubois L, Lieuwes NG, Maresca A, Thiry A, Supuran CT, Scozzafava A, Wouters BG, Lambin P (2009) Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother Oncol 92:423–428 Durrbach A, Angevin E, Poncet P, Rouleau M, Chavanel G, Chapel A, Thierry D, Gorter A, Hirsch R, Charpentier B, Senik A, Hirsch F (1999) Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma in vitro. Cancer Gene Ther 6:564–571 Eckert AW, Lautner MH, Schutze A, Bolte K, Bache M, Kappler M, Schubert J, Taubert H, Bilkenroth U (2010) Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. J Oral Pathol Med 39:313–317 Fukumura D, Jain RK (2007) Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 101:937–949 Garaj V, Puccetti L, Fasolis G, Winum JY, Montero JL, Scozzafava A, Vullo D, Innocenti A, Supuran CT (2004) Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/ tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. Bioorg Med Chem Lett 14:5427–5433 Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899 Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, Bersiga A, Allevi G, Milani M, Aguggini S, Gandolfi V, Dogliotti L, Bottini A, Harris AL, Fox SB (2006a) Hypoxiainducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 12: 4562–4568 Generali D, Fox SB, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield SM, Bruzzi P, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Bottini A, Harris AL (2006b) Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/ tamoxifen therapy for breast cancer. Endocr Relat Cancer 13:921–930 Gut MO, Parkkila S, Vernerova Z, Rohde E, Zavada J, Hocker M, Pastorek J, Karttunen T, Gibadulinova A, Zavadova Z, Knobeloch KP, Wiedenmann B, Svoboda J, Horak I, Pastorekova S (2002) Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology 123:1889–1903 Haapasalo J, Nordfors K, Jarvela S, Bragge H, Rantala I, Parkkila AK, Haapasalo H, Parkkila S (2007) Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy. Neuro Oncol 9:308–313 Haapasalo JA, Nordfors KM, Hilvo M, Rantala IJ, Soini Y, Parkkila AK, Pastorekova S, Pastorek J, Parkkila SM, Haapasalo HK (2006) Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 12:473–477 Harris AL (2002) Hypoxia – a key regulatory factor in tumour growth. Nat Rev Cancer 2:38–47
4 Molecular Mechanisms Regulating Expression
83
Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK (2002) Acid production in glycolysisimpaired tumors provides new insights into tumor metabolism. Clin Cancer Res 8: 1284–1291 Helmlinger G, Yuan F, Dellian M, Jain RK (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3: 177–182 Hewett-Emmett D, Tashian RE (1996) Functional diversity, conservation, and convergence in the evolution of the alpha-, beta-, and gamma-carbonic anhydrase gene families. Mol Phylogenet Evol 5:50–77 Hilvo M, Baranauskiene L, Salzano AM, Scaloni A, Matulis D, Innocenti A, Scozzafava A, Monti SM, Di Fiore A, De Simone G, Lindfors M, Janis J, Valjakka J, Pastorekova S, Pastorek J, Kulomaa MS, Nordlund HR, Supuran CT, Parkkila S (2008) Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem 283:27799–27809 Hirota K, Semenza GL (2005) Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochem Biophys Res Commun 338:610–616 Holotnakova T, Tylkova L, Takacova M, Kopacek J, Petrik J, Pastorekova S, Pastorek, J (2010) Role of the HBx oncoprotein in carbonic anhydrase 9 induction. J Med Virol 82:32–40 Hulikova A, Zatovicova M, Svastova E, Ditte P, Brasseur R, Kettmann R, Supuran CT, Kopacek J, Pastorek J, Pastorekova S (2009) Intact intracellular tail is critical for proper functioning of the tumor-associated, hypoxia-regulated carbonic anhydrase IX. FEBS Lett 583:3563–3568 Hussain SA, Ganesan R, Reynolds G, Gross L, Stevens A, Pastorek J, Murray PG, Perunovic B, Anwar MS, Billingham L, James ND, Spooner D, Poole CJ, Rea DW, Palmer DH (2007) Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br J Cancer 96:104–109 Hussain SA, Palmer DH, Ganesan R, Hiller L, Gregory J, Murray PG, Pastorek J, Young L, James ND (2004) Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder. Oncol Rep 11:1005–1010 Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, Harris AL (2001) Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 19:3660–3668 Chiang WL, Chu SC, Yang SS, Li MC, Lai JC, Yang SF, Chiou HL, Hsieh YS (2002) The aberrant expression of cytosolic carbonic anhydrase and its clinical significance in human non-small cell lung cancer. Cancer Lett 188:199–205 Chiche J, Ilc K, Brahimi-Horn MC, Pouyssegur J (2010) Membrane-bound carbonic anhydrases are key pH regulators controlling tumor growth and cell migration. Adv Enzyme Regul 50:20–33 Chiche J, Ilc K, Laferriere J, Trottier E, Dayan F, Mazure NM, Brahimi-Horn MC, Pouyssegur J (2009b) Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 69:358–368 Cho M, Grabmaier K, Kitahori Y, Hiasa Y, Nakagawa Y, Uemura H, Hirao Y, Ohnishi T, Yoshikawa K, Ooesterwijk E (2000) Activation of the MN/CA9 gene is associated with hypomethylation in human renal cell carcinoma cell lines. Mol Carcinog 27:184–189 Choi SW, Kim JY, Park JY, Cha IH, Kim J, Lee S (2008) Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma. Hum Pathol 39:1317–1322 Ihnatko R, Kubes M, Takacova M, Sedlakova O, Sedlak J, Pastorek J, Kopacek J, Pastorekova S (2006) Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia. Int J Oncol 29:1025–1033 Ilies MA, Vullo D, Pastorek J, Scozzafava A, Ilies M, Caproiu MT, Pastorekova S, Supuran CT (2003) Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives. J Med Chem 46:2187–2196 Innocenti A, Pastorekova S, Pastorek J, Scozzafava A, De Simone G, Supuran CT (2009) The proteoglycan region of the tumor-associated carbonic anhydrase isoform IX acts as anintrinsic
84
J. Pastorek and S. Pastorekova
buffer optimizing CO2 hydration at acidic pH values characteristic of solid tumors. Bioorg Med Chem Lett 19:5825–5828 Innocenti A, Vullo D, Scozzafava A, Casey JR, Supuran C (2005) Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett 15:573–578 Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI, Stanbridge EJ (2001) Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158:905–919 Ivanov SV, Kuzmin I, Wei MH, Pack S, Geil L, Johnson BE, Stanbridge EJ, Lerman MI (1998) Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 95:12596–12601 Jakubickova L, Biesova Z, Pastorekova S, Kettmann R, Pastorek J (2005) Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines. Int J Oncol 26:1121–1127 Jarvela S, Parkkila S, Bragge H, Kahkonen M, Parkkila AK, Soini Y, Pastorekova S, Pastorek J, Haapasalo H (2008) Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer 8:1 Kaluz S, Kaluzova M, Chrastina A, Olive PL, Pastorekova S, Pastorek J, Lerman MI, Stanbridge EJ (2002) Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3¢-kinase. Cancer Res 62:4469–4477 Kaluz S, Kaluzova M, Liao SY, Lerman M, Stanbridge EJ (2009) Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta 1795:162–172 Kaluz S, Kaluzova M, Opavsky R, Pastorekova S, Gibadulinova A, Dequiedt F, Kettmann R, Pastorek J (1999) Transcriptional regulation of the MN/CA 9 gene coding for the tumorassociated carbonic anhydrase IX. Identification and characterization of a proximal silencer element. J Biol Chem 274:32588–32595 Kappler M, Taubert H, Holzhausen HJ, Reddemann R, Rot S, Becker A, Kuhnt T, Dellas K, Dunst J, Vordermark D, Hansgen G, Bache M (2008) Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters. Strahlenther Onkol 184:393–399 Karumanchi SA, Jiang L, Knebelmann B, Stuart-Tilley AK, Alper SL, Sukhatme VP (2001) VHL tumor suppressor regulates Cl-/HCO3- exchange and Na+/H+ exchange activities in renal carcinoma cells. Physiol Genomics 5:119–128 Kim JY, Shin HJ, Kim TH, Cho KH, Shin KH, Kim BK, Roh JW, Lee S, Park SY, Hwang YJ, Han IO (2006) Tumor-associated carbonic anhydrases are linked to metastases in primary cervical cancer. J Cancer Res Clin Oncol 132:302–308 Kim SJ, Rabbani ZN, Dewhirst MW, Vujaskovic Z, Vollmer RT, Schreiber EG, Oosterwijk E, Kelley MJ (2005) Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 49:325–335 Kim SJ, Rabbani ZN, Vollmer RT, Schreiber EG, Oosterwijk E, Dewhirst MW, Vujaskovic Z, Kelley MJ (2004) Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res 10:7925–7933 Kim SJ, Shin HJ, Jung KY, Baek SK, Shin BK, Choi J, Kim BS, Shin SW, Kim YH, Kim JS, Oosterwijk E (2007) Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue. Jpn J Clin Oncol 37:812–819 Kirkpatrick JP, Rabbani ZN, Bentley RC, Hardee ME, Karol S, Meyer J, Oosterwijk E, Havrilesky L, Secord AA, Vujaskovic Z, Dewhirst MW, Jones EL (2008) Elevated CAIX expression is associated with an increased risk of distant failure in early-stage cervical cancer. Biomark Insights 3:45–55 Kivela AJ, Saarnio J, Karttunen TJ, Kivela J, Parkkila AK, Pastorekova S, Pastorek J, Waheed A, Sly WS, Parkkila TS, Rajaniemi H (2001) Differential expression of cytoplasmic carbonic
4 Molecular Mechanisms Regulating Expression
85
anhydrases, CA I and II, and membrane-associated isozymes, CA IX and XII, in normal mucosa of large intestine and in colorectal tumors. Dig Dis Sci 46:2179–2186 Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Kawaoka K, Wong SG, Belldegrun AS, Pantuck AJ (2009) Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer 115:1448–1458 Kon-no H, Ishii G, Nagai K, Yoshida J, Nishimura M, Nara M, Fujii T, Murata Y, Miyamoto H, Ochiai A (2006) Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma. Lung Cancer 54:409–418 Kopacek J, Barathova M, Dequiedt F, Sepelakova J, Kettmann R, Pastorek J, Pastorekova S (2005) MAPK pathway contributes to density- and hypoxia-induced expression of the tumorassociated carbonic anhydrase IX. Biochim Biophys Acta 1729:41–49 Korkeila E, Talvinen K, Jaakkola PM, Minn H, Syrjanen K, Sundstrom J, Pyrhonen S (2009) Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer. Br J Cancer 100:874–880 Korkolopoulou P, Perdiki M, Thymara I, Boviatsis E, Agrogiannis G, Kotsiakis X, Angelidakis D, Rologis D, Diamantopoulou K, Thomas-Tsagli E, Kaklamanis L, Gatter K, Patsouris E (2007) Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX. Hum Pathol 38:629–638 Kowalewska M, Radziszewski J, Kulik J, Barathova M, Nasierowska-Guttmajer A, Bidzinski M, Pastorek J, Pastorekova S, Siedlecki JA (2005) Detection of carbonic anhydrase 9-expressing tumor cells in the lymph nodes of vulvar carcinoma patients by RT-PCR. Int J Cancer 116:957–962 Kozin SV, Shkarin P, Gerweck LE (2001) The cell transmembrane pH gradient in tumors enhances cytotoxicity of specific weak acid chemotherapeutics. Cancer Res 61:4740–4743 Kreis TE, Lodish HF (1986) Oligomerization is essential for transport of vesicular stomatitis viral glycoprotein to the cell surface. Cell 46:929–937 Kummola L, Hamalainen JM, Kivela J, Kivela AJ, Saarnio J, Karttunen T, Parkkila S (2005) Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa. BMC Cancer 5:41 Kuo WH, Chiang WL, Yang SF, Yeh KT, Yeh CM, Hsieh YS, Chu SC (2003) The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma. Life Sci 73:2211–2223 Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA (2005) G250: a carbonic anhydrase IX monoclonal antibody. Curr Oncol Rep 7:109–115 Lendahl U, Lee KL, Yang H, Poellinger L (2009) Generating specificity and diversity in the transcriptional response to hypoxia. Nat Rev Genet 10:821–832 Li Y, Wang H, Oosterwijk E, Selman Y, Mira JC, Medrano T, Shiverick KT, Frost SC (2009) Antibody-specific detection of CAIX in breast and prostate cancers. Biochem Biophys Res Commun 386:488–492 Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ (1997) Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 57: 2827–2831 Liao SY, Brewer C, Zavada J, Pastorek J, Pastorekova S, Manetta A, Berman ML, DiSaia PJ, Stanbridge EJ (1994) Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol 145: 598–609 Liao SY, Darcy KM, Randall LM, Tian C, Monk BJ, Burger RA, Fruehauf JP, Peters WA, Stock RJ, Stanbidge EJ (2010) Prognostic relevance of carbonic anhydrase-IX in high-risk, earlystage cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol 116:452–458 Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ, West CM (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61:6394–6399
86
J. Pastorek and S. Pastorekova
Malentacchi F, Simi L, Nannelli C, Andreani M, Janni A, Pastorekova S, Orlando C (2009) Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer. Lung Cancer 64:271–276 Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ, Maxwell PH (2002) HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1:459–468 Maresca A, Temperini C, Vu H, Pham NB, Poulsen SA, Scozzafava A, Quinn RJ, Supuran CT (2009) Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors (#). J Am Chem Soc 131:3057–3062 Maseide K, Kandel RA, Bell RS, Catton CN, O’Sullivan B, Wunder JS, Pintilie M, Hedley D, Hill RP (2004) Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin Cancer Res 10:4464–4471 McKiernan JM, Buttyan R, Bander NH, Stifelman MD, Katz AE, Chen MW, Olsson CA, Sawczuk IS (1997) Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma. Cancer Res 57:2362–2365 McMurtrie HL, Cleary HJ, Alvarez BV, Loiselle FB, Sterling D, Morgan PE, Johnson DE, Casey JR (2004) The bicarbonate transport metabolon. J Enzyme Inhib Med Chem 19:231–236 Morgan PE, Pastorekova S, Stuart-Tilley AK, Alper SL, Casey JR (2007) Interactions of transmembrane carbonic anhydrase, CAIX, with bicarbonate transporters. Am J Physiol Cell Physiol 293:C738–C748 Mori M, Staniunas RJ, Barnard GF, Jessup JM, Steele GD Jr, Chen LB (1993) The significance of carbonic anhydrase expression in human colorectal cancer. Gastroenterology 105: 820–826 Morsy SM, Badawi AM, Cecchi A, Scozzafava A, Supuran CT (2009) Carbonic anhydrase inhibitors. Biphenylsulfonamides with inhibitory action towards the transmembrane, tumor-associated isozymes IX possess cytotoxic activity against human colon, lung and breast cancer cell lines. J Enzyme Inhib Med Chem 24:499–505 Mulders P, Bleumer I, Debruyne F, Oosterwijk E (2004) Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN). Urologe A 43(Suppl 3):S146–S147 Nakao M, Ishii G, Nagai K, Kawase A, Kenmotsu H, Kon-No H, Hishida T, Nishimura M, Yoshida J, Ochiai A (2009) Prognostic significance of carbonic anhydrase IX expression by cancer-associated fibroblasts in lung adenocarcinoma. Cancer 115:2732–2743 Niemela AM, Hynninen P, Mecklin JP, Kuopio T, Kokko A, Aaltonen L, Parkkila AK, Pastorekova S, Pastorek J, Waheed A, Sly WS, Orntoft TF, Kruhoffer M, Haapasalo H, Parkkila S, Kivela AJ (2007) Carbonic anhydrase IX is highly expressed in hereditary nonpolyposis colorectal cancer. Cancer Epidemiol Biomarkers Prev 16:1760–1766 Oosterwijk E (2008a) Carbonic anhydrase IX/G250/MN: a molecule too good to be true? BJU Int 101:527–528 Oosterwijk E (2008b) Carbonic anhydrase IX: historical and future perspectives. BJU Int 101(Suppl 4):2–7 Opavsky R, Pastorekova S, Zelnik V, Gibadulinova A, Stanbridge EJ, Zavada J, Kettmann R, Pastorek J (1996) Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 33:480–487 Pantuck AJ, Klatte T, Seligson D, Atkins M, Belldegrun A (2008) Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma. J Clin Oncol 26:3105–3107; author reply 3107–3109 Parkkila S, Innocenti A, Kallio H, Hilvo M, Scozzafava A, Supuran CT (2009) The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alphacarbonic anhydrase isoforms. Bioorg Med Chem Lett 19:4102–4106 Parkkila S, Rajaniemi H, Parkkila AK, Kivela J, Waheed A, Pastorekova S, Pastorek J, Sly WS (2000) Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci USA 97:2220–2224
4 Molecular Mechanisms Regulating Expression
87
Parkkila S, Lasota J, Fietcher JA, Ou WB, Kivelä AJ, Nuorva K, Parkkila AK, Ollikainen J, Sly WS, Waheed A, Pastorekova S, Pastorek J, Isola J, Miettinen M (2010). Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. Mod Pathol 23:743–750 Pastorek J, Pastorekova S, Callebaut I, Mornon JP, Zelnik V, Opavsky R, Zat’ovicova M, Liao S, Portetelle D, Stanbridge EJ et al (1994) Cloning and characterization of MN, a human tumorassociated protein with a domain homologous to carbonic anhydrase and a putative helixloop-helix DNA binding segment. Oncogene 9:2877–2888 Pastorekova S, Casini A, Scozzafava A, Vullo D, Pastorek J, Supuran CT (2004a) Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumorassociated isozyme IX. Bioorg Med Chem Lett 14:869–873 Pastorekova S, Parkkila S, Parkkila AK, Opavsky R, Zelnik V, Saarnio J, Pastorek J (1997) Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 112:398–408 Pastorekova S, Parkkila S, Pastorek J, Supuran CT (2004b) Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 19: 199–229 Pastorekova S, Parkkila S, Zavada J (2006) Tumor-associated carbonic anhydrases and their clinical significance. Adv Clin Chem 42:167–216 Pastorekova S, Zatovicova M, Pastorek J (2008) Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des 14:685–698 Pastorekova S, Zavadova Z, Kostal M, Babusikova O, Zavada J (1992) A novel quasi-viral agent, MaTu, is a two-component system. Virology 187:620–626 Peles E, Nativ M, Campbell PL, Sakurai T, Martinez R, Lev S, Clary DO, Schilling J, Barnea G, Plowman GD, Grumet M, Schlessinger J (1995) The carbonic anhydrase domain of receptor tyrosine phosphatase beta is a functional ligand for the axonal cell recognition molecule contactin. Cell 82:251–260 Potter C, Harris AL (2004) Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 3:164–167 Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441:437–443 Rafajova M, Zatovicova M, Kettmann R, Pastorek J, Pastorekova S (2004) Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int J Oncol 24: 995–1004 Raghunand N, Gatenby RA, Gillies RJ (2003) Microenvironmental and cellular consequences of altered blood flow in tumours. Br J Radiol 76 Spec No 1:S11–S22 Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25:5675–5686 Ruas JL, Poellinger L (2005) Hypoxia-dependent activation of HIF into a transcriptional regulator. Semin Cell Dev Biol 16:514–522 Saarnio J, Parkkila S, Parkkila AK, Haukipuro K, Pastorekova S, Pastorek J, Kairaluoma MI, Karttunen TJ (1998) Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 153:279–285 Saczewski F, Slawinski J, Kornicka A, Brzozowski Z, Pomarnacka E, Innocenti A, Scozzafava A, Supuran CT (2006) Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors. Bioorg Med Chem Lett 16: 4846–4851 Sansone P, Storci G, Giovannini C, Pandolfi S, Pianetti S, Taffurelli M, Santini D, Ceccarelli C, Chieco P, Bonafe M (2007) p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells 25:807–815
88
J. Pastorek and S. Pastorekova
Scott FL, Stec B, Pop C, Dobaczewska MK, Lee JJ, Monosov E, Robinson H, Salvesen GS, Schwarzenbacher R, Riedl SJ (2009) The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature 457:1019–1022 Shin KH, Diaz-Gonzalez JA, Russell J, Chen Q, Burgman P, Li XF, Ling CC (2007) Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole. Cancer Biol Ther 6:70–75 Schrijvers ML, van der Laan BF, de Bock GH, Pattje WJ, Mastik MF, Menkema L, Langendijk JA, Kluin PM, Schuuring E, van der Wal JE (2008) Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 72:161–169 Signoretti S, Regan M, Atkins M (2008) Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy. BJU Int 101(Suppl 4):31–35 Smaine FZ, Winum JY, Montero JL, Regainia Z, Vullo D, Scozzafava A, Supuran CT (2007) Carbonic anhydrase inhibitors: Selective inhibition of the extracellular, tumor-associated isoforms IX and XII over isozymes I and II with glycosyl-thioureido-sulfonamides. Bioorg Med Chem Lett 17:5096–5100 Smyth LG, O’Hurley G, O’Grady A, Fitzpatrick JM, Kay E, Watson RW (2010) Carbonic anhydrase IX expression in prostate cancer. Prostate Cancer Prostatic Dis 13:178–181 Stiti M, Cecchi A, Rami M, Abdaoui M, Barragan-Montero V, Scozzafava A, Guari Y, Winum JY, Supuran CT (2008) Carbonic anhydrase inhibitor coated gold nanoparticles selectively inhibit the tumor-associated isoform IX over the cytosolic isozymes I and II. J Am Chem Soc 130: 16130–16131 Stock C, Schwab A (2009) Protons make tumor cells move like clockwork. Pflugers Arch 458:981–992 Stubbs M, McSheehy PM, Griffiths JR, Bashford CL (2000) Causes and consequences of tumour acidity and implications for treatment. Mol Med Today 6:15–19 Supuran CT (2007) Carbonic anhydrases as drug targets – an overview. Curr Top Med Chem 7:825–833 Supuran CT (2008) Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 7:168–181 Svastova E, Hulikova A, Rafajova M, Zat’ovicova M, Gibadulinova A, Casini A, Cecchi A, Scozzafava A, Supuran CT, Pastorek J, Pastorekova S (2004) Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 577: 439–445 Svastova E, Zilka N, Zat’ovicova M, Gibadulinova A, Ciampor F, Pastorek J, Pastorekova S (2003) Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp Cell Res 290:332–345 Swietach P, Patiar S, Supuran CT, Harris AL, Vaughan-Jones RD (2009) The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths. J Biol Chem 284:20299–20310 Swietach P, Wigfield S, Supuran CT, Harris AL, Vaughan-Jones RD (2008) Cancer-associated, hypoxia-inducible carbonic anhydrase IX facilitates CO2 diffusion. BJU Int 101 (Suppl 4): 22–4 Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL, O’Byrne KJ (2003) Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 21: 473–482 Takacova M, Holotnakova T, Vondracek J, Machala M, Pencikova K, Gradin K, Poellinger L, Pastorek J, Pastorekova S, Kopacek J (2009) Role of aryl hydrocarbon receptor in modulation of the expression of the hypoxia marker carbonic anhydrase IX. Biochem J 419: 419–425 Takacova M, Holotnakova T, Barathova M, Pastorekova S, Kopacek J, Pastorek J (2010). Src induces expression of carbonic anhydrase IX via hypoxia-inducible factor 1. Oncol Rep 23:869–874
4 Molecular Mechanisms Regulating Expression
89
Tan EY, Yan M, Campo L, Han C, Takano E, Turley H, Candiloro I, Pezzella F, Gatter KC, Millar EK, O’Toole SA, McNeil CM, Crea P, Segara D, Sutherland RL, Harris AL, Fox SB (2009) The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer 100:405–411 Teicher BA (2009) Acute and chronic in vivo therapeutic resistance. Biochem Pharmacol 77: 1665–1673 Teicher BA, Liu SD, Liu JT, Holden SA, Herman TS (1993) A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res 13:1549–1556 Temperini C, Innocenti A, Mastrolorenzo A, Scozzafava A, Supuran CT (2007) Carbonic anhydrase inhibitors. Interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett 17:4866–4872 Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, Pouyssegur J, Berra E (2007) HIF1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer 120:1451–1458 Turner JR, Odze RD, Crum CP, Resnick MB (1997) MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. Hum Pathol 28:740–744 van den Beucken T, Koritzinsky M, Niessen H, Dubois L, Savelkouls K, Mujcic H, Jutten B, Kopacek J, Pastorekova S, van der Kogel AJ, Lambin P, Voncken W, Rouschop KM, Wouters BG (2009a) Hypoxia-induced expression of carbonic anhydrase 9 is dependent on the unfolded protein response. J Biol Chem 284:24204–24212 van den Beucken T, Ramaekers CH, Rouschop K, Koritzinsky M, Wouters BG (2009b) Deficient carbonic anhydrase 9 expression in UPR-impaired cells is associated with reduced survival in an acidic microenvironment. Radiother Oncol 92:437–442 Vermylen P, Roufosse C, Burny A, Verhest A, Bosschaerts T, Pastorekova S, Ninane V, Sculier JP (1999) Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma. Eur Respir J 14:806–811 Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aarbodem Y, van Tinteren H, Harris AL, van Diest PJ, van der Wall E (2005) Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol 58: 172–177 Vukovic V, Tannock IF (1997) Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br J Cancer 75:1167–1172 Vullo D, Franchi M, Gallori E, Pastorek J, Scozzafava A, Pastorekova S, Supuran CT (2003) Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett 13:1005–1009 Vullo D, Scozzafava A, Pastorekova S, Pastorek J, Supuran CT (2004) Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered. Bioorg Med Chem Lett 14: 2351–2356 Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, Klebe G (2004) Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem 47:550–557 Wilkinson BL, Bornaghi LF, Houston TA, Innocenti A, Supuran CT, Poulsen SA (2006) A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by “click-tailing”. J Med Chem 49:6539–6548 Willam C, Warnecke C, Schefold JC, Kugler J, Koehne P, Frei U, Wiesener M, Eckardt KU (2006) Inconsistent effects of acidosis on HIF-alpha protein and its target genes. Pflugers Arch 451: 534–543 Winum JY, Cecchi A, Montero JL, Innocenti A, Scozzafava A, Supuran CT (2005a) Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with boron-containing sulfonamides, sulfamides, and sulfamates: toward agents for boron neutron capture therapy of hypoxic tumors. Bioorg Med Chem Lett 15:3302–3306
90
J. Pastorek and S. Pastorekova
Winum JY, Dogne JM, Casini A, de Leval X, Montero JL, Scozzafava A, Vullo D, Innocenti A, Supuran CT (2005b) Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/ membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties. J Med Chem 48:2121–2125 Winum JY, Pastorekova S, Jakubickova L, Montero JL, Scozzafava A, Pastorek J, Vullo D, Innocenti A, Supuran CT (2005c) Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett 15:579–584 Winum JY, Vullo D, Casini A, Montero JL, Scozzafava A, Supuran CT (2003a) Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J Med Chem 46:2197–2204 Winum JY, Vullo D, Casini A, Montero JL, Scozzafava A, Supuran CT (2003b) Carbonic anhydrase inhibitors: inhibition of transmembrane, tumor-associated isozyme IX, and cytosolic isozymes I and II with aliphatic sulfamates. J Med Chem 46:5471–5477 Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60:7075–7083 Yin Q, Lin SC, Lamothe B, Lu M, Lo YC, Hura G, Zheng L, Rich RL, Campos AD, Myszka DG, Lenardo MJ, Darnay BG, Wu H (2009) E2 interaction and dimerization in the crystal structure of TRAF6. Nat Struct Mol Biol 16:658–666 Yoshiura K, Nakaoka T, Nishishita T, Sato K, Yamamoto A, Shimada S, Saida T, Kawakami Y, Takahashi TA, Fukuda H, Imajoh-Ohmi S, Oyaizu N, Yamashita N (2005) Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy. Clin Cancer Res 11:8201–8207 Zat’ovicova M, Tarabkova K, Svastova E, Gibadulinova A, Mucha V, Jakubickova L, Biesova Z, Rafajova M, Ortova Gut M, Parkkila S, Parkkila AK, Waheed A, Sly WS, Horak I, Pastorek J, Pastorekova S (2003) Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX. J Immunol Methods 282:117–134 Zatovicova M, Sedlakova O, Svastova E, Ohradanova A, Ciampor F, Arribas J, Pastorek J, Pastorekova S (2005) Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br J Cancer 93:1267–1276 Zatovicova M, Jeleuska L, Hulikova A, Csaderova L, Ditte P, Goliasova T, Pastorek J, Pastorekova S (in press). Carbonic anhydrase IX as an anticancer target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr Pharm Design Zavada J, Zavadova Z, Pastorek J, Biesova Z, Jezek J, Velek J (2000) Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer 82:1808–1813 Zavada J, Zavadova Z, Pastorekova S, Ciampor F, Pastorek J, Zelnik V (1993) Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer 54: 268–274 Zavada J, Zavadova Z, Zat’ovicova M, Hyrsl L, Kawaciuk I (2003) Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br J Cancer 89: 1067–1071 Zhang J (2008) Recent advances in preoperative imaging of renal tumors. Curr Opin Urol 18: 111–115 Zheng J, Avvaru BS, Tu C, McKenna R, Silverman DN (2008) Role of hydrophilic residues in proton transfer during catalysis by human carbonic anhydrase II. Biochemistry 47: 12028–12036 Zhou GX, Ireland J, Rayman P, Finke J, Zhou M (2010) Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials. Urology 75:257–261
Chapter 5
Glycolytic Pathway as a Target for Tumor Inhibition Weiqin Lu and Peng Huang
Abstract It has been known for decades that cancer cells exhibit elevated aerobic glycolysis, a phenomenon first observed by Otto Warburg. The imaging technique 18 fluoro-deoxyglucose-positron emission tomography (FDG-PET) widely used in clinical diagnosis of cancer is based on the increased glucose uptake by cancer cells, likely due to a significant increase in glucose flow into the glycolytic pathway to generate ATP and conversion to other metabolic intermediates and building blocks for cell growth and proliferation. Furthermore, the increased glucose uptake in cancer tissues seems correlated with tumor aggressiveness and poor prognosis. Such profound metabolic alterations suggest that cancer cells may prefer to use glycolysis for their proliferative and survival advantage. Recent studies have begun to elucidate the molecular mechanisms underlying these metabolic alterations, and provide important new insights into the mechanistic links between oncogenic signals and metabolic regulation. Importantly, targeted inhibition of glycolysis and its regulatory pathways may provide exciting opportunities for the development of therapeutic strategies to preferentially kill cancer cells. This chapter will summarize our current understanding of glycolytic alterations in cancer cells and the relevant regulatory mechanisms, and discuss possible therapeutic strategies that exploit the metabolic abnormalities in cancer to preferentially kill malignant cells.
Introduction Glucose is a major source of fuel for ATP generation. It can be converted into two molecules of pyruvate in the cytosol with a net gain of 2 ATP and a reduction of 2 NAD+ to 2 NADH per glucose through a sequence of reactions known as glycolysis.
P. Huang (*) Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA e-mail:
[email protected] R.G. Bagley (ed.), The Tumor Microenvironment, Cancer Drug Discovery and Development, DOI 10.1007/978-1-4419-6615-5_5, © Springer Science+Business Media, LLC 2010
91
92
W. Lu and P. Huang Glucose GLUT
Glucose
ROS
HK
PPP (oxidative)
G6P PFK2
NADPH anabolic process
G6PD
GPI
Ribose-5-P
F6P
F2,6-BP
TKL/TAL
PFK1
F1,6-BP Aldolase
Dihydroxyacetone-P
Nucleotide synthesis
PPP (non-oxidative) GA3P
Mitochondria
GAPDH
1,3-BPG 3-PG 2-PG
PDH Enolase
PEP
ATP Succinate
OAA
TCA cycle SDH
Pyr PK
Malate Pyr
Lactate
NADH
Ac-CoA
PGM
ATP
MRC
NAD+ Citrate
PGK
Fumarate Fumerase
LDH
MCT
Lactate
Fig. 5.1 Overview of glycolysis, PPP, and the TCA cycle. Glucose is metabolized through the glycolytic pathway and the TCA cycle in the mitochondria in conjunction with mitochondrial respiratory to generate ATP. Glucose can also be metabolized through the PPP (in dashed line) to generate ribose-5-phosphate (ribose-5-P) as a precursor for the synthesis of nucleic acids, and NADPH for anabolic synthesis of fat acids or as a reducing equivalent to combat ROS. Notes: Dihydroxyacetone-P, Dihydroxyacetone-phosphate; F6P, fructose-6-phosphate; F1,6-BP, fructose1,6-bisphosphate; G6PD, glucose-6-phosphate dehydrogenase; GA3P, glyceraldehyde-3-phosphate; G6P, glucose-6-phoaphate; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GLUT, glucose transporter; GPI, glucose-phosphate isomerase; LDH, lactate dehydrogenase; HK, hexokinases; MCT, monocarboxylate transporter; MRC, mitochondrial respiratory chain (complexes I-V); PFK1, phosphofructokinase 1; PFK2, phosphofructokinase 2; PGK, phosphoglycerate kinase; PGM, phosphoglycerate mutase; PK, pyruvate kinase; Pyr, pyruvate; Ribose-5-P, ribose-5-phosphate; Ac-CoA, acetyl-CoA; OAA, oxaloacetate; PDH, pyruvate dehydrogenase; PPP, pentose phosphate pathway; ROS, reactive oxygen species; SDH, succinate dehydrogenase; TAL, transaldolases; TKL, transketolase
As illustrated in Fig. 5.1, glucose can be actively transported from blood stream into cells by Na+-dependent glucose specific transporters (GLUTs). Once it enters the cell, glucose is phosphorylated into glucose-6-phosphate (G6P) by a family of enzymes called hexokinases (HKs), the first rate-limiting enzyme of the glycolysis. G6P is a key metabolic intermediate at the branching point of two major metabolic pathways, namely glycolysis and pentose phosphate pathway (PPP). G6P can be
5 Glycolytic Pathway as a Target for Tumor Inhibition
93
dehydrogenated by glucose 6-phosphate dehydrogenase (G6PD) in the PPP to generate ribose 5-phosphate and NADPH when the cellular ratio of NADP+/ NADPH is increased. If cellular ATP level decreases, G6P will be actively converted to fructose-6-phosphate (F6P) by glucose phosphate isomerase (GPI) and thus favoring the glycolytic pathway. With ATP energy expenditure, F6P is then converted to fructose-1,6-bisphosphate (F1,6-BP) catalyzed by another rate-limiting enzyme phosphofructokinase 1 (PFK1). This reaction is energetically favored. The glycolytic process appears irreversible beyond this point, thus this is the key regulatory step in glycolysis. Aldolase further splits F1,6-BP into two triose sugars, dihydroxyacetone phosphate and glyceraldehyde-3-phosphate (GA3P). The former can be converted to GA3P by triosephosphate isomerase and proceeds further into glycolysis. GA3P is then dehydrogenated to 1, 3-bisphosphoglycerate (1,3-BPG) by an oxidoreductase glyceraldehyde dehydrogenase (GAPDH). This step requires NAD+ as a hydrogen carrier accepting H+ to generate NADH. Thus, the presence of sufficient amount of NAD+ is important to support a sustained level of glycolysis. 1,3BPG is then further metabolized by phosphoglycerate kinase (PGK) to 3-phosphoglycerate (3-PG), which is converted to 2-phosphoglycerate (2-PG) by phosphoglycerate mutase (PGM) and further converted to phosphoenolpyruvate (PEP) by enolase. Finally, pyruvate is produced from PEP by pyruvate kinase, one of the three key rate-limiting enzymes in glycolysis. If pyruvate is not further utilized in the mitochondria, it will be converted into lactate by lactate dehydrogenase (LDH) in the cytosol, generating NAD+ as substrate for the GAPDH-catalyzed reaction to allow continued glycolysis. NAD+/NADH ratio is important in regulating LDH activity. Because cells can obtain ATP supply through the oxygen-independent glycolytic pathway in cytosol and the oxygen-dependent oxidative phosphorylation (OXPHOS) pathway in mitochondria, the availability of oxygen and the mitochondrial functional status of the cells play important roles in determining the proportion of each pathway in ATP generation. In the presence of oxygen and functional mitochondria, pyruvate can be transported into the mitochondria and decarboxylated into acetyl CoA by the pyruvate dehydrogenase (PDH) complex in the mitochondria. The oxidation of acetyl CoA is achieved by the tricarboxylic acid (TCA) cycle generating CO2, H2O, GTP and other bioenergetic products including NADH and FADH2 (Krebs 1970a,b). The electrons from NADH and FADH2 are transported through the respiratory chain complexes (I–IV) and donated to oxygen to generate water, and the proton gradient generated through this process is used as the energy source for ATP production in complex V, where the ATP generation is highly efficient (Mitchell and Moyle 1967; Skulachev 1994). Under normal physiological conditions, mitochondria play an important role in OXPHOS generating most of the ATP for cellular function (Newmeyer and Ferguson-Miller 2003). However, in cancer cells the glucose metabolism seems significantly altered, and such alterations may serve as a biochemical basis to selectively kill malignant cells. A major goal of chemotherapy is to selectively kill cancer cells without significant toxicity to normal cells. Tremendous progress has been made recently in our
94
W. Lu and P. Huang
understanding of the biochemical and metabolic characteristics of cancer cells and the molecular mechanisms that govern cancer development and progression. It has been recognized that cancer cells exhibit a high degree of heterogeneity, adaptability, and genetic instability, making it difficult to eliminate the entire cancer cell population using target-specific agents. However, despite the different genetic or epigenetic alterations in cancer cells, aerobic glycolysis seems to be a common feature of the malignant cells as originally observed by Otto Warburg (1956a). Compared to normal adult cells, which mainly use OXPHOS to generate ATP, cancer cells have a higher tendency to generate ATP by converting glucose to lactate through the glycolytic pathway even in the presence of adequate oxygen (an aerobic glycolytic process known as the Warburg effect). It was estimated that more than 90% of metastatic tumors tested are highly glycolytic (Czernin and Phelps 2002). Such widespread metabolic alterations in cancer suggests that the malignant cells may prefer to use aerobic glycolysis rather than the highly efficient OXPHOS pathway to generate energy for their survival advantages, and perhaps facilitating tumor invasion and metastasis through acidification of the tumor microenvironment that in turn select the cancer cells with more aggressive malignant behaviors (Gatenby and Gawlinski 1996; Gatenby et al. 2006; Schornack and Gillies 2003; Wallace 2005). The increase in glucose uptake by cancer cells has been used as a metabolic basis in FDG-PET scan, which uses the glucose analogue 18 F-deoxyglucose as a tracer, for diagnosis of cancer and monitoring of tumor progression or therapeutic response (Czernin and Phelps 2002; Seemann 2004). The sustained activation of glycolysis observed in cancer cells may play a crucial role in cancer cell transformation and promotion of malignant cell behaviors (Gatenby 1995). With further understanding of the tumor micro-environment related to hypoxia and hypoxia-inducible factor (HIF) function, and the roles of Myc, Akt, Ras, p53, and AMPK in the glycolytic regulation, the metabolic diffe rences between cancer and normal cells have gained broad attention recently, and study in this area is likely to have profound influence on our understanding on cancer biology and cancer therapeutics.
Alterations of Glucose Metabolism in Cancer More than 80 years ago, Warburg pioneered the research on mitochondrial respiratory chain defects in the context of cancer, and was the first to recognize that tumors are highly glycolytic. His decades of work in this area was perhaps best illustrated in his landmark publication in Science more than 50 years ago (Warburg 1956b). It is estimated that over 50% of ATP in many tumor cells is derived from glycolysis to meet the needs for rapid cell growth and proliferation, although some of the highly proliferating tumor cells do not have obvious defects in oxidative metabolism. FDG-PET scan of tumor tissues has unequivocally demonstrated the increase in glucose uptake as a hallmark of human cancer, showing a profound alteration of glucose metabolism in tumors (Haberkorn et al. 1991; Weber 2006).
5 Glycolytic Pathway as a Target for Tumor Inhibition
95
It should be pointed out, however, that an increase in glucose uptake dose not necessarily indicate that this increase is solely due to increased glycolysis. The increase in glycolysis in cancer cells is likely to provide proliferative and survival advantages. In addition to ATP generation, the glycolysis also produces important metabolic intermediates for the biosynthesis of macromolecules and avoids ROS generation. Some of the glycolytic enzymes also have anti-apoptotic function. The metabolic switch or “reprogramming” from aerobic mitochondrial metabolism to glycolysis in tumor cells might be achieved through a number of putative mechanisms, including up-regulation of the glycolytic enzymes, suppression of the mitochondrial function due to mitochondrial mutation and/or defects in respiratory chain function at various points of the electron transport complexes, decreased pyruvate utilization by mitochondria, impaired TCA cycle, activation of oncogenes, mutation or loss of tumor suppressors, and adaptation to hypoxic tumor environment. Mitochondrial dysfunction may promote cancer cell survival and drug resistance through alterations in cell survival pathways such as activation of the Akt pathway and attenuation of the mitochondria-mediated apoptotic process (Carew and Huang 2002; Ohta 2006).
Overexpression of Glycolytic Enzymes in Cancer Favors Aerobic Glycolysis A large body of evidence suggests that tumor cells have enhanced enzyme activities or/and increased transcription of genes of glycolytic enzymes such as HKII, PFKs, LDH-A, and GLUTs when compared with non-tumorigenic cells (Brown et al. 2002; Mathupala et al. 1997; Minchenko et al. 2002; Smith 2000). Interestingly, some of the elevated glycolytic enzymes were found to have anti-apoptotic function and may confer resistance to anticancer agents. GLUT1 The entry of glucose into the cells relies on a family of membrane transporters that facilitate the cellular uptake of glucose. GLUTs are an important family of membraneassociated proteins with isoform-specific tissue distribution, some of which are over-expressed in cancer cells. Among the 12 isoforms of GLUTs (GLUT1-GLUT12), GLUT1, 2, and 5 are found to be expressed in tumor cells (Godoy et al. 2006). GLUT1, which transfers glucose from bloodstream into the cells, seems to play an important role in tumor development. It has a high affinity for glucose and transports glucose at a high rate. Compared to normal tissues, tumor tissues having higher 18fluoro-deoxyglucose (FDG) uptake by PET scan are associated with a higher GLUT1 expression. HIF-1 was found to bind to the promoter of GLUT1 in human HepG2 cells to stimulate glucose uptake, and deregulation of GLUT1 by c-Myc was also reported (Dombrauckas et al. 2005). Activated AKT can also
96
W. Lu and P. Huang
enhance GLUT function. Thus, it is likely that GLUT1 up-regulation and increased glucose uptake in cancer are associated with oncogene regulation. HKII HKs, the first rate-limiting enzymes in glycolysis, catalyze the conversion of glucose to G6P. There are four isoforms of HKs with different tissue expression patterns and regulation. Besides catalyzing the phosphorylation of glucose, HKII has been suggested to promote cell survival by preventing apoptosis through association with the mitochondrial permeability transition pore component. It has been shown that HKII may interact with the voltage-dependent anion channel (VDAC) to induce permeability transition pore closure, and prevents BAX/BAK oligomerization on the mitochondrial membrane, blocking cytochrome c release from the mitochondria (GolshaniHebroni and Bessman 1997; Mathupala et al. 2006). As such, the mitochondriaassociated HK (HKII) is regarded as a guardian of the mitochondria to prevent apoptosis (Robey and Hay 2005). Enhanced transcription of HKII occurs in many cancers, especially in breast cancer, suggesting a possibility of HKII promoter activation during tumorigenesis (Kim and Dang 2006). The promoter region of HKII has putative binding sites for p53, HIF, and c-Myc. Interestingly, p53 was found to downregulate HKII while c-Myc and HIF could upregulate HKII mRNA transcription (Mathupala et al. 1997; Pastorino et al. 2005). Therefore, mutation or loss of p53, activation of c-Myc, and/or stabilization of HIF may lead to upregulation of HKII expression and result in hyperpolarization of the mitochondria and suppression of apoptosis. AKT activation can also signal HKII to bind to the mitochondrial membrane and remove the G6P inhibitory regulation (Majewski et al. 2004). Thus, it is conceivable that increased HKII due to oncogene activation or tumor suppressor dysfunction can stimulate glycolysis and promote cancer cell survival and drug resistance. Previous study in mitochondrial defective cells (r0 cells) showed that inhibition of glycolysis using the HKII inhibitor 3-bromopyruvate was effective in killing cancer cells with high glycolytic activity or under hypoxic conditions (Xu et al. 2005b). PFK1 PFK1, a rate-limiting enzyme under a tight regulation during glycolysis, catalyzes the phosphorylation of F6P to F1,6BP. Interestingly, fructose-2,6-biphosphate (F2,6,BP) is an extremely potent allosteric activator of PFK1 and thus exerts a major regulatory control over the rate of glycolysis and glucose utilization. The enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphase (PFKBF) catalyzing the reversible reaction to produce F2,6,BP plays an essential role in the regulation of glycolysis. F1,6-BP level and PFK1 activity are significantly increased in most tumors (Sanchez-Martinez and Aragon 1997). Through the transcriptional regulation of TIGAR (TP53-induced glycolysis and apoptosis regulator), p53 inhibits F2,6,BP production and therefore lowers PFK1 activity and downregulates
5 Glycolytic Pathway as a Target for Tumor Inhibition
97
g lycolysis (Bensaad et al. 2006). AKT was shown to phosphorylate and activate PFK1 to upregulate glycolysis (Rathmell et al. 2003). Several other oncoproteins such as Myc and Ras have been reported to activate PFK1 in immortalized cells (Kole et al. 1991; Osthus et al. 2000). PKM2 Pyruvate kinase, another key rate-limiting enzyme in glycolysis, has four isoforms (L, R, M1, and M2). Proliferating cancer cells of various histological types seem to mainly express the human embryonic M2 isoform PKM2 (Altenberg and Greulich 2004). When PKM2 forms a highly active tetramer, this enzyme favors the formation of pyruvate and ATP. However, when PKM2 is in a less active dimer form, it impairs pyruvate formation and causes an accumulation of the upstream intermediate F1,6BP. PKM2 can selectively bind to tyrosine-phosphorylated peptides, resulting in the release of its allosteric activator F1,6BP and thus induces a diversion of glucose metabolites from energy production to the non-oxidative PPP pathway leading to anabolic processes. A recent study showed that a knockdown of PKM2 in tumor cells by shRNAs and a replacement with isoform PKM1 led to reduced lactate production, increased oxygen consumption, and reduced tumor formation in a mouse xenograft model (Christofk et al. 2008). In proliferating cancer cells, expression of PKM2 enhances the cells’ ability to use glucose for anabolic processes and this metabolic phenotype seems to provide a selective growth advantage for the tumor cells (Vander Heiden et al. 2009). LDH-A LDH catalyzes the conversion of pyruvate to lactate and provides NAD+ to support glycolysis. LDH-A is an enzyme that favors the conversion of pyruvate to lactate in anaerobic condition, while LDH-B seems to favor the conversion of lactate to pyruvate in aerobic condition. Since NAD+ is required for the glycolytic reaction catalyzed by GAPDH, regeneration of NAD+ by LDH is important to maintain glycolysis, especially when mitochondrial respiration is compromised. It is reported that cancer cells produce more lactate and have increased LDH-A activity than normal cells (Hove et al. 1993; Schwickert et al. 1995). LDH-A plays an important role in cancer cell survival, invasion, and metastasis not only by regenerating NAD+ to maintain glycolysis but also by causing cellular acidosis due to the generation of the metabolic product lactate, which may exit cancer cells through a lactate carrier monocarboxylate transporter 4 (MCT4), and induce tissue acidosis. LDH-A gene transcription can be induced by hypoxia through the activation of HIF-1. Interestingly, MCT4 also appears to be a downstream target of HIF-1. Lactate was reported to stimulate HIF-1 expression regardless of hypoxia and lactate-induced acidosis often precedes angiogenesis (Lu et al. 2002; Shi et al. 2001). Thus, through transcriptional activation of LDH-A and MCT4, HIF1 stimulates glycolysis and lactate exit out of the cells. Lactate generation
98
W. Lu and P. Huang
due to an increased LDH-A activation in turn stimulates HIF1 expression and creates a cycle of sustained enhancement of glycolysis. LDH-A is also a transcriptional target of c-Myc and its overexpression is required for c-Myc-mediated transformation, since lowering its expression by LDH-A-antisense reduces the transformation capacity of c-Myc (Shim et al. 1997). A recent study showed that a knockdown of LDH-A in tumor cells by shRNAs led to a stimulation of mitochondrial OXPHOS, a decrease of cell proliferation under hypoxia, and a suppression of tumorigenicity (Fantin et al. 2006). Acidification of tumor microenvironment by lactate may facilitate a selection of more malignant cancer cells with highly aggressive behaviors, and thus promote tumor development, invasion, and metastasis (Gatenby and Gillies 2004).
The PPP The biological roles of glucose are not only to function as a major fuel source for ATP generation but also to serve as a metabolic precursor to provide carbon source for the biosynthesis of macromolecules in proliferating cells. For the fast-growing tumor cells, production of sufficient amount of such metabolic intermediates is particularly important for the timely replication of their genome, synthesis of amino acids, membrane lipids, and the package of daughter cells. As such, only a portion of the glucose utilized by the tumor cells is used to convert to lactate during aerobic glycolysis, while a significant portion of glucose is metabolized through the PPP (Kuo et al. 2000; Poulsen and Frederiksen 1981). PPP is a major branch of metabolic flow derived from glycolysis, with G6PD as the rate-limiting enzyme locating at the branching point of PPP (Fig. 5.1). This pathway is essential for generating metabolic intermediates pentose-5-phosphate for nucleotide synthesis and the reducing equivalent NADPH for the reductive biosynthesis of lipids and fats. Significantly, NADPH is also an important reducing equivalent that is essential for the maintenance of redox homeostasis (Tian et al. 1999). The sugar moiety of the nucleotide precursor ribose-5-phosphate can be synthesized either from the oxidative or non-oxidative part of PPP (for review, see Tong et al. 2009). Both the oxidative portion (including steps catalyzed by G6PD and 6-phosphogluconate dehydrogenase enzymes) and the non-oxidative steps (including those catalyzed by transketolase-like-1 and transaldolases) of PPP have been reported to be activated or over-expressed in cancer cells (Langbein et al. 2006; Ramos-Montoya et al. 2006). Transketolase and transaldolase seem to play an important role in the inter-conversion of the metabolic intermediates between PPP and glycolysis. When the requirement for NADPH exceeds the need for pentose-phosphate in biosynthesis, the excess amount of pentose-phosphate can be converted to the glycolytic intermediates F6P and GA3P by the metabolic steps catalyzed by transaldolase and transketolase. On the other hand, when pentose-phosphate is in high demand due to fast cell growth and proliferation, the generation of a large amount of pentosephosphate can be met by conversion from F6P and GA3P catalyzed by transaldolase and transketolase. Targeted inhibition of PPP is reported to be effective in preventing tumor metastasis (Langbein et al. 2008). The exact roles of oxidative PPP and nonoxidative PPP in different stages of tumorigenesis remain to be elucidated.
5 Glycolytic Pathway as a Target for Tumor Inhibition
99
Mitochondrial Dysfunction and Increased Glycolysis in Cancer Mitochondria consume the majority of the oxygen utilized in cellular metabolism, and are responsible for aerobic ATP generation from glucose through OXPHOS (Newmeyer and Ferguson-Miller 2003; Wallace 1999). Embedded in the inner mitochondrial membrane, the mitochondrial respiratory chain is composed of five multi-enzyme complexes, including NADH dehydrogenase (complex I), succinate dehydrogenase (complex II), cytochrome bc1 complex (complex III), cytochrome c oxidase (complex IV), and the ATP synthase (complex V) (for review see Mandavilli et al. 2002). One unique feature of mitochondria is that these cellular organelles have their own genetic materials, mitochondrial DNA (mtDNA). It should be noted that mtDNA lacks histone protection, has limited DNA repair capacity, and is located in a close proximity to the electron transport chain, the major site for ROS generation. As such, mtDNA is more vulnerable to damage compared to nuclear DNA. Since mitochondrial genome is devoid of introns, mutations in mtDNA are more likely to have significant functional consequences, leading to dysfunction in respiration and alterations in energy metabolism. Thus, mitochondrial genomic integrity is essential for maintaining normal ATP production and metabolic homeostasis (Wallace 1999). Because mitochondrial transcription is polycistronic, any deletion or insertion of a nucleo tide may cause a frame-shifting of the codon and thus affect the downstream genes encoding for the respiratory chain components (Zastawny et al. 1998). It was reported that mtDNA mutation rates are 10–20 times greater than nuclear DNA (Olgun et al. 2002), and increased mutations in mtDNA have been reported in various cancer cells (Verma et al. 2003; Wallace 1999). Patients bearing mtDNA mutations show refractory to conventional therapeutic agents (Carew et al. 2003; Ohta 2006). ROS-induced mtDNA mutations may play a key role in many diseases including cancer, ageing, and neurodegenerative diseases. mtDNA mutations, which may directly cause defective mitochondrial respiration to generate ATP through the coupled electron-transport chain and OXPHOS, have been found to alter cellular energy metabolism and induce higher glycolysis in a large spectrum of human cancers, suggesting that mitochondrial respiratory dysfunction may be mechanistically linked with increased glycolysis in human cancer (Cavalli and Liang 1998; Halabe Bucay 2007). In cancer cells with altered mitochondrial metabolism, mitochondria seem to export a large amount of citrate, which may be utilized as a metabolic intermediate for the biosynthesis of cholesterol and fatty acids (Parlo and Coleman 1986). Interestingly, citrate has been observed to increase in certain subsets of cancers (Kuhajda et al. 1994; Ristow 2006). The impaired activity of mitochondrial aconitase in cancer cells may negatively affect the TCA cycle, leading to elevated fatty acid generation and a coupling of increased glycolysis with lipogenesis. In addition, impairment of the mitochondrial Fe-S complex activity and a decrease in OXPHOS can lead to altered energy metabolism and tumor formation (Thierbach et al. 2005). ATP synthase, an enzyme required for OXPHOS, was found to be decreased in certain cancer types (Isidoro et al. 2004). Recently it was
100
W. Lu and P. Huang
reported that cells bearing mutations in mtDNA encoding for the NADH dehydrogenase complex component ND6 may cause defect in complex I, leading to elevated ROS production and increased metastatic potential (Ishikawa et al. 2008). The mitochondrial fumarate hydratase and succinate dehydrogenase (SDH), two enzymes involved in the TCA cycle and encoded by the nuclear DNA, have recently been reported to have tumor suppressor function (Baysal et al. 2000; Tomlinson et al. 2002). SDH is also an integral component of the electron transport chain complex II. Patients with inherited mutations in succinate dehydrogenase and fumarate hydratase are more likely to develop hereditary paraganglioma and papillary renal cell carcinoma (Baysal et al. 2000; Tomlinson et al. 2002). This may be due to the accumulation of succinate or fumarate, resulting in the inhibition of prolyl hydroxylase function that otherwise promotes HIF degradation. These tumors display high HIF activity even in the presence of oxygen (Isaacs et al. 2005; Pollard et al. 2005; Selak et al. 2005). Further study in fumarate hydratase-deficient cells showed an increase in LDH-A expression due to HIF-1a stabilization. Interestingly, inhibition of LDH-A in these cells led to ROS-mediated apoptosis. A knockdown of LDH-A resulted in a significant reduction in tumor growth in xenograft mouse model (Xie et al. 2009). Recently, it is reported that SDH5, a gene required for the interaction and flavination of SDH, is mutated in paraganglioma, a neuroendocrine tumor previously linked to mutations in genes encoding for SDH subunits (Hao et al. 2009). In addition, cells with increased HIF-1 stabilization or p53 mutation also show elevated aerobic glycolysis and reduced mitochondrial respiration. Such metabolic shift is characteristic of the Warburg effect and seems to play an important role in malignant transformation, not just a bystander in cancer (Frezza and Gottlieb 2009).
Tumor Microenvironment and Selection of Highly Glycolytic Cancer Cells HIF-1 and Glycolysis Cancer cells in a tumor mass often endure hypoxia, especially when the tumor mass has overgrown the capacity of blood supply. The ability of cancer cells to adapt and survive in hypoxic environment is a crucial step in tumor progression (Dang and Semenza 1999). Under hypoxic conditions, mitochondrial respiration may be limited and ATP generation through OXPHOS is decreased, forcing the cancer cells to utilize alternative mechanisms such as increased glycolysis to maintain sufficient cellular ATP for cell growth and proliferation. During adaptation to hypoxic microenvironment, the increase in HIF-1 plays an essential role (Sharp and Bernaudin 2004). HIF-1 is a heterodimer of HIF1a and HIF1b and functions as a transcription factor that regulates a number of genes critical for glycolysis, angiogenesis, cell proliferation, mitochondrial function, and cell sur-
5 Glycolytic Pathway as a Target for Tumor Inhibition
101
vival. Under physiologic conditions, the half-life (protein stability) and the transcriptional activity of HIF1a are negatively regulated by the O2-dependent prolyl and asparaginyl hydroxylation, respectively (Semenza 2003). Prolyl hydroxylase is a key enzyme capable of modifying HIF-1a at proline sites and marking it for Von Hippel Lindau protein (VHL)-mediated degradation by the 26S proteasome (Cockman et al. 2000; Thomas et al. 2003). The stabilized HIF-1a may be transported into the nucleus and forms a heterodimer with HIF-1b. The HIF1 heterodimer can then recruit p300/CBP and bind to the promoter region of the specific DNA sequence known as the hypoxia responsive element (HRE) to promote the expression of its targeted genes (Dang and Semenza 1999). Examples of HIF-1 downstream genes include a number of molecules involved in glycolysis such as GLUT1, HKII, aldolase A, enolase 1, LDHA, PFK, PGK, and pyruvate kinase (Dang and Semenza 1999; Denko 2008). The increased glycolytic gene expression due to HIF-1a stabilization in turn leads to enhanced glycolysis (Lu et al. 2002; Safran and Kaelin 2003). Clinically, cancer patients whose tumors with a greater hypoxic fraction seem to be associated with high HIF-1 expression and resistance to chemotherapy and radiotherapy (Hockel et al. 1993; Hockel and Vaupel 2003). Furthermore, due to the lack of pVHL tumor suppressor in some clear cell renal carcinoma, HIF-1 is consistently expressed and its targeted glycolytic genes are upregulated even under normoxic condition, resulting in the increased glucose uptake, increased lactate production, and decreased mitochondrial respiration (Semenza 2007). HIF-1 can also be activated by other non-hypoxic stimuli such as oncogenes and ROS, leading to increased glycolysis.
HIF-1 and Mitochondria In addition to promoting glycolysis, HIF-1 can also suppress aerobic respiration by enhancing the expression of pyruvate dehydrogenase kinase 1 (PDK1), which inhibits the activity of PDH. As illustrated in Fig. 5.2, an increased expression of PDK1 promotes the phosphorylation of PDH, leading to its inactivation, and thus reduces the conversion of pyruvate to acetyl CoA. As such, an increase in HIF-1 due to hypoxic microenvironment may limit the entry of pyruvate into the TCA cycle in the mitochondria, and thus suppresses the utilization of glucose as the energy supply via OXPHOS pathway (Papandreou et al. 2006). This suppression of substrate entry into the TCA cycle would further enhance the dependence of cells on glycolysis for ATP generation. The ability of HIF-1 to enhance glycolysis has been observed in many tumor cells. As described above, glycolysis not only serves as a rapid energetic pathway to generate ATP but also provides the building blocks for the synthesis of other biomolecules in cancer cells. For instance, the metabolic intermediates of the glycolytic pathway can be converted to ribose for the synthesis of nucleic acids via the PPP. Thus, it is possible that
102
W. Lu and P. Huang Glucose GLUT1
p53
Glucose
AMPK
LKB -1
Bioenergetic stress
HK
TIGAR
AMP
G6P PFK2
H 2O
PGI
F6P
F2,6-BP
O2
SCO2 Respiration Chain
PFK1
F1,6-BP Aldolase
NADH FADH2
Dihydroxyacetone-P + GA3P GAPDH
Pyr
1,3-BPG
Myc
Ac-CoA PDH
TCA cycle Mito.
PGK
3-PG
PDK1
PGM
2-PG Enolase
PEP
PK-M2
Pyr Lactate
LDH-A
AKT HIF-1
PIP3 Ras
PTEN
PI3K
MCT 4
Lactate
Fig. 5.2 Potential metabolic regulatory mechanisms contributing to the Warburg effect. Several important molecules including the oncogenic molecule Myc, the tumor suppressor p53, the transcription factor HIF-1, and the kinase Akt play essential roles in the regulation of cellular metabolism and contribute to the development of Warburg phenomenon in cancer cells. Activation of Myc oncogene upregulates the expression of many glycolytic molecules including the glucose transporter GLUT1, HK, and LDH, leading to increased glycolysis (orange arrows). Similarly, stabilization of HIF-1 due to hypoxia in tumor microenvironment or oncogenic signaling (e.g. Ras) may transactivate many glycolytic genes including GLUT1, HKII, PK-M2, and LDH-A, and enhances glycolytic flux (red arrows). HIF-1 also activates PDK1 gene expression, which in turn inhibits PDH and thus limits pyruvate entry into the mitochondria as fuel to generate ATP. Akt promotes plasma membrane association of GLUT1 to increase glucose uptake, and enhance HK association with the mitochondria and prevent apoptosis (blue arrows). On the contrary, the tumor suppressor p53 inhibits glycolysis by regulating the expression of HKII, PGM, and TIGAR, and stimulates mitochondrial respiration through transcriptional upregulation of SCO2 (green arrows). The loss of p53 function in cancer cells will lead to an increase in glycolysis and a decrease in respiration. The AMP-dependent kinase (AMPK) regulates glycolysis in part through its activation of p53
even in cancer cells without significant mitochondrial structural defects, the abnormal increase of HIF-1 may block normal mitochondrial function through transcriptional activation of PDK1, leading to a decrease in OXPHOS and an increase in glycolysis (Lu et al. 2002; Safran and Kaelin 2003). As such, the suppression of PDH by elevated HIF-1 in hypoxic tissue microenvironment may
5 Glycolytic Pathway as a Target for Tumor Inhibition
103
significantly contribute to the decrease in mitochondrial function and increase in glycolysis in cancer cells, characteristic of the Warburg effect.
Mutations of Tumor Suppressor Genes and Metabolic Alterations p53 Regulation of Glycolysis and Mitochondrial Respiration The tumor suppressor p53 plays major roles in a number of important cellular processes including stress responses (Vogelstein et al. 2000). Through transcriptional activation of its target genes, p53 involves in the regulation of cell cycle, DNA damage response, apoptosis, senescence, and metabolism. Through the transcriptional regulation of HK, PGM, TIGAR, and SCO2, p53 seems to prevent a switch from aerobic respiration to glycolysis (Green and Chipuk 2006; Shaw 2006). As illustrated in Fig. 5.2, HKII is the first rate-limiting enzyme of the glycolysis. The wildtype p53 protein can bind to the HKII promoter region and down-regulate HKII gene expression, limiting the entry of glucose into the glycolytic pathway. Similarly, p53 down-regulates the function of PGM, a glycolytic enzyme that converts 3-PG to 2-PG, and thus modulates the overall flux of glycolysis (Kondoh et al. 2005; Smith et al. 2006). The ability of p53 to modulate glycolysis has been further substantiated by the demonstration that p53 promotes the expression of TIGAR, a novel isoform of phosphofructose kinase (PFK2) that only contains the FBPase domain but lacks the kinase domain. It functions to lower the intracellular levels of fructose-2,6-bisphosphate. Because fructose-2,6-bisphosphate is a key allosteric activator of PFK1 (a key rate-limiting glycolytic enzyme), the elevated expression of TIGAR in cells with functional p53 would have low fructose-2, 6-bisphosphate levels and thus a lower flow of glucose metabolism through the step catalyzed by PFK1 (Bensaad et al. 2006). This causes a shift toward the PPP shunt, leading to increased production of NADPH, the major reducing equivalent for the generation of reduced glutathione and other cellular antioxidants, which in turn promote the scavenging of ROS and prevent mutational events associated with cancer. PPP can also produce ribose-5-phosphate, which could contribute to nucleotide biosynthesis and DNA repair. Therefore, through upregulation of TIGAR, p53 sets a glycolytic checkpoint to suppress glycolysis, to enhance ROS-scavenging capacity, and to promote genomic stability (Green and Chipuk 2006). A loss of p53 function in cancer cells, on the other hand, would promote glycolysis, leading to the Warburg phenomenon. Recently, p53 has been found to directly regulate mitochondrial energy production through transcriptional regulation of the synthesis of cytochrome c oxidase 2 (SCO2), a regulator of mitochondrial respiration and the oxygen utilization in the eukaryotic cells. SCO2 encodes a copper-binding protein required for the assembly of cytochrome c oxidase subunit II into the mitochondrial respiratory chain complex IV. Disruption of the SCO2 gene in human cancer cells with wild-type p53 recapitulated
104
W. Lu and P. Huang
the metabolic switch toward glycolysis similar to that observed in p53-deficient cells (Bensaad et al. 2006; Matoba et al. 2006). Therefore, p53 is able to regulate glycolysis and mitochondrial respiration in the concerted manner through HK, PGM, TIGER, and SCO2. Because p53 mutations and deletion are common in human cancer, it is likely that the loss of p53 function may contribute significantly to the switch from aerobic respiration to glycolysis observed in many cancer types (Shaw 2006), and provide a molecular link between genetic alterations and the Warburg effect. AMPK and Glycolytic Regulation AMP-activated protein kinase (AMPK) is a master metabolic regulator that plays an important role in cellular energy homeostasis. AMPK is a heterotrimeric protein complex consisting of an a catalytic subunit and b, g regulatory subunits (Kahn et al. 2005). It functions as a serine–threonine kinase at a regulatory pathway that integrates signals from energy metabolism (Fig. 5.2). As cellular ATP decreases and AMP level increases, AMPK is allosterically activated by increased cellular AMP levels, a condition that occurs under energetic stress such as cellular ATP depletion or hypoxia. Through binding to the regulatory g-subunit of the AMPK complex, AMP triggers a conformational change of the g-subunit, leading to the exposure of the active site Thr-172 on the a catalytic subunit. This in turn inhibits dephosphorylation and facilitates phosphorylation at Thr-172 by the upstream kinases (Suter et al. 2006). LKB-1, functioning as a tumor suppressor, is a primary upstream kinase of AMPK (Hardie 2007). LKB1 is required for AMPK activation under bioenergetic stress such as glucose withdrawal (Hawley et al. 2003; Shaw et al. 2004b; Woods et al. 2003). Activation of AMPK promotes phosphorylation of p53 at Ser-15 to regulate glycolysis. AMPK can also stimulate GLUT1,3mediated glucose uptake, and therefore enhances glycolytic pathway (Cidad et al. 2004). In addition, AMPK can phosphorylate the TSC1-TSC2 complex or/and block TORC1 activity to inhibit mammalian target of rapamycin (mTOR)-dependent protein translation in an LKB-dependent manner (Inoki et al. 2003). AMPK has been reported to down-regulate lipid synthesis through inhibition of acetylCoA carboxylase-1 (ACC1) (Hardie and Pan 2002). Mutations in LKB-1 have been associated with Peutz–Jeghers Syndrome (Scott et al. 2008). Mice with heterozygous disruption of LKB-1 develop neoplasia similar to Peutz–Jeghers Syndrome (Bardeesy et al. 2002). Loss of LKB-1 results in unchecked cell growth and the development of aggressive cancer (Gurumurthy et al. 2008; Ji et al. 2007).
Activation of Oncogenes and Increased Glycolysis c-Myc c-Myc is an oncogenic transcription factor with the helix-loop-helix leucine zipper structure. Through dimerization with its partner Max, c-Myc binds to specific DNA sequences known as E box, and stimulates the transcription of many genes
5 Glycolytic Pathway as a Target for Tumor Inhibition
105
involved in cell proliferation, metabolism, and apoptosis (Dang 1999). Max can form heterodimer with the Mad family proteins to repress transcription and therefore antagonize c-Myc function and achieve tight c-Myc regulation. Deregulated expression of the c-Myc gene is a common feature of human malignancies (Little et al. 1983). c-Myc expression enhances aerobic glycolysis by directly upregulating the expression of glycolytic genes such as enolase A, HK II, LDH-A, PFK, GAPDH, and GLUT1 independent of hypoxia (Kim et al. 2004). Many of the genes regulated by c-Myc are known to be regulated by HIF-1 as well (Dang et al. 2008). This suggests a possibility that in normal cells the low expression of glycolytic genes may be due to the tightly controlled Myc and HIF-1 expression, while in cancer cells, the increased expression of glycolytic enzymes may be attributed to the constitutive activation of c-Myc and/or elevated HIF-1 in response to the hypoxic tumor microenvironment. Genes of mitochondrial biogenesis and function such as cytochrome c and TFAM (transcription factor A of mitochondria) constitute another group of molecules upregulated by c-Myc overexpression (Dang et al. 2005). It is suggested that imbalanced expression of nuclear encoded versus mitochondrial encoded proteins could result in defective respiratory chain complex as noted in prostate cancer progression (Herrmann et al. 2003). The ability of c-Myc to upregulate glycolysis in the normoxic condition suggests that Myc may play a role in a switch to glycolytic metabolism during tumorigenesis.
Ras Ras is a guanine nucleotide triphosphatase that functions as a molecular switch in a large network of intracellular signaling pathways. Two major downstream signal pathways, MAPK and PI3K/Akt, are found to be upregulated in many cancer cells and may collaboratively promote the malignant phenotype of cancer cells. In particular, it has been shown that PI3K is required for both the development and maintenance of certain tumors driven by mutant H-Ras (Lim and Counter 2005). Alteration in the Ras-PI3K-Akt signal transduction pathway can result in the upregulation of HKII and elevation of glycolytic activity. Ras activation can also upregulate HIF1, NF-kB, PFK1 and thus enhances tumor glycolysis (Kole et al. 1991). PI3K/Akt Pathway Phosphatidylinositol 3-kinase (PI3K) is a heterodimer consisting of a catalytic subunit p110 and a regulatory subunit p85. Binding of growth factor molecules to their receptor tyrosine kinase activates PI3K, resulting in the phosphorylation of phosphatidylinositol on the plasma membrane and the activation of its downstream pathways such as Akt and mTOR. Tumor suppressor phosphatase and tensin homolog (PTEN) is a critical negative counterpart of PI3K by dephospho-
106
W. Lu and P. Huang
rylation PIP3 (phosphatidylinositol 3,4,5-triphosphate) to PIP2, leading to an inhibition of the Akt signal pathway, which is a serine/threonine kinase regulated by PIP3. Akt activation may result from PI3K activation or loss of PTEN function. Other oncogenes, such as Ras, HER2/neu, and Bcr-Abl, can also activate Akt. The PI3K/Akt kinase pathway is a central regulator of cell metabolism, proliferation, and survival and is deregulated in many cancer types. A recent paper reports that Akt stimulates glucose consumption in transformed cells and Akt-expressing cells are more susceptible to death after glucose withdrawal than control cells (Elstrom et al. 2004). Activation of the PI3K/Akt pathway results in coordinated localization of glucose transporters to the cell surface and upregulation of glycolytic enzymes such as PFK2 and enhances glucose capture through glucose phosphorylation by HK (Pozuelo Rubio et al. 2003). Akt can also inactivate p53 through stabilization of Mdm2 (Gottlieb et al. 2002). Thus, Akt activation seems to be able to cause a metabolic switch from OXPHOS to aerobic glycolysis in cancer cells. As such, Akt is considered as “Warburg kinase” by some investigators (Robey and Hay 2009). In addition to its role in glycolysis, Akt is also involved in other metabolic processes. For instance, Akt phosphorylates and inhibits glycogen synthase kinase-3, leading to the dephosphorylation of glycogen synthase by the glycogenassociated form of protein phosphatase 1, and a stimulation of glycogen synthesis. Activation of Akt stimulates the transport of both glucose and amino acids, which in turn support the mTOR-dependent promotion of protein translation. On the contrary, the LKB-1 tumor suppressor negatively regulates mTOR signaling (Shaw et al. 2004a). Many human tumors display an increased expression of lipogenic enzymes including ATP citrate lyase (ACL, an enzyme that converts cytosolic citrate to acetyl-CoA for fatty acid synthesis), fatty acid synthase, and acetyl-CoA carboxylase (Milgraum et al. 1997; Rossi et al. 2003; Swinnen et al. 2000; Yahagi et al. 2005). Besides, some tumors have a high rate of de-novo fatty acid synthesis from carbohydrate precursors as shown by 14C-glucose studies (Kuhajda 2000; Ookhtens et al. 1984). Such an increase of lipogenic activity in cancer cells may in part be attributed to Akt activation, which stimulates the synthesis and nuclear accumulation of a key lipogenic transcription factor sterol regulatory element binding protein-1, resulting in the upregulation of lipogenic enzymes (Porstmann et al. 2005). Akt also directly phosphorylates and activates ACL (Swinnen et al. 2006). Thus, it appears that the PI3K/Akt/mTOR axis is a major regulatory pathway that governs glycolysis and cellular biosynthesis (DeBerardinis et al. 2008a).
Glycolytic Pathway as a Target for Tumor Inhibition Compelling evidence shows that cancer cells have profound alterations in their energy metabolism, with an increase in aerobic glycolysis as one of the most prominent metabolic changes. As described above, multiple factors including mitochondrial dysfunction, oncogenic signals, loss of tumor suppressor function, and aberrant expression of certain regulatory molecules and enzymes can all contribute
5 Glycolytic Pathway as a Target for Tumor Inhibition
107
to the highly glycolytic phenotype of cancer cells. Several key regulators of cancer metabolism and their influence on the major metabolic steps are illustrated in Fig. 5.2. Although whether an increase in glycolysis is a cause or a “symptom” of malignant transformation still remains as a matter of debate, the profound metabolic alterations in cancer cells are likely to have significant therapeutic implications. In particular, the increased dependency of cancer cells on the glycolysis for energy supply and for metabolic intermediates as the building blocks for cell proliferation provides a biochemical basis to preferentially inhibit tumor growth by targeting the glycolytic pathway. Recent studies suggest that it is indeed possible to use small compounds or siRNA to abrogate certain key steps in the glycolytic pathway by suppression of the key enzymes such as HK and LDH, leading to selective killing of cancer cells (Fantin et al. 2006; Pelicano et al. 2006; Xu et al. 2005b). Theoretically, many of the enzymes and regulatory molecules shown in Figs. 5.1 and 5.2 may serve as potential targets for such a metabolic intervention. The following sections provide a brief summary of several important compounds that have been shown to inhibit glycolysis with potential use in cancer therapeutics.
2-Deoxyglucose 2-Deoxyglucose is a glucose molecule which has the 2-hydroxyl group replaced by hydrogen. Upon transport into the cells, 2-deoxyglucose is phosphorylated by HK to 2-deoxyglucose-phosphate, which cannot be further metabolized by phosphohexose isomerase. Thus, 2-deoxyglucose-phosphate accumulates in the cells and interferes with glycolytic metabolism by competing with glucose for glycolytic enzymes such as HK and phosphoglucose isomerase. Because of the presence of abundant glucose in the cell culture medium and in the blood circulation, high concentrations of 2-deoxyglucose in the millimolar range are required to be effective to inhibit cancer cell growth. An in vivo study showed that this compound alone exhibited limited anticancer activity, but could significantly enhance the therapeutic efficacy of doxorubicin and taxol in animal tumor models (Maschek et al. 2004). This compound has been evaluated clinically in phase I trials to determine its safety profile and pharmacokinetics in 34 patients with solid tumors who had relapsed after chemotherapy with other agents. It appears that a combination of 2-deoxyglucose and docetaxel was safe with no evidence of pharmacokinetic interaction (http://www.thresholdpharm.com/sec/pipe_2deoxyglucose). The clinical therapeutic activity of this compound, alone or in combination with other anticancer agents, still remains unclear and requires further evaluation.
3-Bromopyruvate The pyruvate analog 3-bromopyruvate (3-BrPA) has been shown to inhibit HK and cause severe depletion of cellular ATP, leading to massive cancer cell death, especially in cells with mitochondrial respiratory dysfunction or under hypoxic conditions
108
W. Lu and P. Huang
(Geschwind et al. 2004; Ko et al. 2001; Xu et al. 2005b). Although depletion of cellular ATP is thought to be a key mechanism by which 3-BrPA exerts its cytotoxic effect, a recent study also showed that this compound could covalently modify HKII protein and cause its dissociation from mitochondria. Dissociation of HKII from mitochondria could in turn cause the release of apoptosis-inducing factor and subsequent cell death (Chen et al. 2009). It is worth noting that cancer cells with mitochondrial dysfunction or in hypoxic environment usually become less sensitive to many anticancer drugs currently used in clinic, due in part to the accumulation of HIF-1 and activation of Akt survival pathways. These cancer cells, however, are particularly sensitive to the cytotoxic action of 3-BrPA because of their high dependency on glycolysis. Furthermore, ATP depletion by 3-BrPA may disable the ATPdependent drug-exporting pump and thus overcome multi-drug resistance associated with increased expression of MDR pump (Xu et al. 2005b). Thus, the unique mechanism of action of 3-BrPA makes this compound potentially useful in killing cancer cells in hypoxic tumor and overcoming multi-drug resistance. Interestingly, combination of glycolytic inhibition with the mTOR inhibitor rapamycin seems to have synergistic anticancer effect (Xu et al. 2005a). It should be pointed out, however, that 3-BrPA is an alkylating agent, which may potentially attack other cellular molecules, and the cytotoxic action of this compound may not be entirely due to its inhibition of HKII. Although there is compelling evidence showing that 3-BrPA has promising anticancer activity both in vitro and in vivo in several animal tumor models, this compound is still in its pre-clinical development, and has not yet entered clinical trials.
Lonidamine Lonidamine (1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid) is a derivative of indazole-3-carboxylic acid known to inhibit glycolysis in tumor cells. This compound is an orally administered small molecule that has been evaluated in phase II/III clinical trials for the treatment of various solid tumors (Di Cosimo et al. 2003). The mechanism by which lonidamine suppresses glycolysis appears through the inhibition of the mitocondrially bound HK (Floridi et al. 1998). Interestingly, studies using murine cells showed that this compound inhibits aerobic glycolysis in tumor cells but enhances glycolysis in the normal cells (Floridi et al. 1998). The mechanism responsible for this differential effect on glycolysis in normal and cancer cells still remains unclear. Further studies by the same group showed that lonidamine may also inhibit mitochondrial respiration, as evidenced by the suppression of oxygen consumption in both normal and cancer cells (Floridi et al. 1998). The anticancer activity of this compound may be ascribed to its overall ability to abrogate energy metabolism in cancer cells. In clinical trials, lonidamine appeared to be able to enhance the therapeutic activity of several major anticancer agents, including paclitaxel and cisplatin in the treatment of advanced ovarian cancer (De Lena et al. 2001).
5 Glycolytic Pathway as a Target for Tumor Inhibition
109
Oxythiamine and 6-Aminonicotinamide The PPP is important for cancer cell survival because this pathway provides the metabolic intermediates ribose-5-phosphate for the synthesis of nucleic acids and NADPH for scavenging of reactive oxygen species (ROS). In addition, the non-oxidative phase of PPP also converts 5-carbon metabolic intermediates to 6-carbon and 3-carbon compounds (e.g. F6P and glyceraldehydes-3-phosphate), which can then be used in the glycolytic pathway. Thus, PPP is an important sugar metabolic pathway that generates the key building blocks for cell proliferation, reducing equivalents for redox regulation, and metabolic intermediates for energy metabolism. The enzymes transketolase and transaldolase are essential for the non-oxidative phase of PPP, and seem to be increased in tumor cells (Coy et al. 2005; Heinrich et al. 1976). Oxythiamine is a thiamine antagonist that inhibits transketolase and PDH, which use thiamine pyrophosphate (TPP) as a cofactor for their enzymatic activities. Oxythiamine has been shown to have anticancer activity both in vitro and in vivo (Comin-Anduix et al. 2001; Rais et al. 1999). Specific inhibition of TKTL1 by RNAi can inhibit cancer cell proliferation and compromise cell viability (Hu et al. 2007; Zhang et al. 2007). The compound 6-aminonicotinamide (6-AN) is an inhibitor of G6PD, an enzyme that catalyzes the conversion of G-6-P to 6-phosphogluconolactone at the first step of PPP. This compound exhibits anticancer activity, causes oxidative stress, and sensitizes cells to anticancer agents (Budihardjo et al. 1998; Varshney et al. 2003). However, potential neurotoxicity is a concern for using 6-AN as a therapeutic agent.
Dichloroacetate Dichloroacetate (DCA) is a small compound capable of penetrating most tissues after oral administration, and has been used in the treatment of human lactic acidosis and inherited mitochondrial diseases. Although this compound could lower blood lactate levels, it showed no significant clinical benefit in a controlled clinical trial (Stacpoole and Greene 1992). However, a recent study showed that DCA exhibited significant anticancer activity by inhibiting pyruvate dehydrogenase kinase and thus activating PDH and enhancing the flux of pyruvate into the mitochondria (Bonnet et al. 2007). As such, DCA is able to decrease aerobic glycolysis and promote glucose oxidation and mitochondrial function, leading to a reversion of the Warburg effect in cancer cells. Through promoting cytochrome c release and ROS generation, DCA was shown to induce apoptosis in various human cancer cells (Bonnet et al. 2007; Cao et al. 2008), and enhance the effectiveness of hypoxiaspecific cytotoxic chemotherapy in solid tumor (Cairns et al. 2007). Administration of DCA decreases lactate level, activates PDH activity, and decreases tumor growth in xenograft models (Bonnet et al. 2007; Parolin et al. 2000). With its apparent advantages in drug delivery and anticancer activity/selectivity, DCA is currently in phase I trial in Canada for the treatment of recurrent or metastatic solid tumors.
110
W. Lu and P. Huang
Other Metabolic Modulators Other metabolic modulators, which either involve in the direct inhibition of glycolysis or target the relevant regulatory pathways, are also under investigation in pre-clinical and clinical settings (Chen et al. 2007; Lopez-Lazaro 2008; Pelicano et al. 2006). For instance, metformin is an inhibitor of gluconeogenesis and has been used for clinical treatment of diabetes. This compound is able to activate AMPK and attenuate the mTOR pathway, thus impacting glycolysis and inhibiting tumor growth. Interestingly, a large case–control study suggests that the use of metformin may significantly reduce the risk of developing pancreatic cancer (Li et al. 2009). A potent inhibitor of the glycolytic enzyme PGM was identified as an effective agent against breast cancer in a chemical screening study (Evans et al. 2005). Selective LDH inhibitors such as dihydroxynaphthoic acids have been developed (Yu et al. 2001), and their potential anticancer activity should be further tested. The MCT, which functions to export lactate out of the cells, is upregulated in various human tumor and may be considered as a potential target for tumor inhibition (Sonveaux et al. 2008). NVP-BEZ235, a small molecule that inhibits PI3K and mTOR, is able to decrease glucose uptake and cause marked tumor regression as measured by FDG-PET (Engelman et al. 2008). Disruption of glucose transport may also be a strategy to inhibit glucose metabolism in cancer. Imatinib, a BCRABL tyrosine kinase inhibitor, was found to reduce the expression of GLUT1 and decrease glycolysis in leukemic cells (Gottschalk et al. 2004).
Summary Increased aerobic glycolysis is a hallmark of cancer metabolism. Recent studies suggest that this metabolic alteration may confer proliferative and survival advantages to cancer cells, and help the selection of aggressive malignant cells in the tumor microenvironment. Although OXPHOS in the mitochondria is highly efficient in ATP generation, glycolysis can rapidly generate ATP and, in conjunction with the PPP, can provide the building bricks for the synthesis of nucleic acids, lipids, and proteins to meet the needs of cancer cell proliferation (Bui and Thompson 2006). On the contrary, normal cells mainly use mitochondrial OXPHOS to oxidize glucose to CO2 and H2O and generate a large amount of ATP to fulfill the energy needs of cellular activity with little or low requirements for proliferation in welldifferentiated adult tissues. This profound metabolic difference between cancer and normal cells provides a biochemical basis for therapeutic intervention to preferentially kill cancer cells by inhibition of glycolysis. In addition, beyond their roles in catalyzing glucose breakdown and providing metabolic intermediates for the anabolic reactions, the elevated glycolytic enzymes in cancer cells may also contribute to tumor adaptation and survival through their non-glycolytic functions. For example, HKII exerts its anti-apoptotic function through association with the mitochondria
5 Glycolytic Pathway as a Target for Tumor Inhibition
111
and preventing cytochrome c release. Sustained aerobic glycolysis may also protect cancer cell from ROS-induced cell damage (Ahmad et al. 2005). The metabolic transformation of cancer cells can be achieved by upregulation of the key glycolytic enzymes and glucose transporters through various regulatory mechanisms, including oncogene activation and loss of tumor suppressors. Cancer cells are able to overproduce lactic acid aerobically, whereas normal cells undergo anaerobic glycolysis only when deprived of oxygen. The increase in aerobic glycolysis and elevation of lactate may confer cancer cells an advantage to invade surrounding tissues and facilitate their invasion and metastasis. Thus, inhibition of glycolysis may also be effective in suppressing cancer metastasis. It should be pointed out, however, that cancer cells are genetically unstable with a high degree of heterogeneity in gene regulation and metabolism. Some cancer cells may be more dependent on glutamine metabolism instead of glycolysis for energy supply (Deberardinis et al. 2008b), and inhibition of glycolysis may not be effective in killing these cancer cells. Furthermore, because certain normal tissues such as heart and brain also use glucose as an important fuel source, inhibition of glucose utilization in these tissues might compromise their normal functions. Thus, it is extremely important to understand the exact differences between normal and cancer cells in their metabolic regulation, and specifically target the unique metabolic alterations in cancer cells to improve therapeutic selectivity. With the new discoveries of metabolic regulatory mechanisms and novel glycolytic inhibitors with improved pharmacokinetic and pharmacodynamic properties, it is possible to develop more effective therapeutic strategies with high selectivity against cancer.
References Ahmad IM, Aykin-Burns N, Sim JE, Walsh SA, Higashikubo R, Buettner GR, Venkataraman S, Mackey MA, Flanagan SW, Oberley LW et al (2005) Mitochondrial O2*- and H2O2 mediate glucose deprivation-induced stress in human cancer cells. J Biol Chem 280:4254–4263. Altenberg B, Greulich KO (2004) Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84:1014–1020. Bardeesy N, Sinha M, Hezel AF, Signoretti,S, Hathaway NA, Sharpless NE, Loda,M, Carrasco DR, DePinho RA (2002) Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 419:162–167. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myers EN et al (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science (New York, NY) 287:848–851. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126:107–120. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S et al (2007) A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11: 37–51. Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL (2002) Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nuclear Med Biol 29:443–453.
112
W. Lu and P. Huang
Budihardjo II, Walker DL, Svingen PA, Buckwalter CA, Desnoyers S, Eckdahl S, Shah GM, Poirier GG, Reid JM, Ames MM et al (1998) 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin. Clin Cancer Res 4:117–130. Bui T, Thompson CB (2006) Cancer’s sweet tooth. Cancer Cell 9:419–420. Cairns RA, Papandreou I, Sutphin PD, Denko NC (2007) Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci USA 104: 9445–9450. Cao W, Yacoub S, Shiverick KT, Namiki K, Sakai Y, Porvasnik S, Urbanek C, Rosser CJ (2008) Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate 68:1223–1231. Carew JS, Huang P (2002) Mitochondrial defects in cancer. Mol Cancer 1:9. Carew JS, Zhou Y, Albitar M, Carew JD, Keating MJ, Huang P (2003) Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia 17:1437–1447. Cavalli LR, Liang BC (1998) Mutagenesis, tumorigenicity, and apoptosis: are the mitochondria involved? Mutat Res 398:19–26. Chen Z, Lu W, Garcia-Prieto C, Huang P (2007) The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 39:267–274. Chen Z, Zhang H, Lu W, Huang P (2009) Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochim et Biophys Acta 1787:553–560. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC (2008) Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452:181–186. Cidad P, Almeida A, Bolanos JP (2004) Inhibition of mitochondrial respiration by nitric oxide rapidly stimulates cytoprotective GLUT3-mediated glucose uptake through 5’-AMP-activated protein kinase. Biochem J 384:629–636. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH (2000) Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275:25733–25741. Comin-Anduix B, Boren J, Martinez S, Moro C, Centelles JJ, Trebukhina R, Petushok N, Lee WN, Boros LG, Cascante M (2001) The effect of thiamine supplementation on tumour proliferation. A metabolic control analysis study. Eur J Biochem/FEBS 268:4177–4182. Coy JF, Dressler D, Wilde J, Schubert P (2005) Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. Clin Lab 51:257–273. Czernin J, Phelps ME (2002) Positron emission tomography scanning: current and future applications. Annu Rev Med 53:89–112. Dang CV (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19:1–11. Dang CV, Kim JW, Gao P, Yustein J (2008) The interplay between MYC and HIF in cancer. Nat Rev 8:51–56. Dang CV, Li F, Lee LA (2005) Could MYC induction of mitochondrial biogenesis be linked to ROS production and genomic instability? Cell Cycle 4:1465–1466. Dang CV, Semenza GL (1999) Oncogenic alterations of metabolism. Trends Biochem Sci 24:68–72. De Lena M, Lorusso V, Latorre A, Fanizza G, Gargano G, Caporusso L, Guida M, Catino A, Crucitta E, Sambiasi D et al (2001) Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. Eur J Cancer 37:364–368. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008a) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7:11–20. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB (2008b) Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 18:54–61. Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev 8: 705–713. Di Cosimo S, Ferretti G, Papaldo P, Carlini P, Fabi A, Cognetti F (2003) Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today (Barc) 39:157–174.
5 Glycolytic Pathway as a Target for Tumor Inhibition
113
Dombrauckas JD, Santarsiero BD, Mesecar AD (2005) Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 44:9417–9429. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM et al (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64:3892–3899. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y et al (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351–1356. Evans MJ, Saghatelian A, Sorensen EJ, Cravatt BF (2005) Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat Biotechnol 23:1303–1307. Fantin VR, St-Pierre J, Leder P (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9:425–434. Floridi A, Bruno T, Miccadei S, Fanciulli M, Federico A, Paggi MG (1998) Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism. Biochem Pharmacol 56:841–849. Frezza C, Gottlieb E (2009) Mitochondria in cancer: not just innocent bystanders. Semin Cancer Biol 19:4–11. Gatenby RA (1995) The potential role of transformation-induced metabolic changes in tumor-host interaction. Cancer Res 55:4151–4156. Gatenby RA, Gawlinski ET (1996) A reaction-diffusion model of cancer invasion. Cancer Res 56:5745–5753. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ (2006) Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res 66:5216–5223. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev 4: 891–899. Geschwind JF, Georgiades CS, Ko YH, Pedersen PL (2004) Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev Anticancer Ther 4:449–457. Godoy A, Ulloa V, Rodriguez F, Reinicke K, Yanez AJ, Garcia Mde L, Medina RA, Carrasco M, Barberis S, Castro T et al (2006) Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol 207:614–627. Golshani-Hebroni SG, Bessman SP (1997) Hexokinase binding to mitochondria: a basis for proliferative energy metabolism. J Bioenerg Biomembr 29:331–338. Gottlieb TM, Leal JF, Seger R, Taya Y, Oren M (2002) Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 21:1299–1303. Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ (2004) Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res 10:6661–6668. Green DR, Chipuk JE (2006) p53 and metabolism: inside the TIGAR. Cell 126:30–32. Gurumurthy S, Hezel AF, Sahin E, Berger JH, Bosenberg MW, Bardeesy N (2008) LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis. Cancer Res 68:55–63. Haberkorn U, Strauss LG, Reisser C, Haag D, Dimitrakopoulou A, Ziegler S, Oberdorfer F, Rudat V, van Kaick G (1991) Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med 32: 1548–1555. Halabe Bucay A (2007) The biological significance of cancer: mitochondria as a cause of cancer and the inhibition of glycolysis with citrate as a cancer treatment. Med Hypotheses 69: 826–828. Hao HX, Khalimonchuk O, Schraders M, Dephoure N, Bayley JP, Kunst H, Devilee P, Cremers CW, Schiffman JD, Bentz BG et al (2009) SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science (New York, NY) 325:1139–1142. Hardie DG (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8:774–785.
114
W. Lu and P. Huang
Hardie DG, Pan DA (2002) Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans 30:1064–1070. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR, Hardie DG (2003) Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2:28. Heinrich PC, Morris HP, Weber G (1976) Behavior of transaldolase (EC 2.2.1.2) and transketolase (EC 2.2.1.1) activities in normal, neoplastic, differentiating, and regenerating liver. Cancer Res 36:3189–3197. Herrmann PC, Gillespie JW, Charboneau L, Bichsel VE, Paweletz CP, Calvert VS, Kohn EC, Emmert-Buck MR, Liotta LA, Petricoin EF, 3rd (2003) Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics 3:1801–1810. Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, Knapstein PG, Vaupel P (1993) Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26:45–50. Hockel M, Vaupel P (2003) Oxygenation of cervix cancers: impact of clinical and pathological parameters. Adv Exp Med Biol 510:31–35. Hove H, Rye Clausen M, Brobech Mortensen P (1993) Lactate and pH in faeces from patients with colonic adenomas or cancer. Gut 34:625–629. Hu LH, Yang JH, Zhang DT, Zhang S, Wang L, Cai PC, Zheng JF, Huang JS (2007) The TKTL1 gene influences total transketolase activity and cell proliferation in human colon cancer LoVo cells. Anticancer Drugs 18:427–433. Inoki K, Zhu T, Guan KL (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577–590. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J et al (2005) HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8:143–153. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, Nakada K, Honma Y, Hayashi J (2008) ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science (New York, NY) 320:661–664. Isidoro A, Martinez M, Fernandez PL, Ortega AD, Santamaria G, Chamorro M, Reed JC, Cuezva JM (2004) Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem J 378:17–20. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA et al (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448:807–810. Kahn BB, Alquier T, Carling D, Hardie DG (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1:15–25. Kim JW, Dang CV (2006) Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res 66: 8927–8930. Kim JW, Zeller KI, Wang Y, Jegga AG, Aronow BJ, O’Donnell KA, Dang CV (2004) Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol Cell Biol 24:5923–5936. Ko YH, Pedersen PL, Geschwind JF (2001) Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173:83–91. Kole HK, Resnick RJ, Van Doren M, Racker E (1991) Regulation of 6-phosphofructo-1-kinase activity in ras-transformed rat-1 fibroblasts. Arch Biochem Biophys 286:586–590. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, Martinez D, Carnero A, Beach D (2005) Glycolytic enzymes can modulate cellular life span. Cancer Res 65:177–185. Krebs HA (1970a) The history of the tricarboxylic acid cycle. Perspect Biol Med 14:154–170. Krebs HA (1970b) Rate control of the tricarboxylic acid cycle. Adv Enzyme Regul 8: 335–353. Kuhajda FP (2000) Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16:202–208.
5 Glycolytic Pathway as a Target for Tumor Inhibition
115
Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, Pasternack GR (1994) Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 91:6379–6383. Kuo W, Lin J, Tang TK (2000) Human glucose-6-phosphate dehydrogenase (G6PD) gene transforms NIH 3T3 cells and induces tumors in nude mice. Int J Cancer 85:857–864. Langbein S, Frederiks WM, Hausen AZ, Popa J, Lehmann J, Weiss C, Alken P, Coy JF (2008) Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer. Int J Cancer 122:2422–2428. Langbein S, Zerilli M, Zur Hausen A, Staiger W, Rensch-Boschert K, Lukan N, Popa J, Ternullo MP, Steidler A, Weiss C et al (2006) Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 94:578–585. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL (2009) Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137:482–488. Lim KH, Counter CM (2005) Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell 8:381–392. Little CD, Nau MM, Carney DN, Gazdar AF, Minna JD (1983) Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306:194–196. Lopez-Lazaro M (2008) The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen? Anticancer Agents Med Chem 8:305–312. Lu H, Forbes RA, Verma A (2002) Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277:23111–23115. Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, Chandel NS, Thompson CB, Robey RB, Hay N (2004) Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 16:819–830. Mandavilli BS, Santos JH, Van Houten B (2002) Mitochondrial DNA repair and aging. Mutat Res 509:127–151. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR, Lampidis TJ (2004) 2-Deoxy-d-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 64:31–34. Mathupala SP, Ko YH, Pedersen PL (2006) Hexokinase II: cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25:4777–4786. Mathupala SP, Rempel A, Pedersen PL (1997) Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 29:339–343. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM (2006) p53 regulates mitochondrial respiration. Science 312:1650–1653. Milgraum LZ, Witters LA, Pasternack GR, Kuhajda FP (1997) Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 3:2115–2120. Minchenko A, Leshchinsky I, Opentanova I, Sang N, Srinivas V, Armstead V, Caro J (2002) Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem 277:6183–6187. Mitchell P, Moyle J (1967) Chemiosmotic hypothesis of oxidative phosphorylation. Nature 213:137–139. Newmeyer DD, Ferguson-Miller S (2003) Mitochondria: releasing power for life and unleashing the machineries of death. Cell 112:481–490. Ohta S (2006) Contribution of somatic mutations in the mitochondrial genome to the development of cancer and tolerance against anticancer drugs. Oncogene 25:4768–4776. Olgun A, Akman S, Serdar MA, Kutluay T (2002) Oxidative phosphorylation enzyme complexes in caloric restriction. Exp Gerontol 37:639–645. Ookhtens M, Kannan R, Lyon I, Baker N (1984) Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am J Physiol 247:R146–R153.
116
W. Lu and P. Huang
Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, Xu Y, Wonsey D, Lee LA, Dang CV (2000) Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 275:21797–21800. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3:187–197. Parlo RA, Coleman PS (1986) Continuous pyruvate carbon flux to newly synthesized cholesterol and the suppressed evolution of pyruvate-generated CO2 in tumors: further evidence for a persistent truncated Krebs cycle in hepatomas. Biochim Biophys Acta 886:169–176. Parolin ML, Spriet LL, Hultman E, Matsos MP, Hollidge-Horvat MG, Jones NL, Heigenhauser GJ (2000) Effects of PDH activation by dichloroacetate in human skeletal muscle during exercise in hypoxia. Am J Physiol 279:E752–E761. Pastorino JG, Hoek JB, Shulga N (2005) Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res 65:10545–10554. Pelicano H, Martin DS, Xu RH, Huang P (2006) Glycolysis inhibition for anticancer treatment. Oncogene 25:4633–4646. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ et al (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14:2231–2239. Porstmann T, Griffiths B, Chung YL, Delpuech O, Griffiths JR, Downward J, Schulze A (2005) PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24:6465–6481. Poulsen HS, Frederiksen P (1981) Glucose-6-phosphate dehydrogenase activity in human breast cancer. Lack of association with oestrogen receptor content. Acta Pathol Microbiol Scand 89:263–270. Pozuelo Rubio M, Peggie M, Wong BH, Morrice N, MacKintosh C (2003) 14-3-3s regulate fructose-2,6-bisphosphate levels by binding to PKB-phosphorylated cardiac fructose-2,6-bisphosphate kinase/phosphatase. EMBO J 22:3514–3523. Rais B, Comin B, Puigjaner J, Brandes JL, Creppy E, Saboureau D, Ennamany R, Lee WN, Boros LG, Cascante M (1999) Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich’s tumor cells through inhibition of the pentose cycle. FEBS Lett 456:113–118. Ramos-Montoya A, Lee WN, Bassilian S, Lim S, Trebukhina RV, Kazhyna MV, Ciudad CJ, Noe V, Centelles JJ, Cascante M (2006) Pentose phosphate cycle oxidative and nonoxidative balance: a new vulnerable target for overcoming drug resistance in cancer. Int J Cancer 119: 2733–2741. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB (2003) Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factorindependent survival. Mol Cell Biol 23:7315–7328. Ristow M (2006) Oxidative metabolism in cancer growth. Curr Opin Clin Nutr Metab Care 9:339–345. Robey RB, Hay N (2005) Mitochondrial hexokinases: guardians of the mitochondria. Cell cycle (Georgetown, TX) 4:654–658. Robey RB, Hay N (2009) Is Akt the “Warburg kinase”?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 19:25–31. Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M (2003) Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1:707–715. Safran M, Kaelin WG, Jr (2003) HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 111:779–783. Sanchez-Martinez C, Aragon JJ (1997) Analysis of phosphofructokinase subunits and isozymes in ascites tumor cells and its original tissue, murine mammary gland. FEBS Lett 409: 86–90.
5 Glycolytic Pathway as a Target for Tumor Inhibition
117
Schornack PA, Gillies RJ (2003) Contributions of cell metabolism and H+ diffusion to the acidic pH of tumors. Neoplasia (New York, NY) 5:135–145. Schwickert G, Walenta S, Sundfor K, Rofstad EK, Mueller-Klieser W (1995) Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res 55: 4757–4759. Scott R, Crooks R, Meldrum C (2008) Gene symbol: STK11. Disease: Peutz-Jeghers syndrome. Hum Genet 124:300. Seemann MD (2004) PET/CT: fundamental principles. Eur J Med Res 9:241–246. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7:77–85. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732. Semenza GL (2007) HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 39:231–234. Sharp FR, Bernaudin M (2004) HIF1 and oxygen sensing in the brain. Nat Rev Neurosci 5: 437–448. Shaw RJ (2006) Glucose metabolism and cancer. Curr Opin Cell Biol 18:598–608. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, Cantley LC (2004a) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6:91–99. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC (2004b) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 101:3329–3335. Shi Q, Le X, Wang B, Abbruzzese JL, Xiong Q, He Y, Xie K (2001) Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene 20: 3751–3756. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R, Dang CV (1997) c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 94:6658–6663. Skulachev VP (1994) Chemiosmotic concept of the membrane bioenergetics: what is already clear and what is still waiting for elucidation? J Bioenerg Biomembr 26:589–598. Smith TA (2000) Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci 57:170–178. Smith TA, Sharma RI, Thompson AM, Paulin FE (2006) Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro. J Nucl Med 47: 1525–1530. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF et al (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Investig 118:3930–3942. Stacpoole PW, Greene YJ (1992) Dichloroacetate. Diabetes Care 15:785–791. Suter M, Riek U, Tuerk R, Schlattner U, Wallimann T, Neumann D (2006) Dissecting the role of 5’-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J Biol Chem 281:32207–32216. Swinnen JV, Brusselmans K, Verhoeven G (2006) Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 9:358–365. Swinnen JV, Vanderhoydonc F, Elgamal AA, Eelen M, Vercaeren I, Joniau S, Van Poppel H, Baert L, Goossens K, Heyns W et al (2000) Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer 88:176–179. Thierbach R, Schulz TJ, Isken F, Voigt A, Mietzner B, Drewes G, von Kleist-Retzow JC, Wiesner RJ, Magnuson MA, Puccio H et al (2005) Targeted disruption of hepatic frataxin expression causes impaired mitochondrial function, decreased life span and tumor growth in mice. Hum Mol Genet 14:3857–3864. Thomas DD, Miranda KM, Colton CA, Citrin D, Espey MG, Wink DA (2003) Heme proteins and nitric oxide (NO): the neglected, eloquent chemistry in NO redox signaling and regulation. Antioxid Redox Signal 5:307–317.
118
W. Lu and P. Huang
Tian WN, Braunstein LD, Apse K, Pang J, Rose M, Tian X, Stanton RC (1999) Importance of glucose-6-phosphate dehydrogenase activity in cell death. Am J Physiol 276:C1121–C1131. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S et al (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30:406–410. Tong X, Zhao F, Thompson CB (2009) The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev 19:32–37. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (New York, NY) 324:1029–1033. Varshney R, Adhikari JS, Dwarakanath BS (2003) Contribution of oxidative stress to radiosensitization by a combination of 2-DG and 6-AN in human cancer cell line. Ind J Exp Biol 41:1384–1391. Verma M, Kagan J, Sidransky D, Srivastava S (2003) Proteomic analysis of cancer-cell mitochondria. Nat Rev 3:789–795. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307–310. Wallace DC (1999) Mitochondrial diseases in man and mouse. Science (New York, NY) 283:1482–1488. Wallace DC (2005) Mitochondria and cancer: Warburg addressed. Cold Spring Harb Symp Quant Biol 70:363–374. Warburg O (1956a) On respiratory impairment in cancer cells. Science 124:269–270. Warburg O (1956b) On the origin of cancer cells. Science (New York, NY) 123:309–314. Weber WA (2006) Positron emission tomography as an imaging biomarker. J Clin Oncol 24:3282–3292. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M, Carling D (2003) LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 13:2004–2008. Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, Linehan WM, Sukhatme VP, Seth P (2009) LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 8:626–635. Xu RH, Pelicano H, Zhang H, Giles FJ, Keating MJ, Huang P (2005a) Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia 19:2153–2158. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P (2005b) Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65:613–621. Yahagi N, Shimano H, Hasegawa K, Ohashi K, Matsuzaka T, Najima Y, Sekiya M, Tomita S, Okazaki,H, Tamura,Y et al (2005) Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer 41:1316–1322. Yu Y, Deck JA, Hunsaker LA, Deck LM, Royer RE, Goldberg E, Vander Jagt DL (2001) Selective active site inhibitors of human lactate dehydrogenases A4, B4, and C4. Biochem Pharmacol 62:81–89. Zastawny TH, Dabrowska M, Jaskolski T, Klimarczyk M, Kulinski L, Koszela A, Szczesniewicz M, Sliwinska M, Witkowski P, Olinski R (1998) Comparison of oxidative base damage in mitochondrial and nuclear DNA. Free Radical Biol Med 24:722–725. Zhang S, Yang JH, Guo CK, Cai PC (2007) Gene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cells. Cancer Lett 253:108–114.
Part II
Malignant Cells
Chapter 6
Aberrant DNA Methylation in Cancer Cells Toshikazu Ushijima
Abstract DNA methylation is inherited upon somatic cell division, and methylation of a promoter CpG island silences its downstream gene. Methylation alterations in cancer cells are characterized by aberrant methylation of specific promoter CpG islands, which can cause inactivation of both tumor-suppressor genes (driver) and other genes (passenger), and by global hypomethylation. Recent studies revealed that aberrant methylation is present even in non-cancerous tissues, and its level is associated with cancer risk (an epigenetic field for cancerization). Quantification of methylation revealed that aberrant methylation can be induced much more frequently than mutations, and it has already been indicated that methylation alterations are involved in epithelial-mesenchymal transition. The high frequency of methylation alterations also suggested that they could be involved in phenotypic changes of stromal cells, and thus formation of cancer microenvironment. DNA methylation alterations are likely to be important players not only in transformation of epithelial cells but also in the formation of cancer microenvironment by stromal cells.
Introduction Epigenetic modifications are responsible for long-term cellular memory of gene expression, and play critical roles in development, differentiation, and reprogramming (Bird 2007). To play these roles, epigenetic modifications must be faithfully replicated upon DNA replication. DNA methylation and histone modifications are known to have such characteristics, and DNA methylation is especially known for its high fidelity in replication (Ushijima et al. 2003; Laird et al. 2004; Riggs and Xiong 2004). It is generally considered that, during developmental processes, epigenetic modifications of the genome (epigenome) are established as a T. Ushijima (*) National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan e-mail:
[email protected] R.G. Bagley (ed.), The Tumor Microenvironment, Cancer Drug Discovery and Development, DOI 10.1007/978-1-4419-6615-5_6, © Springer Science+Business Media, LLC 2010
121
122
T. Ushijima
c onsequence of interactions between cellular lineage and environmental input (Gan et al. 2007). It was previously believed that aberrant DNA methylation occurs rarely, but that, once induced in critical genes, it can be causally involved in development of diseases, such as cancers. However, recent studies indicate that DNA methylation alterations of specific genes can be induced relatively frequently under specific conditions. Epigenetic changes were shown to be physiologically involved in determination of lymphocyte differentiation (Kioussis and Georgopoulos 2007). When gastric epithelial cells are exposed to a specific pathological condition, several to several 10% of them can have aberrant methylation of specific genes (Maekita et al. 2006). These widespread occurrences of epigenetic changes in somatic cells indicate a possibility that they can be responsible for formation of tumor microenvironments, although cells involved in it are polyclonal. This chapter will introduce the basic characteristics of DNA methylation and methylation alterations in cancer cells, and finally discuss possible involvement of altered methylation in formation of tumor microenvironments.
Characteristics of DNA Methylation DNA is physiologically methylated at the 5 position of cytosines at some CpG sites (Fig. 6.1a). This physiological methylation is different from DNA methylations at O6 and N7 positions of guanines, which are abnormal adducts produced by alkylating agents. DNA methylation is characterized by its stable main tenance upon somatic cell division, and critical roles in regulation of gene transcription.
Maintenance of DNA Methylation Statuses When a CpG site is methylated, cytosines on both strands are methylated (Fig. 6.1b). At DNA replication, a newly synthesized DNA strand does not contain methyl groups, and hemi-methylated CpG sites are temporarily formed. However, a maintenance methylase, DNA methyltransferase 1 (DNMT1), associated with a replication fork (Hermann et al. 2004b), restores those hemi-methylated CpG sites into fully methylated CpG sites. DNMT1 has much lower activity on unmethylated CpG sites, and unmethylated CpG sites are kept unmethylated. Therefore, DNA methylation patterns are replicated at somatic DNA replication with a high fidelity (~99.9%), especially in CpG islands (Ushijima et al. 2003; Laird et al. 2004; Riggs and Xiong 2004).
6 Aberrant DNA Methylation in Cancer Cells
a
123
NH2 N
O
3
NH2
1 N
N
O
dR
dR
Cytosine
b 5' 3'
CH3
N
5
5-methylcytosine
M CG
M CG
GC M
GC M
CG
CG
3'
GC
GC
5'
DNA replication
5'
M CG
M CG
CG
CG
3'
3'
GC
GC
GC
GC
5'
5'
CG
CG
CG
CG
3'
3'
GC M
GC M
GC
GC
5'
DNMT1
5' 3'
5' 3'
M CG
M CG
GC M M CG GC M
CG
CG
3'
GC M M CG
GC
GC
5'
CG
CG
3'
GC M
GC
GC
5'
Fig. 6.1 DNA methylation and its maintenance upon DNA replication. (a) Chemical structures of cytosine and 5-methylcytosine. (b) Maintenance of methylated and unmethylated statuses of CpG sites. Upon DNA replication, hemimethylated CpG sites are temporarily formed, but DNMT1 at replication fork restores hemimethylated CpG sites specifically into fully methylated CpG sites
124
T. Ushijima
Regulation of Gene Transcription by DNA Methylation DNA methylation of a CpG island in a gene promoter region has been known to be consistently associated with transcriptional repression of its downstream gene (Baylin and Ohm 2006; Ushijima 2005). Also, in recent genome-wide analysis of DNA methylation and gene expression, the consistent association was clearly observed (Weber et al. 2007; Rauch et al. 2009; Yamashita et al. in press). In contrast, methylation of CpG islands in gene body regions is often, but not consistently, associated with increased gene transcription (Hellman and Chess 2007; Rauch et al. 2009; Yamashita et al. in press). The consistent association between promoter methylation and transcriptional repression is now known to be due to the presence of a cause–consequence relationship, mediated by several mechanisms. First, an approximately 200-bp region just upstream of a transcription start site usually lacks a nucleosome, designated as a nucleosome-free region (NFR) (Fig. 6.2a) (Lee et al. 2004; Li et al. 2007; Ozsolak et al. 2007). However, if the NFR is methylated, a nucleosome is formed, and transcription from the region is severely repressed (Fig. 6.2b) (Lin et al. 2007). Second, DNA methylation is recognized by methylated DNA binding proteins, such as MeCP2 and MBDs, and these proteins recruit histone deacetylases (Richards and Elgin 2002) and a histone methyltransferase, SUV39H1 (Fujita et al. 2003). Deacetylated histones are known to be positively charged and to associate tightly with DNA, inhibiting accession of transcription complexes to DNA. SUV39H1 is a
b
Unmethylated CpG site Methylated CpG site
Fig. 6.2 Transcriptional repression by DNA methylation of a CpG island in a promoter region. (a) A NFR is present when DNA is kept unmethylated. (b) Nucleosome is formed when DNA in the NFR is methylated, and transcription is strongly repressed
6 Aberrant DNA Methylation in Cancer Cells
125
known to be involved in formation of a heterochromatin structure (Stewart et al. 2005). Thirdly, even in naked DNA, some transcription factors, such as CTCF, are known to have much less binding capacity with methylated CpG sites (Bird 2002).
Maintenance and De Novo DNA Methylases DNA methyltransferases are essential machineries to establish and maintain DNA methylation, and individual DNA methyltransferases are known as maintenance methylase, DNMT1, and de novo methylases, DNMT3A, and DNMT3B, respectively (Hermann et al. 2004a). As mentioned above, DNMT1 plays a major role in maintaining DNA methylation upon DNA replication. Homozygous knockout of Dnmt1 is lethal in midgestation (Li et al. 1992). Dnmt3a and Dnmt3b have the activity of methylating CpG sites without any preference for hemimethylated CpG sites (Okano et al. 1998). While Dnmt3a cannot methylate nucleosomal DNA, Dnmt3b can (Takeshima et al. 2006). Homozygous knockout of Dnmt3a causes lethality after birth (Okano et al. 1999), and Dnmt3a is essential in establishment of genomic imprinting (Kaneda et al. 2004b). Homozygous knockout of Dnmt3b causes lethality before birth, and germline mutations of DNMT3B cause a recessive inherited disorder, ICF syndrome, in humans (Okano et al. 1999).
Methylation Alterations in Cancer Cells DNA methylation patterns of the genome (methylome) in normal cells are precisely regulated according to developmental stages (Meissner et al. 2008; Rauch et al. 2009). In brief, the vast majority of CpG islands are kept unmethylated, and repetitive sequences, which consist of more than 40% of the genome (Lander et al. 2001), are heavily methylated. In cancer cells, the presence of altered DNA methylation has been long known, and the alteration is characterized by “genome-overall hypomethylation and regional hypermethylation” (Fig. 6.3).
Genome-Overall Hypomethylation The “genome-overall” hypomethylation was discovered in the early 1980s, and the phenomenon is now observed in almost all types of cancer cells (Feinberg and Tycko 2004). The decrease of 5-methylcytosine content in the genome is mainly due to hypomethylation of repetitive sequences (Feinberg and Tycko 2004; Kaneda et al. 2004a), but can involve demethylation of normally methylated CpG islands. Demethylation of normally methylated promoter CpG islands leads to aberrant transcription of their downstream genes, and a well known example is aberrant
126
T. Ushijima Normal cell Cancer cell Unmethylated Methylated Repetitive sequence CpG island
Fig. 6.3 DNA methylation changes in cancer cells. In normal cells, the vast majority of CpG islands are kept unmethylated, and repetitive sequences are kept methylated. In cancer cells, a limited number of CpG islands are aberrantly methylated, and some repetitive sequences are demethylated
expression of cancer-testis antigen genes, such as melanoma antigen genes (MAGEs) (de Smet et al. 1999). Also, hypomethylation of a differentially methylated region (DMR) of IGF2 is known for its loss of imprinting, leading to its increased expression and tumor development (Cui et al. 2002). Despite the long history, there are still limited findings on the causal role of genome-overall hypomethylation in carcinogenesis. A mouse strain with genomeoverall hypomethylation, due to introduction of a hypomorphic allele of Dnmt1, demonstrated increased rates of chromosomal loss (Chen et al. 1998). The mouse strain showed increased incidences of lymphomas, colonic microadenomas and liver tumors (Chen et al. 1998; Eden et al. 2003; Yamada et al. 2005). At the same time, the systemic low activity of Dnmt1 led to suppression of macroscopic tumors of the intestine (Laird et al. 1995; Yamada et al. 2005).
Aberrant DNA Methylation of CpG Islands “Regional hypermethylation” denotes methylation of CpG islands that are normally unmethylated. If such methylation is induced in promoter CpG islands of tumor-suppressor genes, it leads to their permanent inactivation, and is causally involved in cancer development and progression (Baylin and Ohm 2006; Jones and Baylin 2007). After the RB tumor-suppressor gene was shown to be inactivated by its promoter methylation (Ohtani-Fujita et al. 1993), many tumorsuppressor genes involved in various cellular processes, such as WNT signalling (SFRP family and CDH1), DNA repair (MLH1 and MGMT), and cell cycle regulation (CDKN2A), were shown to be inactivated by promoter methylation (Baylin and Ohm 2006). In some cancer types, such as gastric cancers, tumor-suppressor genes are inactivated more frequently by promoter methylation than by mutations (Ushijima and Sasako 2004). CpG islands aberrantly methylated in cancers are not limited to CpG islands in promoter regions, and methylation of CpG islands in gene bodies are often associated with increased gene expression (Ushijima 2005; Rauch et al. 2009; Yamashita
6 Aberrant DNA Methylation in Cancer Cells
127
et al. in press). However, the biological meaning of physiological and pathological DNA methylation of gene bodies remains unclear.
Driver Methylation and Passenger Methylation Recent genome-wide screening revealed that several hundred to one thousand promoter CpG islands are methylated in cancer cells (Rauch et al. 2009; Yamashita et al. in press). Most of the genes methylated in cancers are not expressed or have only low expression in normal counterpart cells (Takeshima et al. 2009). These clearly show that promoter CpG islands aberrantly methylated in cancers are not always causally involved in cancer development or progression. According to tradition in the field of mutations, methylation causally involved in cancer development and progression is designated as “driver methylation”, and methylation that simply accompanies the process is designated as “passenger methylation”. Although the distinction between driver and passenger is conceptually clear, actual distinctions between the two types are often difficult, especially when methylation is present in a promoter CpG island of a gene. Although most genes with low or no transcription in normal cells have limited functions, tumor suppressor genes can have only low transcription levels in normal cells when not induced. Although an important tumor-suppressor gene is methylated with a high incidence in specific types of cancers, we cannot conclude that genes with methylation at low incidences are not important. At least, to demonstrate that a gene with promoter methylation in cancers is a driver, its expression in normal counterpart cells and gene function at physiological expression levels should be examined. If a gene is inactivated by mutations, the gene is likely to be a tumor-suppressor gene.
Possible Involvement of Altered Methylation in Tumor Microenvironments Traditionally, aberrant DNA methylation was considered to be similar to mutations in terms of its frequency, target genes, and inducers. However, it was recently indicated that DNA methylation of specific genes can be induced in a significant fraction of cells even in polyclonal tissue, and there is a possibility that altered methylation statuses can be involved in formation of tumor microenvironments.
Unique Natures of Aberrant DNA Methylation, in Contrast with Mutations Recent findings showed unique natures of DNA methylation in contrast with mutations. First, as described above, aberrant methylation of promoter CpG islands, which inactivate their downstream genes, is induced in several hundred to
128
T. Ushijima
one thousand genes in cancer cells (Rauch et al. 2009; Yamashita et al. in press) while a cancer cell is estimated to harbor mutations of 90 genes (Sjoblom et al. 2006). Second, aberrant methylation of a specific gene can be present in several 10% of cells in non-cancerous tissues (Maekita et al. 2006; Ushijima 2007) while mutations of a specific gene are quite infrequent, being less than 1 out of 105 cells (Nagao et al. 2001). Third, aberrant methylation is induced in specific genes (Nakajima et al. 2009; Oka et al. 2009) while mutations are considered to occur in random genes. Fourth, chronic inflammation is an important inducer of aberrant methylation, while mutagenic chemicals and radiations induce mutations.
Field for Cancerization and DNA Methylation The presence of aberrant DNA methylation in non-cancerous tissues is important from the viewpoint of the field cancerization. It has long been known that some cancers tend to have multiple independent occurrences, suggesting that there is a field for cancerization produced by exposure to environmental and other carcinogenic stimuli (Braakhuis et al. 2003). It was recently clarified that the degree of accumulation of aberrant methylation in gastric mucosae correlates with risk of developing gastric cancers (Maekita et al. 2006; Nakajima et al. 2006). Similar associations between methylation in non-cancerous tissues and cancer development were obtained in various cancers, such as liver, colorectal, breast, and urothelial cancers (Kondo et al. 2000; Shen et al. 2005; Yan et al. 2006; Arai et al. 2006), and such accumulation is considered to represent an “epigenetic field for cancerization” (epigenetic field defect) (Fig. 6.4) (Ushijima 2007). The epigenetic field for cancerization can be utilized for cancer risk diagnosis that takes account of an individual’s own life history.
Epithelial-Mesenchymal Transition and DNA Methylation Epithelial-mesenchymal transition (EMT) refers to a phenomenon in which epithelial cells lose their epithelial characteristics and acquire mesenchymal features (Polyak and Weinberg 2009). EMT has been known to be critically involved in embryonic development and tumor progression (Polyak and Weinberg 2009; Dumont et al. 2008). In addition, it was recently demonstrated that epithelial cells acquire stem cell features when they undergo EMT, and that stem-like cells in normal epithelium and cancer tissues have EMT markers (Mani et al. 2008). Physiological EMT, which takes place in a group of cells and cannot be attributed to a mutation in a cell, is likely to be due to epigenetic changes (Polyak and Weinberg 2009). Also, EMT involved in tumor progression, which can be due to a mutation or an epigenetic alteration, was recently shown to be mediated by DNA methylation (Dumont et al. 2008; Yang et al. 2009).
6 Aberrant DNA Methylation in Cancer Cells
Noncancerous predisposed tissue
Normal tissue 1
cells
2 3
129
Cancer development
Exposure to carcinogenic factors
4 5 6
Methylated CpG island Unmethylated CpG island
Fig. 6.4 Epigenetic field for cancerization. In a normal tissue, the vast majority of CpG islands are unmethylated. When it is exposed to some carcinogenic stimulus, such as Helicobacter pylori infection, various but specific genes, most of which are passengers, are methylated in various cells. If further genetic or epigenetic alterations take place, clinical cancer will develop. The amount of aberrant DNA methylation accumulated in a tissue can be used as a cancer risk marker
Tumor Microenvironments and DNA Methylation Not only is aberrant DNA methylation present in non-cancerous tissues, but also the degree can be severe, reaching several 10%. If a specific gene is inactivated in a significant fraction of cells in a tissue, it can affect the overall function of the tissue. Functional change of a tissue due to the presence of somatic mutations has been considered very unlikely because the population of cells with mutation of a specific gene is very small. This unique nature of aberrant DNA methylation suggests that it can be involved in pathological conditions without any clonal expansion, including formation of cancer microenvironments and any diseases that involve persistent gene repression. In cancer stromal cells, persistent changes in gene expression have been already reported (Finak et al. 2008; Hu et al. 2005; Lin et al. 2008), and involvement of mutations in such changes was shown to be unlikely (Qiu et al. 2008). Moreover, epigenetic silencing of specific genes due to changes in histone modification has been reported in tumor endothelial cells (Hellebrekers et al. 2007). Mesenchymal cells produced by EMT of tumor cells may contribute to tumor
130
T. Ushijima
microenvironments. Clarification of DNA methylation changes in cancer stromal cells is becoming an important issue.
Epilogue Unique natures of DNA methylation, in sharp contrast with mutations, indicate that altered DNA methylation is involved in formation of tumor microenvironments. Although I did not describe technological aspects of methylation analysis in this chapter, all the technologies for genome-wide screening are not capable of identifying methylation changes present only in a fraction of cells. Therefore, innovation in technology or approach seems to be necessary to identify critical DNA methylation alterations in cancer stromal cells. Even without such an innovation, sensitive analysis of candidate genes might greatly contribute to clarification of genes critically involved in tumor microenvironments. Acknowledgments The author is grateful to Dr. Eriko Okochi for her critical reading of the manuscript. The author’s research described here was supported by a Grant-in-Aid for the 3rd-term Comprehensive Cancer Control Strategy from Ministry of Health, Labor, and Welfare, Japan.
References Arai E, Kanai Y, Ushijima S et al (2006) Regional DNA hypermethylation and DNA methyl transferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues. Int J Cancer 119:288–296 Baylin SB, Ohm JE (2006) Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:107–116 Bird A (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16:6–21 Bird A (2007) Perceptions of epigenetics. Nature 447:396–398 Braakhuis BJ, Tabor MP, Kummer JA et al (2003) A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res 63:1727–1730 Chen RZ, Pettersson U, Beard C et al (1998) DNA hypomethylation leads to elevated mutation rates. Nature 395:89–93 Cui H, Onyango P, Brandenburg S et al (2002) Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 62:6442–6446 de Smet C, Lurquin C, Lethe B et al (1999) DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 19: 7327–7335 Dumont N, Wilson MB, Crawford YG et al (2008) Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci USA 105:14867–14872 Eden A, Gaudet F, Waghmare A et al (2003) Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300:455 Feinberg AP, Tycko B (2004) The history of cancer epigenetics. Nat Rev Cancer 4:143–153 Finak G, Bertos N, Pepin F et al (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14:518–527
6 Aberrant DNA Methylation in Cancer Cells
131
Fujita N, Watanabe S, Ichimura T et al (2003) Methyl-CpG binding domain 1 (MBD1) interacts with the Suv39h1-HP1 heterochromatic complex for DNA methylation-based transcriptional repression. J Biol Chem 278:24132–24138 Gan Q, Yoshida T, McDonald OG et al (2007) Concise review: epigenetic mechanisms contribute to pluripotency and cell lineage determination of embryonic stem cells. Stem Cells 25:2–9 Hellebrekers DM, Melotte V, Vire E et al (2007) Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res 67:4138–4148 Hellman A, Chess A (2007) Gene body-specific methylation on the active X chromosome. Science 315:1141–1143 Hermann A, Gowher H, Jeltsch A (2004a) Biochemistry and biology of mammalian DNA methyltransferases. Cell Mol Life Sci 61:2571–2587 Hermann A, Goyal R, Jeltsch A (2004b) The Dnmt1 DNA-(cytosine-C5)-methyltransferase methylates DNA processively with high preference for hemimethylated target sites. J Biol Chem 279:48350–48359 Hu M, Yao J, Cai L et al (2005) Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 37:899–905 Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683–692 Kaneda A, Tsukamoto T, Takamura-Enya T et al (2004a) Frequent hypomethylation in multiple promoter CpG islands is associated with global hypomethylation, but not with frequent promoter hypermethylation. Cancer Sci 95:58–64 Kaneda M, Okano M, Hata K et al (2004b) Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting. Nature 429:900–903 Kioussis D, Georgopoulos K (2007) Epigenetic flexibility underlying lineage choices in the adaptive immune system. Science 317:620–622 Kondo Y, Kanai Y, Sakamoto M et al (2000) Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis – a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 32:970–979 Laird PW, Jackson-Grusby L, Fazeli A et al (1995) Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81:197–205 Laird CD, Pleasant ND, Clark AD et al (2004) Hairpin-bisulfite PCR: assessing epigenetic methylation patterns on complementary strands of individual DNA molecules. Proc Natl Acad Sci USA 101:204–209 Lander ES, Linton LM, Birren B et al (2001) Initial sequencing and analysis of the human genome. Nature 409:860–921 Lee CK, Shibata Y, Rao B et al (2004) Evidence for nucleosome depletion at active regulatory regions genome-wide. Nat Genet 36:900–905 Li E, Bestor TH, Jaenisch R (1992) Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69:915–926 Li B, Carey M, Workman JL (2007) The role of chromatin during transcription. Cell 128: 707–719 Lin JC, Jeong S, Liang G et al (2007) Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell 12:432–444 Lin HJ, Zuo T, Lin CH et al (2008) Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells. Cancer Res 68:10257–10266 Maekita T, Nakazawa K, Mihara M et al (2006) High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 12:989–995 Mani SA, Guo W, Liao MJ et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715 Meissner A, Mikkelsen TS, Gu H et al (2008) Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454:766–770 Nagao M, Ochiai M, Okochi E et al (2001) LacI transgenic animal study: relationships among DNA-adduct levels, mutant frequencies and cancer incidences. Mutat Res 477:119–124
132
T. Ushijima
Nakajima T, Maekita T, Oda I et al (2006) Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomarkers Prev 15:2317–2321 Nakajima T, Yamashita S, Maekita T et al (2009) The presence of a methylation fingerprint of Helicobacter pylori infection in human gastric mucosae. Int J Cancer 124:905–910 Ohtani-Fujita N, Fujita T, Aoike A et al (1993) CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene 8:1063–1067 Oka D, Yamashita S, Tomioka T et al (2009) The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history: a target for risk diagnosis and prevention of esophageal cancers. Cancer 115:3412–3426 Okano M, Xie S, Li E (1998) Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 19:219–220 Okano M, Bell DW, Haber DA et al (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99:247–257 Ozsolak F, Song JS, Liu XS et al (2007) High-throughput mapping of the chromatin structure of human promoters. Nat Biotechnol 25:244–248 Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9:265–273 Qiu W, Hu M, Sridhar A et al (2008) No evidence of clonal somatic genetic alterations in cancerassociated fibroblasts from human breast and ovarian carcinomas. Nat Genet 40:650–655 Rauch TA, Wu X, Zhong X et al (2009) A human B cell methylome at 100-base pair resolution. Proc Natl Acad Sci USA 106:671–678 Richards EJ, Elgin SC (2002) Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects. Cell 108:489–500 Riggs AD, Xiong Z (2004) Methylation and epigenetic fidelity. Proc Natl Acad Sci USA 101: 4–5 Shen L, Kondo Y, Rosner GL et al (2005) MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 97:1330–1338 Sjoblom T, Jones S, Wood LD et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268–274 Stewart MD, Li J, Wong J (2005) Relationship between histone H3 lysine 9 methylation, transcription repression, and heterochromatin protein 1 recruitment. Mol Cell Biol 25:2525–2538 Takeshima H, Suetake I, Shimahara H et al (2006) Distinct DNA methylation activity of Dnmt3a and Dnmt3b towards naked and nucleosomal DNA. J Biochem 139:503–515 Takeshima H, Yamashita S, Shimazu T et al (2009) The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. Genome Res 19:1974–1982 Ushijima T (2005) Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 5:223–231 Ushijima T (2007) Epigenetic field for cancerization. J Biochem Mol Biol 40:142–150 Ushijima T, Sasako M (2004) Focus on gastric cancer. Cancer Cell 5:121–125 Ushijima T, Watanabe N, Okochi E et al (2003) Fidelity of the methylation pattern and its variation in the genome. Genome Res 13:868–874 Weber M, Hellmann I, Stadler MB et al (2007) Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 39:457–466 Yamada Y, Jackson-Grusby L, Linhart H et al (2005) Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc Natl Acad Sci USA 102:13580–13585 Yamashita S, Hosoya K, Gyobu K et al (2009) Development of a novel output value for quantitative assessment in methylated DNA immunoprecipitation-CpG island microarray analysis. DNA Research 16:275–286 Yan PS, Venkataramu C, Ibrahim A et al (2006) Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 12:6626–6636 Yang X, Pursell B, Lu S et al (2009) Regulation of beta 4-integrin expression by epigenetic modifications in the mammary gland and during the epithelial-to-mesenchymal transition. J Cell Sci 122:2473–2480
Chapter 7
DNA Repair and Redox Signaling Mark R. Kelley, Millie M. Georgiadis, and Melissa L. Fishel
Abstract DNA repair pathways have long been recognized as important in protecting the genome from damage caused by endogenous and exogenous DNA damaging agents. However, the role of reduction–oxidation (redox) signaling as a regulatory mechanism in these pathways is a comparatively recent discovery. We have attempted to cover the general aspects of DNA repair, while focusing more attention on the interface between redox regulation and DNA repair activity and response in mammalian cells. The primary focus of this chapter is on APE1, the only DNA repair protein currently known to serve a dual role as a DNA repair enzyme and redox signaling factor. APE1 has been shown to regulate a number of downstream transcription factors (TF) such as HIF-1a, Egr-1, AP-1, NFkB, CREB, p53 and an increasing number of other TFs and other proteins. Additionally, this redox signaling function of APE1 indirectly alters the activity of other DNA repair pathways through its regulation of TF binding to DNA. Included in this chapter is also an overview of general redox systems. We also discuss the role small molecule inhibitors play in the modulation of APE1 redox activity and the potential for chemotherapeutic development via targeting redox regulation of DNA repair. Abbreviations 8-oxoG AAG AGT Ang II AP AP-1
8 oxoguanine alkyladenine DNA glycosylase O-6-alkylguanine-DNA methyltransferase angiotension II apurinic/apyrimidinic activator protein 1
M.R. Kelley (*) Department of Pediatrics, Section of Hematology/Oncology, Herman B Wells Center for Pediatric Research, Indiana University, Indianapolis, IN 46202, USA e-mail:
[email protected] R.G. Bagley (ed.), The Tumor Microenvironment, Cancer Drug Discovery and Development, DOI 10.1007/978-1-4419-6615-5_7, © Springer Science+Business Media, LLC 2010
133
134
M.R. Kelley et al.
APE1 apurinic/apyrmidinic endonuclease 1 ATF activating transcription factor ATFa activating transcription factor a ATF2 activating transcription factor 2 ATF3 activating transcription factor 3 ATF4 activating transcription factor 4 ATM ataxia telangiectasia mutated protein BER base excision repair BKca Large-conductance Ca2+-activated K+channels BLM Bloom’s syndrome gene product BRCA1 breast cancer 1, early onset BRCA2 breast cancer 2, early onset BSO buthionine sulfoximine CD40L CD40 ligand CHO Chinese hamster ovary cells CREB cyclic AMP response-element binding protein CSA Cockayne’s syndrome protein A CSB Cockayne’s syndrome protein B CTL cytotoxic T lymphocyte DDB1 DNA damage binding protein 1 DDB2 DNA damage binding protein 2 DNA-PKcs DNA-dependent kinase catalytic subunit DSBs double-strand breaks DR direct repair dRP deoxyribophosphate dRPase deoxyribophosphodiesterase E3330 2E-3-[5-(2, 3 dimethoxy-6-methyl-1, 4-benzoquinolyl)]-2-nonyl-2propenoic acid Egr-1 early growth response protein 1 ERCC1 excision repair cross-complementation group 1 ERCC3 excision repair cross-complementation group 3 ERCC5 excision repair cross-complementation group 5 flavin adenine dinucleotide dehydrogenase FADH2 FEN1 flap endonuclease 1 Flk-1/KDR fetal liver kinase 1/kinase insert domain receptor FosB FBJ murine osteosarcoma viral oncogene homolog B FPG formamidopyrimidine DNA glycosylase Fra-1 fos related antigen 1 Fra-2 fos related antigen 2 GAPDH glyceraldehyde-3-phosphate dehydrogenase GGR global genome repair GRX glutaredoxin GSH glutathione GSSG glutathione disulfide GTPase Guanosine-5’-triphosphate
7 DNA Repair and Redox Signaling
HEK293 HeLa HIF-1 HIF-1a HR HRE HR32B HUVES IL-2 LP-BER Lys6 Lys7 MeSeH MGMT MiTF MLH1 MMR MMS MPG MRN MSH2 MSH3 MSH6 MSI MYH NAC NADPH Nbs1 NEIL NER NFkB NHEJ NK NTH O6-meG OGG1 P2Y PARP1 PCEC PCNA PEBP-2 PMS2 PRX Pol b Pol d
Human embryonic kidney 293 cells Henrietta Lacks cells hypoxia-inducible factor-1 hypoxia-inducible factor-1 alpha homologous recombination hypoxia response elements human homologue of the yeast RAD23 protein human umbilical vein endothelial cells interleukin 2 long-patch base excision repair lysine 6 lysine 7 methylselenol O6-methylguanine-DNA methyltransferase Microphthalmia-associated transcription factor MutL homolog 1 mismatch repair methyl methane sulfonate N-methylpurine DNA glycosylase Mre11/Rad50/Nbs1 MutS homolog 2 MutS homolog 3 MutS homolog 6 microsatellite instability MutY homolog N-acetyl-L-cysteine Nicotinamide adenine dinucleotide phosphate Nijmegen breakage syndrome 1 fgp/nei family DNA glycosylase nucleotide excision repair nuclear factor kappa B non-homologous end joining natural killer homolog of E. coli endonuclease III (nth) O6 methyl guanine oxoguanine glycosylase 1 purinergic receptor poly ADP ribose polymerase 1 pancreatic cancer-associated endothelial cells proliferating cell nuclear antigen phosphatidylethanolamine-binding protein 2 postmeiotic segregation increased 2 peroxiredoxin DNA polymerase beta DNA polymerase delta
135
136
M.R. Kelley et al.
Pol e DNA polymerase epsilon PMS1 post-meiotic-segregation increased-1 protein PMS2 post-meiotic-segregation increased-2 protein PTEN Phosphatase and tensin homolog deleted on chromosome 10 Ref-1 redox effector factor 1 RF-C replication factor C rRNA ribosomal RNA RNA Pol II RNA polymerase II ROS reactive oxygen species RPA replication protein A SeMet selenomethionine SETMAR SET domain and mariner transposase fusion siRNA small interfering RNA SMUG1 mammalian 5-formyluracil DNA glycosylase SP-BER short-patch base excision repair ssDNA single-strand DNA TCR transcription-coupled repair TDG thymine-DNA glycosylase TFIIH transcription factor IIH TNF-a tumor necrosis factor alpha Trx thioredoxin TrxR thioredoxin reductase TSH thyroid stimulating hormone TTF-1 thyroid transcription factor 1 UNG uracil-DNA glycosylase UV-DDB UV-damaged DNA-binding protein WRN Werner protein, deficient in Werner’s syndrome XPB xeroderma pigmentosum complementary group B protein XPC xeroderma pigmentosum complementary group C protein XPD xeroderma pigmentosum complementary group D protein XPF1 xeroderma pigmentosum complementary group F protein XPG xeroderma pigmentosum group XRCC1 X-ray repair complementing defective repair in Chinese hamster cells 1 XRCC4 X-ray repair complementing defective repair in Chinese hamster cells 4
Introduction Genomic stability relies on efficient, effective methods of repairing DNA. Unrepaired damage can cause cell cycle arrest, apoptosis or accumulation of mutations (Eker et al. 2009; Hofmann et al. 2002). To protect DNA and keep the genome intact, a number of DNA repair pathways exist. Although much has been written about these pathways, the role of redox regulation in DNA repair is a relatively recent discovery. This chapter discusses the mechanisms for human DNA repair,
7 DNA Repair and Redox Signaling
137
redox signaling and its regulation of DNA repair transcription factors, the unique APE1 protein that participates in both categories of activities, how DNA repair differs in tumor cells and implications for emerging cancer therapies.
Overview of DNA Repair Pathways DNA repair is a never-ending task of all eukaryotic cells, as endogenous and exogenous agents constantly assault DNA. Damage from endogenous agents include oxidation by reactive oxygen species (ROS) from normal metabolic processes, alkylation by agents such as S-adenosylmethionine, adduct formation caused by reactive carbonyl species created during lipid peroxidation, hydrolytic depurination that forms abasic sites and deamination of bases, primarily cytidine (and, to a lesser extent, adenine) (De Bont and van Larebeke 2004). Environmental insults from exogenous agents include chemicals, carcinogens and ultraviolet light, as well as chemotherapeutic agents and ionizing radiation damage (Christmann et al. 2003; Fleck and Nielsen 2004). Failure to repair DNA damage can cause a host of problems that ultimately lead to genomic instability (Arcangeli et al. 1997; Kelley and Fishel 2008). For example, improper DNA damage response in mitotic cells can halt cell cycle progress. In post-mitotic cells, DNA damage may result in cell cycle activation without proper coordination of cell cycle machinery, leading to deleterious events, including potentially lethal DNA double-strand breaks (Kruman et al. 2004; Schwartz et al. 2007). However, eukaryotic cells possess a cadre of DNA repair pathways to correct the damage: direct repair (DR), base excision repair (BER), mismatch repair (MMR), nucleotide excision repair (NER), non-homologous end joining (NHEJ) and homologous recombination (HR) (Hoeijmakers 2001, 2001) (Fig. 7.1). The number of known DNA repair proteins and other factors involved in the cellular response to DNA damage keeps growing as we learn more details about each repair pathway and induction of regulatory networks when the damage persists (Wood et al. 2005). The type of DNA damage dictates which pathway is activated to perform repairs. However, some overlap exists among the pathways. Although they are not redundant, certain pathways can function as “backup systems” to others. In addition, some mechanisms overlap. (See Table 7.1 for examples.) These overlaps and interactions provide the most efficient and effective defense net for preserving the cell genome, whereas reduced repair capacity can lead to genomic modification.
DR The DR pathway, sometimes called direct reversal, repairs damaged bases by removing the alteration to the base – as opposed to removing the damaged base itself. This unique mechanism may be the most efficient of all repair pathways
138
M.R. Kelley et al.
Direct Repair
Base Excision
MGMT
Glycosylase
Mismatch
MSH2/6 MSH2/3
TCR
RNA PoLII, CSA, CSB, XPAB2
APE1
Long Patch
Nucleotide Excision
Short Patch
Non-homologous End Joining (NHEJ)
Homologous Recombination (HR)
GGR
DDB-XPE, XPC, HR23β
Ku70, Ku80
ATM
MLH1-PMS2 MLH1-PMS1 DNA-PK RPA, XPA, XPCTFIIH, XPB, XPC, XPD, XPG, XPFERCC1
EX01, RFC, PCNA, RPA, NA Polδ, Ligase
RFC, PCNA, Polδ/ε, Ligase I
MRN
MRN, Rad51, Rad52, Rad54, BRCA1, BRCA2, PCNA, Polδ/ε, Ligase I
DNA Polµ, XRCC4, Ligase 4, Artemis
Fig. 7.1 Schematic overview of DNA repair pathway. Several DNA repair pathways are involved in maintaining cell genomic stability; these include DR, BER, NER, MMR, HR, and NHEJ. More than 150 proteins are involved. Only selected genes of each pathway are shown here. (Adapted from: Fishel et al. (Fishel and Kelley 2007))
Table 7.1 Examples of overlap in DNA repair pathways Overlap Mechanism DR/MMR In the DR pathway, if O6-methylguanine-DNA methyltransferase (AGT) is unsuccessful in removing O6-methylguanine, the MMR pathway can recognize and fix O6-meG mispairs (Fishel and Wilson 1997) BER/NER The BER pathway is primarily responsible for repairing oxidative DNA damage, but NER can serve as a backup for repairing some minor damage (Farmer et al. 2005) BER/HR If BER does not repair single-strand DNA breaks (SSBs), they may lead to double-strand breaks (DSBs), which HR can repair HR/NHEJ HR also can repair DNA DSBs that the NHEJ pathway fails to process (Essers et al. 2000)
(Kaina et al. 2007). O6-alkylguanine-DNA methyltransferase, or AGT, removes an alkyl group from the O6position of guanine on the damaged base, the alkyl group is transferred to the active site of AGT and AGT is subsequently degraded. AGT performs this function to a lesser extent on the O4position of thymine. This is a stoichiometric reaction, as AGT can work only once before being inactivated. It is essential to repair O6-meG adducts, as they cause thymine mispairing errors during replication, leading to G:C-to-A:T transitions or a strand break.
7 DNA Repair and Redox Signaling
139
Clinical application: small-molecule inhibitors of AGT Indication for utility Increased AGT levels in tumors correlate with tumor resistance How it works
A chemotherapy agent generates lesions at the O 6 position of guanine, causing interstrand crosslink formation, which blocks DNA replication. An AGT inhibitor would allow crosslink formation by a chemotherapeutic agent by blocking AGT’s removal of the O6lesion NOTE: AGT was one of the first DNA repair targets identified for cancer therapeutics
Anti-AGT agents in use
• BG (O6-benzylguanine) • PARP1 inhibitors
Additional applications
A mutant AGT protein is in development to protect the bone marrow from myelosuppression while inhibiting tumors with anti-AGT therapies
BER The BER pathway is responsible for repairing DNA damage caused by oxidation, alkylation, deamination and ionizing radiation (Christmann et al. 2003; Altieri et al. 2008; Evans et al. 2000). This pathway repairs single-base lesions including N-alkylated purines (N3-methyladenine, N7-methylguanine and N3-methylguanine), 8-oxo-7,8-dihydroguanine(8-OxoG), thymine glycols, 5-OH and 6-OH dihydrothymine, uracil glycol, 5-hydroxycytosine, urea residues and other adducts (Aiyer et al. 2008; Bindra and Glazer 2007; Chen and Olkowski 1994). The process starts when a DNA glycosylase recognizes and excises the damaged base, leaving an abasic site. The type of DNA lesion dictates which glycosylase performs this activity. For example, methylpurine DNA glycosylase (MPG, AAG), 8-oxoguanine DNA glycosylase (OGG1), uracil DNA glycosylase (UNG), thymine DNA glycosylase (TDG) and others remove specific lesions as their names suggest (Essers et al. 2000). In addition to acting on a specific target, glycosylases may be monofunctional or bifunctional. Monofunctional glycosylases excise the damaged base to generate an apurinic/apyrimidinic (AP) or abasic site. Bifunctional glycosylases do the same, but also perform a lyase function (Chen et al. 1991; David and Williams 1998) that nicks the phosphodiester backbone 3¢ to the AP site. Monofunctional glycosylases repair alkylated DNA damage, while bifunctional glycosylases repair oxidative DNA damage. In contrast to the plethora of glycosylases that can remove damaged bases in BER, only one enzyme processes BER abasic sites: APE1/Ref-1 (apurinic apyrimidinic endonuclease redox effector factor-1, or APE1). APE1 hydrolyzes the phosphodiester backbone 5¢ to the AP site, creating a normal 3¢ hydroxyl terminus and an abasic 5¢ deoxyribose phosphate (5¢ dRP) terminus. In addition, APE1 recruits other proteins to assist with the repair, which includes processing by various polymerases and ligases. At this stage, DNA repair can progress via the short-patch BER (SP-BER) pathway or the long-patch BER (LP-BER) pathway. These branches of BER differ in the proteins involved, as well as the length of DNA synthesized during the repair process. The mechanisms by which one pathway is chosen over the other are still
140
M.R. Kelley et al.
being investigated; however, the type of damage and the glycosylase that removes the damage appear to be two contributing factors. The predominant BER pathway is SP-BER. SP-BER preferentially repairs normal AP sites, while LP-BER preferentially repairs oxidized and reduced AP sites (Bapat et al. 2009). SP-BER removes single-base damage by DNA polymerase b (Pol b) acting upon APE1’s endonuclease activity. Pol b removes the 5¢ dRP moiety and inserts the correct base at the 3¢ hydroxyl termimus that APE1 creates. DNA ligase III/ XRCC1 closes the nick to finish the repair. LP-BER repairs damage to two or more bases. In LP-BER, flap endonuclease 1 (FEN1) displaces a segment of 3–8 nucleotides surrounding the AP site. A DNA polymerase (d, e, or b), along with the DNA clamp PCNA (proliferating cell nuclear antigen) and replication factor-C (RF-C) inserts the correct nucleotides; then DNA ligase I finishes the repair (Bapat et al. 2009). APE1 is responsible for 95% of the endonuclease activity in the cell; in addition, its ability to recruit repair proteins to the site is critical to both BER sub-pathways (Demple and Harrison 1994; Doetsch and Cunningham 1990) (See Fig. 7.3). APE1’s reduction/oxidation signaling also influences DNA repair indirectly via modulation of transcription factors, as discussed later in this chapter. APE1’s multifunctional abilities are unique, and there is effectively no backup to any of APE1’s intracellular activities. Clinical application: small-molecule inhibitors of APE1 Indication for APE1 is responsible for almost all endonuclease activity in both branches utility of the BER pathway. Because it performs direct DNA repair functions and also influences DNA transcription proteins through redox regulation, APE1 is an attractive target for chemotherapeutics How it works Potentially two ways: • Inhibiting APE1 can sensitize tumor cells to alkylating and oxidizing agents • Some chemotherapeutic agents, including platinum-based drugs and anthracyclines, generate ROS as a by-product, which could inhibit APE1’s redox functions. Keeping transcription factors in an oxidized state adversely affects gene transcription Anti-BER agents None yet in use A dozen APE1-inhibiting compounds are under investigation. However, many challenges exist in creating a usable inhibitory APE1 agent. Some compounds have proven to be non-specific, binding to the AP site instead of to APE1; others have difficulty penetrating the cell membrane or reaching APE1’s location in the nucleus. To date, E3330 is the sole compound that can selectively inhibit APE1’s redox functions only
MMR The MMR pathway recognizes and repairs single base-pair mismatches (A-G, T-C) or misaligned short nucleotide repeats (e.g., small-loop insertions). Base–base mismatches can be due to endogenous causes: spontaneous deamination of 5-methylcytosine to
7 DNA Repair and Redox Signaling
141
thymine that causes a guanine-to-thymine mismatch, cytosine deamination to uracil resulting in a guanine-to-uracil mismatch, damage to the cellular nucleotide pool or incorrect incorporation by a DNA polymerase. The process starts when MSH2 (MutS homolog 2) combines with MSH3 or MSH6, depending on which type of mismatch is present. MSH2:MSH6 recognizes both insertion–deletion mispairs and single-base mismatches; the MSH2:MSH3 dimer recognizes only insertion–deletion mispairs. After identifying the type of mismatch, MSH proteins recruit MutL homolog 1 (MLH1) and its binding partners, post-meiotic-segregation increased-1 protein (PMS1) and PMS2, to determine the specific strand error. An exonuclease removes the DNA lesion; a DNA polymerase (d or e) synthesizes a new strand, and a DNA ligase completes the repair (Jiricny 2006; Lopez de Saro et al. 2006). Clinical application: small-molecule inhibitors of MMR Indication for Unclear. Genetic diseases linked to MMR defects (e.g., hereditary utility non-polyposis colon cancer; HNPCC) are deterrents to researching MMR inhibitors. Defective MMR repair functions actually increase tumor resistance to cisplatin How it works Inhibiting MMR enzymes is probably not an effective approach for developing new chemotherapeutics. However, reactivation of MMR enzymes may re-sensitize tumors to chemotherapy Anti-MMR agents None yet in use Experimentally, MLH1 reactivation by decitabine can increase cisplatin sensitivity – but the actual mechanism by which it does this is unknown and may not be specific to MLH reactivation
NER The NER pathway is responsible for repairing bulky DNA lesions: cyclobutane– pyrimidine dimers induced by ultraviolet light, adducts induced by polycyclic aromatic hydrocarbons and other adducts induced by cross-linking agents and basedamaging chemical carcinogens. The NER and MMR pathways are presumed to be the major pathways for repairing cross-link damage, which has significant implications for tumor survival. More than 25 proteins participate in the NER pathway, which can be divided into two sub-pathways: global genome repair (GGR) and transcription-coupled repair (TCR). The distinction is predicated on which complex recognizes the helix-distorting damage (Altieri et al. 2008; Friedberg 2001). After the initial recognition step, both sub-pathways operate the same way. A multi-protein complex binds at the damaged site. Then incisions are made on either side of the damaged strand, several nucleotides away from the actual damage. Both the 5¢ and 3¢ sides are cut. The damage-containing oligonucleotide is removed; a DNA polymerase fills the gap, and a ligase completes the repair. In TCR, recognition occurs when RNA polymerase II (RNA Pol II) stalls at a site of DNA damage. TCR-specific factors, including the Cockayne’s Syndrome
142
M.R. Kelley et al.
proteins, CSA and CSB, are recruited at the site of transcription arrest. The GGR sub-pathway starts when the heterodimer XPC/HR23B recognizes the damage, binds to the damaged DNA (distorting it so other complexes can bind) and recruits other proteins to the site. In addition, the UV-DNA damage binding protein (UV-DDB) is required for recruitment when NER repairs UV-induced cyclobutane pyrimidine dimers. Following recognition, both TCR and GGR use the same proteins to repair the damaged DNA. Transcription factor IIH (TFIIH) is recruited to the site of DNA damage. This large complex includes two helicases, XPB and XPD (xeroderma pigmentosum group B and D proteins), which use ATP energy to unwind the DNA strand on either side of the damage. The helicases work in complementary fashion: XPB unwinds DNA in the 3¢ to 5¢ direction; XPD unwinds DNA in the opposite direction. Then, XPA and RPA (replication protein A) stabilize the exposed single-strand DNA. XPA fine-tunes the location of normal versus abnormal DNA, while RPA protects both of the separated strands in the open complex. Endonucleases XPG, ERCC1 (excision repair cross-complementing group 1), XPF1 and XPC cleave the 27- to 30-nucleotide fragment and 3¢ and 5¢ of the lesion. Finally, DNA polymerase d or e, along with PCNA, RPA and replication factor C (RFC), fill the gap, using the undamaged DNA strand as a template (Kelley and Fishel 2008). Research in clinical applications for exploiting various steps in the NER pathway to develop new chemotherapeutics points to the fact that we still have much to learn about pathway signaling proteins. As we elucidate the actions of each step and the implications of inhibiting selected proteins, the opportunity for developing targeted therapies will become more apparent.
Clinical application: small-molecule inhibitors of NER Indication for utility Unclear. Genetic diseases linked to NER defects (xeroderma pigmentosum, Cockayne’s Syndrome) are a deterrent to researching NER inhibitors How it works Efforts in modulating NER response primarily have focused on potentiating the effects of platinum-based drugs, so any smallmolecule inhibitors developed would be chemotherapeutic adjuncts. Inhibitors to two NER proteins (XPA, RPA) and a NER enzyme (ERCC1) are currently under investigation • A global cyclin-dependent kinase inhibitor (UCN-01; 7-hydroxystaurosporine) blocks the interaction between XPA and ERCC1, which can affect the damage-recognition and incision steps of NER • An RPA inhibitor targets RPA’s ability to bind to single-strand DNA • ERCC1 expression may be modulated by a number of small molecules, including gefitinib (an epidermal growth factor receptor tyrosine kinase) and vascular epidermal growth factor (VEGF). Whether their action is specific to NER is unclear Anti-NER agents in use None yet
7 DNA Repair and Redox Signaling
143
NHEJ Repair NHEJ is the main repair pathway for DNA double-stranded breaks (DSBs) in mammalian cells. DSBs are the most severe form of DNA damage, as they can cause deletion or translocation of chromosomal DNA. Ionizing radiation, chemotherapeutic drugs, cleavage during V(D)J-recombination, meiotic recombination or the collapse of replication forks can cause DSBs. NHEJ rejoins DSBs at the ends of the broken DNA, regardless of sequence homology. In NHEJ, the break ends are ligated directly without requiring a homologous template – hence, the name of the pathway. Furthermore, NHEJ can repair DNA double-strand breaks during any phase of the cell cycle (Kelley and Fishel 2008). NHEJ begins when Ku70 and Ku80 proteins bind to the ends of the DNA breaks. Then, the Ku proteins recruit the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs), which creates a nick to mark the spot for repair. The Ku/DNAPKcscomplex recruits additional proteins to make the actual repair. DNA Ligase IV and XRCC4 function as a complex to ligate the nick and complete the process (Burma et al. 2006). Discovery of new proteins involved in NHEJ includes Metnase (also known as SETMAR, histone–lysine N-methyltransferase, SET domain and mariner transposase fusion gene-containing protein) (Lee et al. 2005), which has been shown to interact with DNA Ligase IV to enhance the efficiency and accuracy of NHEJ (Hromas et al. 2008). Because repairing DNA DSBs is critical for tumor cell survival, the search for inhibitors to this pathway is an ongoing pursuit (Altieri et al. 2008; Aiyer et al. 2008; Akamatsu et al. 1997; Akterin et al. 2006). Currently, DNA-PKcsis the most highly researched target in the NHEJ pathway. Clinical application: small-molecule inhibitors of NHEJ Indication for utility DNA-protein kinase is a member of the phosphatidylinostitol 3-kinase (PI3-K) superfamily (Shinohara et al. 2005), which plays a key role in repairing non-homologous doublestranded DNA breaks How it works Inhibition of DNA-PKcsmakes cells hypersensitive to ionizing radiation and numerous DNA cross-linking agents by blocking re-ligation of DNA DSBs Anti-NHEJ agents in use None yet Several compounds in development (NU7441, IC60211, IC86621, AMA37 and others) are being tested in animal models
HR HR is also involved in repairing DNA DSBs. In contrast to NHEJ, HR operates only during the cell cycle’s S and G2 phases during DNA replication. The HR pathway is aptly named, as a sister chromatid must be available nearby to provide a repair template.
144
M.R. Kelley et al.
Repair starts when the MRN complex (Mre11/Rad50/Nbs1) recognizes the DSB and recruits ATM (ataxia telangiectasia mutated protein) to monitor the cell cycle’s checkpoints and analyze the break (Aiyer et al. 2008). MRN’s nuclease activity creates single-strand DNA (ssDNA). When ATM sees the block in replication, it activates numerous downstream proteins via phosphorylation to create a complex that protects the ends of the ssDNA and enables the repair process. ATM-activated BRCA1 (breast cancer 1, early onset) attracts BRCA2 and RAD51 to bind to the ssDNA ends, allowing the RAD52/RAD54 complex to join to and form a larger complex with BLM (Bloom’s syndrome gene product) and WRN (Werner) proteins. These large protein complexes attach to the strand break, direct the pairing of processed DNA with a homologous region on the sister chromatid and initiate strand exchange (Sung and Klein 2006). Clinical application: small-molecule inhibitors of HR Indication for utility ATM regulates cell cycle checkpoints. It interrupts the cell cycle when it detects DNA damage, especially double-strand breaks How it works Inhibiting signaling through ATM can impair the cells’ response to DNA damage, which can make cells more sensitive to chemotherapeutic agents. Ionizing radiation, ROS and (indirectly) alkylating agents can easily kill ATM-deficient cells Anti-HR agents in use None yet, as previously investigated. ATM inhibitors were too non-specific and produced too many off-target effects. Under investigation is KU55933, which blocks phosphorylation of numerous ATM targets and CP466722. Early evidence indicates that it can potentiate the effects of camptothecin, doxorubicin and etoposide
Overview of Redox Signaling Oxidation–reduction (redox) signaling maintains cellular homeostasis and regulates numerous cellular processes, including metabolism, growth, reproductive biosynthesis and apoptosis. Two systems are primarily responsible for general redox regulation: the thioredoxin (Trx) and glutaredoxin/glutathione (GRX/GSH) systems. Both perform their redox and cellular regulation functions through a thiol– redox exchange mechanism (Holmgren 1995; Nakamura et al. 1997). Thiol-based redox reactions rely on binding activities of cysteine (Cys) residues. Special properties of Cys allow them to adopt 10 different sulfur oxidation states from +6 to -2 (the latter being the fully reduced state) (Giles et al. 2003; Jacob et al. 2003), enabling them to exist in many forms (Jacob et al. 2003). The thiol/disulfide configurations in Cys drive human redox system functions in general (Giles et al. 2003). In a thiol/disulfide exchange, a reduced redox protein recognizes an oxidized protein containing a disulfide bond; the redox protein donates two hydrogen molecules to create an intermediate mixed disulfide bond on the oxidized protein.
7 DNA Repair and Redox Signaling
145
In doing so, the redox protein becomes oxidized. A reductase restores the redox protein to a reduced state, using cofactors such as FADH2and NADPH (Giles et al. 2003; Jacob et al. 2003). A specific Cys acts as a nucleophile in this type of reaction (Giles et al. 2003; Jacob et al. 2003). Because the proper folding and functionality of many proteins relies in part on the reversible formation of inter- or intramolecular disulfide bonds, redox systems have far-reaching effects on protein-mediated cellular activities (Berndt et al. 2008).
The Thioredoxin (Trx) System This system includes thioredoxin (Trx), thioredoxin reductase (TrxR) and NADPH (Jacob et al. 2003; Holmgren 1989). Thioredoxins (Trxs) are a large family of structurally conserved oxidoreductases that reduce disulfide bonds in a variety of proteins through a thiol/disulfide exchange mechanism (Nakamura 2005). The system has a built-in “recycle-and-reuse” mechanism: thioredoxin reductase, a flavoprotein containing a selenocysteine, reduces oxidized thioredoxin in a reaction using NADPH as an electron donor. Thus, thioredoxin may be used repeatedly (Jacob et al. 2003). Although all thioredoxins contain a similar active-site motif of Cys-X-X-Cys, their most defining structural feature is the “Trx fold:” a four-stranded b-sheet surrounded by three a-helices (Holmgren 1995; Lillig and Holmgren 2007; Powis and Montfort 2001). Cys-X-X-Cys is located on the loop connecting b-sheet 1 and a-helix 1. The N-terminal Cys32 residue in the active site of human Trx is surface exposed and has a low estimated pKavalue of 6.3 (Forman-Kay et al. 1992), while the C-terminal Cys is buried in the molecule and has a much higher pKavalue. The low pKavalue of the N-terminal Cys may be due to the partial positive charge from the dipole moment associated with a-helix 2 (Hol 1985), or its hydrogen bond to the C-terminal Cys (Weichsel et al. 1996). Regardless of the cause, the low pKaof the thiolate group of the Cys increases its selective reactivity. The proposed reaction mechanism of disulfide reduction by thioredoxin is as follows: the N-terminal cysteine thiolate of Trx acts as a nucleophile and attacks the target disulfide on the oxidized protein, resulting in a transient mixed disulfide intermediate. This, in turn, is reduced by the C-terminal active site Cys residue, generating a dithiol in the target protein and a disulfide in thioredoxin (Holmgren 1995; Lillig and Holmgren 2007; Kondo et al. 2006). The resulting disulfide in the active site of Trx can be reduced by TrxR. The mechanism by which it regenerates Trx back to the dithiol involves the formation of a selenylsulfide on the active site of Trx (Datta et al. 2004). A second redox active site located in the other subunit of the dimeric TrxR contains two thiols that reduce the selenylsulfide back to a thiol and selenol, resulting in the formation of a disulfide bond. Electron transfer from FADH2reduces this disulfide; the resulting FAD is then reduced by electron transfer from NADPH (Jacob et al. 2003) to complete the catalytic cycle.
146
M.R. Kelley et al.
The Glutaredoxin/Glutathione (GRX/GSH) System The glutaredoxin system includes glutaredoxin, glutathione, NADPH and the flavoprotein glutathione reductase (Holmgren 1989; Kondo et al. 2006; Lillig et al. 2008). Like the Trx system, this system also works through a cascade of disulfide oxidation and reduction. Glutaredoxins (GRXs) are small redox enzymes (100 amino acids) that use glutathione as a cofactor. Structurally, glutaredoxins are very similar to thioredoxins, exhibiting the same fold and active sites. However, the active site of GRXs includes Cys-X-X-Cys or Cys-X-X-Ser. GRXs catalyze the reversible reduction of substrate protein disulfides, resulting in the oxidation of the GRXs. Oxidized GRXs are reduced non-enzymatically by glutathione (glutamyl-cysteinyl-glycine, or GSH). Then, the oxidized glutathionine disulfide group (GSSG) is returned to a reduced state by the action of glutathione reductase, at the expense of NADPH (Lillig et al. 2008). Although the thioredoxin system and glutaredoxin system share many functions, they are not redundant systems. Trx and GRX act on different substrates (Lillig et al. 2008; Fernandes and Holmgren 2004). For example, Trx – but not GRX – is implicated in the reduction of APE1, a protein exhibiting both redox and DNA repair functions (Akamatsu et al. 1997; Hirota et al. 1997; Huang and Adamson 1993; Tell et al. 2005).
Roles of Redox Systems The thioredoxin and glutaredoxin systems scavage ROS to reduce intracellular oxidative stress. A reduced state is important for optimizing many cell functions including growth and differentiation, biosynthesis and apoptosis. The systems’ collective efforts to maintain a reduced intracellular environment not only facilitate correct protein folding and efficient work of protein chaperones but they also prevent oxidative modifications to DNA, including base changes, changes to the deoxyribose backbone and direct breakage of a strand (Berndt et al. 2008). Both the DNA damage response and the wide-ranging influence of redox systems include activation and control of numerous transcription proteins (Powis and Montfort 2001; Arner and Holmgren 2000; Yamawaki and Berk 2005). The “dark side” of the two redox systems is that they can contribute to the pathophysiology of various human diseases, including cancers, viral infections, neurodegenerative diseases (including Alzheimer’s) and others (Akterin et al. 2006; Arner and Holmgren 2006; Burke-Gaffney et al. 2005; Raffel et al. 2003). For example, APE1 plays a role in the accumulation of amyloid b protein in Alzheimer’s plaques (Bhakat et al. 2008). Thus, inhibition of redox systems is a vital drug target for many therapeutic areas (Biaglow and Miller 2005; Chew et al. 2008; Liu et al. 2009; Liu 2008; Mukherjee and Martin 2008).
7 DNA Repair and Redox Signaling
147
Clinical application: small-molecule inhibitors of Trx (Tonissen and Di Trapani 2009) Indication for utility Increased levels of Trx and TrxR are present in many cancers. This also correlates with increased resistance to chemotherapeutics The Trx system may assist early cancer development via its growth-promoting and anti-apoptotic functions. Later, the Trx system may influence angiogeneis and metastasis How it works All redox-inhibiting agents ultimately force cancer cells to die by creating an oxidative intracellular environment that exceeds the cell’s redox damage–repair abilities; this, in turn, triggers one of the apoptotic pathways. Redox-inhibiting agents often target the selenothiol of TrxR to accomplish this Anti-Trx agents in use • SAHA (a histone deactylase inhibitor): upregulates an endogenous inhibitor of Trx • Platinum compounds: Although they are most well known for forming irreversible DNA-platinum adducts, these compounds also affect both the Trx and GRX redox systems • ATO (arsenic trioxide): inhibits TrxR via a largely unknown mechanism of action Emerging treatments • PX-12 (1-methyl-propyl-2-imidazolyl disulfide): binds to Cys73 of Trx, irreversibly alkylating it, so that TrxR cannot regenerate it. Also decreases expression of VEGF (which Trx indirectly influences)· Gold compounds: inhibit TrxR in a mechanism still being elucidated. Mode of action may be similar to that of platinum compounds • MGd (motexafin gadolinium): inhibits Trx and generates ROS, including superoxides and hydrogen peroxide. Also inhibits an essential enzyme for DNA synthesis • DCNB (nitroaromatic compounds): inhibits TrxR and induces superoxide generation • Curcumin & flavonoids: convert TrxR to a pro-oxidant form that stimulates ROS production
The Redox Activity of APE1 APE1 is the only DNA repair protein known to have a role in redox regulation, which affects the expression of a number of DNA transcription factors. The protein’s dual functions are reflected in the history behind its full designation: APE1/Ref-1. The multifunctional protein was first identified as being responsible for reducing transcription factor AP-1; therefore, it was named “redox effector factor 1,” or “Ref-1” (Xanthoudakis and Curran 1992, 1996). Since this initial discovery, further studies revealed that APE1 is responsible for regulating many transcription factors including NFkB, HIF-1a, p53, PAX and others (Hirota et al. 1997; Cao et al. 2002; Ema et al. 1999; Hirota et al. 1999; Lando et al. 2000; Tell et al. 2000; Ueno et al. 1999) (Fig. 7.3a). And, as discussed in the first section of this chapter, APE1 performs critical DNA endonuclease repair functions. That spawned its other designation: “APE1,” or apurinic/apyrimidinic endonuclease. Today, the complete name of this protein (APE1/Ref-1) is usually truncated to “APE1.”
148
M.R. Kelley et al.
How APE1 Performs Its Redox Functions APE1’s uniqueness is manifested both in its breadth of function and how it functions, which is still somewhat of a mystery (Georgiadis et al. 2008; Walker et al. 1993). Animal and bacterial APE1 proteins contribute to DNA repair but lack any redox abilities. However, human APE1 does both, making it unique in that regard. How APE1 performs its redox activity remains a controversy, as only the Cys65 residue in APE1 has been identified as critical for its redox reactions (Table 7.1). Cys65 is buried near the N-terminus on the first beta strand in the fold, which is part of a beta sheet in the core of the protein. Normally, two Cys residues are required for thiol/disulfide exchange reactions; however, APE1 does not contain two Cys residues within a C-X-X-C motif that are structurally close enough (~2.2Å) to form the disulfide bond required to drive a redox reaction. APE1’s Cys residues that are in closest proximity to each other are buried in APE1’s core and are on opposite sides of the beta sheet (Fig. 7.3a, b) (Luo et al. 2009). Given these apparent obstacles, four possibilities have been proposed regarding the mechanism for APE1’s redox abilities. The first speculation is that a yet undiscovered Cys residue is involved. A second possibility is that an undiscovered Ser reside is involved, as is found in glutaredoxins. However, to function properly, the Ser would require a pKathat is unusually low for its proposed location. A third postulation is that APE1 undergoes a conformational change to restore its reduced state. This type of activity is seen in another group of redox proteins called peroxiredoxins, which are responsible for catalyzing intracellular hydrogen peroxide (Hofmann et al. 2002). Peroxiredoxins lack a C-X-X-C motif, but they do include two Cys residues that are required for activity. Peroxiredoxins exist as fully folded dimeric structures, where the nucleophilic thiolate is sequestered and the resolving thiolate is located near the C-terminus of the molecule. One Cys from each monomer forms the active site (Wood et al. 2003). Being approximately 9Å from each other, one would wonder how they could form an active site; however, a local unfolding places them in close proximity to detoxify hydrogen peroxide. APE1 could have a similar requirement of a conformational change to complete its catalytic cycle. Further support for this theory can be found in the way that GAPDH interacts with APE1. GADPH acts upon APE1’s Cys152 active site, causing a conformational change that enables APE1 to perform its endonuclease activity (Luo et al. 2009). A fourth possibility exists for explaining APE1’s redox functionality: the involvement of two APE1 molecules. This would provide the second Cys or Ser residue needed to resolve the redox reaction. Further studies are needed to elucidate this important feature of APE1, as it has many implications for future clinical therapeutics.
APE1-Regulated Transcription Factors and Their Link to DNA Damage Repair Because APE1 is involved in both DNA damage repair and the redox regulation of a number of stress-inducible transcription factors, APE1 clearly plays pivotal roles
7 DNA Repair and Redox Signaling
149
in both redox signaling that modulates DNA damage response and direct DNA repair functions. APE1 is a reductive activator for several transcription factors, including p53, AP-1 and HIF1-a (Fig. 7.3a, b). Analysis of APE1’s effector action on these proteins underscores additional unique features about APE1. These transcription factors are unrelated multidomain proteins; that is, APE1 does not recognize any common structural motif when acting upon them. Furthermore, the redox-regulated DNA-binding domains of these factors are structurally distinct: p53, a single immunoglobulin-like domain; NFkB (discussed here in conjunction with p53), a dimer of two-domain immunoglobulin-like subunits; AP-1, a heterodimeric bZip family protein; and HIF-1a, a basic helix-loop-helix domain. Redox regulation of transcription factors is one of several mechanisms that control sequence-specific DNA binding and thereby, gene expression. APE1’s influence on p53, AP-1 and HIF-1a affects the DR, BER, HR, MMR and GGR pathways, as discussed on the following pages (Table 7.1 and Fig. 7.2).
p53 Often called “the guardian of the genome” (Zaky et al. 2008), p53 is a transcription regulatory protein that helps preserve genomic integrity by its participation in stress–response pathways and DNA repair pathways (Lando et al. 2000; Helton and Chen 2007; Sengupta and Harris 2005; Zurer et al. 2004). More than half of all cancers contain mutant or inactive p53, underscoring its importance as a tumor suppressor. Two overall strategies that p53 employs in maintaining the genome are to arrest the cell cycle or to induce apoptosis. For example, hypoxia in tumor cells prompts p53 to induce apoptosis (Jayaraman et al. 1997). Under other circumstances, p53 can interrupt the cell cycle to allow sufficient time to complete DNA repairs (Jiang et al. 2009). The far-reaching influence of p53 also includes complex interactions with other proteins and effector genes. Initial investigation of redox regulation of p53 was based on the finding that oxidized p53 has little binding affinity for DNA (Hainaut and Milner 1993). This led to the discovery that APE1 was responsible for enhancing the DNA-binding activity of wild-type p53 by reducing it (Jayaraman et al. 1997). The mechanisms by which APE1 enhances this activity of p53 are still being discovered, but they appear to include both a redox-dependent activation of the DNAbinding domain (through direct reduction of a disulfide bond), as well as a redox-independent mechanism (Jayaraman et al. 1997). APE1 reduces p53 (Jayaraman et al. 1997). This is essential, but not sufficient, for optimizing p53’s DNA-binding function (Jayaraman et al. 1997). Recent evidence shows that APE1 also facilitates tetramerization of p53 by interacting with its C-terminal regulatory domain in a redox-independent manner, producing p53’s optimal configuration for binding to DNA. Thus, APE1 appears to enhance sequence-specific DNA-binding activity of p53 through two independent, coordinated mechanisms (Hanson et al. 2005). Redox signaling involving p53 depends upon APE1 plus a general redox factor as well. Trx has been shown to enhance stimulation of p53-dependent expression
150
M.R. Kelley et al.
APE1 has two major functions: redox regulatory and DNA repair activity
DNA damage
Redox Role
(reduced) APE1 (oxidized)
T A
AP 1 p53 NFkB HLF HIF 1a CREB ATF Egr 1 NF Y PAX
(oxidized)
(reduced)
DNA Repair G C
A T
T A
C G
T G A T C A C T T A G
*
T A
G A T C C T T A G
T A
G C
APE1
5’ P
T G A C
b
T
Glycosylase (Ogg1, Nth1)
Redox control of Transcripon factors
DNA Repair gene expression altered
Alteraon of gene expression
A
A T C T T A G
A
T A
C G
G A A T C T T A
C G
T
A T
DNA Ligase T A
Transcription Factor
H2N
S-S
Oxidized AP-1, HIF-1α, NFkB
COOH
DBD
APE1RED
DNA
H2N
APE1OXIDIZED
COOH HS
DBD
SH
Target gene expression
Regulatory region
Fig. 7.2 Role of APE1 in regulating expression of other DNA repair proteins and pathway through its redox signaling function
7 DNA Repair and Redox Signaling
151
of p21 by APE1, suggesting a link between Trx and APE1 in cellular response to oxidative stress (Ueno et al. 1999). Because p53 influences many DNA repair pathways and APE1 constitutively influences p53, a short discussion of their effects on each pathway is warranted. p53’s regulation of DNA repair is complex, involving both transactivation-dependent and -independent mechanisms that affect the HR, BER, NER, MMR and NHEJ pathways (Sengupta and Harris 2005). The BER pathway, the main mechanism for repairing oxidative and alkylating base modifications, is initiated by highly specialized DNA glycosylases that cleave the DNA base to create an AP site. p53 regulation of BER varies according to the type of genotoxic stress placed on cells. For example, exposure to nitric oxide species causes p53 to down-regulate the specific glycosylase that would begin repairs in response to this threat. Interestingly, NO does not alter APE1 activity. In this respect, p53 acts as a “brake,” stopping repairs to prevent the possibility of engendering a mutagenic phenotype. However, in response to g-ray treatment, p53 promotes activation of AAG (Zurer et al. 2004). The choice of response also may be specific to the cell line involved. Recent studies with human colorectal cancer line HCT116 show that wild-type p53 (but not mutant p53) downregulates APE1 by indirect recruitment of its promoter, possibly blocking binding of SP1 (Zaky et al. 2008). Thus, in this example, APE1 regulates DNA binding of p53; and p53, in turn, regulates both expression of APE1 as well as certain proteins that bind to the promoter of APE1. This system of checks and balances maintains equilibrium between p53’s pro-apoptopic activity and APE1’s pro-survival activity. In addition, p53 regulates DNA polymerase b (Pol b), which replaces excised bases in the SP-BER pathway. The single-nucleotide replacement mechanism of Pol b requires dRP lyase activity for the repair (Allinson et al. 2001). This lyase activity occurs after APE1 activity and is often rate limiting in BER. Pol b expression is down-regulated in p53-deficient cells (Cao et al. 2002), which increases the likelihood of the accumulation of cytotoxic repair intermediates that effectively can halt DNA replication. Additionally, in vitro studies with various cell lines show that CREB (which recruits and stabilizes Pol b) can upregulate Pol b gene expression in response to DNA alkylating exposure (He et al. 2003). CREB (cAMP response element binding) is under redox control for its DNA binding and activating transcription. Other proteins in the DNA repair arsenal are under redox control, and this control regulates DNA repair response (Fig. 7.2). p53 differentially affects the two NER sub-pathways, TCR and GGR. Several studies found that p53 selectively affects GGR, but not TCR. In GGR, sublethal UV radiation causes p53 to arrest the cell cycle in G1, to gain the needed time for DNA repair before progressing to S phase (Smith and Seo 2002; Li et al. 2001). In addition, p53 also regulates GGR downstream effectors, DDB2 and XPC, the main proteins involved in DNA damage recognition (Adimoolam and Ford 2002; Hwang et al. 1999; Tan and Chu 2002). Inactive or absent p53 results in defective GGR repair activity and appears to lead to genomic instability (Xu and Morris 1999). Studies of knockout mice support this: in one study, 100% of XPC-/-mice developed lung cancer and 100% of DDB2-/-mice developed skin tumors (Hollander
152
M.R. Kelley et al.
et al. 2005). PCNA, a progressivity factor in the NER pathway, is also under p53 regulation (Xu and Morris 1999). The MMR pathway removes and repairs DNA mismatches because of the DNA polymerase errors. MSH2, which must be complexed with MSH6 or MSH3 to recognize DNA damage, is under p53 regulation. Low levels of p53 prevent MSH2:MSH6 recognition of single-base mismatches and short insertion/deletion mispairs, and MSH2:MSH3 recognition of larger loops of unpaired nucleotides. MSH2, MLH1, and PMS2 all are under p53 regulation, similar to the way that DDB2 and XPC are in NER (Chen and Sadowski 2005; Scherer et al. 2000). Both the HR and NHEJ pathways address reparation of double-strand breaks. DSBs are the most severe threats to genomic stability because they facilitate deletion and/or translocation of chromosomal DNA. As a result, both pathways are highly regulated. Once again, p53 appears as an important player in the repair of DSBs through regulation of both the HR and NHEJ repair pathways. Mice that are deficient in wild-type p53 exhibit increased levels of HR activity (Bishop et al. 2003; Lu et al. 2003). p53 inhibits HR through repression of RAD51 expression (Arias-Lopez et al. 2006). (Conversely, absent or mutated p53 increases RAD51 DNA repair activity, which contributes to chemotherapeutic resistance.) In the NHEJ pathway, p53 downregulates expression of WRN and RecQ4, two RecQ helicases (Sengupta et al. 2005; Yamabe et al. 1998). Finally, in the DR pathway, studies on murine fibroblast cell lines have demonstrated that AGT is under p53 regulation (Grombacher et al. 1998; Rafferty et al. 1996). Interactions between p53 and AGT are complex and depend on many variables, including the type of cellular stress present. For example, p53 appears to induce AGT in response to ionizing radiation. AGT also appears to be regulated by NFkB, a transcription factor mediating immune and inflammatory responses. For example, overexpression of NFkB in HEK293 cells (human embryonic kidney 293 cells) increases AGT expression (Lavon et al. 2007). NFkB is under redox control by APE1. All these studies point to the possible clinical relevance of redox-controlled DNA repair responses through p53. If reduced p53 is required to bind DNA and either activate or repress the transcription of DNA repair genes, then it follows that APE1 plays an important role not only in the redox modulation of p53, but also in the regulation of DNA repair.
AP-1 Activator protein-1 (AP-1) refers to a family of proteins that recognize AP-1 sites. The AP-1 family is also referred to as tetradecanoylphorbol-13-acetate (TPA)responsive elements. AP-1 mediates diverse cellular functions including proliferation, differentiation, apoptosis and transformation; it also responds to environmental changes including stress, radiation or growth factor signals (Hess et al. 2004). The AP-1 family consists of structurally and functionally related basic leucine zipper
7 DNA Repair and Redox Signaling
153
proteins (bZIP) that intermix to form heterodimeric sequence-specific DNAbinding proteins. These include Jun proteins (c-Jun, JunB and JunD), Fos proteins (c-Fos, FosB, Fra-1 and Fra-2) and some ATF family members (ATFa, ATF-2 and ATF-3) (Hess et al. 2004). Studies of AP-1 activity provided the backdrop for early investigations into APE1’s redox activity. In fact, APE1 was first identified as a result of efforts to determine the nuclear factor responsible for reducing AP-1 (c-Jun/c-Fos) and thereby enhancing its DNA-binding activity (Xanthoudakis and Curran 1992; Abate et al. 1990). Redox regulation of AP-1 was found to result from oxidation/ reduction of conserved Cys residues within the basic DNA-binding domains of c-Jun and c-Fos, which enables them to dimerize (Abate et al. 1990). APE1 copurifies with AP-1 (Xanthoudakis and Curran 1992), which is in stark contrast to APE1’s interaction with p53. The former is a stable interaction; the latter is transient. Trx has also been identified as a factor modulating transcriptional activation of AP-1 through its reduction of APE1 (Hirota et al. 1997). AP-1 is rapidly induced in response to many cellular stimuli, and its activation regulates the expression of several proteins involved primarily in NER and MMR DNA repair pathways. Numerous studies of AP-1’s influence on DNA repair proteins have revealed more than 20 genes whose promoters are bound following cisplatin treatment. The proteins that AP-1 regulates in repairing DNA–cisplatin adducts include RAD23B, XPA, ERCC3, XPF, ERCC1 and ERCC3 in the NER pathway and MSH2, MSH6, MLH1 and PMS2 in the MMR pathway. Phosphorylated c-Jun or ATF2 activates these proteins to increase their DNA-binding capacity (Luo et al. 2009; Luo et al. 2008). Because AP-1 must be converted from an oxidized to a reduced state in order to bind to its target sequence, redox control of this protein has significant implications. APE1 is implicated as a potential point of control for regulating the DNAbinding activity of AP-1, thus modulating the expression of DNA repair proteins (Table 7.1and Fig. 7.2).
HIF-1a Hypoxia inducible factor-1 (HIF-1), as its name suggests, responds to low-oxygen conditions in the cell. Increasing evidence reveals that hypoxic stress in the tumor microenvironment can cause genetic instability in cancer cells. HIF-1 is a heterodimeric transcription factor composed of two subunits; the HIF1a subunit is crucial for regulating cellular response to hypoxia and is frequently overexpressed in human cancers. Under hypoxic conditions, HIF-1a translocates to the nucleus and dimerizes with HIF-1b, forming HIF-1. HIF-1, along with coactivators, binds hypoxia response elements (HRE) within promoters and regulates the expression of their downstream genes, including vascular endothelial growth factor (VEGF) (Forsythe et al. 1996; Jiang et al. 1996). Redox-dependent stabilization of the HIF-1a protein is required for activation of HIF-1 (Huang et al. 1996), and
154
M.R. Kelley et al.
redox signaling regulates the DNA-binding activity of HIF-1. These combined activities suggest a role for APE1 as a redox regulator of HIF-1a. Furthermore, APE1 has been implicated in its role of helping to form the hypoxia-inducible transcriptional complex that includes HIF-1 and transcriptional coactivators p300 and CREB. More recently, HIF-1a has been shown to play a role in down-regulating mRNA and APE1 levels under hypoxic conditions in human microvascular endothelial cells (Loboda et al. 2009). Thus, HIF-1a regulates the expression levels of APE1 and is itself regulated by APE1. Hypoxia downregulates the expression of key genes within two DNA repair pathways. In HR, several critical mediators including BRCA1, BRCA2 and RAD51 are inhibited, resulting in significant genetic instability. In addition, HIF-1a decreases the expression of NBS1, a member of the Mre11-RAD50-NBS1 (MRN) complex that initially recognizes DSBs (To et al. 2006). In MMR, MLH1 and MSH2 are inhibited (Bindra and Glazer 2007; Bindra et al. 2004; Bindra et al. 2005, 2007; Bindra and Glazer 2007; Bristow and Hill 2008; Koshiji et al. 2005; Meng et al. 2005; Mihaylova et al. 2003). The MMR genes appear to be repressed through a mechanism involving c-Myc (Bindra and Glazer 2007). Interactions between HIF-1a and these genes are still being determined, but some studies show that HIF-1a represses MSH2:MSH6 in a p53-dependent manner (Koshiji et al. 2005). Regulation of DNA repair is an integral part of the hypoxic response; and HIF1a, a critical response mediator, influences the DNA repair response (Fig. 7.2). As APE1 is required for redox regulation of HIF-1a, it then also plays a role in the regulation of DNA repair genes controlled by HIF-1a. APE1 also exhibits redox-independent transcriptional regulatory functions that are subject to post-translational modifications including phosphorylation, acetylation and nitrosation. The purposes of these modifications are still being elucidated. For example, acetylation of APE may influence its subcellular localization or transacting functions (Bhakat et al. 2008). Review articles by Bhakat and others describe these implications further (Bhakat et al. 2008; Tell et al. 2009).
Other Global Influences of APE1 APE1 is a critical “master regulator” for maintaining genomic stability (Fig. 7.3). Earlier sections of this chapter discussed APE’1s apurinic/apyrimidinic endonuclease activity that is essential to BER’s DNA repair activities (Bhakat et al. 2008). In addition, APE1 performs redox functions that include modulation of transcription factors. APE1 controls the redox status of either ubiquitous (AP-1, Egr-1, NF-kB, p53, CREB, HIF-1a) or tissue-specific transcription proteins (PEBP-2, Pax-5 and -8 TTF-1) (Fig. 7.3a) (Akamatsu et al. 1997; Huang and Adamson 1993; Xanthoudakis and Curran 1992; Cao et al. 2002; Ema et al. 1999; Hirota et al. 1999; Lando et al. 2000; Tell et al. 2000; Ueno et al. 1999; Xanthoudakis et al. 1992).
7 DNA Repair and Redox Signaling
155
Fig. 7.3 APE1 has dual roles in redox and DNA repair. APE1 possesses two major functions: Redox regulatory/signaling and DNA repair. Through its redox function, APE1 regulates gene expression by modifying the redox status of some transcription factors which are involved in variety of cancer processes. (Adapted from: Luo et al. (Luo et al. 2008))
Cell Survival APE1 is also essential for cell survival and organism development, as evidenced by the fact that no viable knockout model of APE1 exists. The absence of APE1 in mice causes post-implantation embryonic lethality between days E5 and E9 (Xanthoudakis et al. 1996). Conditional knockout and knock-down strategies also confirm the crucial role of this protein in cells (Fishel et al. 2008; Fung and Demple 2005; Izumi et al. 2005). Studies have demonstrated that altering APE1 levels leads to changes in cell growth, survival and sensitivity (Chen and Olkowski 1994; Fishel et al. 2008; Bobola et al. 2005; Fishel et al. 2007; Herring et al. 1998; Lau et al. 2004; McNeill and Wilson 2007; Ono et al. 1994; Walker et al. 1994; Wang et al. 2004). Experiments with normal cells show that siRNA directed against APE1 results in decreased cell proliferation, increased AP sites and increased apoptosis (Fishel et al. 2007). While the extent of APE1’s activities for cell survival and overall growth are still unknown, recent studies show that APE1 acts as a quality control monitor of RNA. During the S phase of the cell cycle (when rRNA is synthesized), APE1 localizes in the nucleus and enhances de novo protein synthesis and cell proliferation by methods only partially understood. The N-terminus of APE1 binds to proteins involved in generating ribosomes and processing RNA (Barnes et al. 2009; Vascotto et al. 2009). APE1 also performs an RNA “cleansing” process that includes cleaving abasic RNA. Perhaps RNA’s single-strand construction makes it more susceptible to oxidative insults than DNA; therefore, APE1’s “cleansing” function affects overall cellular viability. APE1’s nuclear localization corresponds to increased
156
M.R. Kelley et al.
κ
α
β α
κ
Fig. 7.4 Redox control of DNA repair. In its role as a redox factor, APE1 reduces a number of transcription factors including AP-1, Egr-1, NF-kB, p53, CREB, and HIF-1a. Thus, APE1 controls the redox status of several transcription factors that in turn regulate expression of APE1
intracellular resistance to ROS, g radiation, and a number of other cytotoxic agents (Bhakat et al. 2008) Fig. 7.4. Other recent studies propose that APE1’s intracellular redox control may also affect the cell cycle by inducing nucleus–cytoplasm redistribution of p21, which regulates the G1 phase (Merluzzi et al. 2008).
Angiogenesis A mosaic of APE1’s redox influence on angiogenesis can be seen by observing its known functions in normal endothelial cells, plus examining in vitro and preclinical studies of its inhibition. In normal endothelial cells, APE1’s redox activity helps (1) maintain cell differentiation, (2) maintain vascular tone by regulating NO levels (Zou et al. 2009), (3) enable differentiation of angiogenic progenitor cells and (4) prevent apoptosis by repressing pro-apoptotic TNFa signaling and upregulating pro-survival NFkB signaling. Intracellular hypoxia is a feature of many cancers, including pancreatic and prostate carcinomas. Thus, decreased activity of APE1 influences downstream genes that induce endothelial cell death (Bhakat et al. 2009). In vitro studies hint at additional influences of APE1 on endothelial cells. Studies show that inhibition of APE1 attenuates the formation of retinal vascular endothelial cells (RVECs), and, to a lesser extent, their proliferation (Luo et al. 2008). In a
7 DNA Repair and Redox Signaling
157
d ifferent realm of endothelial health, Tat-mediated protein transduction of APE1 decreases vascular cell adhesion molecule-1 expression, blunting the response of monocyte adhesion factors to atherosclerotic injury (Song et al. 2008). Preclinical studies of E3330, a unique quinone that selectively inhibits APE1’s redox functions, allude to APE1’s influence on endothelial cells in the tumor microenvironment. Tumors will not grow larger than a few millimeters unless they have constant access to a blood supply. Migration of endothelial progenitor cells to the tumor microenvironment is essential for neoangiogenesis. Preclinical utility studies with E3330 demonstrate that it inhibits the growth of pancreatic cancer cell lines (Zou and Maitra 2008) as well as in pancreatic cancer-associated endothelial (PCECs) and endothelial progenitor cells (Zou et al. 2009). Because intracellular hypoxia is a common feature of many cancers, E3330’s influence on HIF-1 has been studied as well. E3330 inhibits HIF-1’s DNA-binding activity, which is consistent with E3330’s ability to inhibit APE1’s redox functions. Thus, inhibition of APE1 induces endothelial cell growth arrest via a cascade of signaling upstream from HIF-1a. Additional studies of E3330’s effect on human bone marrow cells, pancreatic cancer cells and human umbilical vein endothelial cells show that E3330 can reduce tumor endothelial VEGF secretion – and, at the same time, downregulate levels of the cognate receptor Flk-1/KDR on PCECs, blocking a potentially critical angiogenic ligand–receptor interaction in the tumor microenvironment. In addition, E3330 can block the differentiation of bone-marrow hemangioblasts (Zou et al. 2009).
Inflammation Long-standing inflammation is a risk factor for tumorgenesis. For example, patients who live with ulcerative colitis (UC) for more than 10 years have a 20- to 30-fold increased risk of developing colorectal cancer. Chromosomal instabilities can be detected even in early-stage dysplastic UC tissues (Guo et al. 2008). Sources of inflammation such as ROS and toxic agents transiently increase intracellular levels of APE1 (Evans et al. 2000; Luo et al. 2009; Tell et al. 2009). Prolonged stimulation and response of APE to intracellular stresses from inflammation can cause genomic instability. It is well known that many DNA repair intermediates are cytotoxic and potentially mutagenic – including abasic sites and single-strand breaks (Bapat et al. 2009). If DNA repairs stall or are performed incorrectly, they can lead to microsatellite instability (MSI) – which is present in the aforementioned dysplastic colon cells. Inflamed areas of UC lesions contain significantly greater amounts of APE1 and AAG than tissues in non-inflamed areas, suggesting that long-term adaptive increases in these proteins contribute to the production of MSI. Many other sporadic tumors also contain MSI, which provides motivation to study BER and other DNA repair pathways in other chronic inflammatory diseases. Overexpression of
158
M.R. Kelley et al.
AAG and APE1 is likely just one example of how long-term dysregulation of a DNA repair pathway can contribute to tumorgenicity (Guo and Loeb 2003).
DNA Repair in the Tumor Microenvironment Little is known about DNA repair in the tumor microenvironment, except that it is abnormal. If DNA repair is imperfect or incomplete, it can result in DNA damage that is genomically unstable, which is a key step for initiation and progression of cancer (Kruman et al. 2004; Schwartz et al. 2007). Tumors can be expected to be defective or deficient in one DNA repair pathway, but they have an astonishing ability to compensate and adapt by using other repair mechanisms. Crossover, interaction and compensation within and among DNA repair pathways often allow cancer cells to avoid or escape apoptosis (Reed et al. 2009). For example, cancer cells deficient in the proteins of the HR pathway may compensate for this deficiency by repairing DSBs through the NHEJ or BER pathway (Christmann et al. 2003; Hess et al. 2004; Beckman and Loeb 2006; Handel et al. 1995). A tumor’s DNA repair abilities are directly related to its unchecked cellular proliferation and its intrinsic or acquired cellular resistance to clinical DNAdamaging agents (Fishel and Wilson 1997; Holmgren 1989; Arner and Holmgren 2006; Bravard et al. 2009). So, in theory, the very defect that makes cancer cells highly mutable should be able to be exploited – to create a drug that makes the original defect lethal to cancer cells without harming normal cells. Therefore, inhibiting specific proteins in DNA damage repair pathways is a promising strategy for developing targeted cancer treatments (Fishel and Wilson 1997; Hromas et al. 2008; Holmgren 1989; Arner and Holmgren 2006; Bravard et al. 2009). It may sound paradoxical to inhibit DNA repair pathway proteins because cancer promotion and deregulated cellular growth are aided by deficient DNA repair pathways. However, a fine balance exists between the induction of DNA damage and its efficient repair (Hromas et al. 2008; Arner and Holmgren 2006). Inhibiting specific DNA repair proteins can selectively sensitize cancer cells to chemotherapeutic agents (Hromas et al. 2008; Holmgren 1989). Great clinical interest exists for combining DNA repair inhibition with current chemotherapy regimens (Beckman and Loeb 2006) to develop targeted therapies. Redox regulation plays an important role in DNA repair, and increasing attention is being focused on redox activities as potential targets for new chemotherapeutic agents. APE1 is a major player in redox signaling to downstream transcription factors that regulate stress and DNA repair responses. Increased levels of APE1 have been linked to tumor promotion, progression, poorer prognosis, shorter time to progression and poorer outcomes from chemotherapy (Hanson et al. 2005). Abnormal APE1 levels are speculated to be one cause of resistance to chemotherapy. Although APE1 largely is restricted to the nucleus in normal cells, its increased level in the cytoplasm has been associated with more aggressive lung, thyroid, breast and ovarian cancers (Zaky et al. 2008; Di Maso et al. 2007). The cause of
7 DNA Repair and Redox Signaling
159
this phenomenon is yet unknown, but it may provide another clue in understanding how APE1 redox activity is altered in the tumor microenvironment. Ample data demonstrate that downregulation or inhibition of APE1 using RNA interference and DNA antisense oligonucleotide techniques can sensitize cancer cells to laboratory and clinical chemotherapeutic agents (Bapat et al. 2009; Lillig et al. 2008; Hainaut and Milner 1993; Herring et al. 1998; Barnes et al. 2009; Langie et al. 2007; Madhusudan and Hickson 2005; Mathers et al. 2007). Thus, regulation of APE1 is emerging as a major player in manipulating the tumor microenvironment and modulating immune response. Redox regulation clearly plays an important role in DNA repair. APE1’s multifunctional abilities in DNA repair and redox signaling of transcription proteins are unique; no backup exists for its critically important activities. Therefore, identifying selective inhibitors of APE1 make it an excellent target for both single-agent and combination therapeutic approaches. Future research in this area will bring additional insights into the importance of redox regulation in DNA repair and will likely result in the identification of other key redox proteins.
Modulating APE1’s Activities as a Cancer Therapeutic Approach Elevated APE1 levels are typically associated with aggressive proliferation, increased resistance to therapeutic agents and poor prognosis (Evans et al. 2000; Wang et al. 2004; Moore et al. 2000; Xu et al. 1997) in various cancers. Altered or elevated levels of APE1 have been observed in breast and ovarian cancers, gliomas, sarcomas (osteosarcomas and rhabdomyosarcomas) and multiple myelomas, among others (Chen and Olkowski 1994; Hainaut and Milner 1993; Hanson et al. 2005; Koshiji et al. 2005; Langie et al. 2007; Madhusudan et al. 2005). Decreasing APE1 levels can block tumor cell growth and increase cellular sensitivity to DNA-damage agents (Fishel et al. 2008, 2007; Lau et al. 2004; Ono et al. 1994; Wang et al. 2004). However, current methods for modulating APE1 alter all its functions. Because of APE1’s diversity, it is important to distinguish and characterize which of APE1’s function(s) are involved in different biological events – especially those that may differ in normal versus pathologic cells such as cancer cells. The relative importance of APE1’s redox vs. repair function in cancer is unknown. Efforts to determine the differential therapeutic effects of inhibiting one or the other are ongoing. Blocking of the redox function of APE1 would be expected to impact the activity of a number of downstream transcription factors and the genes products that they regulate. Exploration of novel targets clearly merits pursuit, particularly in cancers for which current treatments are ineffective. Many small-molecule inhibitors in development are specific to proteins in DNA damage–response. Designed as potentiators of traditional chemotherapeutics, their goal is to inhibit targeted proteins while adding minimal toxicity to the treatment (Reed et al. 2009).
160
M.R. Kelley et al.
There has been considerable debate in the literature regarding the wisdom of inhibiting essential DNA repair enzymes (Kelley and Fishel 2008; Bapat et al. 2009; Madhusudan and Hickson 2005; Damia and D’Incalci 2007; Fishel and Kelley 2007). Targeting a specific protein (particularly one that plays an important role in cellular response to stress) by chemical knockout through the use of a smallmolecule inhibitor may have unintended consequences. However, small-molecule inhibitors have been identified for several DNA repair enzymes including MGMT (AGT), poly ADP-ribose polymerase (PARP1), ataxia-telangiectasia mutated kinase (ATM kinase), APE1 and DNA PKcs (Madhusudan and Hickson 2005; Damia and D’Incalci 2007; Fishel and Kelley 2007). The potential for small-molecule inhibitors to attenuate one or more of APE1’s functions offers potential for reversing drug resistance (Bhakat et al. 2008). Targeting the redox function of APE1 represents a novel approach in the development of a cancer therapeutic agent, as selectively blocking this function seems to lead to cytostatic growth without causing cell death. Finding specific small-molecule inhibitors that can block either of APE1’s repair or redox functions, but not both, will help determine how to best modify its function in treating different diseases. A unique compound called E3330 has single-agent cancer-cell killing abilities in cancer cell lines including ovarian, colon, lung, breast, brain, pancreatic, prostate and multiple myeloma cancers. It is significant that E3330 does not produce cell killing in normal cells, which implies a particular redox role of APE1 in cancer survival, but not “normal” cell survival. This suggests that a “therapeutic window” exists, as the results of the studies of E3330 demonstrate that it has a greater effect on differentiated endothelial tumor cells versus bone marrow stem cells (Zou et al. 2009). The collective data on E3330 suggest that APE1’s redox function is a promising target for cancer treatment Tables 7.2 and 7.3. Table 7.2 APE1’s relationship between redox activities and DNA repair APE1’s Influence on Redox Regulation of DNA Repair Pathways PATHWAY WHAT APE1 ACTS UPON DR Reduces p53, which dictates AGT’s level of activity, depending on the type of cytotoxic stress present Reduces NFkB, which appears to regulate AGT BER Reduces p53 to optimize its DNA-binding ability; which, in turn, influences DNA polymerase b activity NER Reduces p53 so it can activate DDB2 and XPC to recognize DNA damage in the GGR sub-pathway Reduces AP-1 so it can regulate the expression of several proteins, including those that repair DNA-cisplatin adducts MMR Reduces p53 so it can enable MSH2 to complex and recognize DNA damage Reduction of p53 also enables it to activate MLH1 and PMS2 Reduces AP-1 so it can regulate the expression of several proteins, including those that repair DNA-cisplatin adducts Stabilizes HIF-1a so it can activate HIF-1, which, in turn, inhibits NLH1 and MSH2 during hypoxia HR Reduces p53 so it can modulate RAD51 expression Stabilizes HIF-1a so it can activate HIF-1, which, in turn, inhibits BRCA1, BRCA2, and RAD51 during hypoxia NHEJ Reduces p53 so it can regulate the expression of RecQ helicases WRN and RecQ4
Is reduced by
Reduce(s)
Proximity of residues How reaction resolution occurs
TrxR+FADH2+NADPH
N-terminal cys is the nucleophile; attacks the target protein disulfide; creates a transient mixed disulfide intermediate, this is reduced by the C-terminal active site Cys, generat-ing a dithiol in the target protein and a disulfide in thioredoxin Disulfide bonds of signaling and regulatory proteins
Unknown
Disulfide bonds of signaling and regulatory proteins Thioredoxin (for redox activity; GADPH reduces APE1 for its endonuclease activity)
Close
Far apart
Table 7.3 Comparison of APE1’s redox features to other redox systems Redox system Feature APE1 Trx Cys65 Cys32+Cys35 Residues required for activity Location of active Near the N-terminus; Surface accessible; near the C-terminus residue(s) buried
Structural unfolding in the area of the thiolate near the C-terminus places it in close proximity to the nucleophilic thiolate
Hydrogen peroxide
Reduces the target protein disulfide; creates a transient mixed disulfide intermediate, GRX is oxidized; dithiol created in the protein Disulfide bonds of signaling and regulatory proteins Glutathione+glutathione reductase+NADPH
Sulfiredoxin
1 near the N-terminus; other near the C-terminus Far apart
N-terminus
Close
Peroxiredoxins 1 or 2 Cys (depends on which Prx type)
GRX/GSH Cys22+Cys25
7 DNA Repair and Redox Signaling 161
162
M.R. Kelley et al.
Conclusions Redox regulation has an important role in DNA repair, not only directly with the APE1 protein but also through other redox signaling and cellular redox status changes. APE1 has been a major focus of this chapter since it is clearly the DNA repair protein most directly involved in redox control and signaling. Additionally, we discuss recent data demonstrating a new role of APE1 with its involvement in angiogenesis and potential role in the tumor microenvironment. We expect that future research in this area will bring additional insights into the importance or redox regulation in DNA repair, particularly as more interest if brought to bear on this topic. These new studies will likely result in the identification of other proteins that also play important roles in redox regulation and DNA repair. Acknowledgments Financial support for this work was provided by the National Institutes of Health, National Cancer Institute CA106298, CA114571 and CA121168 to M.R.K., CA114571 to M.M.G. and the Riley Children’s Foundation to M.R.K., and National Cancer Institute CA122298 and to M.L.F.
References Abate C, et al (1990) Expression and purification of the leucine zipper and DNA-binding domains of Fos and Jun: both Fos and Jun contact DNA directly. Proc Natl Acad Sci USA 87(3):1032–1036. Abate C, et al (1990) Redox regulation of fos and jun DNA-binding activity in vitro. Science 249(4973):1157–1161. Adimoolam S, Ford JM(2002) p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci USA 99(20):12985–12990. Aiyer HS, Kichambare S, Gupta RC (2008) Prevention of oxidative DNA damage by bioactive berry components. Nutr Cancer 60(Suppl 1):36–42. Akamatsu Y, et al (1997) Redox regulation of the DNA binding activity in transcription factor PEBP2. J Biol Chem 272:14497–14500. Akterin S, et al (2006) Involvement of glutaredoxin-1 and thioredoxin-1 in beta-amyloid toxicity and Alzheimer’s disease. Cell Death Differ 13(9):1454–1465. Allinson SL, Dianova II, Dianov GL (2001) DNA polymerase beta is the major dRP lyase involved in repair of oxidative base lesions in DNA by mammalian cell extracts. EMBO J 20(23):6919–6926. Altieri F, et al (2008) DNA damage and repair: from molecular mechanisms to health implications. Antioxid Redox Signal 10(5):891–938. Arcangeli L, et al (1997) Site- and strand-specific mismatch repair of human H-ras genomic DNA in a mammalian cell line. Carcinogenesis 18(7):1311–1318. Arias-Lopez C, et al (2006) p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Rep 7(2):219–224. Arner ES, Holmgren A (2000) Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267(20):6102–6109. Arner ES, Holmgren A (2006) The thioredoxin system in cancer. Semin Cancer Biol 16(6):420–426. Bapat A, et al (2009) Going ape as an approach to cancer therapeutics. Antioxid Redox Signal 11(3):651–668.
7 DNA Repair and Redox Signaling
163
Barnes T, et al (2009) Identification of Apurinic/apyrimidinic endonuclease 1 (APE1) as the endoribonuclease that cleaves c-myc mRNA. Nucl Acids Res 37(12):3946–3958. Beckman RA, Loeb LA (2006) Efficiency of carcinogenesis with and without a mutator mutation. Proc Natl Acad Sci USA 103(38):14140–14145. Berndt C, Lillig CH, Holmgren A (2008) Thioredoxins and glutaredoxins as facilitators of protein folding. Biochim Biophys Acta (BBA): Mol Cell Res 1783(4):641–650. Bhakat KK, Mantha AK, Mitra S (2009) Transcriptional regulatory functions of mammalian AP-endonuclease (APE1/Ref-1), an essential multifunctional protein. Antioxid Redox Signal 11:621–638. Biaglow JE, Miller RA (2005) The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther 4(1):6–13. Bindra RS, Glazer PM (2007) Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. Oncogene 26(14):2048–2057. Bindra RS, Glazer PM (2007), Co-repression of mismatch repair gene expression by hypoxia in cancer cells: role of the Myc/Max network. Cancer Lett 252(1):93–103. Bindra RS, et al (2004) Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 24(19):8504–8518. Bindra RS, et al (2005) Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability. Ann N Y Acad Sci 1059:184–195. Bindra RS, Crosby ME, Glazer PM (2007) Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev 26(2):249–260. Bishop AJ, et al (2003) Atm-, p53-, and Gadd45a-deficient mice show an increased frequency of homologous recombination at different stages during development. Cancer Res63(17):5335–5343. Bobola MS, et al (2005) Apurinic/apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors. Clin Cancer Res 11(20):7405–7414. Bravard A, et al (2009) Oxidation status of human OGG1-S326C polymorphic variant determines cellular DNA repair capacity. Cancer Res 69(8):3642–3649. Bristow RG, Hill RP (2008) Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8(3):180–192. Burke-Gaffney A, Callister ME, Nakamura H (2005) Thioredoxin: friend or foe in human disease? Trends Pharmacol Sci 26(8):398–404. Burma S, Chen BP, Chen DJ (2006) Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair (Amst) 5(9–10):1042–1048. Cao X, et al (2002) Oxidoreductive modification of two cysteine residues in paired domain by Ref-1 regulates DNA-binding activity of Pax-8. Biochem Biophys Res Commun 297(2):288–293. Chen DS, Olkowski ZL (1994) Biological responses of human apurinic endonuclease to radiationinduced DNA damage. Ann N Y Acad Sci 726:306–308. Chen DS, Herman T, Demple B (1991) Two distinct human DNA diesterases that hydrolyze 3’-blocking deoxyribose fragments from oxidized DNA. Nucl Acids Res 19(21):5907–5914. Chen J, Sadowski I (2005) Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements. Proc Natl Acad Sci USA 102(13):4813–4818. Chew EH, et al (2008) Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity. FASEB J 22(6):2072–2083. Christmann M, et al (2003) Mechanisms of human DNA repair: an update. Toxicology 193(1–2):3–34. Damia G, D’Incalci M (2007) Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer 43(12):1791–1801. Datta K, et al (2004) Sensitizing glioma cells to cisplatin by abrogating the p53 response with antisense oligonucleotides. Cancer Gene Ther 11(8):525–531. David SS, Williams SD (1998) Chemistry of glycosylases and endonucleases involved in baseexcision repair. Chem Rev 98(3):1221.
164
M.R. Kelley et al.
De Bont R, van Larebeke N (2004) Endogenous DNA damage in humans: a review of quantitative data. Mutagenesis 19(3):169–185. Demple B, Harrison L (1994) Repair of oxidative damage to DNA: enzymology and biology. Ann Rev Biochem 63:915–948. Di Maso V, et al (2007) Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol Med 13(1–2):89–96. Doetsch PW, Cunningham RP (1990) The enzymology of apurinic/apyrimidinic endonucleases. Mutat Res 236(2–3):173–201. Eker AP, et al (2009) DNA repair in mammalian cells: Direct DNA damage reversal: elegant solutions for nasty problems. Cell Mol Life Sci 66(6):968–980. Ema M, et al (1999) Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 18(7):1905–1914. Essers J, et al (2000) Homologous and non-homologous recombination differentially affect DNA damage repair in mice. EMBO J 19(7):1703–1710. Evans AR, Limp-Foster M, Kelley MR (2000) Going APE over ref-1. Mutat Res 461(2):83–108. Farmer H, et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917–921. Fernandes AP, Holmgren A (2004) Glutaredoxins: glutathione-dependent redox enzymes with functions far beyond a simple thioredoxin backup system. Antioxid Redox Signal 6(1):63–74. Fishel ML, Kelley MR (2007) The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol Aspects Med 28(3–4):375–395. Fishel ML, et al (2007) Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin Cancer Res 13(1):260–267. Fishel ML, et al (2008) Knockdown of the DNA repair and redox signaling protein Ape1/Ref-1 blocks ovarian cancer cell and tumor growth. DNA Repair (Amst) 7(2):177–186. Fishel R, Wilson T (1997) MutS homologs in mammalian cells. Curr Opin Genet Dev 7(1):105–113. Fleck O and O. Nielsen (2004) DNA repair. J Cell Sci 117(Pt 4):515–517. Forman-Kay JD, Clore GM, Gronenborn AM (1992) Relationship between electrostatics and redox function in human thioredoxin: characterization of pH titration shifts using two-dimensional homo- and heteronuclear NMR. Biochemistry 31(13):3442–3452. Forsythe JA, et al (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16(9):4604–4613. Friedberg EC (2001) How nucleotide excision repair protects against cancer. Nat Rev Cancer 1(1):22–33. Fung H, Demple B (2005) A vital role for Ape1/Ref1 protein in repairing spontaneous DNA damage in human cells. Mol Cell 17(3):463–470. Georgiadis M, et al.(2008) Evolution of the redox function in mammalian apurinic/apyrimidinic. Mutat Res 643(1–2):54–63. Giles NM, Giles GI, Jacob C (2003) Multiple roles of cysteine in biocatalysis. Biochem Biophys Res Commun 300(1):1–4. Grombacher T, Eichhorn U, Kaina B (1998) P53 is involved in regulation of the DNA repair gene O-6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents. Oncogene 17(7):845–851. Guo HH, Loeb LA (2003) Tumbling down a different pathway to genetic instability. J Clin Invest 112(12):1793–1795. Guo Y, et al (2008) Granzyme K degrades the redox/DNA repair enzyme Ape1 to trigger oxidative stress of target cells leading to cytotoxicity. Mol Immunol 45(8):2225–2235. Hainaut P, Milner J (1993) Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res 53(19):4469–4473. Handel ML, et al (1995) Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos. Proc Natl Acad Sci USA 92(10):4497–4501. Hanson S, Kim E, Deppert W (2005) Redox factor 1 (Ref-1) enhances specific DNA binding of p53 by promoting p53 tetramerization. Oncogene 24(9):1641–1647.
7 DNA Repair and Redox Signaling
165
He F, et al (2003) DNA polymerase beta gene expression: the promoter activator CREB-1 is upregulated in Chinese hamster ovary cells by DNA alkylating agent-induced stress. Biol Chem 384(1):19–23. Helton ES, Chen X (2007) p53 modulation of the DNA damage response. J Cell Biochem 100(4):883–896. Herring CJ, et al (1998) Levels of the DNA repair enzyme human apurinic/apyrimidinic endonuclease (APE1, APEX, Ref-1) are associated with the intrinsic radiosensitivity of cervical cancers. Br J Cancer 78(9):1128–1133. Hess J, Angel P, Schorpp-Kistner M (2004) AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 117(Pt 25):5965–5973. Hirota K, Matsui M, Yodoi J (1997) AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA 94(8):3633–3638. Hirota K, et al (1999) Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J Biol Chem 274(39):27891–27897. Hoeijmakers JH (2001) DNA repair mechanisms. Maturitas 38(1):17–22; discussion 22–23. Hoeijmakers JH (2001) Genome maintenance mechanisms for preventing cancer. Nature 411(6835):366–374. Hofmann B, Hecht HJ, Flohe L (2002) Peroxiredoxins. Biol Chem 383(3–4):347–364. Hollander MC, et al (2005) Deletion of XPC leads to lung tumors in mice and is associated with early events in human lung carcinogenesis. Proc Natl Acad Sci USA 102(37):13200–13205. Holmgren A (1989) Thioredoxin and glutaredoxin systems. J Biol Chem 264(24):13963–13966. Holmgren A (1995) Thioredoxin structure and mechanism: conformational changes on oxidation of the active-site sulfhydryls to a disulfide. Structure 3(3):239–243. Hol WG (1985) The role of the alpha-helix dipole in protein function and structure. Prog Biophys Mol Biol 45(3):149–195. Hromas R, et al (2008) The human set and transposase domain protein Metnase interacts with DNA Ligase IV and enhances the efficiency and accuracy of non-homologous end-joining. DNA Repair (Amst) 7(12):1927–1937. Huang LE, et al (1996) Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271(50):32253–32259. Huang RP, Adamson ED (1993) Characterization of the DNA-binding properties of the early growth response-1 (Egr-1) transcription factor: evidence for modulation by a redox mechanism. DNA & Cell Biol 12(3):265–273. Hwang BJ, et al (1999) Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc Natl Acad Sci USA 96(2):424–428. Izumi T, et al (2005) Two essential but distinct functions of the mammalian abasic endonuclease. Proc Natl Acad Sci USA 102(16):5739–5743. Jacob C, et al (2003) Sulfur and selenium: the role of oxidation state in protein structure and function. Angew Chem Int Ed Engl 42(39):4742–4758. Jayaraman L, et al (1997) Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes and Develop 11:558–570. Jiang BH, et al (1996) Dimerization, DNA binding, and transactivation properties of hypoxiainducible factor 1. J Biol Chem 271(30):17771–17778. Jiang Y, et al (2009) Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response to oxidative stress: use of APE1 small molecule inhibitors to delineate APE1 functions. DNA Repair 8:1273–1282. Jiricny J (2006) The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 7(5):335–346. Kaina B, et al (2007) MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 6(8):1079–1099. Kelley MR, Fishel ML (2008) DNA repair proteins as molecular targets for cancer therapeutics. Anticancer Agents Med Chem 8(4):417–425. Kondo N, et al (2006) Redox regulation of human thioredoxin network. Antioxid Redox Signal 8(9–10):1881–1890.
166
M.R. Kelley et al.
Koshiji M, et al (2005) HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell 17(6):793–803. Kruman, II, et al (2004) Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron 41(4):549–561. Lando D, et al (2000) A redox mechanism controls differential DNA binding activities of hypoxiainducible factor (HIF) 1alpha and the HIF-like factor. J Biol Chem 275(7):4618–4627. Langie SA, et al (2007) The role of glutathione in the regulation of nucleotide excision repair during oxidative stress. Toxicol Lett 168(3):302–309. Lau JP, et al (2004) Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides. Br J Cancer 91(6):1166–1173. Lavon I, et al (2007) Novel Mechanism whereby nuclear factor {kappa}B mediates DNA damage repair through regulation of O6-methylguanine-DNA-methyltransferase. Cancer Res 67(18):8952–8959. Lee SH, et al (2005) The SET domain protein Metnase mediates foreign DNA integration and links integration to nonhomologous end-joining repair. Proc Natl Acad Sci USA 102(50):18075–18080. Lillig CH, Holmgren A (2007) Thioredoxin and related molecules – from biology to health and disease. Antioxid Redox Signal 9(1):25–47. Lillig CH, Berndt C, Holmgren A (2008) Glutaredoxin systems. Biochim Biophys Acta 1780(11):1304–1317. Li SL, et al (2001) Transcriptional regulation of the p67phox gene: role of AP-1 in concert with myeloid-specific transcription factors. J Biol Chem 276(42):39368–39378. Liu F, Fu Y, Meyskens FL, Jr (2008) MiTF regulates cellular response to reactive oxygen species through transcriptional regulation of APE-1//Ref-1. J Invest Dermatol 129:422–431. Liu Z, et al (2009) Inhibition of thioredoxin reductase by mansonone F analogues: Implications for anticancer activity. Chem Biol Interact 117(1):48–57. Loboda A, et al (2009) HIF-1 attenuates Ref-1 expression in endothelial cells: Reversal by siRNA and inhibition of geranylgeranylation. Vascul Pharmacol 51(2–3):133–139. Lopez de Saro FJ, et al (2006) The beta sliding clamp binds to multiple sites within MutL and MutS. J Biol Chem 281(20):14340–14349. Luo M, et al (2008) Role of the multifunctional DNA repair and redox signaling protein Ape1/ Ref-1 in cancer and endothelial cells: Small molecule inhibition of Ape1’s redox function. Antioxid Redox Signal 10(11):1853–1867. Luo M, et al (2010) Redox regulation of DNA repair: implications for human health and cancer therapeutic development. Antioxid Redox Signal 12:1247–1269. Lu X, Lozano G, Donehower LA (2003) Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system. Mutat Res 522(1–2):69–83. Madhusudan S, Hickson ID (2005) DNA repair inhibition: a selective tumour targeting strategy. Trends Mol Med 11(11):503–511. Madhusudan S, et al (2005) Isolation of a small molecule inhibitor of DNA base excision repair. Nucleic Acids Res 33(15):4711–4724. Mathers J, Coxhead J, Tyson J (2007) Nutrition and DNA Repair – potential molecular mechanisms of action. Curr Cancer Drug Targets 7(5):425–431. McNeill DR, Wilson DM 3rd (2007) A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents. Mol Cancer Res 5(1):61–70. Meng AX, et al (2005) Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol 76(2):168–176. Merluzzi S, et al (2008) APE/Ref-1 makes fine-tuning of CD40-induced B cell proliferation. Mol Immunol 45(14):3731–3739. Mihaylova VT, et al (2003) Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol Cell Biol 23(9):3265–3273.
7 DNA Repair and Redox Signaling
167
Moore DH, et al (2000) Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers. Clin Cancer Res 6(2):602–609. Mukherjee A, Martin SG (2008) The thioredoxin system: a key target in tumour and endothelial cells. Br J Radiol 81(1):S57–S68. Nakamura H (2005) Thioredoxin and its related molecules: update 2005. Antioxid Redox Signal 7(5–6):823–828. Nakamura H, Nakamura K, Yodoi J (1997) Redox regulation of cellular activation. Annu Rev Immunol 15:351–369. Ono Y, et al (1994) Stable expression in rat glioma cells of sense and antisense nucleic acids to a human multifunctional DNA repair enzyme, APEX nuclease. Mutat Res 315(1):55–63. Powis G, Montfort WR (2001) Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 41:261–295. Raffel J, et al (2003) Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 142(1):46–51. Rafferty JA, et al (1996) Induction of murine O6-alkylguanine-DNA-alkyltransferase in response to ionising radiation is p53 gene dose dependent. Oncogene 12(3):693–697. Reed AM, Fishel ML, Kelley MR (2009) Small-molecule inhibitors of proteins involved in base excision repair potentiate the anti-tumorigenic effect of existing chemotherapeutics and irradiation. Future Oncol 5(5):713–726. Scherer SJ, et al (2000) p53 and c-Jun functionally synergize in the regulation of the DNA repair gene hMSH2 in response to UV. J Biol Chem 275(48):37469–37473. Schwartz EI, et al (2007) Cell cycle activation in postmitotic neurons is essential for DNA repair. Cell Cycle 6(3):318–329. Sengupta S, Harris CC (2005) p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 6(1):44–55. Sengupta S, et al (2005) Tumor suppressor p53 represses transcription of RECQ4 helicase. Oncogene 24(10):1738–1748. Shinohara ET, et al (2005) DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res 65(12):4987–4992. Smith ML, Seo YR (2002) p53 regulation of DNA excision repair pathways. Mutagenesis 17(2):149–156. Song YJ, et al (2008) Tat-APE1/ref-1 protein inhibits TNF-[alpha]-induced endothelial cell activation. Biochem Biophys Res Commun 368(1):68–73. Sung P, Klein H (2006) Mechanism of homologous recombination: mediators and helicases take on regulatory functions. Nat Rev Mol Cell Biol 7(10):739–750. Tan T, Chu G (2002) p53 Binds and activates the xeroderma pigmentosum DDB2 gene in humans but not mice. Mol Cell Biol 22(10):3247–3254. Tell G, et al (2000) An ‘environment to nucleus’ signaling system operates in B lymphocytes: redox status modulates BSAP/Pax-5 activation through Ref-1 nuclear translocation. Nucleic Acids Res 28(5):1099–1105. Tell G, et al (2005) The intracellular localization of APE1/Ref-1: more than a passive phenomenon? Antioxid Redox Signal 7(3–4):367–384. Tell G, et al (2009) The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal 11(3):601–620. To KK, et al (2006) The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF2alpha in NBS1 repression. EMBO J 25(20):4784–4794. Tonissen KF, Di Trapani G (2009) Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res 53(1):87–103. Ueno M, et al (1999) Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 274(50):35809–35815. Vascotto C, et al (2009) APE1/Ref-1 interacts with NPM1 within nucleoli and plays a role in the rRNA quality control process. Mol Cell Biol 29(7):1834–1854.
168
M.R. Kelley et al.
Walker LJ, et al (1993) Identification of residues in the human DNA repair enzyme HAP1 (Ref-1) that are essential for redox regulation of Jun DNA binding. Mol Cell Biol 13(9):5370–5376. Walker LJ, et al (1994) A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. Nucl Acids Res 22(23):4884–4889. Wang D, Luo M, Kelley MR (2004) Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther 3(6):679–686. Weichsel A, et al (1996) Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer. Structure 4(6):735–751. Wood RD, Mitchell M, Lindahl T (2005) Human DNA repair genes, 2005. Mutat Res 577(1–2):275–283. Wood ZA, Poole LB, Karplus PA (2003) Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science 300(5619):650–653. Xanthoudakis S, Curran T (1992) Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. EMBO J 11(2):653–665. Xanthoudakis S, Curran T (1996) Redox regulation of Ap-1: a link between transcription factor signaling and DNA repair. Adv Exp Med Biol 387:387. Xanthoudakis S, et al (1992) Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. EMBO J 11(9):3323–3335. Xanthoudakis S, et al (1996) The redox/DNA repair protein, Ref-1, is essential for early embryonic development in mice. Proc Natl Acad Sci USA 93(17):8919–8923. Xu J, Morris GF (1999) p53-mediated regulation of proliferating cell nuclear antigen expression in cells exposed to ionizing radiation. Mol Cell Biol 19(1):12–20. Xu Y, et al (1997) The apurinic/apyrimidinic endonuclease (APE/ref-1) DNA repair enzyme is elevated in premalignant and malignant cervical cancer. Anticancer Res 17(5B):3713–3719. Yamabe Y, et al (1998) Sp1-mediated transcription of the Werner helicase gene is modulated by Rb and p53. Mol Cell Biol 18(11):6191–6200. Yamawaki H, Berk BC (2005) Thioredoxin: a multifunctional antioxidant enzyme in kidney, heart and vessels. Curr Opin Nephrol Hypertens 14(2):149–153. Zaky A, et al (2008) Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damage. Nucl Acids Res 36(5):1555–1566. Zou G-M, Maitra A (2008) Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration. Mol Cancer Ther 7(7):2012–2021. Zou GM, et al (2009) The Ape-1/Ref-1 redox antagonist E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: therapeutic implications in tumor angiogenesis. J Cell Physiol 219(1):209–218. Zurer I, et al (2004) The role of p53 in base excision repair following genotoxic stress. Carcinogenesis 25(1):11–19.
Chapter 8
Cancer Stem Cells and Microenvironment Mario Federico and Antonio Giordano
Abstract The theory of the cancer stem cell (CSC) is fairly recent and has both challenged and disrupted the previous understandings of cancer biology. From the initial findings of cancer-driving cellular sub-populations, the interest in the CSC theory has flourished. Here we discuss the biology behind both embryonic and adult stem cells and how this biology is the basis for our understanding of CSCs. Furthermore, we elaborate on findings demonstrating the importance of the microenvironment on the stem cell and how changes in the microenvironment alone may direct stem cell differentiation or possibly tumorigenesis. Cancer research has taken a new fork in the road towards the involvement of CSCs and this road has been productive. However, the challenge remains in understanding and identifying CSCs independently from the embryonic and adult stem cell models of the past. Moving beyond the preconceived understanding of stem cells will allow researchers to be able to fully explore the complexity and role of CSCs in cancer and hopefully provide the knowledge necessary to combat cancer from that first initiating cell.
Introduction The traditional model explaining tumor progression assumes that the tumor cell, through a series of stochastic events, acquires increased proliferative capability because of the deregulation of oncogenes and/or tumor suppressor genes. Once the cancerous phenotype is established, every cell within the tumor has the same capacity to proliferate extensively with no differences in the intrinsic tumorigeneity. The occurrence of additional stochastic genetic events (conferring to the tumor cell an increased malignant potential) will lead to the substitution of the former cancer clone with a more aggressive clone, otherwise known as clonal selection. A. Giordano (*) Biology Department, Sbarro Health Research Organization, Temple University, Philadelphia, PA, USA e-mail:
[email protected] R.G. Bagley (ed.), The Tumor Microenvironment, Cancer Drug Discovery and Development, DOI 10.1007/978-1-4419-6615-5_8, © Springer Science+Business Media, LLC 2010
169
170
M. Federico and A. Giordano
In 1997 Bonnet and Dick (1997) challenged this paradigm. They isolated a subpopulation of CD34+/CD38− leukemic precursors from human AML and demonstrated that only those cells were able to initiate leukemia when engrafted into NOD/SCID mice, whereas the other fractions of leukemic blasts representing the vast majority of all leukemic cells (CD34+, CD38+, or CD34−) were unable to do so. Moreover, they found that engrafted CD34+/CD38− leukemic precursors could be serially transplanted into secondary recipients, thus providing evidence of an intrinsic self-renewal capability. After this observation, several other groups also found tumorigenic self-renewal stem-like populations in a wide spectrum of solid tumors, and nice reviews have been published so far (Kakarala and Wicha 2008; Dirks 2008; Maitland and Collins 2008; Sell and Leffert 2008; Boman and Huang 2008; Takaishi et al. 2008; Peacock and Watkins 2008; Huff and Matsui 2008; Lee et al. 2008; Prince and Ailles 2008). Self-renewal and differentiation capability are the hallmarks of staminality, a concept that traditionally has been associated with totipotent embryonic cells (embryonic stem cells, ESCs), which possess characteristics such as asymmetric cellular division and the ability to differentiate into all three germ layers originating all the different cell types within the body. Stem-like cellular populations also exist in adult organisms and are defined adult stem cells (ASCs). ASCs are immature, undifferentiated, and functionally unspecialized cells, which exist in small numbers in nearly all post-embryonic tissues. ASC populations are thought to give rise to multiple, more differentiated cell types, maintaining a long-term capacity for selfrenewal, and so regulating homeostatic tissue regeneration. In contrast to ESCs, ASCs lack the capacity to differentiate into the three germ layers, are capable of regenerating a cellular population of a specific tissue type, and maintain asymmetric cellular division. ASCs are characterized as being in a state of relative proliferative quiescence, with a high dependence on the microenvironment in which they reside: the so-called stem cell niche. Under the proper conditions, they can exit from the quiescent state to obtain the proliferative potential necessary for tissue regeneration or wound repair. Bonnet and Dick sustained the hypothesis that tumors, similar to normal adult tissues, are constituted with a heirarchy of cell types (Fig. 8.1). Stem or stem-like cells (heirin referred to as cancer stem cells or CSCs) are a relatively small population within this heirarchy and are the only population that maintains the ability to initiate tumorigenesis by undergoing self-renewal and differentiation. The differentiation of this specialized population leads to the loss in self-renewal capacity and physically creates the vast majority of cells found within a tumor. This change of landscape is a radical shift from the traditional stochastic model. First of all because it assumes that not any cell can originate a tumor but just a stem cell, which through an acquired deregulation of the self-renewal process becomes tumorigenic. The second reason is that it postulates a histological hierarchy within the tumor, further implying (by analogy with ESCs and ASCs) a series of mechanisms that control CSCs along their differentiation path. Since stem cells generally have a higher resistance to chemo- and radio-therapy than committed cells, CSC
8 Cancer Stem Cells and Microenvironment
171
Fig. 8.1 The CSC hypothesis
theory has been advocated to explain clinical relapses after cancer therapy. In fact, chemo- and radio-therapy normally produce a significant shrinkage of the tumor mass acting mainly on the “mature” cancer cells with limited effect on CSCs or tumor progenitors. The latter is postulated to be the engine of tumor re-formation, leading to subsequent clinical relapse. This hypothesis has been recently validated in a breast cancer clinical trial, in which patients receiving cytotoxic chemotherapy displayed a marked increase in breast CSC frequency in the residual tumor, while a targeted anti-CSC therapeutic stabilized the CSC population (Li et al. 2008). Finally, from the cellular biology point of view, the CSC paradigm challenges our knowledge of the molecular mechanisms that underlie tumorigeneity. What are the molecular mechanisms behind self-renewal and how is this maintained over time? What stimuli are necessary for differentiation to occur and how are these stimuli limited to only a portion of the population? And how does the environment around the stem cell population affect these events? In the last few years, an exponentially growing number of publications have addressed these issues; however, the majority of knowledge on the general biological mechanisms of staminality still derives from the studies on ESCs and ASCs. Even if we can “phenomenologically” define CSCs through their attitude toward self-renewal and differentiation into a “mature” cancer phenotype, we are still dependent upon the ESC and ASC knowledge to guide us through this novel research field in oncology.
172
M. Federico and A. Giordano
ESCs: A Prototype Model of Stem Cell Biology Thomson and Gearhart isolated and characterized the initial human ESCs (hESCs) from the inner cell mass (ICM) of the blastocyst, noting the self-renewing and differentiation capacity of the cells in vitro (Shamblott et al. 1998; Thomson et al. 1998). These cells, through further characterization, were found to express cell surface markers typical of undifferentiated nonhuman primate ESCs (pESCs) and human embryonic carcinoma cells as was originally described (Shamblott et al. 1998; Thomson et al. 1998; Martin and Evans 1974, 1975). These specific markers included stage-specific embryonic antigen (SSEA)-1, SSEA-3, SSEA-4, TRA-1– 60, TRA-1–81, alkaline phosphatase activity, and high levels of telomerase activity. Telomerase is a ribonucleoprotein enzyme that preserves the telomeric regions at the ends of chromosomes by de novo oligonucleotide synthesis (Greider and Blackburn 1987) and is not present in normal diploid somatic cells, which incur shorted telomeres with age, leading to replicative senescence after a finite number of replications (Hayflick 1965; Hayflick and Moorhead 1961; Harley et al. 1990; Allsopp et al. 1992). It has been shown that TRA-1–60 and TRA-1–81 are specific epitopes of a larger membrane-bound protein podocalyxin, which undergoes retinoic acid modification when ESCs differentiate losing its reactivity with the TRA-1–60 and TRA-1–81 antibodies (Schopperle and DeWolf 2007). These characterizations remain to be used to identify stem cells today, along with the expression of the intrinsic transcription factor Oct-4 and in mouse ESCs (mESCs) the constitutive ability to receive extrinsic signals from the cytokine leukemia inhibitory factor (LIF) (Niwa et al. 1998; Nichols et al. 1998; Fuchs and Segre 2000). The specific characteristic of ESCs is to differentiate during development into many different “mature” phenotypes, realizing a sophisticated balance between pluripotency and commitment that allows the timely and spatially appropriate embryo development. Although not completely elucidated, such a unique characteristic relies upon at least four general different mechanisms: a distinctive transcriptional hierarchy, a balanced epigenetic state, a particular cell cycle regulation, and a tight crosstalk with the microenvironment. Transcriptional regulators contribute to the maintenance of pluripotency and three major players have been identified so far in ESCs: POU5FI, NANOG, and SOX2. POU5FI is a member of the POU transcription factor family and is expressed in the mouse embryo from the four to the eight cells stage until the epiblast starts to differentiate. Its presence is essential for the initial development of pluripotency in the ICM and high levels of this transcription factor are restricted to pluripotent lineages (Wobus and Boheler 2005). Mouse embryos lacking POU5FI protein die following implantation because of the lack of ICM (Nichols et al. 1998). POU5FI represses differentiation to the trophoblast; however, appropriate levels are necessary to maintain pluripotency. In fact, a twofold increase in its expression causes differentiation into primitive endoderm and mesoderm, while loss of POU5FI induces the formation of trophectoderm and concomitant loss of pluripotency (Niwa et al. 2000). NANOG homeodomain protein in pre-implantation embryos is restricted to the inner cells of the compacted morula and blastocyst
8 Cancer Stem Cells and Microenvironment
173
and conversely is absent in differentiated cells (Chambers et al. 2003). High expression levels of NANOG confer constitutive self-renewal capacity to mESCs in the absence of LIF stimulation and can be propagated in serum-free media in the absence of otherwise needed stimuli, such as bone morphogenetic protein (Ying et al. 2003). NANOG knockout mice develop to the blastocyst stage, but when cultured, the ICM differentiates to parietal endoderm-like cells. From these findings, NANOG appears to be involved not only in pluripotency maintenance but also in the inhibition of the transition to primitice endoderm. Finally, the SOX2 gene is expressed in the pluripotent lineages of early mouse embryos and functions as a transcription factor with an HMG-DNA-binding domain. Sox2−/− mice fail to develop beyond implantation (Avilion et al. 2003) and down regulation of Sox2 is associated with differentiation. A ChIP-on-chip analysis revealed that all three of these factors co-occupy a substantial portion of target genes (Boyer et al. 2005) with an evident overlapping function. The generation of induced pluripotent stem cells using PUI5FI, SOX2, NANOG, and LIN28 along with the generation of pluripotent cells using POU5FI and SOX2 alone with the histone deacetylase inhibitor, valproic acid (Huangfu et al. 2008), have further demonstrated the role of these transcription factors in maintaining pluripotency. The second crucial mechanism that regulates ESC development relies on a precise epigenetic control of gene expression patterns. The term epigenetics specifically refers to heritable genotypic changes that are caused by mechanisms other than changes in the primary DNA sequence. Central to epigenetic control is chromatin, a complex of DNA, histones, and other proteins that make up chromosomes (Misteli 2004, 2007; Meshorer 2007). Histones are subject to several post-translational modifications that occur primarily in their amino terminal tails including methylation, acetylation, phosphorylation, sumoylation, and ubiquitination (Kouzarides 2007). During differentiation, genes regulating pluripotency and self-renewal become progressively silenced, whereas genes controlling cell-type specific functions are gradually turned on. These alterations in gene expression patterns are orchestrated by defined epigenetic programs that are capable of indirectly altering the expression of hundreds to thousands of genes, proving the efficiency of this type of control in establishing cellular identities (Lunyak and Rosenfeld 2008; Cheng et al. 2005; Shukla et al. 2008; Wu and Sun 2006). Based on a genome-wide analyses of chromatin patterns of multiple cell types, several observations have emerged: acetylation of lysine residues on histones H3 and H4 and methylation of lysine 4 of histone H3 (H3K4me), in general, are associated with transcriptionally active chromatin, whereas methylation of histone H3 lysine 9 (H3K9me) and 27 (H3K27me) are hallmarks of transcriptionally silenced chromatin (Kouzarides 2007). Several studies demonstrated that the differentiation of ESCs is accompanied with an increase in histone H3K9me3 and decreased acetylation of histone H3 and H4 (Lee et al. 2004; Meshorer et al. 2006). However, further studies will be necessary to elucidate the role of epigenetics in stem cell regulation. The third major difference between stem cells and somatic cells is found in the basic regulation of the cell cycle. In somatic cells, the cell cycle is controlled mainly by Rb-E2F family complexes, cyclin–cyclin-dependent kinases (Cdks), and
174
M. Federico and A. Giordano
Cdk inhibitors through the INK4a/ARF pathway. Undulations in expression and post-translational modifications of the proteins involved in these pathways result in the control and regulation of the cell cycle. Similarly, mutations or de-regulation of these proteins can lead to uncontrolled cell proliferation, aneuploidy, and genomic instability (Haas et al. 1997; Mumberg et al. 1996). The cell cycle regulatory mechanisms, which differ between somatic cells and ESCs, have been determined using the mESC model in combination with mESCs, representing a pluripotent lineage (mEPLC) (Rathjen et al. 1999). mESCs of late pre-implantation and early post-implantation embryos proliferate at an unusually rapid rate (Solter et al. 1971). Between 4.5 and 6.0 dpc (days post coitum), the epiblast expands with a generation time of approximately 10 h (Hogan et al. 1994). This increases between 6.5 and 7.0 dpc, where mean generation times are found to be approximately 4.4 h (Hogan et al. 1994; Power and Tam 1993). The cell cycle in mESCs and mEPLCs has been found to curtail G1 and G2 phases with an increased proportion of the cycle, approximately 50–60%, spent in S phase (Savatier et al. 1994; Stead et al. 2002). Under normal somatic cell cycle conditons, Rb/p105, in the hypophosphorylated state, interacts with E2F transcription factors inhibiting the transcription of genes necessary for the progression of the cell cycle through the restriction point (R point). The phosphorylation levels of Rb/p105 are dependent upon the CDK activity present in the cell. Mitogen signaling through the Ras/Raf/mitogen activated protein kinase (MAPK) pathway activates the cyclin D–CDK4/6 complexes, which are believed to initially activate Rb/p105 activity by hypophosphorylating the unphosphorylated protein. To pass the R point of the cell cycle, cyclin E/CDK2 hyperphosphorylates Rb/p105 inhibiting the protein from binding to E2F transcription factors, thus initiating the transcription of genes required in the S phase of the cell cycle. To obtain a cell cycle that is less influenced by mitogen variations, the stem cells appear to adopt a different regulation mechanism as depicted in Fig. 8.2 (Giacinti and Giordano 2006; Kasten 1998). Along with shortened gap phases in the ESC cell cycle, the R point does not seem to regulate the G1–S transition. Stead and collegues found that in both mESCs and mEPLCs, there was a precocious cell cycle-independent expression of CDK2, cyclin A and cyclin E kinase activity (Kasten and Giordano 1998). Furthermore, when CDK2 was suppressed, they found a significant decrease in cell proliferation rate. Instead of CDC2, cyclin B, essential to G2 – M transition, was the only CDK activity that was found to be cell cycle-dependent and E2F target genes were constitutively expressed throughout the cell cycle (Stead et al. 2002). Evidence has also shown a lack in hypophosphorylated Rb/p105, instead findings support the presence of hyperphosphorylated Rb/p105 in mESCs and mEPLCs (Savatier et al. 1994; Fraichard et al. 1995). of cell cycle. There is cell cycle-independent expression of cyclin E – CDK2 maintaining the hyperphosphorylated levels of Rb family member proteins. This results in cell cycle-independent expression of E2F-regulated genes. Cyclin B – CDC2 is the only CDK activity that appears to be regulated by the cell cycle. ESCs have shortened gap phases and an elongated S phase of the cell cycle, with an apparent lack in the R point for G1-S transition
8 Cancer Stem Cells and Microenvironment
175
Fig. 8.2 Specific characteristics of pluripotent cells a) Interplay between the key transcriptional regulators POU5F1, NANOG and SOX2 and their effect on the formation of primitive endoderm and trophectoderm. b) Schematic representation of a nucleosome model and major post-translational modifications which play essential roles in gene expression regulation. c) Cell cycle in somatic cells vs. ESCs. Cell cycle regulation in somatic cells: mitogen signaling through MAPK pathway activates cyclin D – CDK4/6 kinase activity hypophosphorylating Rb family member proteins. Hypophosphorylated Rb family member proteins bind to E2F transcription factors blocking the transcription of E2F-regulated genes. To surpass the R point cyclin E – CDK2 kinase activity is activated hyperphosphorylating Rb family member proteins. Hyperphosphorylated Rb family member proteins are unable to interact with E2F factors, allowing them to activate transcription of genes necessary in the progression of cell cycle. Cell cycle regulation in ESCs as is currently understood: Mitogen signaling through MAPK pathways seems to be irrelevant in the progression
176
M. Federico and A. Giordano
Given the cell-cycle independent expression of cyclin E and CDK2, it would be logical that Rb/p105 would be found in the hyperphosphorylated state, further supporting the absence of the R point in ESC cell cycle progression (Fig. 8.1). Mitogen signaling through the MAPK pathway normally stimulates cell division in somatic cells; however, this signaling when prolonged is a potent inducer of differentiation. mESCs appear to avoid this stimulation by maintaining low levels of cyclin D expression and almost no detectable CDK4 kinase activity (Fluckinger et al. 2006). This corresponds to the lack in hypophosphorylated Rb/p105 levels previously detected in mESCs. These findings support the absence of early G1 in mESCs, allowing them to avoid the differentiation-inducing effects of MAPK signaling as is found in other cell types. Although the majority of studies thus far have been performed in mESCs, hESCs similarly show a truncation of the G1 phase of the cell cycle; however, not much else is known about cell cycle regulation in hESCs. Interestingly, pESCs behave similarly to mESCs in having cell cycle-independent expression of cyclin E, constitutive hyperphosphorylation of Rb/p105 and serum and MAPK-independent cell cycle progression (Fluckinger et al. 2006; Becker et al. 2006). Therefore, it could be inferred that through conserved evolution, hESCs may regulate the cell cycle in a similar fashion. Taken together, these data lead to the hypothesis that the ESC cell cycle is rate-dependent upon high levels of CDK activity, is not regulated by Rb/p105 or E2F gene expression, and lacks the G1 check point and the traditional periodicity found during the somatic cell cycle.
Stem Cells and Microenvironment Soon after the initial isolations and characterizations of hESCs, interest shifted toward understanding the factors involved in their differentiation. For example, if all cells are derived from initial progenitor cells, what directs the timely and spatially appropriate differentiation toward various mature cell types (i.e., glial cells versus adipocytes)? In this sense, it was immediately clear that a crucial role in differentiation was played by the microenvironment. Brüstle et al. (1999) were among the first to demonstrate in vitro controlled differentiation of hESCs using a series of growth factor combinations, which successfully elicited a reactivity to a monoclonal antibody specific for a membrane epitope typically found on the membranes of glial precursors. They initially grew ES cells in a media that favored the growth of neural precursors. They then exposed cells to the following series of growth factors: (1) basic fibroblast growth factor (FGF2), (2) FGF2 and epidermal growth factor (EGF), and (3) FGF2 and platelet-derived growth factor (PDGF) (Brüstle et al. 1999). The cells maintained in the final growth factor-supplemented media could be stored and kept in culture without further differentiation for many passages. However, as growth factors were removed, cells further differentiated into more specific neural cell types such as oligodendrocytes and astrocytes (Brüstle et al. 1999). Today, it is well established that ESC microenvironment
8 Cancer Stem Cells and Microenvironment
177
provides a dynamic regulatory niche for stem cell function constituting a finely regulated network of cell–cell communication that is critical to cell behavior and fate determination throughout embryogenesis. The stem cell niche can be defined as the production of local signal(s) and spatial organization of cells receptive to those signals to generate location-dependent control over contrasting cell-fate decisions such as self-renewal and differentiation. The concept of niche is also crucial in the regulation of ASCs as demonstrated by the pioneering studies on Drosophila (Deng and Lin 1997). Deng showed that the female fly has cells named “cap cells” at the tip of the ovary to which germ line stem cells adhere. During mitosis, daughter stem cells divided in such a way that they no longer adhered to the cap cells and started differentiating and growing into cystoblasts. On the contrary, daughter stem cells that stayed attached to the cap cells after cell division remained germ line stem cells. These results suggested that the cap cells provided a special environment for the germ line stem cells and played a role as a stem cell niche in the fly ovary. Today, human ASC niches have been characterized in several body regions; however, how they function as stem cell niches is far from being elucidated. In ESCs molecular cues in the embryonic milieu, originating from various cell types, possess various signaling characteristics with diverse effects on specific target cells or tissues. Certain stimulatory factors such as Activin, Nodal, and FGF maintain pluripotency in ESCs, while other factors, such as ngn3, Notch, and ASK-1 (endocrine, hematopoietic, and neuronal lineages, respectively), dictate a differentiated fate (Serafimidis et al. 2007; Radtke et al. 2004; Elmi et al. 2007; Vallier et al. 2005). These signals regulate the phenotype of stem cells or their progeny, are at times antagonistic and may be separated in a spatial and/or temporal fashion. These processes are extremely complex, and their sophistication is far to be fully understood (Constantinescu 2000; Lensch et al. 2006). It has to be underlined that the stem niche environment is not only determined by soluble endocrine or paracrine growth factors through cell–cell cross-talk but also on the contrary is regulated by a more complex interplay of different factors such as cell–matrix adhesion and the physical and physical–chemical environment. Peerani et al. (2007) in a series of sophisticated experiments demonstrated that the modulation of ESCs’ density per se can be used to generate distinct patterns of selfrenewal and differentiation. It has been demonstrated that in the osteoblastic niche, hematopoietic stem cells are predominantly located at the lowest end of an oxygen gradient in the bone marrow (Parmar et al. 2007); therefore, it is reasonable to think that physiochemical properties of the niche (pH, oxygen abundance, and size) are important factors regulating stem cell fate. Moreover, an increasing number of experimental evidence suggests that physical forces acting on stem cells through extracellular matrix or physical–chemical parameters, such as hypoxia (pH), can commit their fate. For example, the shear forces exerted by the blood flow have been found to direct isolated ESCs through an endothelial differentiation (Yamamoto et al. 2005) and slight mechanical deformations can induce mesenchymal stem cells (MSCs) to differentiate into smooth muscle cells (Kurpinski et al. 2006). A wide range of in vitro studies confirm the relevance of the so-called mechanobiology to
178
M. Federico and A. Giordano
stem cell differentiation. Undifferentiated MSCs grown on polymer gels mimicking the extracellular matrix elasticity of a given tissue were found to express precursor proteins for the cell type typically present in that tissue in the absence of specific growth factors. Cells grown on gels of elasticity comparable to brain express neuronal markers and their phenotypes and are not contractile. Conversely, MSCs cultured on more rigid gels (mimicking muscular tension) begin to express early skeletal muscle proteins. Finally, more rigid substrates that mimic pre-calcified bone yield MSCs that resemble bone cells and exert significant traction on their environment (Reilly and Engler 2009). Recently, to highlight the contribution of extracellular matrix to stem cell behavior, the physical parameters of the microenvironment have been proposed to act also as homing signals to migrating stem cells. As seen from the use of various gel matrices with controlled elasticity and non-limiting ligand density, most, if not all, cells are found to adhere and to anchor more strongly to stiff substrates compared with soft substrates. In a gradient of elasticity, cells therefore accumulate on stiffer substrates in a process called durotaxis, which might constitute a biophysical basis for which MSCs home to sites of injury, scar formation, and fibrosis (Disher et al. 2009).
CSCs and the Microenvironment Some of the general mechanisms, mentioned above, that regulate stem cell selfrenewal and differentiation are also crucial in CSC biology. The analogies are so many that maybe cancer could be considered a disease of unregulated self-renewal, in which mutations convert normal stem cell self-renewal pathways into the promoters of neoplastic proliferation (Pardal et al. 2003; Al-Hajj and Clarke 2004; Beachy et al. 2004). The Bmi-1 (B-cell specific Moloney murineleukemia virus integration site 1), Notch, Wnt, and Sonic hedgehog pathways (Park et al. 2003; Lessard and Sauvageau 2003; Duncan et al. 2005; Bhardwaj et al. 2001/2002) were initially identified to play a role in carcinogenesis and were later related to stem cell self-renewal (Taipale and Beachy 2001; Weng and Aster 2004). Studies on these pathways have revealed close links between cancer cells and normal ASCs (Pardal et al. 2003; Reya et al. 2001; Reya and Clevers 2005). Uncontrolled activation of these pathways may result in specific cancers, possibly as an attempt to recapitulate normal embryonic organogenesis (Molofsky et al. 2004; Ruiz i Altaba et al. 2004). Aberrant Notch signaling has been detected in several cancers and has recently been strongly connected to T-cell acute lymphoblastic leukemia (Grabher et al. 2006). Aberrant activation of the Wnt pathway has been found in various human tumors and is strongly associated with colorectal cancer (Taipale and Beachy 2001). Increased Hedgehog signaling has been linked not only to a small subset of tumors in the brain, skin, and muscle but also recently to cancers in the lungs, gastrointestinal tract, and pancreas (Pasca di Magliano and Hebrok 2003). Bmi-1 is an oncogene that is found overexpressed in several human cancers (Valk-Lingbeek et al. 2004) as for instance in the majority
8 Cancer Stem Cells and Microenvironment
179
of medulloblastomas (Leung et al. 2004; Marino 2005). As for ESCs and ASCs, also for CSCs the spatial definition of these signaling pathways in a particular microenvironment is crucial and the concept of CSC niche is rapidly emerging. A study of stem cells in brain tumors has made significant progress in this area. Calabrese and colleagues showed that brain tumor cells co-expressing Nestin and CD133 (the fraction believed to contain the CSCs) were found near the capillaries in the brain tumor (Calabrese et al. 2007). When these cells were co-cultured, the CSCs selectively adhered to the endothelial cells, similar to the cap cells in drosophila. This suggested that endothelial cells secrete factors necessary to maintain brain tumor CSCs. Moreover, it has been shown that the CD133-positive cells derived from human medulloblastoma together with endothelial cells developed brain tumors when xenografted into the brain of a recipient nude mouse. Comparably, Krause and colleagues (2006) showed that there was impaired induction of chronic myeloid leukemia (CML)-like myeloproliferative disease among recipient mice that received transplanted BCR–ABL1transduced CML progenitors from CD44-mutant donors. These results indicate that cell–cell interactions are crucial in providing a homing signal to CSCs; however, they are also able to interfere with engraftment in their niche within the recipient organism. Tumor hypoxia is a well-established factor of aggressiveness that since the 1980s and recent studies on ASC and CSC microenvironments offer a molecular explanation of the former clinical observation (Overgaard 1989). In fact, as for some ASC populations, hypoxia is thought to play a critical role also in CSC regulation. Soeda colleagues (2009) clearly demonstrated that human-derived CSCs when cultured in hypoxic conditions are promped toward self-renewal and strongly retain the undifferentiated phenotype, whereas CSCs cultured in normoxia do not. Moreover, it has been recently reported (Li et al. 2009) that physiological oxygen levels differentially induce hypoxia inducible factor-2a (HIF2a) levels in CSCs. HIF1a is known to function in proliferation and survival of all cancer cells, while HIF2 seems to be essential only in CSCs and was not expressed by normal neural progenitors. Heddleston et al. (2009) extended these studies to examine the role of hypoxia in regulating tumor cell plasticity and found that hypoxia promotes the self-renewal capability of the stem and non-stem populations. Furthermore, hypoxia induces a more stem-like phenotype in the non-stem population with a marked increased in neurosphere formation as well as upregulation of important stem cell factors, such as OCT4, NANOG, and c-MYC. The importance of HIF2a was further supported as forced expression of non-degradable HIF2a-induced expression of a CSC marker and augmented the tumorigenic potential of the non-stem population. It has to be underlined that the influence of the microenvironment on the tumor progenitor is eventually even greater. Several groups have reported the ability of the microenvironment to be able to dramatically reprogram the cancer phenotype. In the early seventies, Mintz and Illmensee reported that teratocarcinoma cells injected into murine blastocysts aquired totipotency and a reversion to a normal phenotype (Mintz and Illmensee 1975; Illmensee and Mintz 1976). This model clearly established a non-mutational basis for the transformation of these teratocarcinoma cells
180
M. Federico and A. Giordano
into a malignant phenotype, and demonstrated the unique ability of an embryonic microenvironment to reprogram these cells to a normal phenotype. In more recent years, other researchers (Lee et al. 2005; Kulesa et al. 2006) demonstrated that the chick and zebrafish embryonic microenvironments not only repress tumor formation when implanted with aggressive human melanoma cells but induce lineagespecific genes and migratory behaviors associated with a more normal phenotypes, representative of an epigenetic reprogramming event. The same group with an elegant in vitro model showed that apart from any cell–cell interaction, the extracellular matrix when conditioned by specific cell types can clearly influence the phenotype of aggressive cancers (melanoma) in a reversible (epigenetic) way (Abbott et al. 2008). To further demonstrate a specific influence of tumor microenvironment on stem cells, Taylor et al. (2008) combined human ES cells with cancer-associated fibroblasts (CAFs) from patients with prostate cancer. When grafted into the kidney capsule of host mice, human ES cells form teratomas that rapidly enlarge and kill the host. When combined with CAFs, the teratoma formation is significantly abrogated, demonstrating that the stromal tumor niche is able to influence human ES cell differentiation. Furthermore, the CAF-derived niche differs from that derived from nonmalignant prostatic fibroblasts that were unable to alter or impede teratoma formation. Further data in support of the relevance of the environmental influence on CSC plasticity comes from Knutson et al. (2006; Santisteban et al. 2009), who demonstrated that in vivo the induction of an immune response against an epithelial breast cancer led to the T-cell-dependent outgrowth of a tumor, the cells of which had undergone epithelial to mesenchymal transition (EMT). The resulting mesenchymal tumor cells had a CD24/low/CD44+ phenotype, consistent with breast CSCs. EMT induced by CD8 T cells produced tumors that had characteristics of breast CSCs, including potent tumorigenicity, ability to re-establish an epithelial tumor, and enhanced resistance to drugs and radiation. These data in contrast to the hierarchical CSC hypothesis suggest that breast cancer arises from the transformation of a resident tissue stem cell and that EMT can produce the breast CSC phenotype. These findings have two important implications: first, the observed phenotypic plasticity suggests that a dynamic equilibrium may exist between CSCs and nonCSCs within tumors; second, this equilibrium may be shifted in one direction or another by contextual signals within the tumor microenvironment influencing the probability for there to be interchanged between the CSC and non-CSC compartments and thus regulating the overall tumor homeostasis.
Concluding Remarks CSCs represent a budding field of research that has yet to emerge on its own. We are still completely reliant on our understanding of embryonic and ASC biology to explain the role of stem cells in cancer. However, it is clear from the initial studies that CSCs play a critical role in tumorigenisis and resistance to cancer therapies;
8 Cancer Stem Cells and Microenvironment
181
therefore, our continued efforts are essential in elucidating the biological role of these tumor sub-populations. Here we have given an overview of what is known so far in CSC biology, from the initial documentations of CSCs to the role of specific growth factors and transcriptional regulators in CSC biology. We have also discussed major findings in the ESC and ASC research fields, which we retain necessary for the proper physiological understanding of CSCs. It is important to note that these correlations are assumed because of the similarities between CSCs and ESCs or ASCs, respectively. It will be imparitive in the future to better characterize CSCs on their own to understand their origin and their unique role in cancer biology.
References Abbott DE, Bailey CM, Postovit LM et al. (2008) The epigenetic influence of tumor and embryonic microenvironments: how different they are? Cancer Microenvironment 1:13–21. Al-Hajj M, Clarke MF (2004) Self-renewal and solid tumor stem cells. Oncogene 23:7274–7282. Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher B, Greider CW, Harley CB (1992) Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A 89:10114–10118. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R (2003) Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 17:126–140. Beachy PA, Karhadkar SS, Berman DM (2004) Tissue repair and stem cell renewal in carcinogenesis. Nature 432 :324–331, 639–648. Becker KA, Ghule PN, Therrien JA, Lian JB, Stein JL, van Wijnen AJ, Stein GS (2006) Selfrenewal of human embryonic stem cells is supported by a shortened G1 cell cycle phase. J Cell Physiol 209:883–893. Bhardwaj G, Murdoch B, Wu D et al. (2001/2002) Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol 2:172–180, 542–545. Boman BM, Huang E (2008) Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol June:2828–2838. Bonnet D, Dick J (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730–737. Boyer LA, Lee TI, Cole MF et al. (2005) Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122:947–956. Brüstle O, Jones KN, Learish RD, Karram K, Choudhary K, Wiestler OD, Duncan ID, McKay RDG (1999). Embryonic stem cell-derived glial precursors: a source of myelinating transplants. Science 285:754–756. Calabrese C, Poppleton H, Kocak M et al. (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11:69–82. Cheng LC, Tavazoie M, Doetsch F (2005) Stem cells: from epigenetics to microRNAs. Neuron 46:363–367. Constantinescu SN (2000) Stem cell generation and choice of fate: role of cytokines and cellular microenvironment. J Cell Mol Med 4(4):233–248. Deng W, Lin H (1997) Spectrosomes and fusomes anchor mitotic spindles during asymmetric germ cell divisions and facilitate the formation of a polarized microtubule array for oocyte specification in Drosophila. Dev Biol 189:79–94. Dirks PB (2008) Brain tumor stem cells: bringing order to the chaos of brain. J Clin Oncol June:2916–2924.
182
M. Federico and A. Giordano
Disher D, Mooney DJ, Zandstra PW (2009) Growth factors, matrices and forces combine and control stem cells. Science 324:1673–1677. Duncan AW, Rattis FM, Dimascio LN, Congdon KL et al. (2005) Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol 6:314–322. Elmi M et al. (2007) Mechanism of MASH1 induction by ASK1 and ATRA in adult neural progenitors. Mol Cell Neurosci 36(2):248–259. Fluckinger AC, Marcy G, Marchand M, Négre D, Cosset FL, Mitalipov S, Wolf D, Savatier P, Deh